beta

GILD

Gilead Sciences Inc.

Gild

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

02-04-2019 after market close 10-25-2018 after market close 07-25-2018 after market close 05-01-2018 after market close 02-06-2018 after market close 10-26-2017 after market close 07-26-2017 after market close 05-02-2017 after market close
Actual EPS 1.34 1.7 1.75 1.37 1.6 2.23 2.51 2.2
Consensus EPS 1.61 1.56 1.47 1.65 1.65 2.03 2.11 2.18
Estimated EPS 1.61 1.56 1.47 1.65 1.65 2.03 2.11 2.18
Number of Estimates 8 8 8 7 7 7 5 6
EPS Surprise -$0.27 $0.14 $0.28 -$0.28 -$0.05 $0.20 $0.40 $0.02

Stats

Summary

Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.

Market Cap: 106 Billion

Primary Exchange: Nasdaq Global Select

Website: http://www.gilead.com

Shares Outstanding: 1.31 Billion

Float: 1.3 Billion

Dividend: 2.08 (2.56%)

Beta: 1.195682

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 21.8 Million

Ethical Flags

Animal testing

Longest drawdown: 1171 trading days

From: 2015-06-23 To: 2019-06-12

Lowest Point:

Akero Therapeutics Readies $75 Million IPO

via: SeekingAlpha at 2019-06-13 09:11:26:000

Quick Take Akero Therapeutics ( AKRO ) has filed to raise gross proceeds of $75.0 million from a U.S. IPO, according to an S-1/A registration statement . The firm is developing a treatment for metabolic diseases with high unmet clinical needs, with an initial focus on non-alcoholic steato… read more...

June 2019 Stock Considerations

via: SeekingAlpha at 2019-06-12 23:24:27:000

After a wild May we seem to be trending back up in June. Of course, anyone in the DGI space already knows that these daily, weekly and monthly swings really don't matter to anyone with a very long-term time horizon. All we can do in the meantime is watch the market swing, stay in the game, fin… read more...

BIIB Is For Buy-O-Gen

via: SeekingAlpha at 2019-06-12 06:30:36:000

Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc… read more...

Gilead Hopes To Continue Sales Expansion Of Yescarta - Results From KTE-X19 Step In The Right Direction

via: SeekingAlpha at 2019-06-11 13:29:35:000

Gilead Sciences ( GILD ) reported final results from its phase 1 study using its CAR-T cell therapy KTE-X19 to treat patients with relapsed/refractory acute lymphoblastic leukemia ((ALL)). This was early clinical data that was presented at the American Society for Clinical Oncology ((ASCO)) … read more...

How To Find Undervalued Stocks In The Healthcare Sector

via: SeekingAlpha at 2019-06-10 12:10:41:000

The healthcare sector is underperforming the market by a wide margin on a year to date basis. The Healthcare Select Sector ETF ( XLV ) has gained 5.2%, while the SPDR S&P 500 ( SPY ) is up by almost three times that, with a cumulative gain of 15.1% in the same period. Data by YCharts … read more...

Dividend Challenger Highlights: Week Of June 9

via: SeekingAlpha at 2019-06-10 02:40:50:000

Introduction The Dividend Champions list is a monthly compilation of companies which have consistently increased their annual dividend payouts, and the latest edition may be found here . However, since this list is only produced once per month, the data in it can quickly get out of date. Fu… read more...

Agenus Is A Buy Long Term, Despite Short Interest

via: SeekingAlpha at 2019-06-07 08:51:40:000

Agenus ( AGEN ), a clinical-stage, small-cap, pharmaceutical biotechnology company, has seen its stock price slump since January 2019. On June 6, 2019, Agenus closed at $2.66, down 31% since it peaked at its 52-week high of $3.88 in January. I believe the likely explanation for the slump is … read more...

Agenus Is A Buy Long Term, Despite Short Interest

via: SeekingAlpha at 2019-06-07 08:51:40:000

Agenus ( AGEN ), a clinical-stage, small-cap, pharmaceutical biotechnology company, has seen its stock price slump since January 2019. On June 6, 2019, Agenus closed at $2.66, down 31% since it peaked at its 52-week high of $3.88 in January. I believe the likely explanation for the slump is … read more...

Agenus Is A Buy Long Term, Despite Short Interest

via: SeekingAlpha at 2019-06-07 08:51:40:000

Agenus ( AGEN ), a clinical-stage, small-cap, pharmaceutical biotechnology company, has seen its stock price slump since January 2019. On June 6, 2019, Agenus closed at $2.66, down 31% since it peaked at its 52-week high of $3.88 in January. I believe the likely explanation for the slump is … read more...

Key events next week - healthcare

via: SeekingAlpha at 2019-06-07 05:22:15:000

Noteworthy events during the week of June 9 - 15 for healthcare investors. More news on: Merck & Co., Inc., Xeris Pharmaceuticals, Inc., Mallinckrodt plc, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2019-06-07 05:22:15:000

Noteworthy events during the week of June 9 - 15 for healthcare investors. More news on: Merck & Co., Inc., Xeris Pharmaceuticals, Inc., Mallinckrodt plc, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2019-06-07 05:22:15:000

Noteworthy events during the week of June 9 - 15 for healthcare investors. More news on: Merck & Co., Inc., Xeris Pharmaceuticals, Inc., Mallinckrodt plc, Healthcare stocks news, , Read more … read more...

Gilead Sciences, Inc. (GILD) CEO Daniel O'Day presents at Jefferies 2019 Global Healthcare Brokers Conference (Transcript)

via: SeekingAlpha at 2019-06-05 09:58:09:000

Gilead Sciences, Inc. (GILD) Jefferies 2019 Global Healthcare Brokers Conference June 5, 2019 11:30 am ET Corporate Participants Daniel ODay - Chairman and Chief Executive Officer Conference Call Participants Michael Yee - Jefferies Presentation Michael Yee Al… read more...

Gilead Sciences, Inc. (GILD) CEO Daniel O'Day presents at Jefferies 2019 Global Healthcare Brokers Conference (Transcript)

via: SeekingAlpha at 2019-06-05 09:58:09:000

Gilead Sciences, Inc. (GILD) Jefferies 2019 Global Healthcare Brokers Conference June 5, 2019 11:30 am ET Corporate Participants Daniel ODay - Chairman and Chief Executive Officer Conference Call Participants Michael Yee - Jefferies Presentation Michael Yee Al… read more...

5%+ Dividend Yield Portfolio: Coping With Existential Dread (May 2019 Review)

via: SeekingAlpha at 2019-06-05 08:40:10:000

Musings May was a particularly weird month in a weird period for the markets (though I suppose that could be said about most times). The furious rally from the December 2018 lows (spurred by the narratives of a cool-headed Fed and Administration) fizzled spectacularly against the realities… read more...

5%+ Dividend Yield Portfolio: Coping With Existential Dread (May 2019 Review)

via: SeekingAlpha at 2019-06-05 08:40:10:000

Musings May was a particularly weird month in a weird period for the markets (though I suppose that could be said about most times). The furious rally from the December 2018 lows (spurred by the narratives of a cool-headed Fed and Administration) fizzled spectacularly against the realities… read more...

Total USD Portfolio Monthly Review - May 2019

via: SeekingAlpha at 2019-06-05 01:26:20:000

Overview "Sell in May and go away!" - this long-standing adage just describes what Mr. Market was doing last month, causing big drops in major equity indices. Our referenced benchmarks were down 5-8% (as displayed below) as the volatility comes back into play. In May, our portfolio managed… read more...

Total USD Portfolio Monthly Review - May 2019

via: SeekingAlpha at 2019-06-05 01:26:20:000

Overview "Sell in May and go away!" - this long-standing adage just describes what Mr. Market was doing last month, causing big drops in major equity indices. Our referenced benchmarks were down 5-8% (as displayed below) as the volatility comes back into play. In May, our portfolio managed… read more...

Dividend Portfolio Review: New Dividend Record For May

via: SeekingAlpha at 2019-06-03 07:04:28:000

It's May, and this is the best time of the year for a German dividend investor, as this is the month where most of Germany's companies distribute their annual dividends. As such, it was no surprise that May set a new record in dividend income, but I am still baffled by the amount and the growt… read more...

Dividend Portfolio Review: New Dividend Record For May

via: SeekingAlpha at 2019-06-03 07:04:28:000

It's May, and this is the best time of the year for a German dividend investor, as this is the month where most of Germany's companies distribute their annual dividends. As such, it was no surprise that May set a new record in dividend income, but I am still baffled by the amount and the growt… read more...

Kite Announces New Yescarta® Data From ZUMA-1

via: Business Wire at 2019-06-03 05:00:00:000

-- Sub-Population Analysis Demonstrates High Rates of Durable Response and Overall Survival Regardless of Age at Two Years Post-Treatment -- -- Safety Management Study Shows Early Use of Steroids May Help Manage Severe Cytokine Release Syndrome and Neurologic Events without Effect o… read more...

Kite Announces New Yescarta® Data From ZUMA-1

via: Business Wire at 2019-06-03 05:00:00:000

-- Sub-Population Analysis Demonstrates High Rates of Durable Response and Overall Survival Regardless of Age at Two Years Post-Treatment -- -- Safety Management Study Shows Early Use of Steroids May Help Manage Severe Cytokine Release Syndrome and Neurologic Events without Effect o… read more...

Gilead's CAR T KTE-X19 shows positive action in early-stage ALL study

via: SeekingAlpha at 2019-06-03 03:20:40:000

Results from the first phase of a Phase 1/2 clinical trial, ZUMA-3, evaluating Gilead Sciences (NASDAQ: GILD ) unit Kite Pharma's CAR T candidate KTE-X19 in adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL) showed a positive effect. The data were presented at A… read more...

Gilead's CAR T KTE-X19 shows positive action in early-stage ALL study

via: SeekingAlpha at 2019-06-03 03:20:40:000

Results from the first phase of a Phase 1/2 clinical trial, ZUMA-3, evaluating Gilead Sciences (NASDAQ: GILD ) unit Kite Pharma's CAR T candidate KTE-X19 in adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL) showed a positive effect. The data were presented at A… read more...

Kite Announces End of Phase 1 ZUMA-3 Results for KTE-X19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

via: Business Wire at 2019-06-01 14:00:00:000

-- Data Show High Rates of Response to Single Infusion of KTE-X19 -- -- Phase 2 Portion of ZUMA-3 is Ongoing and Includes Dosing and Revised Safety Management Protocol Studied in Phase 1 -- Kite, a Gilead Company (Nasdaq: GILD), today announced results from the completed Phas… read more...

Kite Announces End of Phase 1 ZUMA-3 Results for KTE-X19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

via: Business Wire at 2019-06-01 14:00:00:000

-- Data Show High Rates of Response to Single Infusion of KTE-X19 -- -- Phase 2 Portion of ZUMA-3 is Ongoing and Includes Dosing and Revised Safety Management Protocol Studied in Phase 1 -- Kite, a Gilead Company (Nasdaq: GILD), today announced results from the completed Phas… read more...

Gilead: The Next Shoe To Drop

via: SeekingAlpha at 2019-05-31 11:52:18:000

Gilead CEO Daniel O'day. Source: Fortune I have been bearish on Gilead ( GILD ) ever since its HVC sales began to crack. The stock has been buttressed by share buybacks and the melt up in financial markets. It could come under pressure after Goldman ( GS ) analyst Terence Flynn issued a s… read more...

Gilead teams up with Humanigen in study of combo therapy for DLBCL

via: SeekingAlpha at 2019-05-31 06:11:34:000

Gilead Sciences ( GILD -1.7% ) unit Kite Pharma will collaborate with Humanigen ( OTCQB:HGEN +8.7% ) on a Phase 1/2 clinical trial evaluating the combination of CAR T therapy Yescarta (axicabtagene ciloleucel) and lenzilumab in patients with relapsed/refractory diffuse large B-cell lym… read more...

Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (Axicabtagene Ciloleucel) with Lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

via: Business Wire at 2019-05-31 04:30:00:000

-- Phase 1/2 Multi-Center Clinical Trial to Begin Enrolling in Q4 2019 -- Kite, a Gilead Company (Nasdaq: GILD), and Humanigen, Inc. (HGEN) announced today the formation of a clinical collaboration to conduct a Phase 1/2 study of lenzilumab, an investigational anti-GM-CSF monoclon… read more...

Recent Stock Purchase May 2019

via: SeekingAlpha at 2019-05-30 16:43:27:000

Looks like I waited for the last few days of May to make my monthly purchase. All good, as I have been busy moving my accounts over to Schwab. Long story short, I now have zero commission trades on Schwab for twenty years. The offer is so good that I am also moving Mrs. DivHut's account too,… read more...

Gilead and Galapagos to Present Latest Data on Filgotinib at the Annual European Congress of Rheumatology (EULAR 2019)

via: Business Wire at 2019-05-29 12:30:00:000

-- Phase 3 FINCH 1 and FINCH 3 Data of Filgotinib in Rheumatoid Arthritis to Be Featured in Opening Plenary and Late Breaker Sessions -- Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that data on filgotinib, an investigational, o… read more...

Gilead and Galapagos to Present Latest Data on Filgotinib at the Annual European Congress of Rheumatology (EULAR 2019)

via: Business Wire at 2019-05-29 12:30:00:000

-- Phase 3 FINCH 1 and FINCH 3 Data of Filgotinib in Rheumatoid Arthritis to Be Featured in Opening Plenary and Late Breaker Sessions -- Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that data on filgotinib, an investigational, o… read more...

New commercial chief at Gilead

via: SeekingAlpha at 2019-05-29 04:44:42:000

Gilead Sciences (NASDAQ: GILD ) appoints Johanna Mercier as Chief Commercial Officer effective July 1 succeeding the departing Laura Hamill. More news on: Gilead Sciences, Inc., Bristol-Myers Squibb Company, Healthcare stocks news, Read more … read more...

New commercial chief at Gilead

via: SeekingAlpha at 2019-05-29 04:44:42:000

Gilead Sciences (NASDAQ: GILD ) appoints Johanna Mercier as Chief Commercial Officer effective July 1 succeeding the departing Laura Hamill. More news on: Gilead Sciences, Inc., Bristol-Myers Squibb Company, Healthcare stocks news, Read more … read more...

Gilead Sciences Appoints Johanna Mercier as Chief Commercial Officer

via: Business Wire at 2019-05-29 04:31:00:000

- Laura Hamill to Depart Gilead - Gilead Sciences, Inc.(NASDAQ: GILD) today announced thatJohanna Mercier will join the company as Chief Commercial Officer, and will become a member of the companys senior leadership team. Ms. Mercier will assume responsibility fo… read more...

Gilead Sciences Appoints Johanna Mercier as Chief Commercial Officer

via: Business Wire at 2019-05-29 04:31:00:000

- Laura Hamill to Depart Gilead - Gilead Sciences, Inc.(NASDAQ: GILD) today announced thatJohanna Mercier will join the company as Chief Commercial Officer, and will become a member of the companys senior leadership team. Ms. Mercier will assume responsibility fo… read more...

Teva launches generic Ranexa in U.S.

via: SeekingAlpha at 2019-05-28 08:53:55:000

Teva Pharmaceutical Industries ( TEVA -12.9% ) commences the U.S. commercial launch of its generic version of Gilead Sciences' ( GILD -3.2% ) angina med Ranexa (ranolazine) Extended-Release Tablets, 500 mg and 1,000 mg. More news on: Teva Pharmaceutical Industries Limited, Gilead S… read more...

The Retiree's Dividend Portfolio - Jane's April Update: Why You Should Consider Canadian Banks

via: SeekingAlpha at 2019-05-24 10:41:52:000

It's hard to top a month like March (my article can be found here ) when it produced a massive amount of dividend income and eight companies paid increased dividends. So when April produced even more dividend income and had an additional seven companies that raised their dividend, I couldn't … read more...

The Retiree's Dividend Portfolio - Jane's April Update: Why You Should Consider Canadian Banks

via: SeekingAlpha at 2019-05-24 10:41:52:000

It's hard to top a month like March (my article can be found here ) when it produced a massive amount of dividend income and eight companies paid increased dividends. So when April produced even more dividend income and had an additional seven companies that raised their dividend, I couldn't … read more...

The Retiree's Dividend Portfolio - Jane's April Update: Why You Should Consider Canadian Banks

via: SeekingAlpha at 2019-05-24 10:41:52:000

It's hard to top a month like March (my article can be found here ) when it produced a massive amount of dividend income and eight companies paid increased dividends. So when April produced even more dividend income and had an additional seven companies that raised their dividend, I couldn't … read more...

The Retiree's Dividend Portfolio - Jane's April Update: Why You Should Consider Canadian Banks

via: SeekingAlpha at 2019-05-24 10:41:52:000

It's hard to top a month like March (my article can be found here ) when it produced a massive amount of dividend income and eight companies paid increased dividends. So when April produced even more dividend income and had an additional seven companies that raised their dividend, I couldn't … read more...

High Short Interest, Strong Performance Stocks: May 2019

via: SeekingAlpha at 2019-05-22 06:18:08:000

Higher short interest is an odd indicator in the market. On one hand, it's a good indicator of sentiment as a high level generally suggests skepticism of the company's outlook, bringing bears to expect eventually lower share prices. It's also a poor indicator because significant levels of shor… read more...

High Short Interest, Strong Performance Stocks: May 2019

via: SeekingAlpha at 2019-05-22 06:18:08:000

Higher short interest is an odd indicator in the market. On one hand, it's a good indicator of sentiment as a high level generally suggests skepticism of the company's outlook, bringing bears to expect eventually lower share prices. It's also a poor indicator because significant levels of shor… read more...

Gilead Sciences to Present at the Jefferies 2019 Global Healthcare Conference on Wednesday, June 5

via: Business Wire at 2019-05-21 12:01:00:000

Webcast Available Through Gilead Corporate Website Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Daniel ODay, Gileads Chairman and Chief Executive Officer, will participate in a fireside chat at the Jefferies 2019 Global Healthcare Conference in New York … read more...

Credit Suisse likes Amgen in premarket analyst action

via: SeekingAlpha at 2019-05-21 04:09:59:000

Amgen (NASDAQ: AMGN ) resumed with Outperform rating and $208 (24% upside) price target at Credit Suisse. More news on: Amgen Inc., Biogen Inc., Gilead Sciences, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Gilead Sciences: Still A Good Pick Despite Risks

via: SeekingAlpha at 2019-05-20 05:54:14:000

Originally, in January 2017, I recommended Gilead Sciences (NASDAQ: GILD ) as my top biotech pick for the next decade. I reaffirmed this approximately 8 months ago , despite the companys relative difficulty throughout the past few years. As we will see throughout this article, the … read more...

Enanta And EDP-305 In NASH: An Update

via: SeekingAlpha at 2019-05-18 09:59:23:000

Market Assessment Enanta ( ENTA ) is a commercial-stage small market cap ($1.8B) biopharma that has established itself as an innovator of effective therapeutics for the viral liver disease, HCV infection, through the approval of paritaprevir and glecaprevir. Its license agreement with Ab… read more...

Enanta And EDP-305 In NASH: An Update

via: SeekingAlpha at 2019-05-18 09:59:23:000

Market Assessment Enanta ( ENTA ) is a commercial-stage small market cap ($1.8B) biopharma that has established itself as an innovator of effective therapeutics for the viral liver disease, HCV infection, through the approval of paritaprevir and glecaprevir. Its license agreement with Ab… read more...

Gilead chief defends hefty Truvada price at government hearing

via: SeekingAlpha at 2019-05-17 07:34:43:000

Endpoints News reports that Gilead Sciences ( GILD +1.6% ) CEO Daniel O'Day spent more than three hours yesterday trying to justify the $2,000/month price of Truvada (emtricitabine and tenofovir disoproxil fumarate) before a U.S. House committee on oversight and reform. The FDA approved … read more...

AbbVie Grabs FDA Approval In HCV, Faces Several Risks

via: SeekingAlpha at 2019-05-16 06:34:16:000

AbbVie ( ABBV ) announced that the FDA had approved its drug Mavyret to treat children and adolescents with Hepatitis C. This FDA approval should do well to help expand the market opportunity for the drug around the globe. The company first received approval for Mavyret back in 2017 for … read more...

Kite to Present New Data From Leading Cell Therapy Portfolio at ASCO 2019

via: Business Wire at 2019-05-15 13:00:00:000

-- New Safety Data Involving Steroid Use and New Subpopulation Analyses from Pivotal ZUMA-1 Trial to Provide Greater Understanding of Yescarta in Patients with Relapsed or Refractory Large B-cell Lymphoma -- -- End of Phase 1 Results from ZUMA-3 Evaluating KTE-X19 in… read more...

Gilead Sciences Is A Good Long-Term Investment Without A Moat

via: SeekingAlpha at 2019-05-15 08:01:34:000

Gilead Sciences (Nasdaq: GILD ) has not been a good investment in the last few years. In 2017, Gilead Sciences hit its lows around $65 for the first time. Since then it was mostly trading sideways and in between it briefly dipped to $60 and briefly even rallied to $90. Most investors probably… read more...

Galectin Therapeutics: Primed For Takeoff After The Rights Offering And New Clinical Evidence

via: SeekingAlpha at 2019-05-15 07:33:00:000

Editor's note: Seeking Alpha is proud to welcome Dan Komaromi as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Introducti… read more...

Gilead Has Levers To Pull

via: SeekingAlpha at 2019-05-14 07:04:16:000

Gilead logo. Source: Forbes Heading into Q1 earnings Gilead ( GILD ) was facing margin pressure and loss of exclusivity ("LOE") for certain products. I assumed Q1 would be painful for the company. Gilead generated revenue of $5.3 billion, which was in-line with expectations. Product sales … read more...

FDA finalizes guidance on interchangeable biosimilars

via: SeekingAlpha at 2019-05-13 03:43:20:000

The FDA has completed its long-anticipated guidance on interchangeability of biosimilars, allowing their substitution for reference biologics without prescribers' sign-off. More news on: AbbVie Inc., ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Healthcare & Wellness Rx Tru… read more...

Gilead to donate Truvada to help prevent HIV

via: SeekingAlpha at 2019-05-10 03:12:21:000

Gilead Sciences (NASDAQ: GILD ) has agreed to provide up to 2.4M bottles of Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets) each year to the U.S. Centers for Disease Control and Prevention (CDC) in support of national efforts to help prevent HIV for uninsure… read more...

Gilead to donate Truvada to help prevent HIV

via: SeekingAlpha at 2019-05-10 03:12:21:000

Gilead Sciences (NASDAQ: GILD ) has agreed to provide up to 2.4M bottles of Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets) each year to the U.S. Centers for Disease Control and Prevention (CDC) in support of national efforts to help prevent HIV for uninsure… read more...

Gilead to donate Truvada to help prevent HIV

via: SeekingAlpha at 2019-05-10 03:12:21:000

Gilead Sciences (NASDAQ: GILD ) has agreed to provide up to 2.4M bottles of Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets) each year to the U.S. Centers for Disease Control and Prevention (CDC) in support of national efforts to help prevent HIV for uninsure… read more...

Gilead Sciences to Provide Free Truvada for PrEP® to Support U.S. Initiative to End the HIV Epidemic

via: Business Wire at 2019-05-09 13:11:00:000

Donation Provides up to 2.4 Million Free Bottles Annually to Uninsured Americans at Risk for HIV Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it will donate Truvada for PrEP (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets… read more...

Gilead Sciences At The Filgotinib And Selonsertib Crossroads

via: SeekingAlpha at 2019-05-09 09:52:53:000

Gilead Sciences ( GILD ) generates most of its revenue from the sales of therapies for HIV and hepatitis C. Revenue and earnings have been declining for years following a peak when it had the first hepatitis C cure on the market. For 3 years, the stock price has also trended lower. It picked u… read more...

Biotech News Recap: Merck Announces Yet Another Successful Readout For A Key Asset

via: SeekingAlpha at 2019-05-08 16:17:46:000

Merck & Co ( MRK ) - The company announced results from the phase 2 study of V114 (15-valent pneumococcal conjugate vaccine) as compared to currently available 13-valent pneumococcal conjugate vaccine in healthy infants 6-12 weeks of age. The primary endpoint was met by demonstrating n… read more...

Gilead's Earnings Might Point To A Potential Turnaround In Coming Year

via: SeekingAlpha at 2019-05-08 14:56:08:000

Gilead Sciences ( GILD ) seemed to have found its stride after reporting its latest earnings for Q1 2019 . That's because it reported a really good quarter. So much so that earnings were 28% higher for the quarter. A big reason earnings came out so well is because of the HIV franchise, whic… read more...

CryoPort: Powerful Industry Tailwind Signals Robust Growth Ahead

via: SeekingAlpha at 2019-05-08 09:04:39:000

The reason why the growth stocks do so much better is that they seem to show gains in value in the hundreds of percent each decade. In contrast, it is an unusual bargain that is as much as 50 percent undervalued. The cumulative effect of this simple arithmetic should be obvious. - The Patri… read more...

Drug makers to face added pricing pressure in Canada under new proposal - Reuters

via: SeekingAlpha at 2019-05-08 06:30:30:000

In lockstep with the U.S., Canadian officials are poised to implement a new initiative aimed at corralling high prescription drug costs, despite an offer by drug makers to pay C$8.6B (US$6.6B) over 10 years, freeze prices or reduce the cost of treating rare diseases. More news on: ProSha… read more...

Drug makers to disclose prices in TV ads as early as this summer

via: SeekingAlpha at 2019-05-08 05:55:42:000

Following through on its commitment to promote lower drug costs, the Trump administration announces that pharmaceutical and biotech companies will be required to disclose prices in television commercials for medications covered by Medicare that cost more than $35 for a month's supply (mean… read more...

Gilead teams up with Goldfinch Bio in kidney diseases

via: SeekingAlpha at 2019-05-08 03:46:54:000

Gilead Sciences (NASDAQ: GILD ) will collaborate with privately-held, Cambridge, MA-based Goldfinch Bio to discover, develop and commercialize treatments for diabetic kidney disease (DKD)and certain orphan kidney disorders. More news on: Gilead Sciences, Inc., Healthcare stocks n… read more...

Gilead Sciences and Goldfinch Bio Announce Strategic Collaboration to Develop Novel Therapies for Kidney Disease

via: Business Wire at 2019-05-08 03:00:00:000

-- Companies to Pursue a Human Genetics Approach to Drug Discovery and Development -- Gilead Sciences, Inc.(Nasdaq: GILD) andGoldfinch Bio, Inc., a biotechnology company focused on developing precision therapies for patients with kidney diseases, today announced a strate… read more...

Road To Financial Independence: 107 Stocks April Update

via: SeekingAlpha at 2019-05-07 04:45:00:000

It's been a rather mediocre month for my income generation in April. Dividend income just barely topped the $200-mark as the overall portfolio rallied to new highs despite some heavy earnings-related blows on my top holdings. Going forward, I will try to better balance my dividend income and s… read more...

AstraZeneca's Calquence successful in late-stage leukemia study

via: SeekingAlpha at 2019-05-07 03:43:23:000

AstraZeneca (NYSE: AZN ) announces positive results from a Phase 3 clinical trial, ASCEND, evaluating Calquence (acalabrutinib) as monotherapy in previously treated patients with chronic lymphocytic leukemia (CLL). More news on: AstraZeneca PLC, Gilead Sciences, Inc., Roche Holding AG, H… read more...

Gilead Sciences to Present at the Bank of America Merrill Lynch 2019 Health Care Conference on Tuesday, May 14

via: Business Wire at 2019-05-06 12:01:00:000

Webcast Available Through Gilead Corporate Website Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Robin L. Washington, Gileads Executive Vice President and Chief Financial Officer, and John McHutchison, AO, MD, Gileads Chief Scientific Officer and Head of … read more...

5%+ Dividend Yield Portfolio: The Number Of Stocks To Own (Apr 2019 Review)

via: SeekingAlpha at 2019-05-05 08:44:46:000

Musings More than any single topic, I get a LOT of comments on my articles about ideal portfolio size (the age old concentration vs. diversification debate). This is especially true of my extensive ETF holdings (about 50% of my total assets) where I own small pieces of … read more...

AbbVie: No Reason To Throw In The Towel

via: SeekingAlpha at 2019-05-03 05:22:07:000

AbbVie's ( ABBV ) stock price development has turned into a nightmare for investors it seems. The stock is down 30% from its 52-week high and even better than expected earnings in combination with raised guidance couldn't lift the stock price. No matter how good AbbVie's business is performi… read more...

AbbVie: No Reason To Throw In The Towel

via: SeekingAlpha at 2019-05-03 05:22:07:000

AbbVie's ( ABBV ) stock price development has turned into a nightmare for investors it seems. The stock is down 30% from its 52-week high and even better than expected earnings in combination with raised guidance couldn't lift the stock price. No matter how good AbbVie's business is performi… read more...

Gilead advancing U.S. application for Kite cell therapy for mantle cell lymphoma

via: SeekingAlpha at 2019-05-03 05:06:16:000

In yesterday's Q1 earnings call , Gilead Sciences (NASDAQ: GILD ) Chief Scientific Officer and R&D Head John Hutchison stated that the company plans to announce topline results from its pivotal Phase 2 clinical trial, ZUMA-2 , evaluating CAR-T candidate KTE-X19 in patients with relapse… read more...

Gilead advancing U.S. application for Kite cell therapy for mantle cell lymphoma

via: SeekingAlpha at 2019-05-03 05:06:16:000

In yesterday's Q1 earnings call , Gilead Sciences (NASDAQ: GILD ) Chief Scientific Officer and R&D Head John Hutchison stated that the company plans to announce topline results from its pivotal Phase 2 clinical trial, ZUMA-2 , evaluating CAR-T candidate KTE-X19 in patients with relapse… read more...

O'Day: The Man Of The Hour For Gilead

via: SeekingAlpha at 2019-05-03 04:04:35:000

Background - can GILD go from despised to loved? The easiest way to learn if a drug stock is disliked is its relative P/E. Gilead ( GILD ) is certainly at a discount to the S&P 500 ( SPY ), for which S&P projects roughly $150 GAAP EPS for 2019. At Thursday's close of $291, that puts … read more...

O'Day: The Man Of The Hour For Gilead

via: SeekingAlpha at 2019-05-03 04:04:35:000

Background - can GILD go from despised to loved? The easiest way to learn if a drug stock is disliked is its relative P/E. Gilead ( GILD ) is certainly at a discount to the S&P 500 ( SPY ), for which S&P projects roughly $150 GAAP EPS for 2019. At Thursday's close of $291, that puts … read more...

It's Jobs Day (Wall Street Breakfast Podcast)

via: SeekingAlpha at 2019-05-03 03:10:55:000

Today's Top Stories: Its jobs day; Fedspeak coming up; and IPO watch. If you are interested in listening to Wall Street Breakfast to start your day, look for us in the following places: iTunes (find all Seeking Alpha Podcasts here ) Stitcher SoundCloud Googl… read more...

It's Jobs Day (Wall Street Breakfast Podcast)

via: SeekingAlpha at 2019-05-03 03:10:55:000

Today's Top Stories: Its jobs day; Fedspeak coming up; and IPO watch. If you are interested in listening to Wall Street Breakfast to start your day, look for us in the following places: iTunes (find all Seeking Alpha Podcasts here ) Stitcher SoundCloud Googl… read more...

Wall Street Breakfast: It's Jobs Day

via: SeekingAlpha at 2019-05-03 02:42:21:000

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify (click the highlighted links). Dow futures are up 75 points , with S&P 500 and Nasdaq futures ahead by 0.3% and 0.5% , respectiv… read more...

Wall Street Breakfast: It's Jobs Day

via: SeekingAlpha at 2019-05-03 02:42:21:000

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify (click the highlighted links). Dow futures are up 75 points , with S&P 500 and Nasdaq futures ahead by 0.3% and 0.5% , respectiv… read more...

Gilead Sciences, Inc. (GILD) CEO Daniel O'Day on Q1 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-05-02 18:09:07:000

Gilead Sciences, Inc. (GILD) Q1 2019 Earnings Conference Call May 02, 2019 4:30 PM ET Company Participants Sung Lee - Vice President of Investor Relations Daniel O'Day - Chairman & Chief Executive Officer Robin Washington - Executive Vice President & Chief Financial Offic… read more...

Gilead Sciences, Inc. (GILD) CEO Daniel O'Day on Q1 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-05-02 18:09:07:000

Gilead Sciences, Inc. (GILD) Q1 2019 Earnings Conference Call May 02, 2019 4:30 PM ET Company Participants Sung Lee - Vice President of Investor Relations Daniel O'Day - Chairman & Chief Executive Officer Robin Washington - Executive Vice President & Chief Financial Offic… read more...

Gilead turning the corner, Q1 earnings up 28%

via: SeekingAlpha at 2019-05-02 12:14:41:000

Gilead Sciences (NASDAQ: GILD ) Q1 results ($M): Revenues: 5,281 (+3.8%); product: 5,200 (+4.0%). More news on: Gilead Sciences, Inc., Healthcare stocks news, Earnings news and commentary, Read more … read more...

Gilead Sciences beats by $0.16, revenue in-line

via: SeekingAlpha at 2019-05-02 12:02:55:000

Gilead Sciences (NASDAQ: GILD ): Q1 Non-GAAP EPS of $1.76 beats by $0.16 ; GAAP EPS of $1.54. Revenue of $5.28B (+3.5% Y/Y) in-line. Press Release More news on: Gilead Sciences, Inc., Earnings news and commentary, Healthcare stocks news, read more...

Gilead Sciences Announces Second Quarter 2019 Dividend

via: Business Wire at 2019-05-02 12:02:00:000

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the companys Board of Directors has declared a cash dividend of $0.63 per share of common stock for the second quarter of 2019. The dividend is payable on June 27, 2019, to stockholders of record at the close of business on Ju… read more...

Gilead Sciences Announces First Quarter 2019 Financial Results

via: Business Wire at 2019-05-02 12:01:00:000

- Product Sales of $5.2 billion - - Diluted EPS of $1.54 per share - - Non-GAAP Diluted EPS of $1.76 per share - - Reiterates Full Year 2019 Guidance - Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter ended March 31,… read more...

IPO Update: Axcella Health Readies Plan For $75 Million IPO

via: SeekingAlpha at 2019-05-02 10:45:11:000

Quick Take Axcella Health ( AXLA ) intends to raise $75 million from the sale of its common stock in a U.S. IPO, per an amended registration statement . The company is advancing a pipeline of treatment candidates primarily for liver disease conditions. Given the uncertainties with the f… read more...

May 2019 Stock Considerations

via: SeekingAlpha at 2019-05-01 23:49:30:000

New month… new stock considerations? Well, I guess if you call picking the same stocks for the last four or five months as new then, yes... these are my "new" stock considerations. Ever since going the DGI route, I don't recall considering the same four or five stocks for several months in a... read more...

Notable earnings after Thursday's close

via: SeekingAlpha at 2019-05-01 13:35:38:000

ACA , ACIA , AIV , ALEX , AMH , AMKR , AMN , ANET , ANIK , APPF , APPN , ARCB , ATGE , ATUS , ATVI , BAND , BGS , BKH , BL , BLDR , BRKR , BZH , CARB , CATM , CBLK , CBS , CC , CPSI , CPT , CRC , CSLT , CTSH , CUB , CYRX , DATA , DEI , EBS , ECOL , ED … read more...

Gilead Sciences Q1 2019 Earnings Preview

via: SeekingAlpha at 2019-05-01 13:35:04:000

Gilead Sciences (NASDAQ: GILD ) is scheduled to announce Q1 earnings results on Thursday, May 2nd, after market close. The consensus EPS Estimate is $1.60 (+8.1% Y/Y) and the consensus Revenue Estimate is $5.29B (+3.7% Y/Y). Over the last 2 years, gild has beaten EPS estimates 63% of… read more...

DGI For The DIY: Q1 2019 Dividend Portfolio Update

via: SeekingAlpha at 2019-05-01 12:04:08:000

Project Background The DGI For The DIY portfolio was created in 2013 when I liquidated the mutual funds in my IRA and used the proceeds to create a new portfolio of dividend growth stocks. I've been writing quarterly updates on the portfolio ever since, documenting the its progress and my … read more...

The Retiree's Dividend Portfolio - Jane's March Update - Dividend Increases Galore

via: SeekingAlpha at 2019-05-01 08:46:11:000

This article was longer than expected but the reason why is because so many companies paid increased dividends during the month of March (I think we can all agree that this is a great reason for an article to be longer than normal). We continue to see mixed reports with a number of companies… read more...

Gilead Sciences' Chief Financial Officer Robin Washington to Step Down in Early 2020

via: Business Wire at 2019-04-30 12:27:00:000

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Robin Washington, Executive Vice President (EVP) and Chief Financial Officer (CFO), plans to retire from her role, effective March 1, 2020. Ms. Washington will continue as EVP and CFO while the company works to identify a succes… read more...

AbbVie: Value Trap? Maybe, But Here's Why It Can Revive

via: SeekingAlpha at 2019-04-30 00:33:11:000

Introduction It's not the best portent when AbbVie ( ABBV ) beats and raises , yet still gets a muted response as happened last week. With the 10-Q not out yet, and "risa" - now Skyrizi - on the market, that led me to read through the 10-K and read the Q1 conference call which I had lis… read more...

Market At New Highs, But Healthcare And Biotechs Feel The Heat

via: SeekingAlpha at 2019-04-29 09:22:32:000

Source: Shutterstock The stock market has continued to edge higher and the two major indexes, the Nasdaq ( QQQ ) and S&P 500 ( SPY ), touched the all-time high milestone last week. The steady gain reflects a diminishing concern relating to the pace of a global economic slowdown, as m… read more...

The U.S. Week Ahead (Apr 29-May 3), Financial Market Frenzy: Fed, Jobs, Earnings

via: SeekingAlpha at 2019-04-29 01:05:42:000

Investors in the week ahead will be bracing for a busy calendar, including the Federal Reserves interest rate decision, an update on the U.S. employment situation, as well as a raft of corporate earnings. Frenzied activity is set to envelop the financial markets straight out of the g… read more...

2 Quality Dividend Stocks Trading Near 52-Week Lows

via: SeekingAlpha at 2019-04-28 19:51:04:000

I remember watchlisting both Bristol-Myers Squibb ( BMY ) and Gilead ( GILD ) after seeing both of them listed in the Top 50 list for gross profit per employee by Craft : (Source: Craft.co ) Both of these stocks recently lit up for me as they are near their 52-week lows. I like bot… read more...

Eyes On Apple, Uber, F8 And Avengers (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-04-28 04:00:29:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c… read more...

Stocks To Watch: Eyes On Apple, Uber, F8 And Avengers

via: SeekingAlpha at 2019-04-27 05:12:19:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The U.S. will send a high-level delegation to Beijing next week as trade negotiatio… read more...

Biotech News Recap: Gilead Sciences' STELLAR Data Falls Short

via: SeekingAlpha at 2019-04-26 09:01:07:000

Gilead Sciences ( GILD ) - The company announced that a phase 3 NASH study for key asset selonsertib failed to meet its primary endpoint. Dubbed STELLAR-3, the trial was investigating the oral inhibitor of ASK1 in patients with bridging fibrosis (F3) due to nonalcoholic steatohepatitis. Th… read more...

European advisory group back's Mylan's generic version of Glaxo's Volibris

via: SeekingAlpha at 2019-04-26 08:04:32:000

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval for Mylan's ( MYL +0.4% ) ambrisentan, a generic version of GlaxoSmithKline's ( GSK +0.3% ) pulmonary arterial hypertension med Volibris . More news on: Mylan N.V., Gilead Scienc… read more...

Bernstein likes Gilead in premarket analyst action

via: SeekingAlpha at 2019-04-26 04:53:24:000

Aurora Cannabis (NYSE: ACB ) initiated with Buy rating and C$16.50 (35% upside) price target at Desjardins. Shares up 1% premarket on the heels of its license deal with EnWave. More news on: Aurora Cannabis Inc., Gilead Sciences, Inc., Tocagen Inc., Healthcare stocks news, Stoc… read more...

Sector Study: Healthcare Vs. Technology Dividend Dogs, Which To Buy?

via: SeekingAlpha at 2019-04-25 23:04:18:000

Actionable Conclusions (1-5): Brokers Predicted 26.35% To 53.85% Net Gains From Top Five Healthcare Sector Dogs By April 2020 One of five top dividend-yielding Healthcare dogs was verified as being among the top ten gainers for the coming year based on analyst 1-year target prices. (… read more...

Gilead's selonsertib flunks another NASH study; shares down 1% premarket

via: SeekingAlpha at 2019-04-25 04:14:57:000

Gilead Sciences (NASDAQ: GILD ) slips 1% premarket on light volume on the heels of its announcement that a Phase 3 clinical trial, STELLAR-3 , evaluating selonsertib in patients with bridging fibrosis due to nonalcoholic steatohepatitis (NASH) failed to achieve the primary end… read more...

Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH)

via: Business Wire at 2019-04-25 04:00:00:000

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that STELLAR-3, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once daily, oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1), for patients wi… read more...

5 Stocks To Own As Healthcare Bottoms

via: SeekingAlpha at 2019-04-24 14:21:05:000

Image Source As risk-on returns to markets, we've seen the healthcare sector underperform significantly in recent months. While sectors like technology, communication, discretionary and others surge to new all-time highs, healthcare lags noticeably. However, many healthcare names have … read more...

Gilead Sciences Isn't Satisfied With Only A Few NASH Deals, Presses On With More

via: SeekingAlpha at 2019-04-24 11:57:09:000

Gilead Sciences ( GILD ) announced a new NASH deal with another company by the name of insitro. This new deal is a good one for Gilead, because it didn't have to give up a lot of cash to get the deal going. This deal generated is one of many for the company, which is trying to create a lar… read more...

Kite Announces Plans for New State-of-the-Art Facility to Expand Cell Therapy Production Capabilities

via: Business Wire at 2019-04-24 04:30:00:000

Kite, a Gilead Company (Nasdaq: GILD), today announced plans for a new facility in Frederick County, Maryland, which will produce innovative cell therapies for people with cancer. The 20-acre site will significantly expand Kites ability to manufacture a variety of chimeric antigen re… read more...

Milestone Pharmaceuticals: At Phase 3 Of Development

via: SeekingAlpha at 2019-04-23 14:52:07:000

It is very likely that institutional investors will review the new IPO of Milestone Pharmaceuticals ( MIST ) closely. Besides, the company does not only have one product candidate at Phase 3 of development, it also raised more than $139 million through the sale of equity. Investors should reme… read more...

Re-engineered CAR-T eliminates dangerous side effect in lymphoma study

via: SeekingAlpha at 2019-04-22 10:10:09:000

A study conducted by University of Southern California researchers evaluating a redesigned CAR-T therapy with a significantly improved safety profile showed impressive results. More news on: Novartis AG, Gilead Sciences, Inc., Healthcare stocks news, Read more … read more...

Re-engineered CAR-T eliminates dangerous side effect in lymphoma study

via: SeekingAlpha at 2019-04-22 10:10:09:000

A study conducted by University of Southern California researchers evaluating a redesigned CAR-T therapy with a significantly improved safety profile showed impressive results. More news on: Novartis AG, Gilead Sciences, Inc., Healthcare stocks news, Read more … read more...

Quarterly Review Of DivGro: Q1-2019

via: SeekingAlpha at 2019-04-21 05:52:08:000

Welcome to another quarterly review of DivGro, my portfolio of dividend growth stocks. My quarterly reviews provide a summary of dividend income, dividend changes, and transactions executed in the past quarter. I also provide some charts showing various portfolio statistics. While these re… read more...

Gilead Sciences to Release First Quarter 2019 Financial Results on Thursday, May 2, 2019

via: Business Wire at 2019-04-18 12:05:00:000

-- Conference Call and Webcast to Follow -- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2019 financial results will be released on Thursday, May 2, after the market closes. At 4:30 p.m. Eastern Time, Gileads management will host a conference c… read more...

Gilead Sciences to Release First Quarter 2019 Financial Results on Thursday, May 2, 2019

via: Business Wire at 2019-04-18 12:05:00:000

-- Conference Call and Webcast to Follow -- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2019 financial results will be released on Thursday, May 2, after the market closes. At 4:30 p.m. Eastern Time, Gileads management will host a conference c… read more...

Gilead Sciences to Release First Quarter 2019 Financial Results on Thursday, May 2, 2019

via: Business Wire at 2019-04-18 12:05:00:000

-- Conference Call and Webcast to Follow -- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2019 financial results will be released on Thursday, May 2, after the market closes. At 4:30 p.m. Eastern Time, Gileads management will host a conference c… read more...

Is Healthcare Berning?

via: SeekingAlpha at 2019-04-18 04:04:18:000

Yes, it shrinks As you know, healthcare stocks and ETFs, such as the Health Care Select SPDR ETF ( XLV ), have gotten slammed following additional publicity given just a few days ago to Senator Bernie Sanders and his "Medicare for all" ((MFA)) program. Before the political season began this … read more...

Is Healthcare Berning?

via: SeekingAlpha at 2019-04-18 04:04:18:000

Yes, it shrinks As you know, healthcare stocks and ETFs, such as the Health Care Select SPDR ETF ( XLV ), have gotten slammed following additional publicity given just a few days ago to Senator Bernie Sanders and his "Medicare for all" ((MFA)) program. Before the political season began this … read more...

Is Healthcare Berning?

via: SeekingAlpha at 2019-04-18 04:04:18:000

Yes, it shrinks As you know, healthcare stocks and ETFs, such as the Health Care Select SPDR ETF ( XLV ), have gotten slammed following additional publicity given just a few days ago to Senator Bernie Sanders and his "Medicare for all" ((MFA)) program. Before the political season began this … read more...

Gilead Sciences Wants To Reignite Its NASH Portfolio With 2 Advancements

via: SeekingAlpha at 2019-04-17 15:00:30:000

Gilead Sciences ( GILD ) announced two key news items recently. It started off with positive proof of concept NASH results with a double combination treatment, which was presented at the International Liver Congress 2019. Then a few days later, it announced a partnership with Novo Nordisk ( NV… read more...

Axcella Health Files For U.S. IPO

via: SeekingAlpha at 2019-04-17 12:49:21:000

Quick Take Axcella Health ( AXLA ) has filed to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing therapeutics for the treatment of metabolism-related conditions of the liver, muscles, and blood. AXLA is not curre… read more...

Merck's Keytruda + Galectin's Belapectin (GR-MD-02): Thoughts On The Evidence

via: SeekingAlpha at 2019-04-17 11:08:15:000

Preface In September 2018, I contributed to Vision and Value's blog article GR-MD-02: Keytruda's Partner . A long read, but a very good source of essential research if I do say so myself More articles have come out since by both Vision and Value and First Genesis Consulting , whi… read more...

Sell-off intensifies as drug makers face pricing headwinds from Washington

via: SeekingAlpha at 2019-04-17 08:59:25:000

Investors in biotechs and biopharma firms appear to have intensified their profit-taking after the Q1 run-up, stoked, no doubt, from the sour mood in Congress over high drug prices and the Trump administration's stated priority to tackle the problem. More news on: SPDR Biotech ETF, SPDR S&… read more...

Gilead And The Pain Ahead

via: SeekingAlpha at 2019-04-16 09:00:00:000

Gilead logo. Source: Forbes I have been bearish on Gilead Sciences ( GILD ) for a few years now. Even the staunchest GILD supporters may become alarmed at its recent news. The company announced it would lay off about 20% of its sales force as financial pressures weigh: Gilead wil… read more...

Gilead teams up with insitro in NASH; shares up 1% premarket

via: SeekingAlpha at 2019-04-16 03:22:43:000

Gilead Sciences (NASDAQ: GILD ) is up 1% premarket on light volume in reaction to its three-year collaboration with privately held insitro to discover and development treatments for nonalcoholic steatohepatitis (NASH). More news on: Gilead Sciences, Inc., Healthca… read more...

Gilead and insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for Nonalcoholic Steatohepatitis

via: Business Wire at 2019-04-16 03:00:00:000

Gilead Sciences Inc. (Nasdaq: GILD) and insitro announced today that the companies have entered into a strategic collaboration to discover and develop therapies for patients with nonalcoholic steatohepatitis (NASH). This press release features multimedia. View the full release here: htt… read more...

Gilead Sciences and Novo Nordisk Announce Intent to Initiate a Clinical Collaboration in NASH

via: Business Wire at 2019-04-12 00:00:00:000

Gilead Sciences, Inc. (NASDAQ: GILD) and Novo Nordisk A/S (NASDAQ Copenhagen: NOVO B) today announced that the companies intend to collaborate on a clinical trial combining compounds from their respective pipelines in nonalcoholic steatohepatitis (NASH). The intended clinical trial will be a… read more...

Gilead Sciences and Novo Nordisk Announce Intent to Initiate a Clinical Collaboration in NASH

via: Business Wire at 2019-04-12 00:00:00:000

Gilead Sciences, Inc. (NASDAQ: GILD) and Novo Nordisk A/S (NASDAQ Copenhagen: NOVO B) today announced that the companies intend to collaborate on a clinical trial combining compounds from their respective pipelines in nonalcoholic steatohepatitis (NASH). The intended clinical trial will be a… read more...

Gilead Sciences and Novo Nordisk Announce Intent to Initiate a Clinical Collaboration in NASH

via: Business Wire at 2019-04-12 00:00:00:000

Gilead Sciences, Inc. (NASDAQ: GILD) and Novo Nordisk A/S (NASDAQ Copenhagen: NOVO B) today announced that the companies intend to collaborate on a clinical trial combining compounds from their respective pipelines in nonalcoholic steatohepatitis (NASH). The intended clinical trial will be a… read more...

Gilead Sciences and Novo Nordisk Announce Intent to Initiate a Clinical Collaboration in NASH

via: Business Wire at 2019-04-12 00:00:00:000

Gilead Sciences, Inc. (NASDAQ: GILD) and Novo Nordisk A/S (NASDAQ Copenhagen: NOVO B) today announced that the companies intend to collaborate on a clinical trial combining compounds from their respective pipelines in nonalcoholic steatohepatitis (NASH). The intended clinical trial will be a… read more...

Gilead Sciences: Hitting Bottom

via: SeekingAlpha at 2019-04-11 11:48:13:000

The last few years have been brutal for shareholders of Gilead Sciences ( GILD ). The biotech actually started healing Hep C patients causing a plunge in revenues from a key drug. The company has now shifted to a HIV growth machine and when combined with a reduced dependence on HCV drugs mak… read more...

NASH players in the red as EASL announcements fail to excite investors

via: SeekingAlpha at 2019-04-11 08:58:25:000

Most developers of therapies to treat nonalcoholic steatohepatitis (NASH) are under modest pressure as investors remain unimpressed with the initial announcements from The International Liver Congress in Vienna. More news on: Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Enanta P… read more...

Gilead Presents New Data on Viral Hepatitis at the International Liver Congress(TM) 2019

via: Business Wire at 2019-04-11 05:18:00:000

Data Demonstrate Role of Gilead HCV Medicines in Difficultto-Treat Patient Populations and in Real-World Settings Latest HBV Data Reinforce Role of Treatment with Vemlidy and Demonstrate Progress in Cure Research Gilead Sciences, In… read more...

Gilead's GS-9674/GS-0976 shows positive action in POC NASH study

via: SeekingAlpha at 2019-04-11 03:08:04:000

Results from a proof-of-concept (POC)study assessing Gilead Sciences' (NASDAQ: GILD ) farnesoid X receptor agonist cilofexor (GS-9764) and acetyl-CoA carboxylase inhibitor firsocostat (GS-0976) in 20 NASH patients showed a positive effect. The data are being presented at The Interna… read more...

Gilead Presents New Data in Nonalcoholic Steatohepatitis (NASH) at the International Liver Congress(TM) 2019

via: Business Wire at 2019-04-10 22:00:00:000

-- New Proof-of-Concept Data for Combination of Investigational FXR Agonist Cilofexor and ACC Inhibitor Firsocostat in NASH -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from the companys clinical research program in nonalcoholic steatohepatitis (NASH) bei… read more...

UBS likes Gilead in premarket analyst action

via: SeekingAlpha at 2019-04-10 04:01:46:000

Alexion Pharmaceuticals (NASDAQ: ALXN ) resumed with Outperform rating and $161 (17% upside) price target at Raymond James. More news on: Alexion Pharmaceuticals, Inc., Biogen Inc., Cerner Corporation, Healthcare stocks news, Stocks on the move, , Read more … read more...

Gilead Announces New Grant Programs Supporting Investigator-Sponsored Research in Liver Diseases

via: Business Wire at 2019-04-09 08:00:00:000

Funding will Support Research to Advance Scientific Understanding and Improve Patient Care in Viral Hepatitis, Co-Infection, Nonalcoholic Steatohepatitis and Primary Sclerosing Cholangitis Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of five new … read more...

Dividend Income Update March 2019

via: SeekingAlpha at 2019-04-09 04:10:08:000

The start of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. March was exciting, as ever as my year-over-year numbers continue to highlight the trifecta magic of dividend investin… read more...

Don't Be A Worrywart (My Little Conglomerate Q1 2019 Update)

via: SeekingAlpha at 2019-04-08 09:12:52:000

As the S&P 500 index ( SPY ) approaches spitting distance of all-time-high, the street has no shortage of pundits trying to call an inflection point. In fact, the whole 330% run-up from the 2008 low has probably been one of the most hated rallies in memory. Euphoria is absent despite the… read more...

Road To Financial Independence: New Dividend Record In March

via: SeekingAlpha at 2019-04-08 01:25:16:000

We all love records, and March was a record month, as for the very first time I was able to hit $400 in dividend income, the next milestone reached on my long journey towards financial independence. Markets were rallying strongly in March and posting one of their best performances ever since… read more...

Divorce: The Forced Portfolio Colonoscopy And The Lessons I Learned

via: SeekingAlpha at 2019-04-07 06:46:23:000

In this article, I would like to share with you some lessons that I have learned about my portfolio as a byproduct of my recent divorce. First off, divorce truly is an emotional, physical and financial earthquake. It shakes who you are as a person, and it provides forced reflection of your p… read more...

Genfit And The National Education Program: The Race To Inform On NASH

via: SeekingAlpha at 2019-04-05 15:24:02:000

Authors note: I am grateful to Dr. Pascaline Clerc, U.S Campaign Manager, The National Education Program. Introduction 2019, designated as the year of NASH in the biotech industry, was the year to demonstrate the clinical achievements in NASH therapeutics. In the beginning of… read more...

Genfit And The National Education Program: The Race To Inform On NASH

via: SeekingAlpha at 2019-04-05 15:24:02:000

Authors note: I am grateful to Dr. Pascaline Clerc, U.S Campaign Manager, The National Education Program. Introduction 2019, designated as the year of NASH in the biotech industry, was the year to demonstrate the clinical achievements in NASH therapeutics. In the beginning of… read more...

Gilead files U.S. application HIV prevention claim for Descovy

via: SeekingAlpha at 2019-04-05 04:47:07:000

Gilead Sciences (NASDAQ: GILD ) submits a supplemental marketing application to the FDA seeking approval for Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection among individuals … read more...

Gilead files U.S. application HIV prevention claim for Descovy

via: SeekingAlpha at 2019-04-05 04:47:07:000

Gilead Sciences (NASDAQ: GILD ) submits a supplemental marketing application to the FDA seeking approval for Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection among individuals … read more...

Gilead Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Once-Daily Descovy® for HIV Pre-Exposure Prophylaxis

via: Business Wire at 2019-04-05 04:30:00:000

- Filing Supported by Data Demonstrating Non-inferiority Compared to Truvada Coupled with Bone and Renal Safety Advantages in People at Risk of Sexually Acquired HIV Infection - Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the company has submitted a suppl… read more...

Gilead Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Once-Daily Descovy® for HIV Pre-Exposure Prophylaxis

via: Business Wire at 2019-04-05 04:30:00:000

- Filing Supported by Data Demonstrating Non-inferiority Compared to Truvada Coupled with Bone and Renal Safety Advantages in People at Risk of Sexually Acquired HIV Infection - Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the company has submitted a suppl… read more...

Key events next week - healthcare

via: SeekingAlpha at 2019-04-05 03:00:52:000

Noteworthy events during the week of April 7 - 13 for healthcare investors. More news on: Cigna Corporation, CVS Health Corporation, Humana Inc., Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2019-04-05 03:00:52:000

Noteworthy events during the week of April 7 - 13 for healthcare investors. More news on: Cigna Corporation, CVS Health Corporation, Humana Inc., Healthcare stocks news, , Read more … read more...

Gilead Has A Shot To Regain Investor Confidence With Inflammatory Disorder Drug Filgotinib

via: SeekingAlpha at 2019-04-02 17:10:31:000

Gilead Sciences ( GILD ) and its partner Galapagos ( GLPG ) have done well to obtain positive results from a late-stage study in patients with rheumatoid arthritis ((RA)) using their drug filgotinib. This is good news for Gilead, which really needed a major win after the Gilead NASH tr… read more...

Gilead Has A Shot To Regain Investor Confidence With Inflammatory Disorder Drug Filgotinib

via: SeekingAlpha at 2019-04-02 17:10:31:000

Gilead Sciences ( GILD ) and its partner Galapagos ( GLPG ) have done well to obtain positive results from a late-stage study in patients with rheumatoid arthritis ((RA)) using their drug filgotinib. This is good news for Gilead, which really needed a major win after the Gilead NASH tr… read more...

5%+ Dividend Yield Portfolio: Improvements Years In The Making (Mar 2019 Review)

via: SeekingAlpha at 2019-04-02 08:05:47:000

Milestone This is my 50 th article for Seeking Alpha (my first submission was in July of 2015). What a ride it has been as I went from an unwieldy portfolio of 81 (!) different positions spread across 8 (!!) different strategies with sucker yields galore to my current portfolio with a l… read more...

Total USD Portfolio Review - March And Q1 2019

via: SeekingAlpha at 2019-04-02 05:04:14:000

Overview The US stock market ( SPY ) ( DIA ) just booked the best starting quarter in decades . The gross total return (assuming dividend reinvested) for the S&P 500 during Q1 was 13.6% after a 1.9% gain in March. Meanwhile, my total USD portfolio generated an almost 15% return on a… read more...

Dividend Champions For April 2019

via: SeekingAlpha at 2019-03-31 20:36:32:000

About the Dividend Champions List The Dividend Champions list is a monthly publication tracking companies with a history of consistently increasing their dividends. Wider in scope than the well-known S&P 500 Dividend Aristocrats and Nasdaq Dividend Achievers , the Dividend Champions… read more...

How To Retire: Don't Go To College

via: SeekingAlpha at 2019-03-30 04:43:19:000

Think youve got the perfect retirement plan? Think again. Weve found many new retirees end up modifying their plan after they retire. No plan is perfect, so investors need to remain open to considering alternatives. Were going to cover: The reality of drawing Social… read more...

How To Retire: Don't Go To College

via: SeekingAlpha at 2019-03-30 04:43:19:000

Think youve got the perfect retirement plan? Think again. Weve found many new retirees end up modifying their plan after they retire. No plan is perfect, so investors need to remain open to considering alternatives. Were going to cover: The reality of drawing Social… read more...

IMF March Buys: The 18 Stocks Added To My Fund

via: SeekingAlpha at 2019-03-29 10:05:14:000

Ian's Million Fund "IMF" is a real-money portfolio that I've written about monthly since January 2016 here at Seeking Alpha. The portfolio is a largely buy-and-hold group of ~120 stocks. Each month, I buy 10-25 of the most compelling stocks available at then-current prices, deploying $1,000 o… read more...

Filgotinib worth as much as $6/share to Gilead - Leerink

via: SeekingAlpha at 2019-03-29 03:55:28:000

Leerink's Geoffrey Porges likes the upside of arthritis med filgotinib for Gilead Sciences (NASDAQ: GILD ), projecting a $5 - 6/share potential bump in value. He says the JAK1 inhibitor has an 80% (unclear how he arrived at this specific figure) chance of reaching $3.7B in peak sales (how fa… read more...

Gilead and Galapagos up premarket on positive filgotinib data

via: SeekingAlpha at 2019-03-29 03:17:27:000

Galapagos NV (NASDAQ: GLPG ) and collaboration partner Gilead Sciences (NASDAQ: GILD ) are up 14% and 2% , respectively, premarket on light volume on the heels of successful results from a Phase 3 clinical trial, FINCH 3 , evaluating JAK1 inhibitor filgotinib in adults w… read more...

Gilead and Galapagos Announce Filgotinib Meets Primary Endpoint in the Phase 3 FINCH 3 Study in Methotrexate-Naïve Rheumatoid Arthritis Patients

via: Business Wire at 2019-03-28 13:04:00:000

-- Filgotinib 100 mg and 200 mg Plus Methotrexate (MTX) Demonstrated Significantly Higher ACR20/50/70 Responses Than Methotrexate Alone -- -- Filgotinib Safety Profile Consistent With Previously Reported Results -- regulated information Gilead Sciences, Inc.(… read more...

Gilead and Galapagos Announce Filgotinib Meets Primary and Key Secondary Endpoints in the Phase 3 FINCH 1 Rheumatoid Arthritis Study

via: Business Wire at 2019-03-28 13:03:00:000

-- Filgotinib 100 mg and 200 mg Doses Demonstrated Significantly Higher ACR20/50/70 Responses than Placebo in Patients with Prior Inadequate Methotrexate Response -- -- Significant Inhibition of Radiographic Progression Demonstrated with Both Doses of Filgotinib versus Placebo -- … read more...

Gilead and Galapagos Report Updated Safety Information for Filgotinib in Rheumatoid Arthritis (RA)

via: Business Wire at 2019-03-28 13:02:00:000

-- Pooled Interim Phase 3 FINCH Program Data up to 24 Weeks and Phase 2b DARWIN 3 Long-Term Data Add to Evidence Supporting Filgotinib Safety Profile -- regulated information Gilead Sciences, Inc.(NASDAQ: GILD) andGalapagos NV(Euronext & NASDAQ: GLPG… read more...

Gilead Launches HepConnect Initiative to Reduce Hepatitis C Infections in Greater Appalachia

via: Business Wire at 2019-03-28 01:00:00:000

-- Funding will Expand Testing, Harm Reduction Services and Healthcare Infrastructure in States with Highest Infection Rates -- -- Harm Reduction Coalition Selected as Lead Grantee to Oversee 5-year Effort to Implement Proven Harm Reduction Strategies in Indiana, Kentucky, North Car… read more...

Using Ratios To Identify Stocks Set To Outperform Their Peers: Pharmaceutical Rankings Update

via: SeekingAlpha at 2019-03-27 09:44:38:000

Intro As I begin to collect a 3rd year of data for companies in my analyses, I'm overcome with excitement. Having 3 years of data not only allows me to start analyzing multi-year trends, but gives me a larger amount of data in general, which will help establishing validity for any conclusion… read more...

Gilead to Present New Data From Multiple Liver Disease Research and Development Programs at The International Liver Congress(TM) 2019

via: Business Wire at 2019-03-27 02:06:00:000

-- More Than 35 Abstracts Across NASH, PSC and Viral Hepatitis Reflect Ongoing Commitment to Advancing Liver Disease Research and Patient Care -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that data from the companys research and development programs in nonalcoholi… read more...

Japan's Ministry of Health, Labour and Welfare Approves Gilead's Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection

via: Business Wire at 2019-03-26 04:30:00:000

In Clinical Trials, Biktarvy Demonstrated High Efficacy, Few Interactions with Other Drugs and a High Barrier to Resistance Through 48 Weeks Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Japans Ministry of Health, Labour and Welfare (MHLW) has ap… read more...

What Will Provide Gilead The Growth Needed For Multiple Expansion?

via: SeekingAlpha at 2019-03-25 03:28:29:000

The key debate for Gilead ( GILD ) is on what will drive growth that will get the stock trading like a growth stock again, and not like a mature biotech stock. There are two key issues that institutional investors are discussing that would help move the stock in the near-term: 1) the durabilit… read more...

Hookipa Pharma on deck for IPO

via: SeekingAlpha at 2019-03-23 08:26:42:000

Hookipa Pharma ( HOOK ) has filed a prospectus for an $86M IPO. More news on: Gilead Sciences, Inc., HOOKIPA Pharma Inc., Healthcare stocks news, IPO News, Read more … read more...

Hookipa Pharma on deck for IPO

via: SeekingAlpha at 2019-03-23 08:26:42:000

Hookipa Pharma ( HOOK ) has filed a prospectus for an $86M IPO. More news on: Gilead Sciences, Inc., HOOKIPA Pharma Inc., Healthcare stocks news, IPO News, Read more … read more...

Conatus flop fails to move NASH players

via: SeekingAlpha at 2019-03-22 06:31:28:000

The broad market's down move notwithstanding, most companies working on NASH therapies have moved in lockstep with market following Conatus Pharmaceuticals' ( CNAT -56% ) failed Phase 3 study of emricasan. Many times investors perceive that one company's pain is another's gain. More ne… read more...

Some Thoughts On Biogen's Drop

via: SeekingAlpha at 2019-03-21 09:08:38:000

Thinking about pipelines One of the ongoing lessons I take from observing the business world is the importance of a company taking prudent risks. Another observation as an investor is the value of companies that under-promise and over-deliver. The Biogen ( BIIB ) stock crash Thursday on t… read more...

GSK Prescribes A $3.5bn Bond In 3 Parts

via: SeekingAlpha at 2019-03-20 22:18:00:000

British pharma GlaxoSmithKline (NYSE: GSK) joined the recent groundswell of high-grade corporate bond issuers Monday to sell new debt. The UK-based firm priced US$3.5bn worth of A-rated, three-, five- and 10-year notes to help pay for its estimated US$5.1bn purchase of oncolo… read more...

Undervalued Growth And Dividend Growth In Health Technology: Part 11

via: SeekingAlpha at 2019-03-20 09:03:51:000

Introduction Although many Health Technology Sector companies have significantly outperformed the market on a long-term basis, they have significantly underperformed the market since the beginning of 2015. With only a few minor exceptions, this is true for most companies, especially the ph… read more...

Jane's February Retirement Account Update - Why You Should Consider Capital Recycling

via: SeekingAlpha at 2019-03-20 07:35:46:000

It wasn't that long ago that the market was tanking and we saw even more articles than normal on MarketWatch implying that the results were in and the best of the market had already passed us by. For those who were paying close attention to their portfolios, it wasn't uncommon to see a drop of… read more...

IPO Update: Precision BioSciences Readies Plan For IPO

via: SeekingAlpha at 2019-03-19 11:26:10:000

Quick Take Precision BioSciences ( DTIL ) intends to raise $126 million in an IPO of its common stock, per an amended registration statement . The company has created an advanced gene-editing platform for a variety of disease conditions and crop modification purposes. DTIL has promising… read more...

IPO Update: Genfit Files Proposed Terms For IPO And Private Placement

via: SeekingAlpha at 2019-03-19 07:54:51:000

Quick Take Genfit S.A. ( GNFT ) intends to raise $130 million in a global IPO from the sale of ADSs representing underlying ordinary shares, per an amended registration statement . The company is developing treatments for non-alcoholic steatohepatitis [NASH] conditions. GNFT expects Pha… read more...

BMO likes Amgen and Gilead in premarket analyst action

via: SeekingAlpha at 2019-03-15 04:48:21:000

Agilent (NYSE: A ) initiated with Buy rating and $92 (14% upside) price target at UBS. More news on: Agilent Technologies, Inc., Amgen Inc., Fluidigm Corporation, Healthcare stocks news, Stocks on the move, , Read more … read more...

BMO likes Amgen and Gilead in premarket analyst action

via: SeekingAlpha at 2019-03-15 04:48:21:000

Agilent (NYSE: A ) initiated with Buy rating and $92 (14% upside) price target at UBS. More news on: Agilent Technologies, Inc., Amgen Inc., Fluidigm Corporation, Healthcare stocks news, Stocks on the move, , Read more … read more...

BMO likes Amgen and Gilead in premarket analyst action

via: SeekingAlpha at 2019-03-15 04:48:21:000

Agilent (NYSE: A ) initiated with Buy rating and $92 (14% upside) price target at UBS. More news on: Agilent Technologies, Inc., Amgen Inc., Fluidigm Corporation, Healthcare stocks news, Stocks on the move, , Read more … read more...

BMO likes Amgen and Gilead in premarket analyst action

via: SeekingAlpha at 2019-03-15 04:48:21:000

Agilent (NYSE: A ) initiated with Buy rating and $92 (14% upside) price target at UBS. More news on: Agilent Technologies, Inc., Amgen Inc., Fluidigm Corporation, Healthcare stocks news, Stocks on the move, , Read more … read more...

Conatus up 22% ahead of Emricasan data presentation

via: SeekingAlpha at 2019-03-13 09:32:22:000

Nano cap Conatus Pharmaceuticals ( CNAT +22.2% ) is up on more than a 4x surge in volume. Shares have rallied 43% this week. More news on: Conatus Pharmaceuticals Inc., Madrigal Pharmaceuticals, Inc., Viking Therapeutics, Inc., Healthcare stocks news, Stocks on the move, … read more...

Conatus up 22% ahead of Emricasan data presentation

via: SeekingAlpha at 2019-03-13 09:32:22:000

Nano cap Conatus Pharmaceuticals ( CNAT +22.2% ) is up on more than a 4x surge in volume. Shares have rallied 43% this week. More news on: Conatus Pharmaceuticals Inc., Madrigal Pharmaceuticals, Inc., Viking Therapeutics, Inc., Healthcare stocks news, Stocks on the move, … read more...

Gilead Sciences, Inc. (GILD) Presents at Barclays Global Healthcare Conference (Transcript)

via: SeekingAlpha at 2019-03-12 11:35:15:000

Gilead Sciences, Inc. (GILD) Barclays Global Healthcare Conference Call March 12, 2019 10:45 AM ET Company Participants Robin Washington - CFO John McHutchison - Head, R&D and CSO Conference Call Participants Geoff Meacham - Barclays Jason Zemansky - Barclays Present… read more...

Trump 2020 drug pricing initiatives - part 2

via: SeekingAlpha at 2019-03-12 11:12:42:000

Additional proposals in President Trump's 2020 budget aimed at drug prices: More news on: ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Healthcare & Wellness Rx Trust, Tekla World Healthcare Fund, Healthcare stocks news, News on ETFs, Read more … read more...

Biotechs Smashed: Reasons To Like Last Week's Sale Prices

via: SeekingAlpha at 2019-03-11 03:21:52:000

Sell-Off in Biotech-Land Last week, biotechs were blindsided Tuesday when it was announced that FDA Commissioner Scott Gottlieb will be resigning imminently. A broad index of biotech stocks ((BTK)) - not an ETF (which is managed) - dropped from an intra-day high of 5,123 to close the week ne… read more...

Total USD Portfolio Review - February 2019

via: SeekingAlpha at 2019-03-11 01:27:45:000

Overview This is my second monthly review of my total USD portfolio (see my first episode - Total USD Portfolio Review - January 2019 ). This "real cash" portfolio aggregates all my positions in USD-denominated securities, including ADRs and OTC stocks, across my taxable and non-taxable acc… read more...

Precision Sets Itself Up For An IPO, With An Already Impressive Partnership On The Table

via: SeekingAlpha at 2019-03-09 08:06:00:000

Recently, it was announced that Precision BioSciences ( DTIL ) will perform an IPO that is set to be valued at about $100 million . This is not the final amount, but currently it is a placeholder in value. The reason why I believe this biotech will have a strong IPO is because of its divers… read more...

Precision Sets Itself Up For An IPO, With An Already Impressive Partnership On The Table

via: SeekingAlpha at 2019-03-09 08:06:00:000

Recently, it was announced that Precision BioSciences ( DTIL ) will perform an IPO that is set to be valued at about $100 million . This is not the final amount, but currently it is a placeholder in value. The reason why I believe this biotech will have a strong IPO is because of its divers… read more...

Gilead's GS-6207 shows encouraging action in early-stage studies

via: SeekingAlpha at 2019-03-07 17:02:42:000

Gilead Sciences (NASDAQ: GILD ) announces positive data from early-stage studies evaluating HIV candidate GS-6207, a capsid inhibitor, that it says supports three-month dosing at levels greater than 100 mg . The results were presented at the Conference on Retroviruses and Opportunistic Inf… read more...

Gilead Announces Data From Two Studies Supporting Further Development of GS-6207, a Novel, Investigational HIV-1 Capsid Inhibitor as a Component of Future Long-Acting HIV Therapies

via: Business Wire at 2019-03-07 12:30:00:000

Gilead Sciences, Inc. (NASDAQ:GILD) today announced findings from two studies that support the further development of GS-6207, a novel, selective, first-in-class inhibitor of HIV-1 capsid function, for potential future use as part of long-acting HIV combination therapy. Interim blinded data … read more...

Your 55 March Quarter NASDAQ Dividend Dogs By Yield, Upside And Net Gains

via: SeekingAlpha at 2019-03-07 02:50:01:000

Actionable Conclusions (1-10): Brokers Forecast 10.66% To 30.28% Net Gains From NASDAQ March Top Ten Six of ten top yield NASDAQ dividend stocks were identified as being among the top ten net gainers for the coming year based on analyst 1-year target prices. (They are tinted gray in the ch… read more...

Gilead Presents New Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) and TAF-Based Regimens for the Treatment of HIV-1 in Children, Older Adults and Women

via: Business Wire at 2019-03-06 12:30:00:000

Gilead Sciences, Inc. (NASDAQ: GILD) today announced 48-week results from a Phase 2/3 study (Study GS-US-380-1474) evaluating the efficacy and safety of Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, BIC/FTC/TAF), a once-daily single tablet … read more...

Gilead Presents Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) in Virologically Suppressed Adults, Including Those With Pre-Existing NRTI Resistance

via: Business Wire at 2019-03-06 12:30:00:000

Gilead Sciences, Inc. (NASDAQ: GILD) today announced data from two studies evaluating the resistance profile of Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, BIC/FTC/TAF) in virologically suppressed adults switching from dolutegravir/abacavir/l… read more...

Sangamo 2018: Coming Up Short

via: SeekingAlpha at 2019-03-06 10:40:00:000

Double Helix Image NIH Sangamo ( SGMO ) closed the book on 2018 last week when they hosted their 4Q18 earnings call . 2018 had started with tremendous promise following the October 2017 first-ever in vivo genome editing treatment and a second Pfizer (NYSE: PFE ) gene regulation co… read more...

Gilead's Descovy on par with Truvada for preventing HIV infection

via: SeekingAlpha at 2019-03-06 10:26:11:000

Results from a two-year Phase 3 clinical trial, DISCOVER , evaluating Gilead Sciences' ( GILD -2.4% ) Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) for HIV pre-exposure prophylaxis showed it to be non-inferior (no worse than) to Truvada (emtricitabine 200 mg… read more...

Gilead Announces Data Demonstrating Non-Inferiority of Once-Daily Descovy® vs. Once-Daily Truvada® for Prevention of HIV Infection

via: Business Wire at 2019-03-06 09:10:00:000

DISCOVER Trial Meets Primary and Secondary Endpoints and Will Support Supplemental Regulatory Filing for Descovy for Pre-Exposure Prophylaxis (PrEP) Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from the DISCOVER trial, a two-year Phase 3 randomized,… read more...

Biotech stocks fall after FDA chief Scott Gottlieb resigns

via: CNBC at 2019-03-06 07:31:00:000

No summary available. read more...

If The Celgene Deal Fails, Who Would Buy Bristol-Myers Squibb?

via: SeekingAlpha at 2019-03-05 14:04:45:000

Who wants BMS? The proposition that there are acquirers who want to own Bristol-Myers Squibb ( BMY ) at a notably higher price than the current $52-53 trading range seems to be taken for granted. As Starboard Value LP said in a recent open letter to BMY shareholders: There is a better … read more...

Gilead Announces Senior Management Change

via: Business Wire at 2019-03-05 11:30:00:000

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Alessandro Riva, MD, Executive Vice President, Oncology Therapeutics, has decided to leave the company to pursue another opportunity. Dr. Riva will remain at Gilead through the end of the month. The company has commenced a search for … read more...

Gilead Sciences to Present at the Barclays Global Healthcare Conference on Tuesday, March 12

via: Business Wire at 2019-03-05 11:05:00:000

Webcast Available Through Gilead Corporate Website Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Robin L. Washington, Gileads Executive Vice President and Chief Financial Officer and John McHutchison, AO, MD, Gileads Chief Scientific Officer and Head of R… read more...

Road To Financial Independence: Rising Dividends And Endless Opportunities

via: SeekingAlpha at 2019-03-04 19:14:25:000

February was a very turbulent month for me. Although the markets rallied strongly the earnings season, as always, has been a wild one and a painful one as well for a few stocks. On top of that, high-flying German fintech Wirecard (WCAGY) (WRCDF) completely collapsed following allegations about… read more...

Here's 68 Top S&P 500 Stocks For Yield, Gains & Upside In March

via: SeekingAlpha at 2019-03-04 15:17:55:000

Actionable Conclusions (1-10): Analysts Estimated 10.25% To 24.83% Net Gains For Ten S&P 500 Dogs Into March 2020 Five of ten top S&P 500 dividend stocks by yield were among the top ten gainers for the coming year based on analyst 1-year target prices. (They are tinted gray i… read more...

Monthly Review Of DivGro: February 2019

via: SeekingAlpha at 2019-03-04 07:06:49:000

Every month, I write a review of my portfolio of dividend growth stocks, DivGro. The goal of these monthly reviews is to share updates I've made to the portfolio and to provide a summary of dividends collected. Additionally, I look at how the month's activities have impacted DivGro's projecte… read more...

March 2019 Stock Considerations

via: SeekingAlpha at 2019-03-04 05:24:24:000

With the start of a new trading month, it is time, once again, for me to highlight some of my potential stock buys for March. First up, I'm thinking about buying more AT&T Inc. ([[T]]), especially if stock prices remain at $30 or below. T was my sole purchase in November as prices remain… read more...

Biotech stocks are going wild, and these two could be your best bet for a bigger breakout

via: CNBC at 2019-03-04 02:11:00:000

No summary available. read more...

European advisory group backs expanded labeling for Gilead's Viread

via: SeekingAlpha at 2019-03-01 04:14:53:000

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending revising labeling for Gilead Sciences' (NASDAQ: GILD ) Viread (tenofovir disoproxil). More news on: Gilead Sciences, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

European advisory group backs expanded labeling for Gilead's Viread

via: SeekingAlpha at 2019-03-01 04:14:53:000

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending revising labeling for Gilead Sciences' (NASDAQ: GILD ) Viread (tenofovir disoproxil). More news on: Gilead Sciences, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

European advisory group backs expanded labeling for Gilead's Viread

via: SeekingAlpha at 2019-03-01 04:14:53:000

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending revising labeling for Gilead Sciences' (NASDAQ: GILD ) Viread (tenofovir disoproxil). More news on: Gilead Sciences, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Genfit Seeks $100 Million Global IPO

via: SeekingAlpha at 2019-02-28 12:43:40:000

Quick Take Genfit S.A. ( GNFT ) intends to raise $100 million in an IPO of ADSs representing ordinary shares, according to an F-1 registration statement . The firm is developing treatment candidates for non-alcoholic steatohepatitis [NASH] conditions. GNFT says it expects results from i… read more...

Intercept And The Clinical Reality Of Treating NASH Fibrosis

via: SeekingAlpha at 2019-02-28 08:35:07:000

Intercept's data in NASH fibrosis get a muted reception Intercept Pharmaceuticals ( ICPT ) last week announced data from its pivotal REGENERATE PhIII trial evaluating lead drug obeticholic acid ('OCA'), currently marketed as OCALIVA , in patients with liver fibrosis due to NASH. OCA has r… read more...

Gilead Sciences Launches Age Positively Initiative to Address Unique Challenges of Aging Population Living with HIV

via: Business Wire at 2019-02-26 16:30:00:000

- Initiative to Provide $17.6 Million to 30 U.S. Organizations to Elevate the Work of Community Groups and Provide Support Needed to Strengthen Care for People Aging with HIV- Gilead Sciences, Inc. (NASDAQ: GILD) today announced it is providing $17.6 million in grants to 30 organiza… read more...

Gilead Sciences Launches Age Positively Initiative to Address Unique Challenges of Aging Population Living with HIV

via: Business Wire at 2019-02-26 16:30:00:000

- Initiative to Provide $17.6 Million to 30 U.S. Organizations to Elevate the Work of Community Groups and Provide Support Needed to Strengthen Care for People Aging with HIV- Gilead Sciences, Inc. (NASDAQ: GILD) today announced it is providing $17.6 million in grants to 30 organiza… read more...

Jane's January Retirement Account Update - Pay Attention To The P/E Ratio

via: SeekingAlpha at 2019-02-21 15:49:10:000

My goal for the new year is to improve the format of my series so that it takes less time to write (it's about as manual of a process as it can get) and to create more tables that do a better job of balancing my articles that might seem a little too wordy for the average investor. After all, t… read more...

Jane's January Retirement Account Update - Pay Attention To The P/E Ratio

via: SeekingAlpha at 2019-02-21 15:49:10:000

My goal for the new year is to improve the format of my series so that it takes less time to write (it's about as manual of a process as it can get) and to create more tables that do a better job of balancing my articles that might seem a little too wordy for the average investor. After all, t… read more...

Jane's January Retirement Account Update - Pay Attention To The P/E Ratio

via: SeekingAlpha at 2019-02-21 15:49:10:000

My goal for the new year is to improve the format of my series so that it takes less time to write (it's about as manual of a process as it can get) and to create more tables that do a better job of balancing my articles that might seem a little too wordy for the average investor. After all, t… read more...

U.S. healthcare spending to rise 5.5% per annum over next decade

via: SeekingAlpha at 2019-02-21 07:14:05:000

According to the Centers for Medicare & Medicaid Services (CMS), U.S. healthcare spending is expected to rise 5.5% each year over the next decade, reaching ~$6T by 2027 (19.4% of GDP). More news on: ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Healthcare & Wellness Rx Tr… read more...

U.S. healthcare spending to rise 5.5% per annum over next decade

via: SeekingAlpha at 2019-02-21 07:14:05:000

According to the Centers for Medicare & Medicaid Services (CMS), U.S. healthcare spending is expected to rise 5.5% each year over the next decade, reaching ~$6T by 2027 (19.4% of GDP). More news on: ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Healthcare & Wellness Rx Tr… read more...

U.S. healthcare spending to rise 5.5% per annum over next decade

via: SeekingAlpha at 2019-02-21 07:14:05:000

According to the Centers for Medicare & Medicaid Services (CMS), U.S. healthcare spending is expected to rise 5.5% each year over the next decade, reaching ~$6T by 2027 (19.4% of GDP). More news on: ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Healthcare & Wellness Rx Tr… read more...

Can Gilead Recover After Latest Earnings Downfall?

via: SeekingAlpha at 2019-02-19 18:43:30:000

Gilead Sciences (GILD) has a very tough road ahead after its latest earnings report. The earnings for the fourth quarter were mixed, but the company needs to take drastic action to redeem itself. The revenue may have come in over expectations, but it won't be long until Gilead finds itself i… read more...

Can Gilead Recover After Latest Earnings Downfall?

via: SeekingAlpha at 2019-02-19 18:43:30:000

Gilead Sciences (GILD) has a very tough road ahead after its latest earnings report. The earnings for the fourth quarter were mixed, but the company needs to take drastic action to redeem itself. The revenue may have come in over expectations, but it won't be long until Gilead finds itself i… read more...

Gilead's Recent NASH Trial Failure Represents Opportunity For Galectin

via: SeekingAlpha at 2019-02-19 16:00:00:000

Earlier this week, on Monday, February 11, Gilead Sciences ( GILD ) announced that selonsertib, the company's lead drug candidate for the treatment of compensated NASH cirrhosis, had failed to meet the primary endpoint of its STELLAR-4 Phase 3 trial. As such, it seems unlikely that selonsertib… read more...

Gilead's Recent NASH Trial Failure Represents Opportunity For Galectin

via: SeekingAlpha at 2019-02-19 16:00:00:000

Earlier this week, on Monday, February 11, Gilead Sciences ( GILD ) announced that selonsertib, the company's lead drug candidate for the treatment of compensated NASH cirrhosis, had failed to meet the primary endpoint of its STELLAR-4 Phase 3 trial. As such, it seems unlikely that selonsertib… read more...

Maryland strikes out in reviving drug price-gouging law

via: SeekingAlpha at 2019-02-19 13:37:18:000

The U.S. Supreme Court has rejected the state of Maryland's appeal of an appeals court ruling that struck down its anti-price gouging law citing the illegality of state-level regulation of interstate commerce. More news on: Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnology E… read more...

Maryland strikes out in reviving drug price-gouging law

via: SeekingAlpha at 2019-02-19 13:37:18:000

The U.S. Supreme Court has rejected the state of Maryland's appeal of an appeals court ruling that struck down its anti-price gouging law citing the illegality of state-level regulation of interstate commerce. More news on: Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnology E… read more...

Teva: Reasons To Avoid It In Favor Of Innovative Biotechs

via: SeekingAlpha at 2019-02-19 04:45:10:000

Introduction - Teva ( TEVA ) versus branded biotechs TEVA reported Q4 and full-year numbers last week, and the stock sank sharply, with its ADS closing at $17.98 Friday. Using the 1.10 B fully diluted shares the company guided for the present period on the c onference call , that puts its … read more...

Teva: Reasons To Avoid It In Favor Of Innovative Biotechs

via: SeekingAlpha at 2019-02-19 04:45:10:000

Introduction - Teva ( TEVA ) versus branded biotechs TEVA reported Q4 and full-year numbers last week, and the stock sank sharply, with its ADS closing at $17.98 Friday. Using the 1.10 B fully diluted shares the company guided for the present period on the c onference call , that puts its … read more...

How To Retire: Kill The TV

via: SeekingAlpha at 2019-02-18 07:00:00:000

100% of our revenue from this article in the first month will be donated to a charity . In February, we will be supporting 2 Blondes All Breed Rescue. Many people are eagerly awaiting retirement. Unfortunately, far fewer retirees are actually planning for it. A shocking percentage of peop… read more...

FDA finalizes guidance for expedited review of cell and gene therapy applications

via: SeekingAlpha at 2019-02-15 11:17:58:000

In (yet another) statement , FDA Commission Scott Gottlieb, M.D. announces the issuance of final updated guidance for gene therapy and cell therapy developers. More news on: Abeona Therapeutics Inc., Bellicum Pharmaceuticals, ZIOPHARM Oncology, Inc., Healthcare stocks news, Read more … read more...

FDA finalizes guidance for expedited review of cell and gene therapy applications

via: SeekingAlpha at 2019-02-15 11:17:58:000

In (yet another) statement , FDA Commission Scott Gottlieb, M.D. announces the issuance of final updated guidance for gene therapy and cell therapy developers. More news on: Abeona Therapeutics Inc., Bellicum Pharmaceuticals, ZIOPHARM Oncology, Inc., Healthcare stocks news, Read more … read more...

FDA finalizes guidance for expedited review of cell and gene therapy applications

via: SeekingAlpha at 2019-02-15 11:17:58:000

In (yet another) statement , FDA Commission Scott Gottlieb, M.D. announces the issuance of final updated guidance for gene therapy and cell therapy developers. More news on: Abeona Therapeutics Inc., Bellicum Pharmaceuticals, ZIOPHARM Oncology, Inc., Healthcare stocks news, Read more … read more...

FDA creates new accelerated review pathway for generic drug applications

via: SeekingAlpha at 2019-02-15 10:48:00:000

In a statement , FDA commissioner Scott Gottlieb, M.D. announces a new pathway for accelerated view of marketing applications from generic drugmakers for off-patent branded medicines facing no generic competition, a situation characterizing "hundreds" of such drugs that serve small patient … read more...

FDA creates new accelerated review pathway for generic drug applications

via: SeekingAlpha at 2019-02-15 10:48:00:000

In a statement , FDA commissioner Scott Gottlieb, M.D. announces a new pathway for accelerated view of marketing applications from generic drugmakers for off-patent branded medicines facing no generic competition, a situation characterizing "hundreds" of such drugs that serve small patient … read more...

FDA creates new accelerated review pathway for generic drug applications

via: SeekingAlpha at 2019-02-15 10:48:00:000

In a statement , FDA commissioner Scott Gottlieb, M.D. announces a new pathway for accelerated view of marketing applications from generic drugmakers for off-patent branded medicines facing no generic competition, a situation characterizing "hundreds" of such drugs that serve small patient … read more...

Gilead's Mousetrap

via: SeekingAlpha at 2019-02-15 08:51:31:000

My previous article forecast problems for selonsertib, as new research indicates that this drug targets mouse-specific pathways that are not present in humans. NASH cirrhosis trials continue to struggle. Intercepts Ocaliva, a NASH cirrhosis drug candidate, is haile… read more...

Gilead's Mousetrap

via: SeekingAlpha at 2019-02-15 08:51:31:000

My previous article forecast problems for selonsertib, as new research indicates that this drug targets mouse-specific pathways that are not present in humans. NASH cirrhosis trials continue to struggle. Intercepts Ocaliva, a NASH cirrhosis drug candidate, is haile… read more...

Gilead's Mousetrap

via: SeekingAlpha at 2019-02-15 08:51:31:000

My previous article forecast problems for selonsertib, as new research indicates that this drug targets mouse-specific pathways that are not present in humans. NASH cirrhosis trials continue to struggle. Intercepts Ocaliva, a NASH cirrhosis drug candidate, is haile… read more...

Gilead: What Just Happened?

via: SeekingAlpha at 2019-02-14 18:30:01:000

Gilead logo. Source: The Wall Street Journal Gilead Sciences (GILD) reported Q4 2018 revenue of $5.8 billion, beating on revenue by $280 million. It missed on GAAP EPS and non-GAAP EPS. GILD is down by nearly 5% since the earnings report was released. The issues are likely hurting the st… read more...

Gilead Could Be The Winner From Washington State's Winner-Take-All Hep C Proposal

via: SeekingAlpha at 2019-02-14 17:57:26:000

The states of Louisiana and Washington are bringing a Netflix (NFLX) model to healthcare services, with Washington exploring the idea with Hepatitis C on a winner-take-all basis. This could be a great deal for Gilead Sciences ( GILD ), which has been continually battered from falling sales i… read more...

Estimating The Potential Success Of Late Clinical Stage NASH Treatments

via: SeekingAlpha at 2019-02-14 12:48:37:000

Editor's note: Seeking Alpha is proud to welcome Richelle Cutler-Strom as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more The… read more...

Biotech Bonanza: The Mergers And Acquisitions Theme

via: SeekingAlpha at 2019-02-13 14:55:11:000

Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an… read more...

Biotech Bonanza: The Mergers And Acquisitions Theme

via: SeekingAlpha at 2019-02-13 14:55:11:000

Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an… read more...

3 Biotech Stocks With Strong Quantitative Drivers

via: SeekingAlpha at 2019-02-13 06:18:47:000

Investing in biotech stocks can lead to massive gains when positioned in the right names in such a promising industry. However, picking the best biotech stocks is much easier said than done. Even for professional asset managers with lots of experience and a deep understanding of the sector, id… read more...

3 Biotech Stocks With Strong Quantitative Drivers

via: SeekingAlpha at 2019-02-13 06:18:47:000

Investing in biotech stocks can lead to massive gains when positioned in the right names in such a promising industry. However, picking the best biotech stocks is much easier said than done. Even for professional asset managers with lots of experience and a deep understanding of the sector, id… read more...

2 Dividend Blue-Chips Set To Soar And 1 You Should Ignore

via: SeekingAlpha at 2019-02-12 16:33:20:000

(Source: imgflip ) My new Deep Value Dividend Growth Portfolio or DVDGP (beating the market by 9% so far) owns 70 companies. However, that level of diversification isn't usually optimal for most investors who aren't professional analysts (I research over 200 companies per year for Simpl… read more...

Boehringer Ingelheim teams up with IBM to explore use of blockchain in clinical trials

via: SeekingAlpha at 2019-02-12 08:27:08:000

Boehringer Ingelheim will collaborate with IBM (NYSE: IBM ) to explore the use of blockchain technology in clinical trials, specifically to determine if blockchain can improve trial quality and patient safety at reduced cost via a decentralized framework enabling data integrity, provenance, … read more...

Stocks making the biggest moves premarket: Under Armour, Coty, Walmart, Amazon.com & more

via: CNBC at 2019-02-12 07:43:00:000

No summary available. read more...

Gilead Sciences: Reaching An Inflection Point

via: SeekingAlpha at 2019-02-12 07:33:00:000

Gilead Sciences Background Gilead Sciences ( GILD ) reported product sales of $5.7 billion for the fourth quarter, up 4% sequentially and down 3% YoY. For the full year, product sales came in at $21.7 billion, down 16% YoY driven by lower HCV sales. More bad news, the company recorded … read more...

Viking Therapeutics, Madrigal move up as Gilead liver drug fails to meet goals

via: SeekingAlpha at 2019-02-11 17:53:42:000

Viking Therapeutics (NASDAQ: VKTX ) +8.4% and Madrigal Pharmaceuticals (NASDAQ: MDGL ) +3.3% after-hours as Gileads (NASDAQ: GILD ) study designed to evaluate a chronic liver disease drug failed to meet its primary endpoint ; GILD -3.6% . More news on: Viking Therapeutic… read more...

Stocks making the biggest moves after hours: Gilead, RingCentral, Chegg and more

via: CNBC at 2019-02-11 17:25:00:000

No summary available. read more...

Gilead's selonsertib flunks late-stage NASH study

via: SeekingAlpha at 2019-02-11 17:00:57:000

Gilead Sciences (NASDAQ: GILD ) is holding steady after hours on the heels of its announcement that its Phase 3 clinical trial, STELLAR-4 , evaluating selonsertib in NASH patients with compensated cirrohosis failed to sufficiently separate from placebo. More news on: Gilead Sciences, In… read more...

Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)

via: Business Wire at 2019-02-11 16:30:00:000

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that STELLAR-4, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once-daily, oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1), in patients wit… read more...

After Humira: AbbVie's Upa Vs Gilead's Filgo

via: SeekingAlpha at 2019-02-08 12:47:17:000

From time to time highly successful biotechs find themselves scrapping for big bucks in one another's wheelhouses. No two biotechs illustrate this more clearly than Gilead ( GILD ) and AbbVie ( ABBV ). Each has highly profitable franchises that have drawn substantial competition. AbbVie's entr… read more...

After Humira: AbbVie's Upa Vs Gilead's Filgo

via: SeekingAlpha at 2019-02-08 12:47:17:000

From time to time highly successful biotechs find themselves scrapping for big bucks in one another's wheelhouses. No two biotechs illustrate this more clearly than Gilead ( GILD ) and AbbVie ( ABBV ). Each has highly profitable franchises that have drawn substantial competition. AbbVie's entr… read more...

After Humira: AbbVie's Upa Vs Gilead's Filgo

via: SeekingAlpha at 2019-02-08 12:47:17:000

From time to time highly successful biotechs find themselves scrapping for big bucks in one another's wheelhouses. No two biotechs illustrate this more clearly than Gilead ( GILD ) and AbbVie ( ABBV ). Each has highly profitable franchises that have drawn substantial competition. AbbVie's entr… read more...

Vertex: Shareholders Might Have Reason To Breathe More Easily

via: SeekingAlpha at 2019-02-07 21:55:28:000

Introduction - Riding out some squalls Vertex Pharmaceuticals ( VRTX ), an innovator in rational drug design, appears to yours truly to have come through a mildly challenging period in a strong position. This is a stock that is beginning to remind me of a mini-Apple ( AAPL ) circa about 2005… read more...

Vertex: Shareholders Might Have Reason To Breathe More Easily

via: SeekingAlpha at 2019-02-07 21:55:28:000

Introduction - Riding out some squalls Vertex Pharmaceuticals ( VRTX ), an innovator in rational drug design, appears to yours truly to have come through a mildly challenging period in a strong position. This is a stock that is beginning to remind me of a mini-Apple ( AAPL ) circa about 2005… read more...

Vertex: Shareholders Might Have Reason To Breathe More Easily

via: SeekingAlpha at 2019-02-07 21:55:28:000

Introduction - Riding out some squalls Vertex Pharmaceuticals ( VRTX ), an innovator in rational drug design, appears to yours truly to have come through a mildly challenging period in a strong position. This is a stock that is beginning to remind me of a mini-Apple ( AAPL ) circa about 2005… read more...

In A World Full Of Numbers, These Non-Numeric Factors That Matter More

via: SeekingAlpha at 2019-02-07 20:08:49:000

Background People with very high IQs and who are good at math naturally look for a system where they can just look at the math and know what security to buy. It's not that easy. You really have to understand the company in its competitive position and the reason why its competitive position… read more...

In A World Full Of Numbers, These Non-Numeric Factors That Matter More

via: SeekingAlpha at 2019-02-07 20:08:49:000

Background People with very high IQs and who are good at math naturally look for a system where they can just look at the math and know what security to buy. It's not that easy. You really have to understand the company in its competitive position and the reason why its competitive position… read more...

In A World Full Of Numbers, These Non-Numeric Factors That Matter More

via: SeekingAlpha at 2019-02-07 20:08:49:000

Background People with very high IQs and who are good at math naturally look for a system where they can just look at the math and know what security to buy. It's not that easy. You really have to understand the company in its competitive position and the reason why its competitive position… read more...

What Gilead's Fourth Quarter Call Told Us About Their Core Business

via: SeekingAlpha at 2019-02-07 16:09:11:000

Gilead's ( GILD ) fourth quarter revenue of $5.8 Billion exceeded Wall Street estimates. However, the earnings per share of $1.44 fell slightly below estimates, driven by one-off Harvoni cost of goods sold impacts. The company's guidance of $21.3-21.8 Billion signifies continued confidence in … read more...

10 Dividend Growth Stocks For February 2019

via: SeekingAlpha at 2019-02-07 08:00:00:000

The CCC list is a great resource for dividend growth investors. The list contains 861 stocks trading on U.S. exchanges with the distinction of having paid higher dividends for at least 5 consecutive years. The list is maintained by Justin Law . In this article, I rank a subset of CCC stoc… read more...

Gilead: What A Difference An O'Day Can Make

via: SeekingAlpha at 2019-02-07 04:58:25:000

Background Gilead Sciences ( GILD ) is about to get its third CEO in less than 9 weeks on or about March 1; he will be the fourth CEO in three years. Daniel O'Day, who had the highly prestigious job of running the pharmaceutical division of the world's largest biotech company, Roche ( RHHBY … read more...

Using Ratios To Identify Stocks Set To Outperform Their Peers: Statistical Summary Of 2 Years Of Research

via: SeekingAlpha at 2019-02-06 15:26:30:000

Intro For the past 2 years, I've been gathering data for a research project with hopes of supporting my hypothesis that stocks which are stronger financially than their peers will outperform similar stocks that don't have as strong of a balance sheet. To determine this financial strength, I … read more...

Gilead Sciences: Stable But Non-Inspiring

via: SeekingAlpha at 2019-02-05 21:02:16:000

Gilead Sciences ( GILD ) has been a name which I have owned at various instances in the past, and still hold a modest position in the shares currently. I have typically been very appealed to the strong balance sheet and modest valuation of the business, following its unprecedented success an… read more...

Stocks making the biggest moves midday: Estee Lauder, Ralph Lauren, Alphabet & more

via: CNBC at 2019-02-05 11:55:00:000

No summary available. read more...

Intercept, Gilead, Pfizer And Genfit In NASH: Overview Of Q1 2019 Catalysts In Liver Therapeutics Investments

via: SeekingAlpha at 2019-02-05 09:28:44:000

Clinical Trials NASH is a progressive chronic liver disease with many causal pathogenic factors. We have learnt from research that dysregulation of the glucose and lipid metabolic pathways could be associated with the development of NASH. Inflammation and activation of the apoptotic (i.e. ce… read more...

Gilead down 3% premarket after Q4 results, $820M impairment charge to R&D

via: SeekingAlpha at 2019-02-05 08:27:29:000

Gilead Sciences (NASDAQ: GILD ) is down 3% premarket on light volume after it posted Q4 results yesterday after the close. Sales were down almost 3% while non-GAAP earnings were down 20%. More news on: Gilead Sciences, Inc., Healthcare stocks news, Stocks on the move, Earning… read more...

Stocks making the biggest moves premarket: Viacom, Centene, Merck, Alphabet & more

via: CNBC at 2019-02-05 07:49:00:000

No summary available. read more...

Europe Stocks Rise, U.S. Set To Open In The Green

via: SeekingAlpha at 2019-02-05 07:23:50:000

Today's Top Stories: Europe stocks rise, U.S. set to open in the green; EU businesses at weakest growth rate since mid-2013; and Alphabet drops after hours in wake of Q4 report. If you are interested in listening to Wall Street Breakfast to start your day, look for us in the following… read more...

Wall Street Breakfast: Europe Stocks Rise, U.S. Set To Open In The Green

via: SeekingAlpha at 2019-02-05 06:15:29:000

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). Stoxx Europe 600 Index is up for the sixth straight day and has risen 0.7% , and FTSE 100 Index has gained 1.1% … read more...

2018 Drug Approvals: A Closer Look

via: SeekingAlpha at 2019-02-05 04:43:00:000

Let's have a look at the recent new drug approvals. 2018 was quite a year, by the numbers. C&E News has a comprehensive roundup : 59 approvals (versus 46 in 2017, which was already a record by itself), and about two-thirds of those small molecules. There are some very interesting molecul… read more...

Dividend Portfolio Review: 22% Y/Y Growth In January

via: SeekingAlpha at 2019-02-05 01:51:31:000

2019 started with a big rally. Following an initial slump, markets rose throughout the month as optimism regarding the outcome of China-U.S trade negotiations, a better-than-expected earnings season and a less hawkish Fed have provided lots of fuel. (Source: onvista.de - Dow Jones Last 3M )… read more...

Gilead Sciences'(GILD) CEO Gregg Alton on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-02-04 20:18:05:000

Gilead Sciences, Inc. (GILD) Q4 2018 Earnings Conference Call February 4, 2019 4:30 PM ET Company Participants Sung Lee Vice President of Investor Relations Robin Washington Executive Vice President and Chief Financial Officer Laura Hamill Executive Vic… read more...

Gilead Sciences, Inc. 2018 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2019-02-04 18:02:37:000

The following slide deck was published by Gilead Sciences, Inc. in conjunction with their 2018 Q4 earnings Read more … read more...

Stocks making the biggest moves after hours: Alphabet, Gilead and more

via: CNBC at 2019-02-04 17:11:00:000

No summary available. read more...

Gilead down 3% after hours on Q4 results, growth remains elusive

via: SeekingAlpha at 2019-02-04 16:16:17:000

Gilead Sciences (NASDAQ: GILD ) Q4 results ($M): Revenues: 5,795 (-2.6%); Product sales: 5,681 (-2.7%). More news on: Gilead Sciences, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more … read more...

Gilead Sciences misses by $0.26, beats on revenue

via: SeekingAlpha at 2019-02-04 16:03:02:000

Gilead Sciences (NASDAQ: GILD ): Q4 Non-GAAP EPS of $1.44 misses by $0.26 ; GAAP EPS of $0.00 misses by $1.29 . Revenue of $5.8B (-2.5% Y/Y) beats by $280M . Press Release More news on: Gilead Sciences, Inc., Earnings news and commentary, Healthcare stocks news, read more...

Gilead Sciences Announces 11 Percent Increase in First Quarter 2019 Dividend

via: Business Wire at 2019-02-04 16:02:00:000

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the companys Board of Directors has declared an increase of 11% in the companys quarterly cash dividend, beginning in the first quarter of 2019. The increase will result in a quarterly dividend of $0.63 per share of co… read more...

Gilead Sciences Announces Fourth Quarter and Full Year 2018 Financial Results

via: Business Wire at 2019-02-04 16:01:00:000

- Fourth Quarter Product Sales of $5.7 billion - - Full Year 2018 Product Sales of $21.7 billion - - Full Year 2018 Diluted EPS of $4.17 per share - - Full Year 2018 Non-GAAP Diluted EPS of $6.67 per share - Gilead Sciences, Inc. (Nasdaq: GILD) announced today its result… read more...

Dow rises more than 150 points as tech shares jump ahead of Alphabet earnings

via: CNBC at 2019-02-04 03:08:00:000

No summary available. read more...

European stocks close mixed amid earnings; Wirecard shares jump 14%

via: CNBC at 2019-02-04 01:39:00:000

No summary available. read more...

Gilead Sciences Q4 Earnings Preview

via: SeekingAlpha at 2019-02-03 17:47:42:000

Gilead Sciences (NASDAQ: GILD ) is scheduled to announce Q4 earnings results on Monday, February 4th, after market close. The consensus EPS Estimate is $1.70 (-4.5% Y/Y) and the consensus Revenue Estimate is $5.52B (-6.4% Y/Y). Over the last 2 years, GILD has beaten EPS estimates 75%… read more...

Notable earnings after Monday's close

via: SeekingAlpha at 2019-02-03 17:35:07:000

AEIS , AIV , APAM , ARE , AVB , CBT , CTRL , CVCO , FN , GILD , GLUU , GOOG , HIG , HLIT , KMT , KRC , LEG , LM , LMNX , MWA , OLN , PCH , QGEN , QTNA , RBC , RTEC , SSD , STX , VSM For Seeking Alpha's full earnings season calendar, click here . More news… read more...

Week In Review: New Shanghai Hi-Tech Exchange To IPO Pre-Revenue Companies

via: SeekingAlpha at 2019-02-03 13:14:15:000

Government and Regulatory The Shanghai Stock Exchange's new Technology Innovation Board will allow still-unprofitable hi-tech companies - including biopharmas - to IPO on the exchange, though each IPOing company must have a valuation of at least $600 million to qualify. Also, biopharmas mu… read more...

Disney, Alphabet And Super Bowl Players (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-02-03 07:35:41:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look f… read more...

VC Deals: Go-Jek Closes Half Of $2B Goal

via: SeekingAlpha at 2019-02-02 10:30:39:000

Welcome to Seeking Alphas Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. 1. Go-Jek gets halfway to $2B goal Google ([[GOOG]], [[GOOGL]]), JD (JD), and Tencent ([[TCEHY]],[[TCTZF]]) co-le… read more...

Stocks To Watch: Disney, Alphabet And Super Bowl Players

via: SeekingAlpha at 2019-02-02 08:39:18:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The market is moving in the right direction after some cooling off of Washington-Be… read more...

Tiny Israeli firm touts cancer cure

via: SeekingAlpha at 2019-01-29 12:53:30:000

Delivering a healthy dose of hyperbole, Dan Aridor, Chairman of Israel-based biotech Accelerated Evolution Biotechnologies Ltd. , says his company will be offering a "complete cure for cancer" in a year's time based on a "disruptive technology of the highest order." More news on: Bristo… read more...

Tiny Israeli firm touts cancer cure

via: SeekingAlpha at 2019-01-29 12:53:30:000

Delivering a healthy dose of hyperbole, Dan Aridor, Chairman of Israel-based biotech Accelerated Evolution Biotechnologies Ltd. , says his company will be offering a "complete cure for cancer" in a year's time based on a "disruptive technology of the highest order." More news on: Bristo… read more...

Tiny Israeli firm touts cancer cure

via: SeekingAlpha at 2019-01-29 12:53:30:000

Delivering a healthy dose of hyperbole, Dan Aridor, Chairman of Israel-based biotech Accelerated Evolution Biotechnologies Ltd. , says his company will be offering a "complete cure for cancer" in a year's time based on a "disruptive technology of the highest order." More news on: Bristo… read more...

3 Top-Notch Healthcare Names I Just Added To My Portfolio

via: SeekingAlpha at 2019-01-29 11:48:04:000

Source: blog.blominvestbank.com 3 Top-Notch Stocks I Just Added To My Portfolio Since early 2018 I've been on a mission to "recession proof" my portfolio. I've held many of the FAANNG + M + BAT names for years. Other significant portions of my portfolio included financials, energy, gold … read more...

3 Top-Notch Healthcare Names I Just Added To My Portfolio

via: SeekingAlpha at 2019-01-29 11:48:04:000

Source: blog.blominvestbank.com 3 Top-Notch Stocks I Just Added To My Portfolio Since early 2018 I've been on a mission to "recession proof" my portfolio. I've held many of the FAANNG + M + BAT names for years. Other significant portions of my portfolio included financials, energy, gold … read more...

3 Top-Notch Healthcare Names I Just Added To My Portfolio

via: SeekingAlpha at 2019-01-29 11:48:04:000

Source: blog.blominvestbank.com 3 Top-Notch Stocks I Just Added To My Portfolio Since early 2018 I've been on a mission to "recession proof" my portfolio. I've held many of the FAANNG + M + BAT names for years. Other significant portions of my portfolio included financials, energy, gold … read more...

Large Cap Growth Strategy Q4 2018 Commentary

via: SeekingAlpha at 2019-01-29 09:00:00:000

Read more … read more...

Large Cap Growth Strategy Q4 2018 Commentary

via: SeekingAlpha at 2019-01-29 09:00:00:000

Read more … read more...

Large Cap Growth Strategy Q4 2018 Commentary

via: SeekingAlpha at 2019-01-29 09:00:00:000

Read more … read more...

All Cap Growth Q4 2018 Commentary

via: SeekingAlpha at 2019-01-29 08:10:00:000

Read more … read more...

All Cap Growth Q4 2018 Commentary

via: SeekingAlpha at 2019-01-29 08:10:00:000

Read more … read more...

All Cap Growth Q4 2018 Commentary

via: SeekingAlpha at 2019-01-29 08:10:00:000

Read more … read more...

Barron's 2019 Roundtable Picks 48 Scrappy Dog Stocks

via: SeekingAlpha at 2019-01-28 17:02:08:000

Actionable Conclusions (1-10): Analysts Project 20.28% To 44.04% Net Gains For Top Ten Barron's 2019 Picks Four top yielders of ten top Barron's 2019 picks (tinted gray in the chart above) were among the top ten gainers for the coming year based on 1-year target estimates. So, the dog stra… read more...

BMS Reports Q4: Analysis Of Its Stock And Of Celgene

via: SeekingAlpha at 2019-01-27 13:51:32:000

BMS reports Q4 and guides for 2019 Bristol-Myers Squibb ( BMY ) reported Q4 and full-year results last week. Revenues were $6 B, up 10% (12% adjusted for currency). R&D was $1.4 B, 23% of revenues, well above the 15% that stalwarts such as Pfizer ( PFE ) and Merck ( MRK ) typically run… read more...

Gilead And Selonsertib In NASH Fibrosis And Compensated Cirrhosis: The FDA Guidelines For Conditional Approval

via: SeekingAlpha at 2019-01-27 12:41:52:000

The Update On Gilead Sciences Gilead Sciences Inc ( GILD ) is a commercial stage large-cap ($87.7B) biopharmaceutical company and a well-recognized visionary for developing innovative therapeutics affecting several disease states and potentially NASH. Its lead anti-NASH investigative drug … read more...

CEOs Aren't Worried About The Shutdown - Yet

via: SeekingAlpha at 2019-01-26 10:30:00:000

Dear ESSENTIAL subscribers: Hi! I'm Seeking Alpha managing editor Mike Taylor. Welcome to ESSENTIAL Weekly, a subscriber-exclusive look at Seeking Alpha's top news and analysis. I'll guide you through this week's market themes, highlight some analysis you might have missed, and preview comin… read more...

The Economics Of Cures - Gilead At A Turning Point

via: SeekingAlpha at 2019-01-25 04:43:23:000

Curing diseases is considered a poor business model by most investors. This is one of the open secrets of our capitalist system. Most pharmaceutical companies would much rather keep providing treatment for chronic diseases, alleviating symptoms for incurable conditions, or supplementing habi… read more...

Healthcare Winners And Losers If This Shutdown Is Prolonged

via: SeekingAlpha at 2019-01-25 01:36:52:000

As the government shutdown becomes the longest on record, most offices, including the Food and Drug Administration, are below operating capacity. This, of course, directly affects the health care sector. It has understandably been hampering new drug efforts, leading to the FDA to not accept pr… read more...

Update On NASH Antifibrotics: Allergan, Gilead, Conatus, Galectin

via: SeekingAlpha at 2019-01-24 17:10:07:000

Previously, I analyzed the NASH cirrhosis space from a scientific perspective, comparing and contrasting the antifibrotic drugs Selonsertib ( GILD ), Emricasan ( CNAT ), and GR-MD-02 ( GALT ), whichwas recently assigned the USAN name belapectin . In retrospect, Allergans ( AGN ) cenic… read more...

Agenus Closes $150 Million Immuno-Oncology Transaction with Gilead

via: PR Newswire at 2019-01-24 08:30:00:000

LEXINGTON, Mass. , Jan. 24, 2019 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies 1 , today announced the closing of its immuno-oncology (I-O) partnership deal with Gil… read more...

Companies that have this one attribute are reporting great earnings and beating the market

via: CNBC at 2019-01-24 07:23:00:000

No summary available. read more...

Jefferies bearish on biotechs, sees 6% near-term downside

via: SeekingAlpha at 2019-01-23 14:05:04:000

Jefferies healthcare strategist Jared Holtz is a short-term biotech bear saying that profit-taking "makes sense" through this earnings season considering the sector's market-leading performance so far this year. He thinks the SPDR S&P Biotech ETF ( XBI -1.3% ) could drop to $75 ( -6% )… read more...

Gilead Sciences to Release Fourth Quarter and Full Year 2018 Financial Results on Monday, February 4, 2019

via: Business Wire at 2019-01-22 16:05:00:000

-- Conference Call and Webcast to Follow -- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2018 financial results will be released on Monday, February 4, after the market closes. At 4:30 p.m. Eastern Time, Gileads management will h… read more...

Nicholas Ward's Dividend Growth Portfolio: 2018 Review

via: SeekingAlpha at 2019-01-22 15:34:09:000

Man oh man, its crazy to think about boiling down a years worth of portfolio management into a single article like this (especially, after a year like 2018). To be honest, Id much rather be writing about the fundamentals of a given company that Ive recently boug… read more...

Retirement: 2018 Performance Of The Future-Proof Portfolio For Young Investors

via: SeekingAlpha at 2019-01-20 09:28:12:000

At the end of January 2018, I started the future-proof portfolio for young investors in an attempt to model a possible portfolio which a young investor could use to finance his retirement. In my portfolio selection, I place emphasis on the stability of companies. I prefer solid firms which pay… read more...

Retirement: 2018 Performance Of The Future-Proof Portfolio For Young Investors

via: SeekingAlpha at 2019-01-20 09:28:12:000

At the end of January 2018, I started the future-proof portfolio for young investors in an attempt to model a possible portfolio which a young investor could use to finance his retirement. In my portfolio selection, I place emphasis on the stability of companies. I prefer solid firms which pay… read more...

The Week That Was In San Francisco: 2019 Should Be A Great Year For Healthcare Stocks

via: SeekingAlpha at 2019-01-18 09:27:40:000

There were numerous highlights in the healthcare sector beginning 2019. First, the announced merger of Bristol Myers ( BMY ) and Celgene ( CELG ) will create a strong entity in oncology and hematology, and will be very accretive to Bristol's earnings per share. Wall Street had driven down Celg… read more...

The Week That Was In San Francisco: 2019 Should Be A Great Year For Healthcare Stocks

via: SeekingAlpha at 2019-01-18 09:27:40:000

There were numerous highlights in the healthcare sector beginning 2019. First, the announced merger of Bristol Myers ( BMY ) and Celgene ( CELG ) will create a strong entity in oncology and hematology, and will be very accretive to Bristol's earnings per share. Wall Street had driven down Celg… read more...

A Real Dividend Growth Machine: 2018 Portfolio Review

via: SeekingAlpha at 2019-01-17 11:56:51:000

Introduction The purpose of this article is to review my investing progress in 2018, which was my seventh full year as a dividend growth investor. I follow a value-oriented dividend growth investing strategy that involves buying attractively valued stocks of companies that consistently pay a… read more...

Jane's FY-2018 Dividend Income Totals - Why Being Patient Pays

via: SeekingAlpha at 2019-01-17 08:33:18:000

Investment Thesis Being told to "be patient" is something no human wants to hear and there is probably no other aspect of life where you hear it more than when it comes to the world of personal finance. I'd like to think that I've learned patience in my 29 years on this earth, but I feel lik… read more...

Hospitals squeezed by high drug costs

via: SeekingAlpha at 2019-01-16 12:20:50:000

A study funded by the American Hospital Association, Federation of American Hospitals and the American Society of Health-System Pharmacists found that total drug spend per hospital admission rose 18.5% between 2015 and 2017, adding $1.8M in additional costs for an average hospital. More … read more...

Shionogi's Strong Core Offers More Capital Return Possibilities

via: SeekingAlpha at 2019-01-16 08:29:34:000

Japanese drug companies are quite a bit different than U.S and European pharma companies, partly because the pricing/reimbursement environment is much different, but those differences arent always bad. In the case of Shionogi ( OTCPK:SGIOY ) (4507.T), investors can take advantage of … read more...

FDA to beef up cell and gene therapy staff

via: SeekingAlpha at 2019-01-15 13:17:05:000

Citing the 800 active INDs for cell therapy and gene therapy candidates and the expectation that it will be receiving more that 200 INDs each year by 2020, FDA Commission Scott Gottlieb, M.D., outlines the agency's initiatives to support timely review and to enable the approval of 10 - 20 … read more...

FDA Commish touts advances/successes

via: SeekingAlpha at 2019-01-15 12:45:44:000

In a stream of tweets , FDA Commissioner Scott Gottlieb, M.D. details a number of accomplishments and advances by the agency. Highlights: More news on: ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Healthcare & Wellness Rx Trust, Tekla World Healthcare Fund, Healthcare stocks … read more...

Why AbbVie Believes In Life After (Humira's) Death

via: SeekingAlpha at 2019-01-15 11:56:54:000

Introduction - valuing AbbVie ( ABBV ) This article provides a quantitative analysis of ABBV's 5 most important existing products, broken down as 3 marketed and 2 very late-stage pipeline products. Along the way, points relevant to thinking about these products may interest readers, an impor… read more...

Cirius Therapeutics Seeks $86 Million IPO

via: SeekingAlpha at 2019-01-15 10:35:20:000

Quick Take Cirius Therapeutics ( CSTX ) intends to raise gross proceeds of $86.25 million from a U.S. IPO, according to an S-1 registration statement . The firm provides is developing small-molecule treatments for nonalcoholic steatohepatitis [NASH] with fibrosis. CSTX has seen promisin… read more...

Rowan Street Capital Q3'18 Letter: Exploiting The Market's Fear And Greed

via: SeekingAlpha at 2019-01-15 04:26:03:000

Rowan Street Capital letter for the third quarter ended September 30, 2018. Dear Partners, Third quarter was uneventful (flat) in terms of market price movement for our fund's portfolio. As of September 30, Rowan Street Capital fund was up 26% in 2018 (before fees) versus 10.6% gain … read more...

Rep. Cummings opens investigation into drug prices

via: SeekingAlpha at 2019-01-14 13:57:17:000

Following through on his previously announced commitment, U.S. Representative Elijah Cummings (D-MD 7th District), Chairman of the House Oversight Committee, has opened an investigation into the pricing practices of 12 drugmakers, demanding information and documents on pricing approaches, … read more...

A Planned Spinoff Of Cancer Vaccines At Generex

via: SeekingAlpha at 2019-01-14 12:02:45:000

In my recent piece, The New Generex: Unlocking the Value , I assigned no value whatever in the current valuation of Generex's ( OTCQB:GNBT ) stock to its cancer vaccine technology, although cancer vaccine companies are not usually valued at zero. And the likes of Kite Pharma and Juno Therap… read more...

Is 2019 The Turnaround Year For Gilead Sciences?

via: SeekingAlpha at 2019-01-14 12:01:42:000

Although it is one of the most successful biotechnology companies the world has known, Gilead Sciences ( GILD ) has seen its rise eroded by declining returns from its most successful products. In light of the companys quest to return to growth, lets take a look at what the upco… read more...

Average American Retirement Portfolio - Twenty Percent Better Than The Average Retiree

via: SeekingAlpha at 2019-01-14 00:54:09:000

The Average American Retirement portfolio is a six-figure retirement portfolio created for Seeking Alpha several years ago. The portfolio was originally created because I realized that the average American doesnt retire with nearly enough money to actually live their lives. Its goal is… read more...

Agenus Gets A Grant: A Good Opportunity To Buy

via: SeekingAlpha at 2019-01-11 13:44:08:000

Editor's note: Seeking Alpha is proud to welcome Oleksandr Pylypenko as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Recen… read more...

Agenus Gets A Grant: A Good Opportunity To Buy

via: SeekingAlpha at 2019-01-11 13:44:08:000

Editor's note: Seeking Alpha is proud to welcome Oleksandr Pylypenko as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Recen… read more...

Agenus Gets A Grant: A Good Opportunity To Buy

via: SeekingAlpha at 2019-01-11 13:44:08:000

Editor's note: Seeking Alpha is proud to welcome Oleksandr Pylypenko as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Recen… read more...

Dem lawmakers introduce bill to lower U.S. drug prices

via: SeekingAlpha at 2019-01-11 11:00:35:000

On the heels of a new round of price increases by drug firms and worn-out patience waiting for President Trump to follow through his campaign promise, Senator Bernie Sanders (D-VT) and Representative Elijah Cummings (D-MD 7th District) have introduced a bill aimed at reining in drug prices… read more...

Dem lawmakers introduce bill to lower U.S. drug prices

via: SeekingAlpha at 2019-01-11 11:00:35:000

On the heels of a new round of price increases by drug firms and worn-out patience waiting for President Trump to follow through his campaign promise, Senator Bernie Sanders (D-VT) and Representative Elijah Cummings (D-MD 7th District) have introduced a bill aimed at reining in drug prices… read more...

Dem lawmakers introduce bill to lower U.S. drug prices

via: SeekingAlpha at 2019-01-11 11:00:35:000

On the heels of a new round of price increases by drug firms and worn-out patience waiting for President Trump to follow through his campaign promise, Senator Bernie Sanders (D-VT) and Representative Elijah Cummings (D-MD 7th District) have introduced a bill aimed at reining in drug prices… read more...

Will Investors Find A Nektar Balm In Gilead?

via: SeekingAlpha at 2019-01-10 10:06:09:000

Nektar Therapeutics ( NKTR Research Report ) attended the 37 th annual JPMorgan Healthcare Conference, held Jan 8 in San Fransico. At the event, CEO Howard Robin announced an agreement with Gilead Sciences, Inc. ( GILD Research Report ) on a virology collabor… read more...

Monthly Review Of DivGro: December 2018

via: SeekingAlpha at 2019-01-10 01:11:44:000

Welcome to this final monthly review of 2018 of my portfolio, DivGro! I write monthly reviews to share updates to my portfolio and to provide a summary of dividends collected. I also look at how DivGro's projected annual dividend income (PADI) has changed. December was a busy trading month f… read more...

Road To Financial Independence: My December 100-Stock Portfolio Review

via: SeekingAlpha at 2019-01-09 16:08:43:000

First of all, Happy New Year everybody! Similarly to 2017, 2018 closed with a bang, this time however the December rally from 2017 was replaced with the Christmas rout of 2018. The absolute low was reached on Christmas Eve but I had already spent too much during the year that I was lacking f… read more...

Gilead Is Gearing Release Of NASH Results Soon, But Other Deals Are Still Rolling In

via: SeekingAlpha at 2019-01-09 11:08:32:000

Gilead Sciences ( GILD ) is getting ready to release NASH results in the 1st half of 2019. This will be from studies dealing with selonsertib to treat patients with NASH fibrosis. The thing is that Gilead doesn't want to hinge its entire future on selonsertib. It also wants to establish a st… read more...

Where Will M&A Strike Next Across Biotech?

via: SeekingAlpha at 2019-01-09 07:25:36:000

The ruling power is always faced with the question, In such and such circumstances, what would you do?, whereas the opposition is not obliged to take responsibility or make any real decisions. George Orwell The biotech sector had a solid week to kick of… read more...

Dividend Income Update December 2018

via: SeekingAlpha at 2019-01-08 17:32:25:000

The start of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. December was exciting as ever as my year over year numbers continue to highlight the trifecta magic of dividend invest… read more...

Japan's Ministry of Health, Labour and Welfare Approves Gilead's Epclusa® (Sofosbuvir/Velpatasvir)

via: Business Wire at 2019-01-08 01:00:00:000

- Epclusa is the First Approved Treatment for Adults with Chronic Hepatitis C Virus with Decompensated Cirrhosis in Japan - Gilead Sciences, Inc. (NASDAQ: GILD) announced today that Japans Ministry of Health, Labour and Welfare (MHLW) has approved Epclusa (sofosbuvir… read more...

2018 Q4 Non-Taxable Portfolio Update

via: SeekingAlpha at 2019-01-07 12:54:52:000

Overview During the 4th quarter of 2018, my non-taxable portfolio generated a loss of 13.86%, while S&P 500 was down 14.28% (see the table below for a full comparison against major indices). Index Data Source: Yahoo Finance. The absolute performance was certainly unsatisfactory, al… read more...

Gilead teams up with Yuhan in NASH

via: SeekingAlpha at 2019-01-07 08:07:57:000

Gilead Sciences (NASDAQ: GILD ) inks a licensing and collaboration agreement with South Korea's Yuhan Corp. ( OTCPK:YUHNF ) to co-develop treatments for advanced fibrosis associated with nonalcoholic steatohepatitis (NASH). More news on: Gilead Sciences, Inc., YuHan Corporation, Healthca… read more...

Gilead Sciences and Yuhan Corporation Announce Collaboration and License Agreement to Develop Novel Investigational Treatments for Advanced Fibrosis Due to Nonalcoholic Steatohepatitis

via: Business Wire at 2019-01-06 17:30:00:000

Gilead Sciences, Inc. (NASDAQ: GILD) and Yuhan Corporation (000100.KS; Yuhan) today announced that the companies have entered into a licensing and collaboration agreement to co-develop novel therapeutic candidates for the treatment of patients with advanced fibrosis due to nonalcoholic steat… read more...

Merck Doesn't Want To Be Left Out Of The NASH Race Either, Uses Option Agreement

via: SeekingAlpha at 2019-01-04 16:57:49:000

Recently, Merck ( MRK ) expanded an old research collaboration with one of its partners known as NGM Biopharmaceuticals, Inc. ( NGM ). The newly expanded deal was made to include an option to license a NASH product from the pipeline. This product showed some pretty good preliminary data … read more...

Merck Doesn't Want To Be Left Out Of The NASH Race Either, Uses Option Agreement

via: SeekingAlpha at 2019-01-04 16:57:49:000

Recently, Merck ( MRK ) expanded an old research collaboration with one of its partners known as NGM Biopharmaceuticals, Inc. ( NGM ). The newly expanded deal was made to include an option to license a NASH product from the pipeline. This product showed some pretty good preliminary data … read more...

Merck Doesn't Want To Be Left Out Of The NASH Race Either, Uses Option Agreement

via: SeekingAlpha at 2019-01-04 16:57:49:000

Recently, Merck ( MRK ) expanded an old research collaboration with one of its partners known as NGM Biopharmaceuticals, Inc. ( NGM ). The newly expanded deal was made to include an option to license a NASH product from the pipeline. This product showed some pretty good preliminary data … read more...

Performance Review: 2018's Realized Returns

via: SeekingAlpha at 2019-01-04 09:35:27:000

Introduction 2019 will mark the fourth year I've shared my investing ideas on Seeking Alpha as a contributor. From the outset, I knew that I wanted to (1) share ideas and strategies that produced alpha (alpha being defined as outperforming the S&P 500 or an explicit alternative investm… read more...

Performance Review: 2018's Realized Returns

via: SeekingAlpha at 2019-01-04 09:35:27:000

Introduction 2019 will mark the fourth year I've shared my investing ideas on Seeking Alpha as a contributor. From the outset, I knew that I wanted to (1) share ideas and strategies that produced alpha (alpha being defined as outperforming the S&P 500 or an explicit alternative investm… read more...

Performance Review: 2018's Realized Returns

via: SeekingAlpha at 2019-01-04 09:35:27:000

Introduction 2019 will mark the fourth year I've shared my investing ideas on Seeking Alpha as a contributor. From the outset, I knew that I wanted to (1) share ideas and strategies that produced alpha (alpha being defined as outperforming the S&P 500 or an explicit alternative investm… read more...

3 Reasons Biotech Should Rally In 2019

via: SeekingAlpha at 2019-01-04 07:37:10:000

If lies are more comforting to you than facts, you need to get out of your comfort zone. - DaShanne Stokes Biotech seems to be off to a good start to begin 2019. After early losses on Thursday, the sector reversed and ended the day up one and half percent. The January effect se… read more...

3 Reasons Biotech Should Rally In 2019

via: SeekingAlpha at 2019-01-04 07:37:10:000

If lies are more comforting to you than facts, you need to get out of your comfort zone. - DaShanne Stokes Biotech seems to be off to a good start to begin 2019. After early losses on Thursday, the sector reversed and ended the day up one and half percent. The January effect se… read more...

3 Reasons Biotech Should Rally In 2019

via: SeekingAlpha at 2019-01-04 07:37:10:000

If lies are more comforting to you than facts, you need to get out of your comfort zone. - DaShanne Stokes Biotech seems to be off to a good start to begin 2019. After early losses on Thursday, the sector reversed and ended the day up one and half percent. The January effect se… read more...

Genomic Medicine 2019: Sangamo Assay Kicks Off A Pivotal Year

via: SeekingAlpha at 2019-01-03 15:08:22:000

Image credit: Pixabay We understand that the results will be what matter next year. The time for promise is gone, and now it's about delivering on things that are important to patients. Sandy Macrae Nov 2018 The February WORLD Symposium kicks C19 off when Sangamo ( SGMO ) presents da… read more...

Needham sees 27% upside in Thermo Fisher in today's analyst action

via: SeekingAlpha at 2019-01-03 13:43:46:000

Aquestive Therapeutics ( AQST +0.3% ) initiated with Buy rating and $14 (97% upside) price target at Lake Street. More news on: Aquestive Therapeutics, Thermo Fisher Scientific Inc., PerkinElmer, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Gilead Sciences: Top Biotech Pick For The Next Decade With An Options Play

via: SeekingAlpha at 2019-01-03 09:43:42:000

Gilead Sciences ( GILD ) is an almost $81 billion biotech company. The company is renowned for a number of things, such as curing Hepatitis C . I originally wrote about the company being my top biotech pick in early-2017 . Recent times have been difficult for biotech, since early-September, … read more...

Drug makers OK with price inclusion with TV ads if done fairly

via: SeekingAlpha at 2019-01-02 11:34:26:000

Four members of Big Pharma, Pfizer ( PFE -1.6% ), Sanofi ( SNY -1.6% ), Eli Lilly ( LLY -1.5% ) and Johnson & Johnson ( JNJ -0.9% ), responding to the federal government's proposed inclusion of prices in TV drug ads generally support the value of increased transparency for pati… read more...

Gilead Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7

via: Business Wire at 2019-01-02 09:01:00:000

Webcast Available Through Gilead Corporate Website Gilead Sciences, Inc. (Nasdaq: GILD) today announced that members of the executive management team will participate in a fireside chat at the 37 th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 7 at 9… read more...

Updated Lists Of Stocks Topping Our Ranking Model

via: SeekingAlpha at 2018-12-31 21:43:52:000

Background It has been a year since we first introduced our factor-based quality ranking model (see " 13 Stocks That Top My Factor-Based Value Investing Ranking Model "). The purpose of the model has always been to find wonderful businesses at fair prices, although the valuation consideratio… read more...

CNBC article highlights $35B market opportunity of NASH drugs

via: SeekingAlpha at 2018-12-31 11:59:50:000

CNBC reports that nonalcoholic steatohepatitis or NASH is "next big thing" for drug makers, a potential market of $35B or more if pharma/biotech firms can successfully navigate the regulatory process, a task none has accomplished to date. More news on: Intercept Pharmaceuticals, Madrigal… read more...

The $35 billion race to cure a liver disease that affects 30 million Americans

via: CNBC at 2018-12-30 08:39:00:000

No summary available. read more...

January 2019 Stock Considerations

via: SeekingAlpha at 2018-12-30 07:01:56:000

With a new year and a new month upon us, it is time, once again, for me to outline my potential stock picks for my dividend growth portfolio. I'll continue to preface this post with my usual rant about how important it is to ignore all the financial panic that's being spewed by the mainstream … read more...

Share In Healthcare And Biotech Gains With 12% Yield From This Tekla Fund

via: SeekingAlpha at 2018-12-27 09:50:00:000

Co-produced with PendragonY for High Dividend Opportunities Defensive Nature of Healthcare and Biotech Stocks The healthcare and biotech sectors should play a role in every balanced portfolio, not only because they provide diversity, but also because of their fast growth, which is ge… read more...

Share In Healthcare And Biotech Gains With 12% Yield From This Tekla Fund

via: SeekingAlpha at 2018-12-27 09:50:00:000

Co-produced with PendragonY for High Dividend Opportunities Defensive Nature of Healthcare and Biotech Stocks The healthcare and biotech sectors should play a role in every balanced portfolio, not only because they provide diversity, but also because of their fast growth, which is ge… read more...

Share In Healthcare And Biotech Gains With 12% Yield From This Tekla Fund

via: SeekingAlpha at 2018-12-27 09:50:00:000

Co-produced with PendragonY for High Dividend Opportunities Defensive Nature of Healthcare and Biotech Stocks The healthcare and biotech sectors should play a role in every balanced portfolio, not only because they provide diversity, but also because of their fast growth, which is ge… read more...

Gilead Doubles Down On Its NASH Pipeline With $1.5B Deal

via: SeekingAlpha at 2018-12-26 16:06:38:000

Recently, Gilead Sciences ( GILD ) announced that it had entered into a strategic collaboration with a company by the name of Scholar Rock Holding Corporation ( SRRK ). The reason for this deal is so that Gilead could gets its hands on another type of technology to target the ever growin… read more...

Agenus Gets Hail Mary Cash Infusion From Gilead Sciences

via: SeekingAlpha at 2018-12-26 14:55:45:000

Recently, Agenus Inc. ( AGEN ) announced that it had entered into a partnership with Gilead Sciences ( GILD ) for an immuno-oncology (I-O) pipeline. This partnership will focus on the development and commercialization of up to 5 novel immuno-oncology therapies for Agenus' pipeline. I bel… read more...

Agenus Wins $1.85 Billion Deal, But Market Cap Is Just $266 Million

via: SeekingAlpha at 2018-12-26 14:45:58:000

Agenus ( AGEN ) is a small cap biotech pharmaceutical company that recently announced a deal potentially worth $1.85 billion with large cap biotech Gilead Sciences ( GILD ). At close on Monday, December 24, Agenus had a stock price of $2.22 and market capitalization of $266 million . I believ… read more...

Agenus teams up with Gilead to develop five I-O therapies; shares up 72% premarket

via: SeekingAlpha at 2018-12-20 07:49:33:000

Agenus (NASDAQ: AGEN ) is up 72% premarket in reaction to its collaboration with Gilead Sciences (NASDAQ: GILD ) to develop five immuno-oncology (I-O) therapies. More news on: Agenus, Gilead Sciences, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Agenus teams up with Gilead to develop five I-O therapies; shares up 72% premarket

via: SeekingAlpha at 2018-12-20 07:49:33:000

Agenus (NASDAQ: AGEN ) is up 72% premarket in reaction to its collaboration with Gilead Sciences (NASDAQ: GILD ) to develop five immuno-oncology (I-O) therapies. More news on: Agenus, Gilead Sciences, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Agenus teams up with Gilead to develop five I-O therapies; shares up 72% premarket

via: SeekingAlpha at 2018-12-20 07:49:33:000

Agenus (NASDAQ: AGEN ) is up 72% premarket in reaction to its collaboration with Gilead Sciences (NASDAQ: GILD ) to develop five immuno-oncology (I-O) therapies. More news on: Agenus, Gilead Sciences, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Gilead And Agenus Enter into Collaboration to Develop Immuno-Oncology Therapies

via: PR Newswire at 2018-12-20 07:30:00:000

FOSTER CITY, Calif. and LEXINGTON, Mass. , Dec. 20, 2018 /PRNewswire/ -- Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc. (NASDAQ: AGEN) announced today the companies have entered into an immuno-oncology (I-O) partnership focused on the development and commercialization of up to fiv… read more...

Gilead And Agenus Enter into Collaboration to Develop Immuno-Oncology Therapies

via: PR Newswire at 2018-12-20 07:30:00:000

FOSTER CITY, Calif. and LEXINGTON, Mass. , Dec. 20, 2018 /PRNewswire/ -- Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc. (NASDAQ: AGEN) announced today the companies have entered into an immuno-oncology (I-O) partnership focused on the development and commercialization of up to fiv… read more...

Gilead And Agenus Enter into Collaboration to Develop Immuno-Oncology Therapies

via: PR Newswire at 2018-12-20 07:30:00:000

FOSTER CITY, Calif. and LEXINGTON, Mass. , Dec. 20, 2018 /PRNewswire/ -- Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc. (NASDAQ: AGEN) announced today the companies have entered into an immuno-oncology (I-O) partnership focused on the development and commercialization of up to fiv… read more...

Gilead and Agenus Enter Into Collaboration to Develop Immuno-Oncology Therapies

via: Business Wire at 2018-12-20 07:23:02:000

-- Agenus Conference Call Scheduled for Today at 8:30 a.m. ET -- Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc. (NASDAQ: AGEN) announced today the companies have entered into an immuno-oncology (I-O) partnership focused on the development and commercialization of up to five nov… read more...

Gilead and Agenus Enter Into Collaboration to Develop Immuno-Oncology Therapies

via: Business Wire at 2018-12-20 07:23:02:000

-- Agenus Conference Call Scheduled for Today at 8:30 a.m. ET -- Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc. (NASDAQ: AGEN) announced today the companies have entered into an immuno-oncology (I-O) partnership focused on the development and commercialization of up to five nov… read more...

Gilead and Agenus Enter Into Collaboration to Develop Immuno-Oncology Therapies

via: Business Wire at 2018-12-20 07:23:02:000

-- Agenus Conference Call Scheduled for Today at 8:30 a.m. ET -- Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc. (NASDAQ: AGEN) announced today the companies have entered into an immuno-oncology (I-O) partnership focused on the development and commercialization of up to five nov… read more...

Scholar Rock teams up with Gilead in fibrotic diseases in partnership valued as high as $1.5B

via: SeekingAlpha at 2018-12-19 09:05:14:000

Scholar Rock Holding (NASDAQ: SRRK ) will collaborate with Gilead Sciences (NASDAQ: GILD ) on developing highly specific inhibitors of transforming growth factor beta (TGF) activation for the treatment of fibrotic diseases. More news on: Scholar Rock Holding, Gilead Sciences, Inc… read more...

Gilead Sciences and Scholar Rock Announce Strategic Collaboration to Develop Novel Therapies for Fibrotic Diseases

via: Business Wire at 2018-12-19 08:01:00:000

Companies to Develop Highly Specific Inhibitors of Local TGF Activation Gilead Sciences, Inc. (NASDAQ: GILD) and Scholar Rock Holding Corporation (NASDAQ: SRRK) announced today that the companies have entered into a strategic collaboration to discover and d… read more...

The New Generex: Unlocking The Value

via: SeekingAlpha at 2018-12-18 12:50:06:000

The principal research of Generex Biotechnology ( GNBT ) for years has been its buccal delivery system. The buccal tissue is the tissue on the inside of the cheek and under the tongue. Generex buccal delivery sprays a solution under a high gas aerosol formulation containing a drug on to the bl… read more...

Liver Therapy Forum: A Specialized Marketplace Service For Liver Therapeutics Investment Opportunities

via: SeekingAlpha at 2018-12-18 09:30:00:000

Editors' Note: This article is meant to introduce First Genesis Consulting's Marketplace service, Liver Therapy Forum . Why Liver Therapeutics Investing? There is significant public interest in chronic liver diseases such as NASH and Cholestatic liver diseases in the last 5-10 years … read more...

Credit Suisse sees 18% upside in Abbott in premarket analyst action

via: SeekingAlpha at 2018-12-18 08:05:22:000

Abbott (NYSE: ABT ) initiated with Outperform rating and $82 (18% upside) price target at Credit Suisse. More news on: Abbott Laboratories, Alnylam Pharmaceuticals, Inc., Baxter International Inc, Healthcare stocks news, Stocks on the move, , Read more … read more...

The First Ever Alphies (Podcast)

via: SeekingAlpha at 2018-12-18 06:30:00:000

by Daniel Shvartsman It's rough out there, or so Jeffrey Gundlach says . After the anodyne rise of 2017, the last quarter of 2018 has been genuinely startling. Whether the king of bonds is right that this marks a true turning point into a bear market or it's just a bit of a jostling befor… read more...

'Safer' Dividend NASDAQ Dogs Hunt 26.5%-59.4% Net Gains Per Broker December Targets

via: SeekingAlpha at 2018-12-17 18:15:09:000

Actionable Conclusions (1-10): Brokers Forecast Top Ten NASDAQ "Safer" Dividend Stocks to Net 26.5% to 59.4% Gains By December, 2019 Four of the ten top yield "safer" Dividend NASDAQ stocks (with name backgrounds tinted grey in the list above) were scattered in with the top ten gainers for… read more...

Zymeworks: Updates To Thesis And 2019 Outlook

via: SeekingAlpha at 2018-12-17 11:16:49:000

Shares of Zymeworks ( ZYME ) doubled a few months after my "Buy the Dip" article was published in late February - although the stock has pulled back, shares are still in the green by about 35%. In December, there's been some technical strength after an Asia-pact was inked with BeiGene ( BG… read more...

Jane's November Dividend Increases And Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-12-17 09:15:11:000

Investment Thesis November marks the ninth month that Jane's retirement (Traditional and Roth IRAs) have been established and received a steady flow of dividend income. Up to this point, Jane's retirement accounts from January 1st to October 31st of 2018 have produced a total dividend inco… read more...

54 Top Nasdaq December Dividend Dears By Yield, Upside, And Net Gains

via: SeekingAlpha at 2018-12-17 08:53:44:000

Source: YCharts Actionable Conclusions (1-10): Brokers Forecast 26.15% To 59.42% Net Gains From December's Nasdaq Top 10 Five of 10 top yield Nasdaq dividend stocks were identified as being among the top 10 net gainers for the coming year based on analyst one-year target prices. (The… read more...

Senate Dems introduce bill to block "excessive" increases in drug prices

via: SeekingAlpha at 2018-12-13 14:24:06:000

Four democratic senators, Richard Blumenthal (D-CT), Kamala Harris (D-CA), Amy Klobuchar (D-MN) and Jeff Merkley (D-OR), have introduced a bill aimed at blocking drug price hikes. Specifically, it will allow the Department of Health and Human Services to prohibit price increases that it co… read more...

Senate Dems introduce bill to block "excessive" increases in drug prices

via: SeekingAlpha at 2018-12-13 14:24:06:000

Four democratic senators, Richard Blumenthal (D-CT), Kamala Harris (D-CA), Amy Klobuchar (D-MN) and Jeff Merkley (D-OR), have introduced a bill aimed at blocking drug price hikes. Specifically, it will allow the Department of Health and Human Services to prohibit price increases that it co… read more...

Senate Dems introduce bill to block "excessive" increases in drug prices

via: SeekingAlpha at 2018-12-13 14:24:06:000

Four democratic senators, Richard Blumenthal (D-CT), Kamala Harris (D-CA), Amy Klobuchar (D-MN) and Jeff Merkley (D-OR), have introduced a bill aimed at blocking drug price hikes. Specifically, it will allow the Department of Health and Human Services to prohibit price increases that it co… read more...

Why Biotech Asset Managers Can (Should?) Make Money In Any Markets

via: SeekingAlpha at 2018-12-13 11:25:18:000

Thesis IBB ( IBB ), iShares Nasdaq Biotechnology ETF tracking Nasdaq Biotechnology Index ( NBI ), has been quite volatile in the last three years, with a standard deviation of 23% : Source: iShares Nasdaq Biotechnology ETF website The 3-year total return was -0.5%: Source: iShares … read more...

Why Biotech Asset Managers Can (Should?) Make Money In Any Markets

via: SeekingAlpha at 2018-12-13 11:25:18:000

Thesis IBB ( IBB ), iShares Nasdaq Biotechnology ETF tracking Nasdaq Biotechnology Index ( NBI ), has been quite volatile in the last three years, with a standard deviation of 23% : Source: iShares Nasdaq Biotechnology ETF website The 3-year total return was -0.5%: Source: iShares … read more...

Why Biotech Asset Managers Can (Should?) Make Money In Any Markets

via: SeekingAlpha at 2018-12-13 11:25:18:000

Thesis IBB ( IBB ), iShares Nasdaq Biotechnology ETF tracking Nasdaq Biotechnology Index ( NBI ), has been quite volatile in the last three years, with a standard deviation of 23% : Source: iShares Nasdaq Biotechnology ETF website The 3-year total return was -0.5%: Source: iShares … read more...

December Call Expirations

via: SeekingAlpha at 2018-12-13 08:13:25:000

I reviewed the calls I have working in December. My idea of a working call is a stock with a covered call option. I do not trade options. I use options to boost income from my income stocks. I review my calls routinely as it is the most actively managed portion of our portfolio. All of these… read more...

December Call Expirations

via: SeekingAlpha at 2018-12-13 08:13:25:000

I reviewed the calls I have working in December. My idea of a working call is a stock with a covered call option. I do not trade options. I use options to boost income from my income stocks. I review my calls routinely as it is the most actively managed portion of our portfolio. All of these… read more...

December Call Expirations

via: SeekingAlpha at 2018-12-13 08:13:25:000

I reviewed the calls I have working in December. My idea of a working call is a stock with a covered call option. I do not trade options. I use options to boost income from my income stocks. I review my calls routinely as it is the most actively managed portion of our portfolio. All of these… read more...

Gilead: The New CEO Will Need More Time

via: SeekingAlpha at 2018-12-12 10:38:51:000

Thesis Gilead ( GILD ) announced on 12/10/18 that it appointed the new Chairman and CEO effective 3/1/2019. The new leader, Daniel ODay, is currently the CEO of Roche Pharmaceuticals ( RHHBY ). While we consider Daniel O'Day to be well qualified for the job, we still think the GI… read more...

Marker Therapeutics Exits ASH An Optimist. Should That Be Enough For You?

via: SeekingAlpha at 2018-12-12 02:53:47:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. If you're interested in this se… read more...

Challenges For Gilead's 2 New CEOs

via: SeekingAlpha at 2018-12-10 13:23:58:000

Introduction: Gilead ( GILD ) will have three CEO's in less than three months In January 2016, GILD announced that its long-serving CEO, John Martin, was being succeeded by GILD lifer John Milligan, with Dr. Martin moving up to the role of executive CEO. Following a multi-month search, GI… read more...

New chief at Gilead an "incremental positive" - Jefferies

via: SeekingAlpha at 2018-12-10 12:41:17:000

In a note , Jefferies' Michael Yee says Gilead Sciences' ( GILD -1.9% ) new CEO, ex-Roche Pharma chief Dan O-Day, is an incremental positive and the first step in the company's turnaround story, adding that feedback from investors has been "neutral to positive." More news on: Gilead Sci… read more...

Trade Truce Shot Clock Keeps Ticking (Wall Street Breakfast Podcast)

via: SeekingAlpha at 2018-12-10 08:13:41:000

Today's Top Stories: Stocks across the globe are flashing red; China's trade surplus with the U.S. jumped in November, and China's foreign ministry called in the U.S. ambassador on Sunday to lodge a "strong protest" over the arrest of Huawei CFO Meng Wanzhou in Vancouver. If you are… read more...

Stocks making the biggest moves premarket: FB, FDX, TSLA, NTRI, TVPT & more

via: CNBC at 2018-12-10 08:00:00:000

No summary available. read more...

Wall Street Breakfast: Trade Truce Shot Clock Keeps Ticking

via: SeekingAlpha at 2018-12-10 07:02:24:000

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). Stocks across the globe are flashing red, while U.S. equity futures were off to a softer start to the new week on … read more...

It's official! O'Day takes top job at Gilead

via: SeekingAlpha at 2018-12-10 02:36:38:000

Gilead Sciences (NASDAQ: GILD ) has named Roche ( OTCQX:RHHBY ) executive Daniel ODay as its new chief executive officer, tapping an industry veteran to fill a management vacuum. He'll begin the job on March 1, 2019. More news on: Gilead Sciences, Inc., Roche Holding Ltd ADR, Roc… read more...

Gilead Sciences Names Daniel O'Day Chairman and Chief Executive Officer

via: Business Wire at 2018-12-10 01:00:00:000

-- Mr. ODay Brings Global Pharmaceutical Leadership Experience Across Geographies and Therapeutic Areas -- -- Appointment Effective March 1, 2019 -- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its Board of Directors has named Daniel ODay Ch… read more...

WSJ: Gilead Sciences to hire Roche exec O'Day as its next CEO

via: SeekingAlpha at 2018-12-09 21:53:10:000

Gilead Sciences (NASDAQ: GILD ) is expected to hire longtime Roche ( OTCQX:RHHBF , OTCQX:RHHBY ) executive Daniel ODay to become its new CEO , possibly as soon as tomorrow, WSJ reports. More news on: Gilead Sciences, Inc., Roche Holding Ltd, Roche Holding Ltd ADR, Healthcare st… read more...

How To Retire At 62 With Just Half A Million

via: SeekingAlpha at 2018-12-08 09:43:00:000

In the previous article that we wrote on our hypothetical couple - John and Lisa - we tried to demonstrate how they could retire in 10 years, starting with a modest savings of $300,000 at the age of 50 years that would grow to $1 Million by the time they actually retire at 60. We had assumed… read more...

How To Retire At 62 With Just Half A Million

via: SeekingAlpha at 2018-12-08 09:43:00:000

In the previous article that we wrote on our hypothetical couple - John and Lisa - we tried to demonstrate how they could retire in 10 years, starting with a modest savings of $300,000 at the age of 50 years that would grow to $1 Million by the time they actually retire at 60. We had assumed… read more...

Celgene Doesn't Want To Be Left Out, Posts Promising JCAR017 Data

via: SeekingAlpha at 2018-12-06 19:46:13:000

Recently, Celgene ( CELG ) announced preliminary data from its study treating patients with relapsed/refractory (r/r) chronic lymphocytic leukemia ((CLL)) and small lymphocytic lymphoma ((SLL)). The data shown was from the dose escalation part of an ongoing, open-label multicenter phase … read more...

Gilead Sciences Gets A Much Needed Confirmation Boost For Yescarta

via: SeekingAlpha at 2018-12-06 18:01:46:000

Recently, Gilead Sciences ( GILD ) announced results from its phase 1/2 trial using Yescarta to treat patients with refractory large B-cell lymphoma. These results were presented at the Annual Meeting of the American Society of Hematology ((ASH)) 2018 conference. A lot of patients have sti… read more...

Performance Review: Stocks That Topped My Factor-Based Quality Ranking Model

via: SeekingAlpha at 2018-12-04 09:05:36:000

Background Last December, I wrote this article describing how I pick stocks to invest for the long run using a quality-focused ranking approach. The ranking model contained a few quantifiable factors covering different dimensions of business fundamentals, some of which I would like to reit… read more...

Performance Review: Stocks That Topped My Factor-Based Quality Ranking Model

via: SeekingAlpha at 2018-12-04 09:05:36:000

Background Last December, I wrote this article describing how I pick stocks to invest for the long run using a quality-focused ranking approach. The ranking model contained a few quantifiable factors covering different dimensions of business fundamentals, some of which I would like to reit… read more...

Performance Review: Stocks That Topped My Factor-Based Quality Ranking Model

via: SeekingAlpha at 2018-12-04 09:05:36:000

Background Last December, I wrote this article describing how I pick stocks to invest for the long run using a quality-focused ranking approach. The ranking model contained a few quantifiable factors covering different dimensions of business fundamentals, some of which I would like to reit… read more...

China National Medical Products Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection

via: Business Wire at 2018-12-04 08:30:00:000

Fixed-Dose Combination HIV Treatment Backbone Can Be Paired with Range of Third Agents Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the China National Medical Products Administration (NMPA) has approved Descovy (emtricitabine 200 mg/tenofovir a… read more...

China National Medical Products Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection

via: Business Wire at 2018-12-04 08:30:00:000

Fixed-Dose Combination HIV Treatment Backbone Can Be Paired with Range of Third Agents Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the China National Medical Products Administration (NMPA) has approved Descovy (emtricitabine 200 mg/tenofovir a… read more...

China's National Medical Products Administration Approves Harvoni® (Ledipasvir/Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Genotype 1-6

via: Business Wire at 2018-12-04 08:30:00:000

--Harvoni Offers Highly Effective, Short-Duration, Pan-Genotypic Treatment for Chinese Patients with HCV Infection-- --Harvoni Achieved Cure Rate (SVR12) of 100 Percent in Clinical Trial of Chinese Patients with Genotype 1-- Gilead Sciences, Inc. (NASDAQ: GILD) announced toda… read more...

China National Medical Products Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection

via: Business Wire at 2018-12-04 08:30:00:000

Fixed-Dose Combination HIV Treatment Backbone Can Be Paired with Range of Third Agents Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the China National Medical Products Administration (NMPA) has approved Descovy (emtricitabine 200 mg/tenofovir a… read more...

China's National Medical Products Administration Approves Harvoni® (Ledipasvir/Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Genotype 1-6

via: Business Wire at 2018-12-04 08:30:00:000

--Harvoni Offers Highly Effective, Short-Duration, Pan-Genotypic Treatment for Chinese Patients with HCV Infection-- --Harvoni Achieved Cure Rate (SVR12) of 100 Percent in Clinical Trial of Chinese Patients with Genotype 1-- Gilead Sciences, Inc. (NASDAQ: GILD) announced toda… read more...

China's National Medical Products Administration Approves Harvoni® (Ledipasvir/Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Genotype 1-6

via: Business Wire at 2018-12-04 08:30:00:000

--Harvoni Offers Highly Effective, Short-Duration, Pan-Genotypic Treatment for Chinese Patients with HCV Infection-- --Harvoni Achieved Cure Rate (SVR12) of 100 Percent in Clinical Trial of Chinese Patients with Genotype 1-- Gilead Sciences, Inc. (NASDAQ: GILD) announced toda… read more...

Kite Announces Updated Data From ZUMA-3 Study of KTE-X19 in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

via: Business Wire at 2018-12-03 20:00:00:000

-- Ongoing Phase 1/2 Study Continues to Demonstrate High Rates of Response to a Single Infusion of KTE-X19 in a Patient Population with Limited Treatment Options -- -- Based on these Data, the Phase 2 Portion of ZUMA-3 is Now Enrolling -- -- Findings Presented in an Oral Sess… read more...

Kite Announces Updated Data From ZUMA-3 Study of KTE-X19 in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

via: Business Wire at 2018-12-03 20:00:00:000

-- Ongoing Phase 1/2 Study Continues to Demonstrate High Rates of Response to a Single Infusion of KTE-X19 in a Patient Population with Limited Treatment Options -- -- Based on these Data, the Phase 2 Portion of ZUMA-3 is Now Enrolling -- -- Findings Presented in an Oral Sess… read more...

Kite Announces Updated Data From ZUMA-3 Study of KTE-X19 in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

via: Business Wire at 2018-12-03 20:00:00:000

-- Ongoing Phase 1/2 Study Continues to Demonstrate High Rates of Response to a Single Infusion of KTE-X19 in a Patient Population with Limited Treatment Options -- -- Based on these Data, the Phase 2 Portion of ZUMA-3 is Now Enrolling -- -- Findings Presented in an Oral Sess… read more...

41 'Safer' Dividend Healthcare Pre-December WallStars From Dividend Dogcatcher

via: SeekingAlpha at 2018-12-03 13:45:10:000

Source: YCharts Actionable Conclusions (1-10): Brokers Forecast Ten High Yield Top Healthcare 'Safer' Dividend Stocks to Net 12.6% to 26.75% Gains To November 2019 Four of ten top 'safer' dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the t… read more...

Stocks making the biggest moves premarket: CAT, F, GM, FCAU, QCOM & more

via: CNBC at 2018-12-03 07:41:00:000

No summary available. read more...

Gilead's CAR-T Yescarta shows long-term benefit in lymphoma study

via: SeekingAlpha at 2018-12-02 17:10:28:000

With median follow-up of 27.1 months and a minimum of 24 months after a single infusion of Yescarta, 39% of patients maintained their responses. The best objective response via investigator assessment was 83% (n=84/101) at year 2, including 58% (n=59/101) with complete responses. More news… read more...

Kite Announces Two-Year Data for Yescarta® (Axicabtagene Ciloleucel) in Patients With Refractory Large B-Cell Lymphoma

via: Business Wire at 2018-12-02 12:04:00:000

-- 39 Percent of Patients in Ongoing Response Two Years after a Single Infusion of Yescarta in the ZUMA-1 Study; Median Overall Survival was Not Reached -- -- Data Presented at the Annual Meeting of the American Society of Hematology (ASH) and Simultaneously Published &#xA… read more...

Cramer's lightning round: I'm not a fan of Netflix's stock as an end-of-year buy

via: CNBC at 2018-11-30 18:50:00:000

No summary available. read more...

Cramer's lightning round: I'm not a fan of Netflix's stock as an end-of-year buy

via: CNBC at 2018-11-30 18:50:00:000

No summary available. read more...

The Oil Turn, Soaring Goose, And Value Traps

via: SeekingAlpha at 2018-11-30 12:16:44:000

by Daniel Shvartsman Today's Idea Guide splits up evenly between short ideas and long ideas in our review. On the short side, there's a mix of value traps, growth trains, and spiraling companies, while on the long side there's a micro-cap turnaround story, a steady grower or two, and a sha… read more...

The Oil Turn, Soaring Goose, And Value Traps

via: SeekingAlpha at 2018-11-30 12:16:44:000

by Daniel Shvartsman Today's Idea Guide splits up evenly between short ideas and long ideas in our review. On the short side, there's a mix of value traps, growth trains, and spiraling companies, while on the long side there's a micro-cap turnaround story, a steady grower or two, and a sha… read more...

Healthcare Yields Of 3% To 4.8% From Top 10 WallStars In November

via: SeekingAlpha at 2018-11-30 11:58:26:000

Actionable Conclusions (1-10): Analysts Projected 14.7% To 40.7% Net Gains For Top Ten Healthcare WallStars By November 2019 Five of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices. … read more...

Healthcare Yields Of 3% To 4.8% From Top 10 WallStars In November

via: SeekingAlpha at 2018-11-30 11:58:26:000

Actionable Conclusions (1-10): Analysts Projected 14.7% To 40.7% Net Gains For Top Ten Healthcare WallStars By November 2019 Five of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices. … read more...

World Economy On Display At G20 Summit

via: SeekingAlpha at 2018-11-30 07:49:01:000

Today's Top Stories: Crude oil prices drop below $50 a barrel for the first time since October 2017; U.S. stock index futures are pulling back after a stellar session on Wednesday, and after a decade at the helm of Unilever (UL), CEO Paul Polman has announced his retirement. If you … read more...

World Economy On Display At G20 Summit

via: SeekingAlpha at 2018-11-30 07:49:01:000

Today's Top Stories: Crude oil prices drop below $50 a barrel for the first time since October 2017; U.S. stock index futures are pulling back after a stellar session on Wednesday, and after a decade at the helm of Unilever (UL), CEO Paul Polman has announced his retirement. If you … read more...

Wall Street Breakfast: World Economy On Display At G20 Summit

via: SeekingAlpha at 2018-11-30 06:59:57:000

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). Shares across Europe and U.S. futures are drifting lower on the final day of November, as markets watch ongoing tr… read more...

Wall Street Breakfast: World Economy On Display At G20 Summit

via: SeekingAlpha at 2018-11-30 06:59:57:000

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). Shares across Europe and U.S. futures are drifting lower on the final day of November, as markets watch ongoing tr… read more...

Congo Ebola outbreak second largest in history

via: SeekingAlpha at 2018-11-30 05:27:04:000

The Ebola outbreak in eastern Congo is now the second biggest in history, with 426 confirmed and probable cases, resulting in 245 deaths since Aug. 1. More news on: Gilead Sciences, Inc., Regeneron Pharmaceuticals, Inc., Healthcare stocks news, Top stock market news, Read more … read more...

Congo Ebola outbreak second largest in history

via: SeekingAlpha at 2018-11-30 05:27:04:000

The Ebola outbreak in eastern Congo is now the second biggest in history, with 426 confirmed and probable cases, resulting in 245 deaths since Aug. 1. More news on: Gilead Sciences, Inc., Regeneron Pharmaceuticals, Inc., Healthcare stocks news, Top stock market news, Read more … read more...

Express Scripts' Miller says Washington at incredible moment on drug pricing

via: CNBC at 2018-11-29 16:51:00:000

No summary available. read more...

December 2018 Stock Considerations

via: SeekingAlpha at 2018-11-28 18:25:42:000

As we soon enter the last month of 2018, it is time, once again, to highlight some of my potential stock buys for December. It's funny how, some months, I prepare a long list of potential stocks to buy, and, other months, I barely scrape a few names together. With the start of December at hand… read more...

Jane's October Dividend Increases And Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-11-27 15:35:06:000

Investment Thesis October marks the eighth month that Jane's retirement (Traditional and Roth IRAs) have been established and received a steady flow of dividend income. Up to this point, Jane's retirement accounts from January 1st to September 30th of 2018 have demonstrated the following inc… read more...

Jane's October Dividend Increases And Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-11-27 15:35:06:000

Investment Thesis October marks the eighth month that Jane's retirement (Traditional and Roth IRAs) have been established and received a steady flow of dividend income. Up to this point, Jane's retirement accounts from January 1st to September 30th of 2018 have demonstrated the following inc… read more...

Gilead Sciences, Inc. (GILD) Management At The Evercore ISI HealthCONx Conference 2018 - Brokers Conference Transcript

via: SeekingAlpha at 2018-11-27 15:18:06:000

Gilead Sciences, Inc. (GILD) Company Conference Presentation November 27, 2018, 09:30 AM ET Executives Robin Washington - EVP & CFO John McHutchison - Chief Scientific Officer and Head of Research & Development Analysts Umer Raffat - Evercore Group LLC Presentation… read more...

Gilead Sciences, Inc. (GILD) Management At The Evercore ISI HealthCONx Conference 2018 - Brokers Conference Transcript

via: SeekingAlpha at 2018-11-27 15:18:06:000

Gilead Sciences, Inc. (GILD) Company Conference Presentation November 27, 2018, 09:30 AM ET Executives Robin Washington - EVP & CFO John McHutchison - Chief Scientific Officer and Head of Research & Development Analysts Umer Raffat - Evercore Group LLC Presentation… read more...

17 'Safer' Dividend Bloomberg 2019 Watchlist Picks Per Broker Nov. Targets And Financials

via: SeekingAlpha at 2018-11-27 08:51:55:000

Bloomberg Selections November 19, Bloomberg Business Week featured a list of 50 news and noteworthy stocks for the upcoming year. The 2019 list caught my dogcatcher eye because so many were dividend payers. Yet Bloomberg editors failed to include dividends as significant data in that art… read more...

17 'Safer' Dividend Bloomberg 2019 Watchlist Picks Per Broker Nov. Targets And Financials

via: SeekingAlpha at 2018-11-27 08:51:55:000

Bloomberg Selections November 19, Bloomberg Business Week featured a list of 50 news and noteworthy stocks for the upcoming year. The 2019 list caught my dogcatcher eye because so many were dividend payers. Yet Bloomberg editors failed to include dividends as significant data in that art… read more...

Viking Therapeutics Won't Live Up To The Hype

via: SeekingAlpha at 2018-11-26 05:00:00:000

NASH an introduction Fatty deposits and mild fibrosis in non-alcoholic fatty liver disease. Source NASH short for non-alcoholic steatohepatitis has been a magnet for biotech investors over the past few years. NASH designates the most severe form of non-alc… read more...

Bloomberg 2019 Watchlist: 50 Dividend Dogs Show Target Gains And Losses

via: SeekingAlpha at 2018-11-25 14:58:48:000

Bloomberg Selections At year end, Bloomberg Business Week features a list of 50 to 100 news and noteworthy stocks for the upcoming year. The 2019 list caught my dogcatcher eye because so many were dividend payers. Yet Bloomberg editors failed to include dividends as significant data in tha… read more...

Week In Review: Alphamab Closes $100 Million Series A For Oncology Candidates

via: SeekingAlpha at 2018-11-25 05:27:36:000

Deals and Financings Alphamab Oncology, a clinical-stage Suzhou biopharma, completed a Series A funding with over $100 million in capital. Earlier this year, Alphamab Oncology was spun out of Suzhou Alphamab with seven oncology assets and related technology platforms, including bispecific, p… read more...

CAR-T Cells In The Real World

via: SeekingAlpha at 2018-11-23 08:20:44:000

Real world experience with CAR-T cells for lymphoma will be discussed at the ASH meetings beginning on December 1, 2018. These discussions will be important to investors because they will give an early glimpse into results outside the clinical trial setting: whether they can live up to the hyp… read more...

CAR-T Cells In The Real World

via: SeekingAlpha at 2018-11-23 08:20:44:000

Real world experience with CAR-T cells for lymphoma will be discussed at the ASH meetings beginning on December 1, 2018. These discussions will be important to investors because they will give an early glimpse into results outside the clinical trial setting: whether they can live up to the hyp… read more...

Tesaro Is Now An Attractive Acquisition Target

via: SeekingAlpha at 2018-11-21 05:18:30:000

Several months ago, I wrote an SA article on Tesaro (TSRO) warning investors of an imminent decline in the stock due to lingering concerns regarding Zejula's safety, competition and its massive cash burn issue. At the time, TSRO was trading near $60/share and subsequently lost more than half… read more...

The Future-Proof Portfolio For Young Investors: Stability In A Volatile Period

via: SeekingAlpha at 2018-11-20 12:05:03:000

At the beginning of this year, I started the future-proof portfolio for young investors to show how young investors who are saving for their retirement can choose to distribute their funds. A focus on the long-term, no trading and stable investments are three cornerstones of my approach. Let u… read more...

NGM Biopharmaceuticals And NASH: Making Progress

via: SeekingAlpha at 2018-11-19 15:29:24:000

Any man or institution that tries to rob me of my dignity will lose - Nelson Mandela Introduction The once dormant clinical research and development of therapies for the non-viral liver disease, NASH, is now characterized by intense competition with over 30 innovative drug candidate… read more...

CytoDyn Unveils Pipeline Growth In Coming Year At Annual Shareholder Meeting

via: SeekingAlpha at 2018-11-19 09:00:00:000

Editor's note: Seeking Alpha is proud to welcome Michael Meltzer as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more CytoDyn I… read more...

Gilead's Vemlidy for chronic hepatitis B virus approved in China

via: SeekingAlpha at 2018-11-19 06:06:43:000

Gilead Sciences (NASDAQ: GILD ) announces that the China National Medical Products Administration (NMPA) has approved Vemlidy(tenofovir alafenamide, TAF) 25 mg, a once-daily treatment for chronic hepatitis B in adults and adolescents. More news on: Gilead Sciences, Inc., Healthcare… read more...

China National Medical Products Administration (NMPA) Approves Gilead's Vemlidy® (Tenofovir Alafenamide) for Chronic Hepatitis B Virus (HBV) Infection

via: Business Wire at 2018-11-18 22:00:00:000

- First New Oral Treatment Approved for HBV in Ten Years Offers Improved Renal and Bone Laboratory Safety Parameters Compared to Tenofovir Disoproxil Fumarate (TDF) Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the China National Medical Products Administration … read more...

5% Income Strategy For 2019 And Beyond

via: SeekingAlpha at 2018-11-17 09:00:00:000

The stock market had a 10% correction last month, and it has been stuck in a narrow range since then. The battle between the bulls and bears is not over yet, and the future direction of the market remains unclear. The risks are elevated due to concerns about future earnings growth, stretched v… read more...

5% Income Strategy For 2019 And Beyond

via: SeekingAlpha at 2018-11-17 09:00:00:000

The stock market had a 10% correction last month, and it has been stuck in a narrow range since then. The battle between the bulls and bears is not over yet, and the future direction of the market remains unclear. The risks are elevated due to concerns about future earnings growth, stretched v… read more...

Gilead And GS-9674 In PSC And NASH: To Itch Or Not To Itch

via: SeekingAlpha at 2018-11-15 15:49:54:000

If you talk to a man in a language he understands, that goes to his head. If you talk to him in his language, that goes to his heart -Nelson Mandela Introduction Ever since the approval in 2016 of the FXR agonist ocaliva ( ICPT ), as a therapy for the cholestatic liver disease, … read more...

Gilead And GS-9674 In PSC And NASH: To Itch Or Not To Itch

via: SeekingAlpha at 2018-11-15 15:49:54:000

If you talk to a man in a language he understands, that goes to his head. If you talk to him in his language, that goes to his heart -Nelson Mandela Introduction Ever since the approval in 2016 of the FXR agonist ocaliva ( ICPT ), as a therapy for the cholestatic liver disease, … read more...

Biotech Giant Should Deliver Mid-Teens Total Returns

via: SeekingAlpha at 2018-11-15 09:30:48:000

Thesis AbbVie ( ABBV ) has turned into one of the most profitable biotech companies in the world. Unlike many of its peers, AbbVie is focused on sharing its profits with investors via dividend payments. AbbVie offers a high dividend yield, generous dividend increases, and its dividend look… read more...

Biotech Giant Should Deliver Mid-Teens Total Returns

via: SeekingAlpha at 2018-11-15 09:30:48:000

Thesis AbbVie ( ABBV ) has turned into one of the most profitable biotech companies in the world. Unlike many of its peers, AbbVie is focused on sharing its profits with investors via dividend payments. AbbVie offers a high dividend yield, generous dividend increases, and its dividend look… read more...

Biotech Bio Series #4: Regeneron Is Not Done

via: SeekingAlpha at 2018-11-14 09:30:03:000

This is the fourth article of the Biotech Bio Series. Big pharma and biotechnology is one of the most exciting sectors in the world today, researching and developing drugs that allow all of us to live longer than ever before. For companies behind this innovation, the approval of one drug may c… read more...

Road To Financial Independence: Growing Dividends, Endless Opportunities But Limited Capital

via: SeekingAlpha at 2018-11-14 08:50:00:000

October was another really intense month as ongoing trade woes, a hawkish interest rate environment and purely black-and-white earnings season mixed a toxic cocktail for most of the stocks. At times with the markets slipping into 10% correction mode the selling into the close was extreme and… read more...

The Acquirer's Portfolio - A Year In Review

via: SeekingAlpha at 2018-11-13 12:43:16:000

Background: Over the past year I have been writing about and tracking a portfolio I created using Tobias Carlisles acquirers multiple investing strategies. This post is the third installment of the series in which I aim to keep updated every 6 months. If you would like to r… read more...

Can-Fite Biopharma And Namodenoson In NAFLD/NASH: A Targeted Therapeutic Approach

via: SeekingAlpha at 2018-11-13 08:55:00:000

Any man or institution that tries to rob me of my dignity will lose-Nelson Mandela Introduction Can-Fite ( CANF ) is an Israeli small market-cap ($26.5M) clinical stage biopharma founded by CEO, Dr. Pnina Fishman, a leading expert on Adenosine A 3 receptor biology. Can-Fites&#x20… read more...

Amazon Selects New York And Virginia Locations For HQ2 And 3

via: SeekingAlpha at 2018-11-13 07:42:09:000

Today's top stories: Amazon selects New York and Virginia as locations for HQ 2 and 3; Apple, global growth and the Fed led to Monday's market rout; and Google plans to double New York City workforce. If you are interested in listening to Wall Street Breakfast to start your day, look … read more...

Wall Street Breakfast: Amazon Finds Homes For New Headquarters

via: SeekingAlpha at 2018-11-13 06:59:35:000

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). Amazon has selected New York's Long Island City and Northern Virginia's Crystal City as the sites for its second a… read more...

Ebola clinical trial to begin in DRC

via: SeekingAlpha at 2018-11-13 04:49:09:000

Health officials in Democratic Republic of Congo are planning to launch a clinical trial of four Ebola treatments as the country faces the worst outbreak in its history. More news on: Gilead Sciences, Inc., Regeneron Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...

Gilead Sciences to Present at the Evercore ISI HealthCONx Conference on Tuesday, November 27

via: Business Wire at 2018-11-12 17:01:00:000

Webcast Available Through Gilead Corporate Website Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Robin L. Washington, Gileads Executive Vice President and Chief Financial Officer, and John McHutchison, AO, MD, Gileads Chief Scientific Officer and Head of … read more...

Biotechs getting slammed again, XBI down almost 4%

via: SeekingAlpha at 2018-11-12 11:45:16:000

In an all-too-frequent narrative, biotechs are getting roughed up yet again. The SPDR S&P Biotech ETF ( XBI -3.5% ) is in the red, albeit on below-average volume. The ETF has lost ~22% of its value in a little over two months. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, In… read more...

Gilead's GS-9674 shows positive effect in mid-stage PSC study

via: SeekingAlpha at 2018-11-09 08:53:58:000

52 PSC patients were randomized to receive either 100 mg or 30 of GS-9674 each day or placebo for 12 weeks. At the end of week 12, patients in the treatment arms showed a median reduction in serum alkaline phosphatase (liver enzyme that is a biomarker for liver damage) of 20.5% compared to a… read more...

Gilead's GS-9674 shows positive effect in mid-stage PSC study

via: SeekingAlpha at 2018-11-09 08:53:58:000

52 PSC patients were randomized to receive either 100 mg or 30 of GS-9674 each day or placebo for 12 weeks. At the end of week 12, patients in the treatment arms showed a median reduction in serum alkaline phosphatase (liver enzyme that is a biomarker for liver damage) of 20.5% compared to a… read more...

Gilead's GS-9674 shows positive effect in mid-stage PSC study

via: SeekingAlpha at 2018-11-09 08:53:58:000

52 PSC patients were randomized to receive either 100 mg or 30 of GS-9674 each day or placebo for 12 weeks. At the end of week 12, patients in the treatment arms showed a median reduction in serum alkaline phosphatase (liver enzyme that is a biomarker for liver damage) of 20.5% compared to a… read more...

Gilead's GS-9674 shows positive action in mid-stage NASH study

via: SeekingAlpha at 2018-11-09 08:35:08:000

Participants received a once-daily oral dose of GS-9674 or placebo for 24 weeks. 38.8% of those receiving 100 mg of GS-9674 experienced at least a 30% decline in liver fat as measured by a type of MRI compared to 12.5% for control (p=0.011). 14% of patients receiving 30 mg of GS-9674 experie… read more...

Gilead's GS-9674 shows positive action in mid-stage NASH study

via: SeekingAlpha at 2018-11-09 08:35:08:000

Participants received a once-daily oral dose of GS-9674 or placebo for 24 weeks. 38.8% of those receiving 100 mg of GS-9674 experienced at least a 30% decline in liver fat as measured by a type of MRI compared to 12.5% for control (p=0.011). 14% of patients receiving 30 mg of GS-9674 experie… read more...

Gilead's GS-9674 shows positive action in mid-stage NASH study

via: SeekingAlpha at 2018-11-09 08:35:08:000

Participants received a once-daily oral dose of GS-9674 or placebo for 24 weeks. 38.8% of those receiving 100 mg of GS-9674 experienced at least a 30% decline in liver fat as measured by a type of MRI compared to 12.5% for control (p=0.011). 14% of patients receiving 30 mg of GS-9674 experie… read more...

How To Retire With Safe And Quality High Yields

via: SeekingAlpha at 2018-11-09 08:15:00:000

This research report was produced by The REIT Forum with assistance from Big Dog Investments . If you want to retire, you are going to need passive income. There are a few ways to tackle that challenge, but some are better than others. Investors who fail to tackle the income issue effec… read more...

How To Retire With Safe And Quality High Yields

via: SeekingAlpha at 2018-11-09 08:15:00:000

This research report was produced by The REIT Forum with assistance from Big Dog Investments . If you want to retire, you are going to need passive income. There are a few ways to tackle that challenge, but some are better than others. Investors who fail to tackle the income issue effec… read more...

How To Retire With Safe And Quality High Yields

via: SeekingAlpha at 2018-11-09 08:15:00:000

This research report was produced by The REIT Forum with assistance from Big Dog Investments . If you want to retire, you are going to need passive income. There are a few ways to tackle that challenge, but some are better than others. Investors who fail to tackle the income issue effec… read more...

Gilead Presents Data From Nonalcoholic Steatohepatitis (NASH) Development Program for Advanced Fibrosis at The Liver Meeting® 2018

via: Business Wire at 2018-11-09 08:00:00:000

-- Phase 2 Data Presented on Investigational FXR Agonist GS-9674 in NASH -- -- Enrollment Complete in Phase 2 ATLAS Combination Trial of Three Investigational Therapies Targeting Distinct Mechanisms of the Disease -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced new da… read more...

Gilead Announces Positive Phase 2 Results for GS-9674 in Primary Sclerosing Cholangitis (PSC) at The Liver Meeting® 2018

via: Business Wire at 2018-11-09 08:00:00:000

GS-9674 Granted Orphan Drug Designation by the U.S. Food and Drug Administration Gilead Sciences, Inc. (Nasdaq: GILD) today announced that treatment with GS-9674, an investigational, selective, nonsteroidal farnesoid X receptor (FXR) agonist, led to significant imp… read more...

Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting® 2018

via: Business Wire at 2018-11-09 08:00:00:000

Data Demonstrate Sofosbuvir-Based Regimens Achieve High Cure Rates in Hepatitis C Patient Populations with Unmet Need Early Data from Gileads Functional Hepatitis B Cure Program Suggest Activation of Immune Cells Crucial to Viral Clearance … read more...

Gilead Presents Data From Nonalcoholic Steatohepatitis (NASH) Development Program for Advanced Fibrosis at The Liver Meeting® 2018

via: Business Wire at 2018-11-09 08:00:00:000

-- Phase 2 Data Presented on Investigational FXR Agonist GS-9674 in NASH -- -- Enrollment Complete in Phase 2 ATLAS Combination Trial of Three Investigational Therapies Targeting Distinct Mechanisms of the Disease -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced new da… read more...

Gilead Announces Positive Phase 2 Results for GS-9674 in Primary Sclerosing Cholangitis (PSC) at The Liver Meeting® 2018

via: Business Wire at 2018-11-09 08:00:00:000

GS-9674 Granted Orphan Drug Designation by the U.S. Food and Drug Administration Gilead Sciences, Inc. (Nasdaq: GILD) today announced that treatment with GS-9674, an investigational, selective, nonsteroidal farnesoid X receptor (FXR) agonist, led to significant imp… read more...

Gilead Announces Positive Phase 2 Results for GS-9674 in Primary Sclerosing Cholangitis (PSC) at The Liver Meeting® 2018

via: Business Wire at 2018-11-09 08:00:00:000

GS-9674 Granted Orphan Drug Designation by the U.S. Food and Drug Administration Gilead Sciences, Inc. (Nasdaq: GILD) today announced that treatment with GS-9674, an investigational, selective, nonsteroidal farnesoid X receptor (FXR) agonist, led to significant imp… read more...

Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting® 2018

via: Business Wire at 2018-11-09 08:00:00:000

Data Demonstrate Sofosbuvir-Based Regimens Achieve High Cure Rates in Hepatitis C Patient Populations with Unmet Need Early Data from Gileads Functional Hepatitis B Cure Program Suggest Activation of Immune Cells Crucial to Viral Clearance … read more...

Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting® 2018

via: Business Wire at 2018-11-09 08:00:00:000

Data Demonstrate Sofosbuvir-Based Regimens Achieve High Cure Rates in Hepatitis C Patient Populations with Unmet Need Early Data from Gileads Functional Hepatitis B Cure Program Suggest Activation of Immune Cells Crucial to Viral Clearance … read more...

Gilead Presents Data From Nonalcoholic Steatohepatitis (NASH) Development Program for Advanced Fibrosis at The Liver Meeting® 2018

via: Business Wire at 2018-11-09 08:00:00:000

-- Phase 2 Data Presented on Investigational FXR Agonist GS-9674 in NASH -- -- Enrollment Complete in Phase 2 ATLAS Combination Trial of Three Investigational Therapies Targeting Distinct Mechanisms of the Disease -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced new da… read more...

Lessons From My Biggest Seeking Alpha Mistakes

via: SeekingAlpha at 2018-11-08 14:48:16:000

Source: Pixabay Introduction While it's best to learn from the mistakes of others, a close runner-up is learning from our own mistakes. I had originally planned to write an update on my unrealized long-ideas for this article, but since I'll be writing a comprehensive update at the end of… read more...

Biotech Analysis Central Pharma News: Gilead's Push, AcelRx's Approval, Trevena's Rejection

via: SeekingAlpha at 2018-11-07 14:58:33:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Gilead Sciences Makes Another Push Towards Immuno-Oncology News: Recently, Gilead Sciences ( GILD ) announced that it had formed a collaboration wi… read more...

Why We Pass On Amgen

via: SeekingAlpha at 2018-11-06 11:53:32:000

Amgen's stock is the leading iShares Nasdaq Biotechnology ETF ( IBB ) component. However, we don't think that its stock is going to grow faster than other stocks represented in IBB. While other major biotech companies have suffered stock declines due to weakened sales forecast, Amgen has not… read more...

A Migrating Biotech Bear

via: SeekingAlpha at 2018-11-06 08:39:35:000

Biotech Pulse Biotechnology is in a Bear Market. At least the midcap and smallcap segment of it. The S&P Biotechnology Select Index ( XBI ), which is weighted towards the midcap and smallcap companies, has dropped 24% from its high recorded on August 30 to its lowest point past Monda… read more...

CAR-T Cell Therapy: Will First To Market Mean First To Disappoint?

via: SeekingAlpha at 2018-11-05 13:05:30:000

Clinical manufacturing of CAR T cells: foundation of a promising therapy So far, the oncology community has greeted CAR T cell therapy with extraordinary enthusiasm. We've had few effective treatment options for difficult-to-treat blood cancers like diffuse large B-cell lymphoma. Th… read more...

How To Retire In 2018 Facing An Uphill Battle

via: SeekingAlpha at 2018-11-05 08:00:00:000

This research report was produced by The REIT Forum with assistance from Big Dog Investments . We wanted to write 2 articles on how investors can allocate their capital in retirement for income. In an upcoming article, we will cover preferred shares in depth. If you follow us, you will be… read more...

November 2018 Stock Considerations

via: SeekingAlpha at 2018-11-03 15:59:33:000

As the calendar shows November, it is time, once again, to highlight some of my potential stock buys for the upcoming month. Are we having fun yet? Are any of you making sense of the market these days? I can honestly tell you that I have zero idea about what's going on and where we'll be in … read more...

November 2018 Stock Considerations

via: SeekingAlpha at 2018-11-03 15:59:33:000

As the calendar shows November, it is time, once again, to highlight some of my potential stock buys for the upcoming month. Are we having fun yet? Are any of you making sense of the market these days? I can honestly tell you that I have zero idea about what's going on and where we'll be in … read more...

Street Fighting Man: Buying More AbbVie

via: SeekingAlpha at 2018-11-02 16:50:44:000

AbbVie's beat and raise The large biotech AbbVie ( ABBV ) reported a beat-and-raise Q3 pre-market Friday. These were the lead bullet points in its press release: Reports Third-Quarter Diluted EPS of $1.81 on a GAAP Basis; Adjusted Diluted EPS of $2.14 Reflects Growth of 51.8 Percent … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-11-02 10:12:14:000

Noteworthy events during the week of November 4 - 10 for healthcare investors. More news on: Dare Bioscience, Inc., EyePoint Pharmaceuticals, Inc., Aduro Biotech, Healthcare stocks news, , Read more … read more...

Economy Is Cooling - Cramer's Mad Money (11/1/18)

via: SeekingAlpha at 2018-11-02 07:47:15:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , November 1. President's softening stance on China and Fed not raising rates are the two events the market wants. That's what happened on Thursday when Trump tweeted China and the U.S. had their … read more...

Evaluating Pfizer's Growth Plans And Valuation

via: SeekingAlpha at 2018-11-01 18:38:52:000

Introduction Hope springs eternal. Maybe Pfizer ( PFE ) is finally ready to catch up with the market ( SPY ) and vault past its Y2K era all-time high, as Microsoft ( MSFT ) and most of its Dow ( DIA ) compatriots have done. On Tuesday, PFE showed a mild sales disappointment in the Q3 earnin… read more...

Drug stocks are 'no longer' reliable safety nets for investors: Cramer

via: CNBC at 2018-11-01 18:27:00:000

No summary available. read more...

Jane's September Dividend Increases And Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-11-01 09:59:36:000

Investment Thesis September marks the seventh month that Jane's retirement (Traditional and Roth IRAs) have been established and received a steady flow of dividend income. Jane's retirement account from February 1st to August 31st of 2018 have demonstrated the following income characterist… read more...

FDA OKs genetic test to inform on drug metabolism

via: SeekingAlpha at 2018-11-01 09:33:04:000

The FDA approves a consumer-targeted molecular diagnostic test from privately held 23andme , the Personal Genome Service Pharmacogenetic Reports, that detects 33 variants for multiple genes from a saliva sample. More news on: Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnolog… read more...

Gilead to Present Latest Scientific Research in Hematologic Malignancies and Solid Tumors at ASH 2018

via: Business Wire at 2018-11-01 09:00:00:000

-- Data Reinforce Breadth of Cell Therapy Portfolio and Commitment to Continued Innovation for People with Advanced Cancers -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from its oncology and cell therapy research programs will be presented at the 60 th American Soci… read more...

A Safe, Simple Means To Earn 3% To 6% On Your Cash Reserves: Part II

via: SeekingAlpha at 2018-11-01 08:10:58:000

Early last month, I authored a piece on Costco ( COST ) that included my strategy for earning an annual income of 3% to 6% on my cash reserves through carefully selected cash secured puts. The following is an excerpt from that article: It is absolutely critical, in my estimation,… read more...

Gilead down 6% as investors unmoved with Tango deal

via: SeekingAlpha at 2018-10-31 12:16:26:000

Gilead Sciences ( GILD -5.7% ) slumps on average volume. Investors appear disappointed with the (lack of) potential for its immuno-oncology partnership with Tango to rekindle growth. More news on: Gilead Sciences, Inc., United Therapeutics Corporation, Healthcare stocks news, Stocks on t… read more...

Gilead teams up with Tango Therapeutics in cancer

via: SeekingAlpha at 2018-10-31 09:39:02:000

Gilead Sciences ( GILD -1.9% ) inks a global collaboration agreement with privately held Tango Therapeutics aimed at discovering, developing and commercializing a lineup of immuno-oncology drugs. More news on: Gilead Sciences, Inc., Healthcare stocks news, Read more … read more...

Gilead Sciences and Tango Therapeutics Announce Strategic Collaboration to Develop Next-Generation Targeted Immuno-Oncology Therapies

via: Business Wire at 2018-10-31 08:30:00:000

Gilead Sciences, Inc. (Nasdaq: GILD) and Tango Therapeutics, Inc., a company focused on the discovery and development of novel cancer therapies, today announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative targeted immuno-oncology treatment… read more...

Gilead Remains A Sell

via: SeekingAlpha at 2018-10-30 10:11:52:000

Heading into Q3 earnings, I surmised Gilead's ( GILD ) revenue could decline sequentially. The company delivered a revenue and earnings beat, and its top line fell less than expected. I had the following takeaways on the quarter. HCV Was A Non-Factor After Gilead's HCV regimen proved it … read more...

Gilead's Biktarvy on par with DTG+FTC/TAF in late-stage HIV study

via: SeekingAlpha at 2018-10-30 07:13:28:000

Results from a Phase 3 clinical trial, Study 1490 , evaluating Gilead Sciences' (NASDAQ: GILD ) Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, BIC/FTC/TAF) in treatment-nave adults with HIV-1 infection showed it to be non-inferior to a regimen… read more...

Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy

via: Business Wire at 2018-10-30 06:36:00:000

Biktarvy Showed High Efficacy and High Barrier to Resistance Through 96 Weeks Gilead Sciences, Inc. (Nasdaq: GILD) today announced 96-week results from a Phase 3, randomized, double-blinded study (Study 1490) evaluating the safety and efficacy of Biktarvy (… read more...

This Stock Reset Requires Patience

via: SeekingAlpha at 2018-10-29 15:53:28:000

Halloween is here, but the goblins seem to have lost their way into the stock market. And they're creating havoc! The relentless volatility and a drip of near-daily 1-2% decline are darkening investor confidence and making it a month of terror. What started as a question of whether the Feder… read more...

Gilead: The Good, The 'Meh' And The Ugly

via: SeekingAlpha at 2018-10-29 15:51:17:000

Q3 is 'meh' and a downgrade and second 'meh' for filgotinib The title notwithstanding, I'll begin with the 'meh' or neutral news. Gilead ( GILD ) reported Q3 on Thursday. It showed pre-tax income of $2.7 B, sharply down yoy from $3.7 B. Results were flattered by $305 MM in "other" income… read more...

Vertex: Great Company But Too Pricey

via: SeekingAlpha at 2018-10-29 11:08:47:000

Vertex's Products And Pipeline Vertex Pharmaceuticals ( VRTX ) is focused on developing and commercializing therapies for the treatment of cystic fibrosis, or CF, with some early-stage pipeline in other diseases. The three marketed CF products are KALYDECO (ivacaftor), ORKAMBI (lumacaftor in… read more...

Equity Investing In This Rate-Hiking Environment

via: SeekingAlpha at 2018-10-29 08:53:37:000

Background "The interest rate is the gravity to stock valuations," Warren Buffett often quoted when responding to how to predict stock prices. While the statement is almost useless for investors to make future returns as no one can really predict the interest rate, it does reflect what happe… read more...

ViiV Healthcare's cabotegravir and rilpivirine regimen shows durable treatment effect in mid-stage HIV study

via: SeekingAlpha at 2018-10-29 07:27:12:000

Three-year data from a Phase 2b clinical trial, LATTE-2 , evaluating ViiV Healthcare's injectable two-drug regimen of cabotegravir and rilpivirine in HIV patients showed a durable treatment effect. The results were presented at the HIV Glasgow Drug Therapy meeting in Scotland. More new… read more...

Gilead: More Of The Same

via: SeekingAlpha at 2018-10-29 01:20:47:000

Gilead Sciences ( GILD ) continues to move along without much progress as the third-quarter results were more or less in line with expectations. By the end of July, Gilead reported second-quarter results, which showed continued sales declines as I continue to anticipate the moment in which… read more...

Trump mulling tieing U.S. drug prices to Europe's

via: SeekingAlpha at 2018-10-26 08:08:52:000

U.S. drug makers are facing a down day today after President Trump announced his first potential tactic aimed at lowering drug prices. Specifically, he is exploring benchmarking Medicare reimbursement to the average price in Europe for drugs administered by doctors, a group of medicines do… read more...

Trump mulling tieing U.S. drug prices to Europe's

via: SeekingAlpha at 2018-10-26 08:08:52:000

U.S. drug makers are facing a down day today after President Trump announced his first potential tactic aimed at lowering drug prices. Specifically, he is exploring benchmarking Medicare reimbursement to the average price in Europe for drugs administered by doctors, a group of medicines do… read more...

Trump mulling tieing U.S. drug prices to Europe's

via: SeekingAlpha at 2018-10-26 08:08:52:000

U.S. drug makers are facing a down day today after President Trump announced his first potential tactic aimed at lowering drug prices. Specifically, he is exploring benchmarking Medicare reimbursement to the average price in Europe for drugs administered by doctors, a group of medicines do… read more...

Wild Ride Ahead Of GDP Data (Wall Street Breakfast Podcast)

via: SeekingAlpha at 2018-10-26 07:55:15:000

Today's top stories: buckle up as stocks are due to take another leg down, FAANG stocks take a hit, and the U.S. government looks at spectrum strategy If you are interested in listening to Wall Street Breakfast to start your day, look for us in the following places: iTunes (fin… read more...

Wild Ride Ahead Of GDP Data (Wall Street Breakfast Podcast)

via: SeekingAlpha at 2018-10-26 07:55:15:000

Today's top stories: buckle up as stocks are due to take another leg down, FAANG stocks take a hit, and the U.S. government looks at spectrum strategy If you are interested in listening to Wall Street Breakfast to start your day, look for us in the following places: iTunes (fin… read more...

Wild Ride Ahead Of GDP Data (Wall Street Breakfast Podcast)

via: SeekingAlpha at 2018-10-26 07:55:15:000

Today's top stories: buckle up as stocks are due to take another leg down, FAANG stocks take a hit, and the U.S. government looks at spectrum strategy If you are interested in listening to Wall Street Breakfast to start your day, look for us in the following places: iTunes (fin… read more...

Stocks making the biggest move premarket: AMZN, GOOGL, INTC, CL, MCO & more

via: CNBC at 2018-10-26 07:44:00:000

No summary available. read more...

Stocks making the biggest move premarket: AMZN, GOOGL, INTC, CL, MCO & more

via: CNBC at 2018-10-26 07:44:00:000

No summary available. read more...

Stocks making the biggest move premarket: AMZN, GOOGL, INTC, CL, MCO & more

via: CNBC at 2018-10-26 07:44:00:000

No summary available. read more...

Premarket analyst action - healthcare, Piper softens view on Gilead Sciences, shares down 3% premarket

via: SeekingAlpha at 2018-10-26 07:24:07:000

ICON (NASDAQ: ICLR ) upgraded to Outperform at Evercore ISI. More news on: Icon PLC, Gilead Sciences, Inc., Cerner Corporation, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare, Piper softens view on Gilead Sciences, shares down 3% premarket

via: SeekingAlpha at 2018-10-26 07:24:07:000

ICON (NASDAQ: ICLR ) upgraded to Outperform at Evercore ISI. More news on: Icon PLC, Gilead Sciences, Inc., Cerner Corporation, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare, Piper softens view on Gilead Sciences, shares down 3% premarket

via: SeekingAlpha at 2018-10-26 07:24:07:000

ICON (NASDAQ: ICLR ) upgraded to Outperform at Evercore ISI. More news on: Icon PLC, Gilead Sciences, Inc., Cerner Corporation, Healthcare stocks news, Stocks on the move, , Read more … read more...

Wall Street Breakfast: Wild Ride Ahead Of GDP Data

via: SeekingAlpha at 2018-10-26 06:59:26:000

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). The Wall Street roller coaster is selling tickets again today as U.S. stock index futures post steep declines afte… read more...

Wall Street Breakfast: Wild Ride Ahead Of GDP Data

via: SeekingAlpha at 2018-10-26 06:59:26:000

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). The Wall Street roller coaster is selling tickets again today as U.S. stock index futures post steep declines afte… read more...

Wall Street Breakfast: Wild Ride Ahead Of GDP Data

via: SeekingAlpha at 2018-10-26 06:59:26:000

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). The Wall Street roller coaster is selling tickets again today as U.S. stock index futures post steep declines afte… read more...

Gilead Sciences (GILD) Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-10-25 23:15:56:000

Gilead Sciences, Inc. (GILD) Q3 2018 Earnings Call October 25, 2018 4:30 pm ET Executives Sung Lee - Gilead Sciences, Inc. Robin L. Washington - Gilead Sciences, Inc. Laura Hamill - Gilead Sciences, Inc. John G. McHutchison, AO, MD - Gilead Sciences, Inc. John F. Milligan, Ph… read more...

Gilead Sciences (GILD) Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-10-25 23:15:56:000

Gilead Sciences, Inc. (GILD) Q3 2018 Earnings Call October 25, 2018 4:30 pm ET Executives Sung Lee - Gilead Sciences, Inc. Robin L. Washington - Gilead Sciences, Inc. Laura Hamill - Gilead Sciences, Inc. John G. McHutchison, AO, MD - Gilead Sciences, Inc. John F. Milligan, Ph… read more...

Gilead Sciences (GILD) Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-10-25 23:15:56:000

Gilead Sciences, Inc. (GILD) Q3 2018 Earnings Call October 25, 2018 4:30 pm ET Executives Sung Lee - Gilead Sciences, Inc. Robin L. Washington - Gilead Sciences, Inc. Laura Hamill - Gilead Sciences, Inc. John G. McHutchison, AO, MD - Gilead Sciences, Inc. John F. Milligan, Ph… read more...

Gilead Sciences Q3 revenue off 14%; earnings down 23%; shares up 1% after hours on consensus beat

via: SeekingAlpha at 2018-10-25 16:19:08:000

Gilead Sciences (NASDAQ: GILD ) Q3 results ($M): Revenues: 5,596 (-14.1%); Product Sales: 5,455 (-14.8%). More news on: Gilead Sciences, Inc., Healthcare stocks news, Earnings news and commentary, Read more … read more...

Gilead Sciences beats by $0.21, beats on revenue

via: SeekingAlpha at 2018-10-25 16:02:01:000

Gilead Sciences (NASDAQ: GILD ): Q3 Non-GAAP EPS of $1.84 beats by $0.21 ; GAAP EPS of $1.60 beats by $0.31 . Revenue of $5.6B (-14.0% Y/Y) beats by $230M . Shares +0.3% . Press Release More news on: Gilead Sciences, Inc., Earnings news and commentary, Healthcare stocks news, … read more...

Gilead Sciences Announces Fourth Quarter 2018 Dividend

via: Business Wire at 2018-10-25 16:02:00:000

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the companys Board of Directors has declared a cash dividend of $0.57 per share of common stock for the fourth quarter of 2018. The dividend is payable on December 28, 2018, to stockholders of record at the close of business o… read more...

Gilead Sciences Announces Third Quarter 2018 Financial Results

via: Business Wire at 2018-10-25 16:01:00:000

- Product Sales of $5.5 billion - - Diluted EPS of $1.60 per share - - Non-GAAP Diluted EPS of $1.84 per share - - Revised Full Year 2018 Guidance - Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter ended Septem… read more...

Amazon, Alphabet tumble after earnings - here's what that could mean

via: CNBC at 2018-10-25 15:04:00:000

No summary available. read more...

More Revenue Declines For Gilead?

via: SeekingAlpha at 2018-10-25 13:59:11:000

Gilead ( GILD ) reports Q3 earnings after-hours. Analysts expect revenue of $5.38 billion and EPS of $1.63. The revenue estimate implies a 4% decline sequentially. Investors should focus on the following key items: It's All About The HIV Franchise… Gilead's HCV regimen has been transfo... read more...

Platinum Asset Management Quarterly Report September 30, 2018

via: SeekingAlpha at 2018-10-25 06:00:00:000

Read more … read more...

Notable earnings after Thursday's close

via: SeekingAlpha at 2018-10-24 17:35:45:000

ACTG , AKS , GOOG , AMZN , ARLO , AJG , AVT , BMRN , SAM , BYD , BGG , BVN , CPT , CBLK , CENX , CERN , CMG , CINF , CLD , CXP , COLM , FIX , OFC , CVA , CUBE , CUBI , CY , DECK , DLR , DFS , BOOM , DORM , EMN , ELLI , ENVA , EXPE , FII , FHB , FSLR , … read more...

Amgen cuts price of cholesterol drug by almost 60%, echoing rival's move

via: CNBC at 2018-10-24 16:01:00:000

No summary available. read more...

Biogen: Examining The Upside Potential

via: SeekingAlpha at 2018-10-24 10:58:38:000

Biogen ( BIIB ) reports Q3 I'd like to make a few comments about BIIB's Q3 results, its pipeline, and how its valuation ties into a theme I've noticed about biotechs the past few years since their fall from grace. All relevant links are BIIB's earnings report, slides and conference call can … read more...

Biotechs set for down gap at open

via: SeekingAlpha at 2018-10-23 09:25:19:000

The SPDR S&P Biotech ETF (NYSEARCA: XBI ) is down 2% premarket on light volume, continuing its 2% slide yesterday. More news on: SPDR Biotech ETF, Amgen Inc., Biogen Inc., Healthcare stocks news, Stocks on the move, News on ETFs, Read more … read more...

Positive Trial Results with Filgotinib in Psoriatic Arthritis and Ankylosing Spondylitis Both Published in The Lancet

via: Business Wire at 2018-10-22 13:15:00:000

-- Phase 2 EQUATOR Data Demonstrating Efficacy in Psoriatic Arthritis Also Presented in a Plenary Session at 2018 ACR/ARHP Annual Meeting -- Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that detailed results from two clinical tr… read more...

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting

via: Business Wire at 2018-10-20 18:30:00:000

-- FINCH 2 Study Results Demonstrate Significant Improvement in Rheumatoid Arthritis Signs, Symptoms and Health-Related Quality of Life Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINC… read more...

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting

via: Business Wire at 2018-10-20 18:30:00:000

-- FINCH 2 Study Results Demonstrate Significant Improvement in Rheumatoid Arthritis Signs, Symptoms and Health-Related Quality of Life Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINC… read more...

Stocks To Watch: Tech Earnings Bellwethers Set To Test Rally

via: SeekingAlpha at 2018-10-20 09:20:31:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. It was a return to (relative) stability for stocks this week after losses that hit … read more...

Stocks To Watch: Tech Earnings Bellwethers Set To Test Rally

via: SeekingAlpha at 2018-10-20 09:20:31:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. It was a return to (relative) stability for stocks this week after losses that hit … read more...

Biotech Stocks Bloodied But Can Now Drive M&A

via: SeekingAlpha at 2018-10-19 12:04:35:000

The precipitous, waterfall-like, decline in indexes this month was led by the sliding small-cap and biotech indexes. The chart below shows the anatomy of the pullback during the first half of October. The lowest two lines are the biotech indexes. The October Fall - Oct 01 to 12Source: Y… read more...

Assembly Biosciences: A Horseman Of The HBV Core-Pocalypse?

via: SeekingAlpha at 2018-10-19 11:23:09:000

Introduction Assembly Biosciences ( ASMB ) is a small-cap biotech company focused on the development of HBV therapeutics and microbiome-based therapies. The company has decidedly focused on a new and promising drug target which has already attracted many startup biotech companies and bi… read more...

Marker Therapeutics: A Safer And Potentially More Effective CAR-T Alternative

via: SeekingAlpha at 2018-10-18 08:49:27:000

Marker Therapeutics, is an immunotherapy innovator bringing an antigen-sensitized T cell product to market in a number of different cancer indications. The company is the product of a merger between TapImmune and Marker Therapeutics that completed on Oct 17th, 2018 and on Thursday, October 1… read more...

Gilead Sciences Is Bottoming - Cramer's Lightning Round (10/17/18)

via: SeekingAlpha at 2018-10-18 06:50:00:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, October 17 . Bullish Calls Ventas (VTR): "I think that the whole glut of nursing homes is now gone. There's not a lot of new ones being built." The stock yields 5.7% and Cramer thinks it's a bu… read more...

Cramer's lightning round: For growth and yield, go with Verizon over Kraft Heinz

via: CNBC at 2018-10-17 18:49:00:000

No summary available. read more...

10 'Safer' Dividend Healthcare WallStars Gain 12-23% Per Broker October Targets And Dividends

via: SeekingAlpha at 2018-10-16 08:28:14:000

Actionable Conclusions (1-10): Brokers Forecast Top Ten High Yield Healthcare "Safer" Dividend Stocks to Net 12.36% to 23.08% Gains To October 2019 Five of ten top 'safer' dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the top ten gainers for t… read more...

10 'Safer' Dividend Healthcare WallStars Gain 12-23% Per Broker October Targets And Dividends

via: SeekingAlpha at 2018-10-16 08:28:14:000

Actionable Conclusions (1-10): Brokers Forecast Top Ten High Yield Healthcare "Safer" Dividend Stocks to Net 12.36% to 23.08% Gains To October 2019 Five of ten top 'safer' dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the top ten gainers for t… read more...

FDA issues new guidance aimed at more efficient drug development

via: SeekingAlpha at 2018-10-15 13:49:33:000

The FDA has issued two guidance documents that it says should help make the drug development process more efficient. More news on: ProShares Ultra Nasdaq Biotechnology ETF, The Gabelli Healthcare & Wellness Rx Trust, Tekla World Healthcare Fund, Healthcare stocks news, News on ETFs, … read more...

Gilead In PBC: The Clinical Pursuit For Dominance

via: SeekingAlpha at 2018-10-15 12:45:26:000

Any man or institution that tries to rob me of my dignity will lose-Nelson Mandela Investment Thesis The once dormant clinical research and development of therapies for non-viral liver diseases is now characterized by intense competition and ongoing scientific advance. By expanding… read more...

Healthcare 16-24% Target Net Gains Pace WallStars For October

via: SeekingAlpha at 2018-10-15 09:57:51:000

Actionable Conclusions (1-10): Analysts Projected 16.2% To 23.9% Net Gains For Top 10 Healthcare WallStars By October 2019 Four of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker one-year target prices (… read more...

Protect Your Portfolio And Increase Returns By Focusing On Earnings Trends

via: SeekingAlpha at 2018-10-15 00:50:49:000

Simplicity is the ultimate sophistication. There is an almost infinite amount of variables to consider when making investment decisions. However, the smart thing to do is focusing on the variables that can have a stronger impact on your returns and risk in the market. At the end of the day, … read more...

The October Pause That Refreshes

via: SeekingAlpha at 2018-10-11 18:02:50:000

Well, here it is! The much-awaited correction, which everybody has been awaiting to finally invest in U.S. equities. Guess whatit will be like it has almost always been (and definitely many times during this, still the most hated/distrusted stock bull market in my memory). Most inv… read more...

The October Pause That Refreshes

via: SeekingAlpha at 2018-10-11 18:02:50:000

Well, here it is! The much-awaited correction, which everybody has been awaiting to finally invest in U.S. equities. Guess whatit will be like it has almost always been (and definitely many times during this, still the most hated/distrusted stock bull market in my memory). Most inv… read more...

The October Pause That Refreshes

via: SeekingAlpha at 2018-10-11 18:02:50:000

Well, here it is! The much-awaited correction, which everybody has been awaiting to finally invest in U.S. equities. Guess whatit will be like it has almost always been (and definitely many times during this, still the most hated/distrusted stock bull market in my memory). Most inv… read more...

Gilead Sciences to Release Third Quarter 2018 Financial Results on Thursday, October 25, 2018

via: Business Wire at 2018-10-11 16:05:00:000

-- Conference Call and Webcast to Follow -- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2018 financial results will be released on Thursday, October 25, after the market closes. At 4:30 p.m. Eastern Time, Gileads management will host a confere… read more...

Gilead Sciences to Release Third Quarter 2018 Financial Results on Thursday, October 25, 2018

via: Business Wire at 2018-10-11 16:05:00:000

-- Conference Call and Webcast to Follow -- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2018 financial results will be released on Thursday, October 25, after the market closes. At 4:30 p.m. Eastern Time, Gileads management will host a confere… read more...

Gilead Sciences to Release Third Quarter 2018 Financial Results on Thursday, October 25, 2018

via: Business Wire at 2018-10-11 16:05:00:000

-- Conference Call and Webcast to Follow -- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2018 financial results will be released on Thursday, October 25, after the market closes. At 4:30 p.m. Eastern Time, Gileads management will host a confere… read more...

Gilead to Present Wide-Ranging New Data on Treatment and Diagnosis of Liver Diseases at The Liver Meeting® 2018

via: Business Wire at 2018-10-11 15:23:00:000

-- More Than 50 Abstracts Across NASH, PSC, HBV and HCV Reflect Ongoing Commitment to Advancing the Care of People with Liver Disease-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that data from the companys liver disease research and development programs in nonalco… read more...

Gilead to Present Wide-Ranging New Data on Treatment and Diagnosis of Liver Diseases at The Liver Meeting® 2018

via: Business Wire at 2018-10-11 15:23:00:000

-- More Than 50 Abstracts Across NASH, PSC, HBV and HCV Reflect Ongoing Commitment to Advancing the Care of People with Liver Disease-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that data from the companys liver disease research and development programs in nonalco… read more...

Gilead to Present Wide-Ranging New Data on Treatment and Diagnosis of Liver Diseases at The Liver Meeting® 2018

via: Business Wire at 2018-10-11 15:23:00:000

-- More Than 50 Abstracts Across NASH, PSC, HBV and HCV Reflect Ongoing Commitment to Advancing the Care of People with Liver Disease-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that data from the companys liver disease research and development programs in nonalco… read more...

Alpine Immune Sciences: Digging Into A Recent Newcomer Onto The Immunotherapy Scene

via: SeekingAlpha at 2018-10-11 09:00:00:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Immunotherapy is easily one of… read more...

Alpine Immune Sciences: Digging Into A Recent Newcomer Onto The Immunotherapy Scene

via: SeekingAlpha at 2018-10-11 09:00:00:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Immunotherapy is easily one of… read more...

Alpine Immune Sciences: Digging Into A Recent Newcomer Onto The Immunotherapy Scene

via: SeekingAlpha at 2018-10-11 09:00:00:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Immunotherapy is easily one of… read more...

All Signs Pointing To Trouble At Cambrex - What Happened In Korea Is A Precursor

via: SeekingAlpha at 2018-10-11 05:00:00:000

Cambrex ( CBM ) is a supplier of active pharmaceutical ingredients (APIs) to the pharmaceutical industries. Based on its 2017 figures, ~66% of revenues are from supplying APIs for innovator drugs (i.e. non-generic), ~20% of revenues are from supplying APIs for generic drugs, and the rest from … read more...

All Signs Pointing To Trouble At Cambrex - What Happened In Korea Is A Precursor

via: SeekingAlpha at 2018-10-11 05:00:00:000

Cambrex ( CBM ) is a supplier of active pharmaceutical ingredients (APIs) to the pharmaceutical industries. Based on its 2017 figures, ~66% of revenues are from supplying APIs for innovator drugs (i.e. non-generic), ~20% of revenues are from supplying APIs for generic drugs, and the rest from … read more...

All Signs Pointing To Trouble At Cambrex - What Happened In Korea Is A Precursor

via: SeekingAlpha at 2018-10-11 05:00:00:000

Cambrex ( CBM ) is a supplier of active pharmaceutical ingredients (APIs) to the pharmaceutical industries. Based on its 2017 figures, ~66% of revenues are from supplying APIs for innovator drugs (i.e. non-generic), ~20% of revenues are from supplying APIs for generic drugs, and the rest from … read more...

Arbutus Biopharma: The Good, The Bad, And The Ugly

via: SeekingAlpha at 2018-10-09 11:25:50:000

Introduction Arbutus Biopharma ( ABUS ) is one of the many biotech companies focused on the research and development of Hepatitis B therapeutics. What helps make the company stand out from the crowd is its diverse pipeline and financial situation. The company has made great strides in deve… read more...

Arbutus Biopharma: The Good, The Bad, And The Ugly

via: SeekingAlpha at 2018-10-09 11:25:50:000

Introduction Arbutus Biopharma ( ABUS ) is one of the many biotech companies focused on the research and development of Hepatitis B therapeutics. What helps make the company stand out from the crowd is its diverse pipeline and financial situation. The company has made great strides in deve… read more...

Quarterly Review Of DivGro: Q3 2018

via: SeekingAlpha at 2018-10-09 06:34:46:000

Welcome to the Q3-2018 review of DivGro, my portfolio of dividend growth stocks. My quarterly reviews provide a summary of dividend income, dividend changes, and transactions executed in the past quarter. I also provide some charts showing various portfolio statistics. While these reviews … read more...

Quarterly Review Of DivGro: Q3 2018

via: SeekingAlpha at 2018-10-09 06:34:46:000

Welcome to the Q3-2018 review of DivGro, my portfolio of dividend growth stocks. My quarterly reviews provide a summary of dividend income, dividend changes, and transactions executed in the past quarter. I also provide some charts showing various portfolio statistics. While these reviews … read more...

Dividend Income Update September 2018

via: SeekingAlpha at 2018-10-09 05:53:35:000

The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. No doubt, these are the best posts to write and read online as it only provides further proof that dividend invest… read more...

Dividend Income Update September 2018

via: SeekingAlpha at 2018-10-09 05:53:35:000

The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. No doubt, these are the best posts to write and read online as it only provides further proof that dividend invest… read more...

Gilead Sciences: We're Not In Bull Territory Yet

via: SeekingAlpha at 2018-10-08 13:47:21:000

I agree with Gilead Sciences' ( GILD ) recent downgrade by Baird. The lack of clear financial catalysts for the next few quarters mean there is likely very little to move the stock price. There is a lot of chatter about the company's pipeline, but the monetary benefit isn't there yet. Furthe… read more...

Road To Financial Independence: Best September Ever, Investing Into Technology Stocks Amid Mounting Trade Woes

via: SeekingAlpha at 2018-10-08 13:43:24:000

The stock markets continued their strong momentum from August in September setting new records despite increasing concerns on a full-scale trade war, an appreciating U.S. dollar, rising commodity cost and interest rates rising further. While the broad market indices set new records select t… read more...

Arrowhead Surges Forward With Major Deal And Its Intentions Were Highly Misunderstood

via: SeekingAlpha at 2018-10-08 12:49:29:000

Recently, Arrowhead Pharmaceuticals ( ARWR ) announced that it had formed a partnership with Johnson & Johnson ( JNJ ). This partnership was formed on the basis for Arrowhead's Hepatitis B drug ARO-HBV. Arrowhead has made good progress ever since it had to abandon its old EX1 platf… read more...

Atara: Forecasting The Upcoming Clinical Binary Of Tab-Cel

via: SeekingAlpha at 2018-10-08 11:37:51:000

Opportunities come infrequently. When it rains gold, put out the bucket, not the thimble. - Warren Buffett Atara Biotherapeutics (NASDAQ: ATRA ) is a powerful grower that is supported by key catalysts to provide further upsides. First, the company will report the outcomes of Phase 3 (MAT… read more...

Week In Review: Shanghai Henlius To File For Hong Kong IPO At Valuation Of Over $1 Billion

via: SeekingAlpha at 2018-10-07 07:20:16:000

Deals and Financings Shanghai Fosun Pharma (HK: 02196: SHA: 600196) announced it will seek a Hong Kong IPO for Shanghai Henlius Biotech, its monoclonal antibody JV subsidiary. At the same time, the company will withdraw its application for a listing on China's Third Board, the National Equit… read more...

The Biotech Conundrum

via: SeekingAlpha at 2018-10-05 14:21:58:000

As the S&P 500 ( SPY ) and the Dow Jones ( DIA ) indexes recorded new highs last month, other indexes were consolidating and drifting lower. The Nasdaq ( QQQ ) retreated a little less than -1%, after being down nearly -3% during the month. The small-cap index, Russell 2000 ( IWM ), held up… read more...

The Biotech Conundrum

via: SeekingAlpha at 2018-10-05 14:21:58:000

As the S&P 500 ( SPY ) and the Dow Jones ( DIA ) indexes recorded new highs last month, other indexes were consolidating and drifting lower. The Nasdaq ( QQQ ) retreated a little less than -1%, after being down nearly -3% during the month. The small-cap index, Russell 2000 ( IWM ), held up… read more...

England's NHS to offer Gilead's Yescarta through Cancer Drugs Fund

via: SeekingAlpha at 2018-10-05 07:13:36:000

Gilead Sciences (NASDAQ: GILD ) and England's National Health Service (NHS) have reached agreement on adding CAR-T therapy YESCARTA (axicabtagene ciloleucel) to the Cancer Drugs Fund, a funding source enabling earlier access to new (and expensive) medicines. More news on: Gilead Sciences… read more...

England's NHS to offer Gilead's Yescarta through Cancer Drugs Fund

via: SeekingAlpha at 2018-10-05 07:13:36:000

Gilead Sciences (NASDAQ: GILD ) and England's National Health Service (NHS) have reached agreement on adding CAR-T therapy YESCARTA (axicabtagene ciloleucel) to the Cancer Drugs Fund, a funding source enabling earlier access to new (and expensive) medicines. More news on: Gilead Sciences… read more...

Merck's Delstrigo shows sustained treatment effect in late-stage HIV study

via: SeekingAlpha at 2018-10-04 09:59:00:000

96-week data from a Phase 3 clinical trial, DRIVE-AHEAD , evaluating Merck's ( MRK -0.6% ) combo pill DELSTRIGO [doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg)] in treatment-nave adults with HIV-1 infection showed a durable treatment… read more...

Monthly Review Of DivGro: September 2018

via: SeekingAlpha at 2018-10-04 06:48:20:000

Welcome to the September review of DivGro, my portfolio of dividend growth stocks. I present details of buys and sells, and I provide a summary of dividends collected. Additionally, I look at how the month's activities have impacted DivGro's projected annual dividend income (PADI). In Sept… read more...

Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy

via: Business Wire at 2018-10-03 08:30:00:000

Biktarvy Showed High Efficacy and a Demonstrated Tolerability Profile Through 96 Weeks Gilead Sciences, Inc. (Nasdaq: GILD) today announced 96-week results from a Phase 3, randomized, double-blinded study (Study 1489) evaluating the safety and efficacy of Biktarv… read more...

Gilead Sciences' Biktarvy(R) gets approval in Hong Kong

via: SeekingAlpha at 2018-10-03 06:43:11:000

Gilead Sciences (NASDAQ: GILD ) announces that the Hong Kong Department of Health has approved Biktarvy (bictegravir 50mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg; BIC/FTC/TAF), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection in adults. Hong Kong is th… read more...

Hong Kong Department of Health Approves Biktarvy(R) (bictegravir, emtricitabine, tenofovir alafenamide)

via: PR Newswire at 2018-10-03 04:58:00:000

In Clinical Trials, Biktarvy Demonstrated High Efficacy and Zero Resistance Through 48 Weeks HONG KONG , Oct. 3, 2018 /PRNewswire/ --Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the Hong Kong Department of Health has approved Biktarvy (bictegravir 50mg/emtr… read more...

NASH players under pressure following Liver Meeting abstract drop

via: SeekingAlpha at 2018-10-02 12:50:37:000

Biotechs developing treatments for nonalcoholic steatohepatitis (NASH) and other fatty liver diseases are seeing some action following the release of abstracts for November's Liver Meeting in San Francisco. More news on: NGM Biopharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals… read more...

FDA issues new draft guidance aimed at speedier generic approvals

via: SeekingAlpha at 2018-10-02 10:55:35:000

In a statement , FDA Commissioner Scott Gottlieb, M.D., outlines new draft guidance that he says should improve the process for reviewing generic drug marketing applications and boost competition in the prescription drugs market. More news on: ProShares Ultra Nasdaq Biotechnology ETF, T… read more...

Kite Pharma teams up with HiFiBiO to develop T cell receptors for cancer

via: SeekingAlpha at 2018-10-02 09:28:33:000

Gilead Sciences' (NASDAQ: GILD ) Kite Pharma inks an agreement with HiFiBiO Therapeutics aimed at developing technology supporting the discovery of neoantigen-reactive T cell receptors (TCRs) for the potential treatment of a range of cancers. More news on: Gilead Sciences, Inc., Health… read more...

Kite and HiFiBiO Therapeutics Announce a Research Collaboration to Develop Technology for the Potential Discovery of Neoantigen-Reactive T Cell Receptors (TCRs) for the Treatment of Cancer

via: Business Wire at 2018-10-02 08:30:00:000

Kite, a Gilead Company (Nasdaq: GILD), and HiFiBiO Therapeutics, a biotechnology company focused on the discovery of therapeutic antibodies through single B cell screening and analysis, announced the companies have entered into a research collaboration and license agreement to develop techno… read more...

ContraVir: A Speculative Contrarian Bet With Lots Of Upside Potential Part II

via: SeekingAlpha at 2018-10-02 08:23:32:000

Introduction ContraVir Pharmaceuticals ( CTRV ) is a nano-cap clinical-stage biotech focusing on the developing of small-molecule Hepatitis B therapeutics. For the over the past year and a half, ContraVir's stock price and market cap have fallen to unprecedented levels. Recently, the compa… read more...

Can Biotech Stocks Power Ahead?

via: SeekingAlpha at 2018-09-28 20:14:38:000

(Image Source ) Biotech stocks have been on fire this year, and the iShares NASDAQ Biotechnology ETF ( IBB ) has surged 14.23% on a year-to-date basis. This soundly outperforms the 9.15% gains which have been seen in the S&P 500 (during what is generally thought to be a continued bull m… read more...

Can Biotech Stocks Power Ahead?

via: SeekingAlpha at 2018-09-28 20:14:38:000

(Image Source ) Biotech stocks have been on fire this year, and the iShares NASDAQ Biotechnology ETF ( IBB ) has surged 14.23% on a year-to-date basis. This soundly outperforms the 9.15% gains which have been seen in the S&P 500 (during what is generally thought to be a continued bull m… read more...

Can Biotech Stocks Power Ahead?

via: SeekingAlpha at 2018-09-28 20:14:38:000

(Image Source ) Biotech stocks have been on fire this year, and the iShares NASDAQ Biotechnology ETF ( IBB ) has surged 14.23% on a year-to-date basis. This soundly outperforms the 9.15% gains which have been seen in the S&P 500 (during what is generally thought to be a continued bull m… read more...

Jane's August Dividend Increases And Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-09-28 15:27:55:000

Investment Thesis August marks the six months that Jane's retirement (Traditional and Roth IRAs) have been established and received a steady flow of dividend income. Jane's retirement account from February 1st to July 31st of 2018 have demonstrated the following income characteristics: T… read more...

47 Nasdaq 'Safer' Dividend Dogs For September 2019

via: SeekingAlpha at 2018-09-28 10:47:15:000

Actionable Conclusions (1-10): Brokers Forecast Top Ten NASDAQ "Safer" Dividend Stocks to Net 17.7% to 52.6% Gains By September 2019 Five of the ten top yield "safer" dividend NASDAQ stocks (with name backgrounds tinted grey in the list above) were scattered in with the top ten gainers for… read more...

On The NASDAQ Bandwagon, Top Yield, Upside, & Net Gain Stocks For September

via: SeekingAlpha at 2018-09-27 16:35:00:000

Actionable Conclusions (1-10): Brokers Cast 19.72% To 60.12% Net Gains From September's NASDAQ Top Ten Four of ten top yield NASDAQ dividend stocks were identified as being among the top ten net gainers for the coming year based on analyst 1-year target prices. (They are tinted gray in the… read more...

Tiziana Life Sciences Plans To Raise $16 Million In U.S. IPO

via: SeekingAlpha at 2018-09-27 13:16:07:000

Quick Take Tiziana Life Sciences plc ( TLSA ) is seeking to raise $16 million in a U.S. IPO, according to an amended registration statement . The company is advancing a pipeline of therapeutic candidates for various cancers and immune diseases. TLSA is developing promising treatments … read more...

Generic HCV Could Benefit Gilead

via: SeekingAlpha at 2018-09-27 12:37:09:000

In my opinion, Gilead ( GILD ) has one of the best management teams in all of healthcare. Unlike competitors, Gilead's management has stayed away from acquiring companies at the height of the market in order to give the illusion of growth. The company is not over-leveraged and does not have to… read more...

Best And Worst-Performing Stocks In The S&P 500 Over The Last 20 Years And How They Have Performed In 2018

via: SeekingAlpha at 2018-09-27 09:32:18:000

Background Twenty years ago, on August 17th, 1998 to be precise, a financial crisis hit Russia ( RSX , ERUS ). It resulted in the Russian government and the Russian Central Bank devaluing the ruble and defaulting on its debt. The Russian crisis of 1998 happened only one year after the Asi… read more...

Biotech Analysis Central Pharma News: Gilead's New Move, Sarepta's Hold Removal, Alexion's Plan

via: SeekingAlpha at 2018-09-26 16:30:30:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Gilead Sciences Implements Generic Hepatitis C Franchise To Boost Sales News: Recently, Gilead Sciences ( GILD ) announced that it will be pushing to … read more...

Verastem Declines On Its Much-Touted Catalyst, Is It Worth Buying Now?

via: SeekingAlpha at 2018-09-26 13:52:37:000

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Every developmental biotech … read more...

Pfizer facing difficult path to ramp up biosimilar business

via: SeekingAlpha at 2018-09-25 15:51:13:000

In an entirely predictable scenario, Pfizer ( PFE -0.3% ) is encountering a broad range of competitive roadblocks in its efforts to gain traction in its biosimilar business, a strategic priority since acquiring Hospira for $17B in 2015. More news on: Pfizer Inc., Amgen Inc., Johnson &amp… read more...

Fracking Business Is Slowing - Cramer's Lightning Round (9/24/18)

via: SeekingAlpha at 2018-09-25 05:54:08:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, September 24 . Bullish Calls bluebird bio (BLUE): It's a speculative play, but Cramer likes it. He called a bottom in Gilead Sciences (GILD) as well. Total (TOT): It's a winner in an environment… read more...

Cramer's lightning round: Oil refiner Total is a winner in this environment

via: CNBC at 2018-09-24 18:50:00:000

No summary available. read more...

Express Scripts taking credit for Gilead's planned launch of generic HCV meds

via: SeekingAlpha at 2018-09-24 16:02:45:000

Express Scripts ( ESRX -0.2% ) is congratulating the organization it sees in the mirror over Gilead Sciences' plan to launch generic versions of HCV meds Epclusa and Harvoni. More news on: Express Scripts, Inc., Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnology ETF, Healthca… read more...

Expected Value Investing: Diving Deeper On Conatus

via: SeekingAlpha at 2018-09-24 12:00:56:000

After providing an overview of the NASH cirrhosis market in my most recent article , I'm now planning on further analyzing Conatus Pharmaceuticals (NASDAQ: CNAT ), the only company in the entire NASH space targeting decompensated liver cirrhosis. After providing an overview of Conatus' lead … read more...

Gilead to launch generic versions of Epclusa and Harvoni

via: SeekingAlpha at 2018-09-24 08:42:11:000

Gilead Sciences (NASDAQ: GILD ) announces that newly created subsidiary Asegua Therapeutics LLC will launch authorized generic versions of hepatitis C meds Epclusa (sofosbuvir/velpatasvir) and Harvoni (ledipasvir/sofosbuvir) in the U.S. More news on: Gilead Sciences, Inc., AbbVie Inc., P… read more...

Gilead Subsidiary to Launch Authorized Generics of Epclusa® (Sofosbuvir/Velpatasvir) and Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C

via: Business Wire at 2018-09-24 08:30:00:000

-- List Price of Authorized Generics to Reflect Discounts in the System Today -- Gilead Sciences, Inc. (NASDAQ: GILD) announced today plans to launch authorized generic versions of Epclusa (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni (ledipasvir 90mg/sofosbuvir 4… read more...

Feds looking into free services from drug makers - WSJ

via: SeekingAlpha at 2018-09-21 09:15:15:000

The Wall Street Journal reports that federal prosecutors are investigating where certain drug markers, including Sanofi (NYSE: SNY ), Gilead Sciences (NASDAQ: GILD ) and Biogen (NASDAQ: BIIB ), violated laws by providing free services, such as nurses and reimbursement assistance, to doctor… read more...

Feds looking into free services from drug makers - WSJ

via: SeekingAlpha at 2018-09-21 09:15:15:000

The Wall Street Journal reports that federal prosecutors are investigating where certain drug markers, including Sanofi (NYSE: SNY ), Gilead Sciences (NASDAQ: GILD ) and Biogen (NASDAQ: BIIB ), violated laws by providing free services, such as nurses and reimbursement assistance, to doctor… read more...

Feds looking into free services from drug makers - WSJ

via: SeekingAlpha at 2018-09-21 09:15:15:000

The Wall Street Journal reports that federal prosecutors are investigating where certain drug markers, including Sanofi (NYSE: SNY ), Gilead Sciences (NASDAQ: GILD ) and Biogen (NASDAQ: BIIB ), violated laws by providing free services, such as nurses and reimbursement assistance, to doctor… read more...

What's Next For Gilead?

via: SeekingAlpha at 2018-09-21 08:33:06:000

Gilead ( GILD ) reported better than expected Q2 results and has been making progress with its pipeline over the last couple of months. It looks like 2018 could be the bottom, and revenues might increase again next year. This, coupled with a promising outlook for some of Gilead's pipeline cand… read more...

What's Next For Gilead?

via: SeekingAlpha at 2018-09-21 08:33:06:000

Gilead ( GILD ) reported better than expected Q2 results and has been making progress with its pipeline over the last couple of months. It looks like 2018 could be the bottom, and revenues might increase again next year. This, coupled with a promising outlook for some of Gilead's pipeline cand… read more...

What's Next For Gilead?

via: SeekingAlpha at 2018-09-21 08:33:06:000

Gilead ( GILD ) reported better than expected Q2 results and has been making progress with its pipeline over the last couple of months. It looks like 2018 could be the bottom, and revenues might increase again next year. This, coupled with a promising outlook for some of Gilead's pipeline cand… read more...

Breaking Down The NASH Cirrhosis Market - Gilead Poised For Success, But Is It Enough To Boost Stock Price?

via: SeekingAlpha at 2018-09-21 08:00:00:000

In my most recent article , I provided a segmentation of the overall NASH market (between fibrosis and cirrhosis) and briefly discussed each of the major players in the NASH fibrosis market. Now, I'd like to discuss the NASH cirrhosis market and provide an overview of the firms operating in t… read more...

Breaking Down The NASH Cirrhosis Market - Gilead Poised For Success, But Is It Enough To Boost Stock Price?

via: SeekingAlpha at 2018-09-21 08:00:00:000

In my most recent article , I provided a segmentation of the overall NASH market (between fibrosis and cirrhosis) and briefly discussed each of the major players in the NASH fibrosis market. Now, I'd like to discuss the NASH cirrhosis market and provide an overview of the firms operating in t… read more...

Breaking Down The NASH Cirrhosis Market - Gilead Poised For Success, But Is It Enough To Boost Stock Price?

via: SeekingAlpha at 2018-09-21 08:00:00:000

In my most recent article , I provided a segmentation of the overall NASH market (between fibrosis and cirrhosis) and briefly discussed each of the major players in the NASH fibrosis market. Now, I'd like to discuss the NASH cirrhosis market and provide an overview of the firms operating in t… read more...

My Quarterly Global Portfolio Update

via: SeekingAlpha at 2018-09-19 10:22:28:000

Background The long-term-focused long-only investment strategy for my global portfolio is no different from the one for my US-centric portfolio , except that it takes taxation into consideration, therefore, leading to the following implications: The portfolio is more biased towards no… read more...

My Quarterly Global Portfolio Update

via: SeekingAlpha at 2018-09-19 10:22:28:000

Background The long-term-focused long-only investment strategy for my global portfolio is no different from the one for my US-centric portfolio , except that it takes taxation into consideration, therefore, leading to the following implications: The portfolio is more biased towards no… read more...

AbbVie used kickbacks to boost Humira sales - CA insurance commissioner

via: SeekingAlpha at 2018-09-18 14:21:30:000

AbbVie ( ABBV -1.7% ) slips on below-average volume in apparent reaction to a lawsuit filed by the California Insurance Commissioner alleging that the company used a "stealthy" network of nurses and kickbacks to doctors to boost prescriptions of top seller Humira. More news on: AbbVie … read more...

For Investors Seeking Exposure To Biotech, BB Biotech AG Might Be An Interesting Alternative To Funds

via: SeekingAlpha at 2018-09-18 10:00:12:000

Biotech is a Growth Sector The biotech sector is largely growth driven. Especially, in the field of medicine lies huge growth potential for biotech. There is an ever-increasing demand for new and better treatments and medication for various diseases. Given the direction of demographic develo… read more...

Gilead: Forming A Base?

via: SeekingAlpha at 2018-09-18 09:35:44:000

(Image Source ) Biotech stocks have surged this year, soundly outperforming the S&P 500. But shareholders of Gilead Sciences ( GILD ) have participated in small portions of this bullish activity, with the stock showing gains of only 2.43% on a YTD basis. Sequential revenue growth, impro… read more...

Can The Hepatitis B Market Become The Next Growth Story For Gilead Sciences?

via: SeekingAlpha at 2018-09-17 21:30:36:000

Recently, Gilead Sciences (GILD) announced that it had entered into a partnership deal with Precision BioSciences for approximately $445 million. The reason for Gilead making a deal like this is so that it can get its hands on a treatment that could potentially cure hepatitis B. It did end u… read more...

My Anniversary: One Year Later, My Articles Outperform The S&P By 50%

via: SeekingAlpha at 2018-09-17 13:55:01:000

Following a long absence from Seeking Alpha, I returned to write a dozen buy articles in 2017. The results below reflect the closing price of each company on the day of the article debut with a comparison to the SPY ETFs closing price on the same day. The gain or loss is from those dat… read more...

GSK's 2-Drug Combo For HIV Could Threaten Gilead

via: SeekingAlpha at 2018-09-17 12:00:59:000

Gilead's ( GILD ) vaunted HCV franchise grew quarterly revenue by double digits in Q2 2018. HCV was less than 20% of total revenue, down from over 40% in the year earlier period. Its HIV franchise will likely drive the narrative from here. That could be problematic as GlaxoSmithKline ( GSK ), … read more...

Gilead Is On Hold For Now

via: SeekingAlpha at 2018-09-14 10:11:11:000

HIV Franchise HIV treatment regimens represent a vast majority of Gilead's ( GILD ) top line. In FY2017, around 70% of Gilead's $25 bn sales were generated due to various HIV agents in its portfolio. Moreover, the net income derived from HIV sales was also disproportionally higher compared… read more...

Gilead Is On Hold For Now

via: SeekingAlpha at 2018-09-14 10:11:11:000

HIV Franchise HIV treatment regimens represent a vast majority of Gilead's ( GILD ) top line. In FY2017, around 70% of Gilead's $25 bn sales were generated due to various HIV agents in its portfolio. Moreover, the net income derived from HIV sales was also disproportionally higher compared… read more...

Gilead Is On Hold For Now

via: SeekingAlpha at 2018-09-14 10:11:11:000

HIV Franchise HIV treatment regimens represent a vast majority of Gilead's ( GILD ) top line. In FY2017, around 70% of Gilead's $25 bn sales were generated due to various HIV agents in its portfolio. Moreover, the net income derived from HIV sales was also disproportionally higher compared… read more...

General Electric Is A Wait And Watch Story - Cramer's Lightning Round (9/13/18)

via: SeekingAlpha at 2018-09-14 07:21:28:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, September 13 . Bullish Call Chevron (CVX): It's a great American company that yields 4%. Hold on to it, but it will not run up quickly. Those looking for more yield should buy BP plc (BP). Neu… read more...

General Electric Is A Wait And Watch Story - Cramer's Lightning Round (9/13/18)

via: SeekingAlpha at 2018-09-14 07:21:28:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, September 13 . Bullish Call Chevron (CVX): It's a great American company that yields 4%. Hold on to it, but it will not run up quickly. Those looking for more yield should buy BP plc (BP). Neu… read more...

General Electric Is A Wait And Watch Story - Cramer's Lightning Round (9/13/18)

via: SeekingAlpha at 2018-09-14 07:21:28:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday, September 13 . Bullish Call Chevron (CVX): It's a great American company that yields 4%. Hold on to it, but it will not run up quickly. Those looking for more yield should buy BP plc (BP). Neu… read more...

Cramer's lightning round: GE may have bottomed, but it's still a wait-and-see story

via: CNBC at 2018-09-13 18:50:00:000

No summary available. read more...

Your Daily Scoop: Foamix Zooms, Pfizer And Merck Report Positive

via: SeekingAlpha at 2018-09-13 13:22:38:000

Stocks in News: FOMX, PFE Foamix Pharma +54% as acne drug meets goals in late-stage trial Share price of Foamix Pharmaceuticals ( FOMX ) had a 54.4% spike on September 11 after-hours on the news of positive topline results of third Phase 3 clinical trial of its FMX101 drug. The candida… read more...

36 'Safer' Dividend Healthcare WallStars For September

via: SeekingAlpha at 2018-09-12 22:35:54:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten High Yield Healthcare "Safer" Dividend Stocks to Net 11.1% to 21.82% Gains To September 2019 Five of ten top 'safer' dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the top ten gainers for… read more...

Gilead Sciences, Inc. (GILD) CEO John Milligan at the Morgan Stanley 16th Annual Global Healthcare Conference (Transcript)

via: SeekingAlpha at 2018-09-12 15:15:40:000

Gilead Sciences, Inc. (GILD) Morgan Stanley 16th Annual Global Healthcare Conference September 12, 2018, 11:05 AM ET Executives John McHutchison - Chief Scientific Officer and Head of R&D John Milligan - President & CEO Robin Washington - EVP & CFO Analysts Matt… read more...

Aceto 72% Target Net Gain Tops WallStar Healthcare Equities For September

via: SeekingAlpha at 2018-09-12 14:40:23:000

Actionable Conclusions (1-10): Analysts Projected 13.4% To 72.2% Net Gains For Top Ten Healthcare WallStars By September 2019 Five of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices…. read more...

Gilead teams up with Precision BioSciences in HBV

via: SeekingAlpha at 2018-09-12 08:56:34:000

Gilead Sciences (NASDAQ: GILD ) will collaborate with privately held Precision BioSciences to develop treatments aimed at eliminating hepatitis B virus (HBV) leveraging Precision's gene editing platform ARCUS . More news on: Gilead Sciences, Inc., Healthcare stocks news, Stocks on the… read more...

Gilead Sciences and Precision BioSciences Announce Collaboration to Develop Therapies Against Hepatitis B Virus Using ARCUS Genome Editing

via: Business Wire at 2018-09-12 08:31:00:000

Gilead Sciences (Nasdaq: GILD) and Precision BioSciences announced today that the companies have entered into a strategic collaboration to develop therapies targeting the in vivo elimination of hepatitis B virus (HBV) with Precisions proprietary genome editing platform, ARCUS. … read more...

Stocks making the biggest move premarket: AAPL, NIO, GILD, TEVA, BMY & more

via: CNBC at 2018-09-12 07:39:00:000

No summary available. read more...

Gilead Sciences Brings Strong Rheumatoid Arthritis Data, This Train Keeps Rolling

via: SeekingAlpha at 2018-09-11 22:11:54:000

Recently, Gilead Sciences ( GILD ) and its partner Galapagos ( GLPG ) announced positive results from a late-stage study treating patients with rheumatoid arthritis ((RA)). This builds upon their FINCH program franchise, which is going after a host of autoimmune disorders. Both companies e… read more...

After Hours Gainers / Losers (09/11/2018)

via: SeekingAlpha at 2018-09-11 17:34:59:000

Top Gainers: GILD +2.3% . AOI +1.7% . RENN +1.4% . STM +1.5% . More news on: Gilead Sciences, Inc., Alliance One International, Inc., Renren Inc., Stocks on the move, , Read more … read more...

After-hours buzz: S, GILD & more

via: CNBC at 2018-09-11 17:21:00:000

No summary available. read more...

Gilead's filgotinib successful in late-stage study in treatment-resistant rheumatoid arthritis

via: SeekingAlpha at 2018-09-11 16:18:22:000

Gilead Sciences (NASDAQ: GILD ) and collaboration partner Galapagos NV (NASDAQ: GLPG ) announce positive results from a Phase 3 clinical trial, FINCH 2 , evaluating JAK1 inhibitor filgotinib in adult patients with moderate-to-severe active rheumatoid arthritis (RA) who had failed to respo… read more...

Gilead and Galapagos Announce Filgotinib Meets Primary and All Key Secondary Endpoints in First Phase 3 Study in Rheumatoid Arthritis

via: Business Wire at 2018-09-11 16:05:00:000

-- Filgotinib 100 mg and 200 mg Doses Achieved Significantly Higher ACR20/50/70 Responses than Placebo in Patients with Active Rheumatoid Arthritis and Prior Inadequate Response to Biologic Agents -- -- Both Filgotinib Doses also Achieved All Key Secondary Efficacy Endpoints, includ… read more...

HQL: A Top-Notch Biotech CEF

via: SeekingAlpha at 2018-09-11 12:40:37:000

Over the past few weeks, I have written a few articles about the income opportunities provided by Tekla's healthcare funds. Thus far, I have covered three of the four funds, so it seems a good time to take a look at the fourth. That fourth fund is called Tekla Life Sciences Investors ( HQL ) a… read more...

Sangamo (Part V): Assessing The Prospects Of SB-913

via: SeekingAlpha at 2018-09-11 04:14:06:000

Cicero learned man that he was, believed in self-improvement so long as his breath lasts. He commends Socrates for learning to play the fiddle late in life and another Roman for mastering Greek when old. - Charlie Munger We are now living in the era of gene therapy. Luxturna (a gene therap… read more...

Gilead Sciences Is On The Right Trajectory Path For Autoimmune Disorders

via: SeekingAlpha at 2018-09-10 10:35:00:000

Recently, Gilead Sciences ( GILD ) and its partner Galapagos ( GLPG ) announced positive results from its phase 2 study treating patients with ankylosing spondylitis ((AS)). These positive results are proof that Gilead is alive and well. Most importantly, filgotinib could potentially becom… read more...

My Quarterly Non-Taxable Portfolio Update

via: SeekingAlpha at 2018-09-10 10:24:13:000

Background My loyal readers should be familiar with the following factors (weights in descending order) that I use to determine the fundamental quality of each stock: Management's capital allocation skills (check out the Importance of ROIC ). Growth ( this matters only in cases of… read more...

Breaking Down The NASH Fibrosis Market - Intercept, Genfit Primed For Potential Market Dominance

via: SeekingAlpha at 2018-09-10 08:00:00:000

Over the past year, interest has heated up in the biotech industry about NASH, with analysts estimating market size in 2025 anywhere between $20-35 billion. Positive Phase 2 data readouts for Madrigal (NASDAQ: MDGL ) and Galmed (NASDAQ: GLMD ) caused both stocks to more than double overnight… read more...

Arrowhead Pharmaceuticals Could Become The Next Gilead

via: SeekingAlpha at 2018-09-07 13:14:03:000

Arrowhead Pharmaceuticals ( ARWR ) announced clinical data on Thursday, September 6, 2018. The data was with regard to their Hepatitis B Virus (HBV) infection treatment known as ABO-HBV, a potential cure for a currently incurable treatment. The data showed promising results from the viewpoin… read more...

Arrowhead Pharmaceuticals Could Become The Next Gilead

via: SeekingAlpha at 2018-09-07 13:14:03:000

Arrowhead Pharmaceuticals ( ARWR ) announced clinical data on Thursday, September 6, 2018. The data was with regard to their Hepatitis B Virus (HBV) infection treatment known as ABO-HBV, a potential cure for a currently incurable treatment. The data showed promising results from the viewpoin… read more...

Arrowhead Pharmaceuticals Could Become The Next Gilead

via: SeekingAlpha at 2018-09-07 13:14:03:000

Arrowhead Pharmaceuticals ( ARWR ) announced clinical data on Thursday, September 6, 2018. The data was with regard to their Hepatitis B Virus (HBV) infection treatment known as ABO-HBV, a potential cure for a currently incurable treatment. The data showed promising results from the viewpoin… read more...

Jobs Report Expected To Be Strong (Wall Street Breakfast Podcast)

via: SeekingAlpha at 2018-09-07 08:15:06:000

Today's Top Stories: The August jobs report is due this morning, President Trump holds off on a shutdown, and Robinhood eyes an IPO. If you are interested in listening to Wall Street Breakfast to start your day, look for us in the following places: iTunes (find all Seeking Alp… read more...

Jobs Report Expected To Be Strong (Wall Street Breakfast Podcast)

via: SeekingAlpha at 2018-09-07 08:15:06:000

Today's Top Stories: The August jobs report is due this morning, President Trump holds off on a shutdown, and Robinhood eyes an IPO. If you are interested in listening to Wall Street Breakfast to start your day, look for us in the following places: iTunes (find all Seeking Alp… read more...

Jobs Report Expected To Be Strong (Wall Street Breakfast Podcast)

via: SeekingAlpha at 2018-09-07 08:15:06:000

Today's Top Stories: The August jobs report is due this morning, President Trump holds off on a shutdown, and Robinhood eyes an IPO. If you are interested in listening to Wall Street Breakfast to start your day, look for us in the following places: iTunes (find all Seeking Alp… read more...

Wall Street Breakfast: Jobs Report Steals The Spotlight

via: SeekingAlpha at 2018-09-07 07:01:16:000

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). Today's jobs data will be the last employment report before the Fed's next meeting on Sept. 26, at which the centr… read more...

Wall Street Breakfast: Jobs Report Steals The Spotlight

via: SeekingAlpha at 2018-09-07 07:01:16:000

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). Today's jobs data will be the last employment report before the Fed's next meeting on Sept. 26, at which the centr… read more...

Wall Street Breakfast: Jobs Report Steals The Spotlight

via: SeekingAlpha at 2018-09-07 07:01:16:000

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). Today's jobs data will be the last employment report before the Fed's next meeting on Sept. 26, at which the centr… read more...

Ebola outbreak spreading in Congo

via: SeekingAlpha at 2018-09-07 03:51:23:000

Congo has confirmed its first Ebola death in the eastern city of Butembo, the first urban outbreak of the virus in a major international trading hub with almost a million residents. More news on: Merck & Co Inc., Gilead Sciences, Inc., Healthcare stocks news, Read more … read more...

Ebola outbreak spreading in Congo

via: SeekingAlpha at 2018-09-07 03:51:23:000

Congo has confirmed its first Ebola death in the eastern city of Butembo, the first urban outbreak of the virus in a major international trading hub with almost a million residents. More news on: Merck & Co Inc., Gilead Sciences, Inc., Healthcare stocks news, Read more … read more...

Ebola outbreak spreading in Congo

via: SeekingAlpha at 2018-09-07 03:51:23:000

Congo has confirmed its first Ebola death in the eastern city of Butembo, the first urban outbreak of the virus in a major international trading hub with almost a million residents. More news on: Merck & Co Inc., Gilead Sciences, Inc., Healthcare stocks news, Read more … read more...

Gilead and Galapagos' TORTUGA Phase 2 study of filgotinib in AS achieves primary endpoint

via: SeekingAlpha at 2018-09-06 06:22:49:000

Gilead Sciences (NASDAQ: GILD ) andGalapagos NV(NASDAQ: GLPG ) announces that the randomized, placebo-controlled Phase 2 TORTUGA study of filgotinib, an investigational, selective JAK1 inhibitor, achieved its primary efficacy endpoint in adults with moderately to severely active … read more...

Gilead and Galapagos Announce TORTUGA Phase 2 Study of Filgotinib in Ankylosing Spondylitis Achieves Primary Endpoint

via: Business Wire at 2018-09-06 01:00:00:000

Gilead Sciences, Inc.(NASDAQ:GILD) andGalapagos NV(Euronext & NASDAQ:GLPG) today announced that the randomized, placebo-controlled Phase 2 TORTUGA study of filgotinib, an investigational, selective JAK1 inhibitor, achieved its primary efficacy endpoint in adults with mo… read more...

Abivax UC candidate shows positive action in mid-stage study

via: SeekingAlpha at 2018-09-05 12:17:43:000

A 32-subject Phase 2a clinical trial evaluating Abivax's ( OTCPK:AAVXF ) lead drug ABX464 in patients with treatment-resistant moderate-to-severe ulcerative colitis (UC) showed promising efficacy. More news on: Abivax SA, Protagonist Therapeutics, Takeda Pharmaceutical Co., Ltd. ADR,… read more...

Biotech Analysis Central Pharma News: Pfizer Axes Drug, Merck's Approvals, Bayer's Green Light

via: SeekingAlpha at 2018-09-04 23:59:39:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Pfizer Dumps DMD Drug After Trial Failures News: Recently, Pfizer ( PFE ) announced that it had failed two studies treating patients with duchenne… read more...

Gilead Enters Licensing Agreement With Trianni for Use of Trianni Transgenic Human Monoclonal Antibody Discovery Platform

via: Business Wire at 2018-09-04 16:05:00:000

Gilead Sciences, Inc. (NASDAQ: GILD) and Trianni, Inc. (TRIANNI) today announced that the companies have entered into a license agreement that grants Gilead the use of the Trianni transgenic human monoclonal antibody discovery platform to support the companys drug dis… read more...

Road To Financial Independence: Growing Dividends, Endless Opportunities But Limited Capital

via: SeekingAlpha at 2018-09-03 02:53:24:000

The stock markets never stop to amaze me. While July was heavily driven by concerns about a deteriorating trade war, August, in general, was a big rally, with markets hitting new highs and the euro dropping down to as low as $1.13. Overall net capital spending was around $2,650 as I divested… read more...

Gilead And NASH: New Heydays Are Ahead

via: SeekingAlpha at 2018-09-02 12:00:00:000

To live is to choose. But to choose well, you must know who you are and what you stand for, where you want to go and why you want to get there-Kofi Annan Investment Thesis Since its establishment in 1987, Gilead Sciences Inc. ( GILD ) has marketed itself as an innovator of HIV, HCV… read more...

Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 12

via: Business Wire at 2018-08-30 16:01:00:000

Webcast Available Through Gilead Corporate Website Gilead Sciences, Inc. (Nasdaq: GILD) today announced that John F. Milligan, PhD, Gileads President and Chief Executive Officer; Robin L. Washington, Gileads Executive Vice President and Chief Financial Officer; and J… read more...

Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 12

via: Business Wire at 2018-08-30 16:01:00:000

Webcast Available Through Gilead Corporate Website Gilead Sciences, Inc. (Nasdaq: GILD) today announced that John F. Milligan, PhD, Gileads President and Chief Executive Officer; Robin L. Washington, Gileads Executive Vice President and Chief Financial Officer; and J… read more...

Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 12

via: Business Wire at 2018-08-30 16:01:00:000

Webcast Available Through Gilead Corporate Website Gilead Sciences, Inc. (Nasdaq: GILD) today announced that John F. Milligan, PhD, Gileads President and Chief Executive Officer; Robin L. Washington, Gileads Executive Vice President and Chief Financial Officer; and J… read more...

A Middle-Class Millennial's Personal Investment Portfolio And Rationale

via: SeekingAlpha at 2018-08-30 13:16:12:000

Editor's note: Seeking Alpha is proud to welcome Steve Kelley as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Introduction… read more...

A Middle-Class Millennial's Personal Investment Portfolio And Rationale

via: SeekingAlpha at 2018-08-30 13:16:12:000

Editor's note: Seeking Alpha is proud to welcome Steve Kelley as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Introduction… read more...

A Middle-Class Millennial's Personal Investment Portfolio And Rationale

via: SeekingAlpha at 2018-08-30 13:16:12:000

Editor's note: Seeking Alpha is proud to welcome Steve Kelley as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Introduction… read more...

Et Tu, Bruton?

via: SeekingAlpha at 2018-08-30 11:15:49:000

Introduction: Since it was first approved to treat mantle cell lymphoma in 2013, ibrutinib (Imbruvica) has rapidly become a hematology hegemon. In 2017, AbbVie ( ABBV ) reported over $2.5 billion in net revenues for ibrutinib, a 40% increase over 2016, and forecasts $5 bn in annual sales … read more...

Et Tu, Bruton?

via: SeekingAlpha at 2018-08-30 11:15:49:000

Introduction: Since it was first approved to treat mantle cell lymphoma in 2013, ibrutinib (Imbruvica) has rapidly become a hematology hegemon. In 2017, AbbVie ( ABBV ) reported over $2.5 billion in net revenues for ibrutinib, a 40% increase over 2016, and forecasts $5 bn in annual sales … read more...

Et Tu, Bruton?

via: SeekingAlpha at 2018-08-30 11:15:49:000

Introduction: Since it was first approved to treat mantle cell lymphoma in 2013, ibrutinib (Imbruvica) has rapidly become a hematology hegemon. In 2017, AbbVie ( ABBV ) reported over $2.5 billion in net revenues for ibrutinib, a 40% increase over 2016, and forecasts $5 bn in annual sales … read more...

By The Numbers: Is Biogen A Buy?

via: SeekingAlpha at 2018-08-30 10:00:58:000

Biogen ( BIIB ) is one of the top players in the biotech industry, and the company benefits from a strong position in treatments for neurological and neurodegenerative diseases, such as multiple sclerosis (NYSE: MS ) and neuroimmunology, Alzheimers disease and dementia, movement disord… read more...

By The Numbers: Is Biogen A Buy?

via: SeekingAlpha at 2018-08-30 10:00:58:000

Biogen ( BIIB ) is one of the top players in the biotech industry, and the company benefits from a strong position in treatments for neurological and neurodegenerative diseases, such as multiple sclerosis (NYSE: MS ) and neuroimmunology, Alzheimers disease and dementia, movement disord… read more...

By The Numbers: Is Biogen A Buy?

via: SeekingAlpha at 2018-08-30 10:00:58:000

Biogen ( BIIB ) is one of the top players in the biotech industry, and the company benefits from a strong position in treatments for neurological and neurodegenerative diseases, such as multiple sclerosis (NYSE: MS ) and neuroimmunology, Alzheimers disease and dementia, movement disord… read more...

Retirement: The Future-Proof Portfolio For Young Investors Becomes 7 Months Old, New Position Opened

via: SeekingAlpha at 2018-08-30 00:51:46:000

On the 25th of January this year, I started the future-proof portfolio for young investors to serve as an example of how young investors who are saving for their retirement can choose to distribute their funds. This means that the portfolio recently became 7 months old. Though it is the long… read more...

Retirement: The Future-Proof Portfolio For Young Investors Becomes 7 Months Old, New Position Opened

via: SeekingAlpha at 2018-08-30 00:51:46:000

On the 25th of January this year, I started the future-proof portfolio for young investors to serve as an example of how young investors who are saving for their retirement can choose to distribute their funds. This means that the portfolio recently became 7 months old. Though it is the long… read more...

Retirement: The Future-Proof Portfolio For Young Investors Becomes 7 Months Old, New Position Opened

via: SeekingAlpha at 2018-08-30 00:51:46:000

On the 25th of January this year, I started the future-proof portfolio for young investors to serve as an example of how young investors who are saving for their retirement can choose to distribute their funds. This means that the portfolio recently became 7 months old. Though it is the long… read more...

Your Daily Pharma Scoop: ESPR Phase 3 Positive, FDA Rejects Volanesorsen, Ozempic Succeeds

via: SeekingAlpha at 2018-08-29 13:18:40:000

Stocks in News: ESPR Esperion announces positive results from phase 3 bempedoic acid/ezetimibe combination pill study Discussion: Positive top-line results from the pivotal Phase 3 trial of Esperions ( ESPR ) bempedoic acid/ezetimibe combination pill study ( 1… read more...

Gilead Sciences Appoints Laura Hamill as Executive Vice President, Worldwide Commercial Operations

via: Business Wire at 2018-08-28 17:00:00:000

Gilead Sciences, Inc.(NASDAQ: GILD) today announced thatLaura Hamill will join the company as Executive Vice President, Worldwide Commercial Operations, and will become a member of Gileads senior leadership team. This press release features multimedia. View the full r… read more...

NASH Cirrhosis: The Real NASH Epidemic

via: SeekingAlpha at 2018-08-28 14:19:37:000

Introduction Cirrhosis of the liver threatens the lives of millions of people, and other than a risky, expensive, and temporary transplant, it has no treatment. This marks cirrhosis among those diseases with the greatest unmet medical needs. Healthy liver, left, versus cirrhotic liver… read more...

30 Stock Portfolio Summer Review

via: SeekingAlpha at 2018-08-28 12:40:00:000

The goal is financial freedom. The path to get there is investing in growing and income producing businesses. Many of my stocks are, "dividend growth investments" that produce a consistent and rising income stream. Hopefully these DGI stocks will beat the market. My non DGI stocks are, "Seekin… read more...

Your Cancer Highlight: Novartis Gets Another CAR-T Approval, But Manufacturing Is A Drag

via: SeekingAlpha at 2018-08-28 11:23:04:000

Chimeric antigen receptor-expressing T cells have ridden an enormous wave of hype, hope, and promise into the treatment landscape of oncology, crashing into some of the most intractable forms of cancer that we currently face. Companies like Kite and Juno were able to parlay this success into h… read more...

UK's NICE not on board with Gilead's Yescarta

via: SeekingAlpha at 2018-08-28 07:32:44:000

Britain's National Institute for Health and Care Excellence (NICE), the advisory group to the National Health Service (NHS) on quality of care and costs, is not recommending Gilead Sciences' (NASDAQ: GILD ) CAR-T therapy Yescarta (axicabtagene ciloleucel), approved yesterday in the EU for … read more...

Is It Time To Take Profits On Merck?

via: SeekingAlpha at 2018-08-27 15:12:27:000

Merck ( MRK ) has been on a fantastic run over the 5 months or so. Since bottoming out at $52.83 in early April, MRK shares have rebounded, recently crossing above the $70 threshold. Much of this success is attributed to MRKs success in oncology, and namely, its flagship immuno-oncolog… read more...

Seattle Genetics Is A Solid Buy In 2018

via: SeekingAlpha at 2018-08-27 12:51:36:000

The year 2018 is definitely turning out to be transformational for Seattle Genetics ( SGEN ). It started with the latest FDA approval for Adcetris, the companys only marketed product, as front-line therapy in combination with chemotherapy in stage III or IV classical Hodgkin lymphoma o… read more...

Biotech Analysis Central Pharma News: J&J And Bayer Failure, Gilead Sciences Unloads Cancer Drug, Mallinckrodt Fails To Get Green Light

via: SeekingAlpha at 2018-08-27 12:35:33:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. J&J And Bayer Fail To Improve Prospects for Blood Clot Drug After Trial Results News: Recently, Johnson & Johnson ( JNJ ) and Bayer ( OTC… read more...

Money flow stays positive in biotechs, XBI up 6% since last week

via: SeekingAlpha at 2018-08-27 11:39:49:000

Biotechs continue their modest rally. The SPDR S&P Biotech ETF ( XBI +1.9% ) is up albeit on below average. It has jumped 6% since last week. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the … read more...

Genfit And Elafibranor In NASH Fibrosis: A Revisit Of The FDA Guidelines

via: SeekingAlpha at 2018-08-27 08:58:53:000

Leadership is solving problems - Colin Powell Investment Thesis In 2015, the stock price of Genfit (GNFTF) stumbled on the release of the top line data of the Phase 2b GOLDEN-505 study of elafibranor therapy in NASH due to misinterpretation of the results. However, reanalysis of th… read more...

Yescarta® (Axicabtagene Ciloleucel) Receives European Marketing Authorization for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy

via: Business Wire at 2018-08-27 06:34:00:000

-- New Option for Adult Patients in Europe as Axicabtagene Ciloleucel Becomes the First CAR T to Receive European Approval for Two Types of Aggressive Non-Hodgkin Lymphoma -- Kite, a Gilead Company (Nasdaq: GILD), today announced that the European Commission (EC) has granted Marketi… read more...

23andMe cuts off app developers from raw genetic data

via: SeekingAlpha at 2018-08-24 13:00:09:000

Privately held 23andMe has informed outside app developers that they will no longer have access to its raw genomic data, one of the largest datasets in the world. More news on: GlaxoSmithKline, Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnology ETF, Healthcare stocks news, Te… read more...

23andMe cuts off app developers from raw genetic data

via: SeekingAlpha at 2018-08-24 13:00:09:000

Privately held 23andMe has informed outside app developers that they will no longer have access to its raw genomic data, one of the largest datasets in the world. More news on: GlaxoSmithKline, Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnology ETF, Healthcare stocks news, Te… read more...

23andMe cuts off app developers from raw genetic data

via: SeekingAlpha at 2018-08-24 13:00:09:000

Privately held 23andMe has informed outside app developers that they will no longer have access to its raw genomic data, one of the largest datasets in the world. More news on: GlaxoSmithKline, Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnology ETF, Healthcare stocks news, Te… read more...

2018 Call Portfolio Update

via: SeekingAlpha at 2018-08-24 03:09:53:000

Last Friday was call expiration for the August 17, 2018, options. We sold a second call on Apple (AAPL) and it was called away early at $200. We did quite nicely on AAPL, having bought at $176.98. Income from call premiums and dividends alone equaled $739 which is an over 4% yield in 8 months…. read more...

2018 Call Portfolio Update

via: SeekingAlpha at 2018-08-24 03:09:53:000

Last Friday was call expiration for the August 17, 2018, options. We sold a second call on Apple (AAPL) and it was called away early at $200. We did quite nicely on AAPL, having bought at $176.98. Income from call premiums and dividends alone equaled $739 which is an over 4% yield in 8 months…. read more...

2018 Call Portfolio Update

via: SeekingAlpha at 2018-08-24 03:09:53:000

Last Friday was call expiration for the August 17, 2018, options. We sold a second call on Apple (AAPL) and it was called away early at $200. We did quite nicely on AAPL, having bought at $176.98. Income from call premiums and dividends alone equaled $739 which is an over 4% yield in 8 months…. read more...

Your 47 Nasdaq 'Safer' Dividend Equities For August

via: SeekingAlpha at 2018-08-23 22:09:02:000

Actionable Conclusions (1-10): Brokers Forecast Top Ten NASDAQ "Safer" Dividend Stocks to Net 19.7% to 60.1% Gains By August 2019 Four of the ten top yield "safer" Dividend NASDAQ stocks (with name backgrounds tinted grey in the list above) were scattered in with the top ten gainers for th… read more...

Your 47 Nasdaq 'Safer' Dividend Equities For August

via: SeekingAlpha at 2018-08-23 22:09:02:000

Actionable Conclusions (1-10): Brokers Forecast Top Ten NASDAQ "Safer" Dividend Stocks to Net 19.7% to 60.1% Gains By August 2019 Four of the ten top yield "safer" Dividend NASDAQ stocks (with name backgrounds tinted grey in the list above) were scattered in with the top ten gainers for th… read more...

Your 47 Nasdaq 'Safer' Dividend Equities For August

via: SeekingAlpha at 2018-08-23 22:09:02:000

Actionable Conclusions (1-10): Brokers Forecast Top Ten NASDAQ "Safer" Dividend Stocks to Net 19.7% to 60.1% Gains By August 2019 Four of the ten top yield "safer" Dividend NASDAQ stocks (with name backgrounds tinted grey in the list above) were scattered in with the top ten gainers for th… read more...

Oklahoma first state to negotiate efficacy-based drug prices

via: SeekingAlpha at 2018-08-23 10:54:56:000

Reuters reports that Oklahoma is the first state where its Medicaid program is negotiating prescription drug prices based on how well they work in practice. CMS signed off on allowing the state to employ the approach two months ago. More news on: Alkermes plc, Health Care Select Sect SPD… read more...

Here's 53 Nasdaq Top Yield, Upside, And Net Gain Stocks For August

via: SeekingAlpha at 2018-08-22 22:29:29:000

Actionable Conclusions (1-10): Brokers Predict 19.72% To 60.12% Net Gains From August's NASDAQ Top Ten Four of ten top yield NASDAQ dividend stocks were identified as being among the top ten net gainers for the coming year based on analyst 1-year target prices. (They are tinted gray in the… read more...

bluebird bio: Heading To $200 On Pipeline Progress And Potential M&A

via: SeekingAlpha at 2018-08-22 12:56:35:000

bluebird bio (NASDAQ: BLUE ) is a clinical-stage biotechnology company focussed on gene therapy, cancer immunopathy and gene editing for the treatment of cancer and rare diseases. I believe that bluebird's therapies have the potential to be truly groundbreaking, not only offering symptom treat… read more...

Gilead Debate Focused On Threat Of GSK In HIV And On Management Departures

via: SeekingAlpha at 2018-08-22 09:44:57:000

Does GSKs ATLAS Present A Legitimate Threat To Gilead's HIV Franchise? ViiV/GSK ( GSK ) has more recently pursued several 2-drug regimens, arguing in favor of its limited toxicity and reduced cost burdens compared to the more frequent 3-drug and 4-drug regimens. With each successive … read more...

Outperforming The Market By Following Earnings Revisions

via: SeekingAlpha at 2018-08-22 08:33:18:000

The stock market is a complex mechanism, and there is an almost infinite amount of variables to consider when making investment decisions. However, simplicity is the ultimate sophistication, and focusing on earnings revisions as a key return driver for both the market as a whole and individual… read more...

Market Caution Amid Political Worries (Wall Street Breakfast Podcast)

via: SeekingAlpha at 2018-08-22 07:39:17:000

Editor's note: Seeking Alpha is proud to welcome WSB Podcast as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Today's top … read more...

Sierra Oncology acquires late-stage candidate from Gilead for up to $198M

via: SeekingAlpha at 2018-08-22 07:10:47:000

Sierra Oncology (NASDAQ: SRRA ) acquires the rights to momelotinib, a JAK 1/2 and ACRV1 inhibitor that has been investigated in two Phase 3 myelofibrosis studies, from Gilead Sciences (NASDAQ: GILD ). It says the drug is different from other JAK inhibitors in that it addresses myelofibrosi… read more...

Wall Street Breakfast: Market Caution Amid Political Worries

via: SeekingAlpha at 2018-08-22 06:54:47:000

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). Futures markets are pointing to slight opening losses as fresh political developments signaled new uncertainty ove… read more...

Congo clears more experimental Ebola treatments

via: SeekingAlpha at 2018-08-22 06:30:15:000

Democratic Republic of Congo has approved four more experimental treatments against the deadly Ebola virus as the country races to contain a new outbreak. More news on: Gilead Sciences, Inc., Merck & Co Inc., Healthcare stocks news, Read more … read more...

Jane's July Dividend Increases And Income Tracker - Retirement Accounts

via: SeekingAlpha at 2018-08-21 15:10:10:000

Investment Thesis July marks the fifth month that I have tracked Jane's dividend income from her Traditional and Roth IRAs. Unlike the Taxable Account, we did not start making significant changes to her retirement accounts until after the first of the year. Because of this, there were a numb… read more...

Gilead Sciences, Inc. 2018 Q2 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-08-20 17:40:20:000

The following slide deck was published by Gilead Sciences, Inc. in conjunction with their 2018 Q2 earnings Read more … read more...

Gilead Sciences: Still My Top Biotech Pick For The Next Decade

via: SeekingAlpha at 2018-08-20 12:32:33:000

Gilead Sciences ( GILD ) has lost its reputation for growth. The companys stock price increased dramatically in late-2015 as a result of the companys Hepatitis C cure. Since then, the companys stock price has dropped. Despite these difficulties, Gilead Sciences continue… read more...

Biotech Analysis Central Pharma News: Gilead's Hope Dashed, Pfizer's Vaccine Deal, Eisai And Merck FDA Approval

via: SeekingAlpha at 2018-08-20 11:59:17:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Gilead Loses Important Patent for Sovaldi In China News: Recently, Gilead Sciences ( GILD ) ran into a bit of a problem with its Hepatitis C patent … read more...

Sangamo Therapeutics: More Catalysts Powering A Gene-Based Innovator

via: SeekingAlpha at 2018-08-18 21:34:54:000

Gene-based therapy is one of the waves of medical innovation that is growing stronger by the day. In our Specialty Report , we featured two highly promising approaches to gene editing for the management of various diseases. The most popular way that is featured in the Hollywood film (Jurassic… read more...

Gilead continues selloff, down 3%

via: SeekingAlpha at 2018-08-17 11:42:02:000

Gilead Sciences ( GILD -3.2% ) slips on below-average volume. Shares have retreated 5% since the company reported the departure of CMO Andrew Cheng, M.D., Ph.D. on Tuesday after the close. He was a company veteran, joining in 1999 to lead the HIV/AIDS program. More news on:… read more...

Gilead continues selloff, down 3%

via: SeekingAlpha at 2018-08-17 11:42:02:000

Gilead Sciences ( GILD -3.2% ) slips on below-average volume. Shares have retreated 5% since the company reported the departure of CMO Andrew Cheng, M.D., Ph.D. on Tuesday after the close. He was a company veteran, joining in 1999 to lead the HIV/AIDS program. More news on:… read more...

A Synopsis Of The HIV Market

via: SeekingAlpha at 2018-08-16 18:12:44:000

Editor's note: Seeking Alpha is proud to welcome Vision and Value as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Introdu… read more...

PepsiCo And Gilead: 2 Very Different CEO Departures

via: SeekingAlpha at 2018-08-16 03:49:50:000

CEO transitions are times when new performance expectations and goals can be established more easily. If properly understood and managed effectively, CEO transitions are a unique opportunity to reset a company's focus and rhythms to the requirements of the future. During such times, there is a… read more...

Investors shun healthcare stocks in broad market selloff

via: SeekingAlpha at 2018-08-15 10:14:45:000

Healthcare stocks are taking it on the chin in today's broad selloff, some more than others. The SPDR S&P Biotech ETF ( XBI -2% ), for example, is down more than the major indexes. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Global Blood Therapeutics, Healthcare stoc… read more...

One Year Later: Lessons Learned In CAR-T

via: SeekingAlpha at 2018-08-14 19:13:01:000

Introduction: With hundreds of ongoing clinical trials and an unprecedented wave of new companies entering the field, chimeric antigen receptor ((CAR)) T-cell therapy represents one of the most important therapeutic and technological developments in the treatment of Leukemia and Lymphoma in … read more...

Gilead Sciences Announces Executive Promotions

via: Business Wire at 2018-08-14 17:00:00:000

Gregg Alton Appointed Chief Patient Officer Diana Brainard, MD, Promoted to Senior Vice President, HIV and Emerging Viral Infections Andrew Cheng, MD, PhD, Chief Medical Officer, to Leave Gilead Gilead Sciences, Inc… read more...

Spark Therapeutics: This Appears To Be A Dip Worth Buying

via: SeekingAlpha at 2018-08-14 10:35:59:000

Today's approval marks another first in the field of gene therapy - both in how the therapy works and in expanding the use of gene therapy beyond the treatment of cancer to the treatment of vision loss - and this milestone reinforces the potential of this breakthrough approach in treating a w… read more...

Is Cocrystal Beating The Dead Hepatitis C Horse?

via: SeekingAlpha at 2018-08-14 05:00:00:000

Introduction The discovery of a safe and highly effective cure for Chronic Hepatitis C is perhaps one of the intriguing biotech success stories of the decade. Over the course of 20 years, the standard of care for Hepatitis C had evolved from a combined course of ribavarin and pegylated i… read more...

Week In Review: Shanghai Junshi Biosciences Files For $500 Million Hong Kong IPO

via: SeekingAlpha at 2018-08-12 15:36:20:000

Deals and Financings Shanghai Junshi Biosciences has filed for a Hong Kong IPO that is expected to raise up to $500 million. Junshi is developing a pipeline of 13 biologic drugs, including immuno-oncology treatments. Its most advanced candidate, toripalimab, is a PD-1 mAb whose NDA is curren… read more...

Week In Review: Shanghai Junshi Biosciences Files For $500 Million Hong Kong IPO

via: SeekingAlpha at 2018-08-12 15:36:20:000

Deals and Financings Shanghai Junshi Biosciences has filed for a Hong Kong IPO that is expected to raise up to $500 million. Junshi is developing a pipeline of 13 biologic drugs, including immuno-oncology treatments. Its most advanced candidate, toripalimab, is a PD-1 mAb whose NDA is curren… read more...

Stocks To Watch: Any Privacy For Tesla?

via: SeekingAlpha at 2018-08-11 09:07:58:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. During what's supposed to be a sleepy period of low-volume market activity amid the… read more...

Sangamo: First Look At June 2018 Results

via: SeekingAlpha at 2018-08-09 17:11:23:000

In the first half of 2018 we made strong progress on important initiatives including our clinical development programs and execution of a significant collaboration with Kite-Gilead for the use of ZFNs for engineered cell therapies in oncology. Sangamo CEO Sandy Macrae Sangamo ( … read more...

Sangamo: First Look At June 2018 Results

via: SeekingAlpha at 2018-08-09 17:11:23:000

In the first half of 2018 we made strong progress on important initiatives including our clinical development programs and execution of a significant collaboration with Kite-Gilead for the use of ZFNs for engineered cell therapies in oncology. Sangamo CEO Sandy Macrae Sangamo ( … read more...

Your Daily Pharma Scoop: Foundation Promising, Paratek Moves Up, Ovid Down

via: SeekingAlpha at 2018-08-08 06:10:18:000

Stocks in News: FMI, PRTK Foundation Medicine test helps predict response to Roche's Tecentriq in lung cancer patients Discussion : Foundation Medicines ( FMI ) announced a positive outcome of its bTMB assay. In a recent publication in Nature Medicine, a retrospective analysis… read more...

AbbVie and Enanta down on loss of preferred status in HCV with Express Scripts

via: SeekingAlpha at 2018-08-07 12:46:14:000

AbbVie ( ABBV -3% ) and collaboration partner Enanta Pharmaceuticals ( ENTA -8.9% ) are down in apparent response to the news that PBM Express Scripts ( ESRX +1.5% ) has dropped HCV med MAVYRET (glecaprevir/pibrentasvir) from its formulary in favor of Merck's ( MRK +0.4% ) ZEPATIER… read more...

Biopharma 2018: Growth At A Reasonable Cost (GARC)

via: SeekingAlpha at 2018-08-07 12:00:53:000

I maintain that the prospects for the biopharmaceutical industry are extremely favorable, driven by new drug discovery in oncology, hematology and inflammatory diseases. However, the stock valuations do not seem to reflect the prospects, with the above listed GARC (Growth At a Reasonable Cost)… read more...

Johnson & Johnson: Headline Risk But Business Solid

via: SeekingAlpha at 2018-08-07 09:43:00:000

By Alexander J. Poulos Examining J&J's Franchise Strength We think a close examination of the underlying trends of Johnson & Johnson's ( JNJ ) three largest components of its pharma division will be helpful to readers. The company remains a stalwart in the high-growth branded pha… read more...

Dividend Portfolio Review: Busy Earnings Season, Heavy Buying, Growing Dividends

via: SeekingAlpha at 2018-08-07 08:55:00:000

More ups and downs in July with earnings season hitting its peak and trade threats and denials coming in every couple of days led to accelerated buying culminating in around $4,400 in fresh capital deployed. Earnings season often triggers some remarkable selloffs and rallies but this time I… read more...

Gilead's Genvoya approved in China for the treatment of HIV-1 infection

via: SeekingAlpha at 2018-08-06 06:44:23:000

China National Drug Administration approves Gilead Sciences' (NASDAQ: GILD ) Genvoya(elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg or E/C/F/TAF) for the treatment of HIV-1 infection. More news on: Gilead Sciences, Inc., Healthcare stocks new… read more...

China National Drug Administration Approves Gilead's Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), a Single Tablet Regimen for the Treatment of HIV-1 Infection

via: Business Wire at 2018-08-06 06:09:00:000

- Genvoya is the First TAF-Based Regimen Approved in China for Adults and Adolescents with HIV - Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the China National Drug Administration (CNDA) has approved Genvoya (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine … read more...

Gilead: A Bell Tolls, And A Window Of Opportunity Opens

via: SeekingAlpha at 2018-08-06 05:39:20:000

Good-bye: Gilead 2.0 ( GILD ). The 1.0 version of GILD is long-forgotten, but outgoing CEO John Milligan was present when GILD's scientific goal was to develop Ionis-like ( IONS ) drugs rather than the antivirals for which GILD became so well-known. Now, the proverbial bell has tolled for … read more...

Gilead Sciences Is A Solid Buy In 2018

via: SeekingAlpha at 2018-08-05 10:53:33:000

You may love it, you may hate it, but it is absolutely impossible to ignore Gilead Sciences ( GILD ). Since 2014, the company has been on a roller coaster ride, as HCV franchise revenues rose dramatically and then fell drastically. While the FY 2018 guidance numbers from the company in its… read more...

Meet The 'Safer' 35 Healthcare High Yield WallStars For July

via: SeekingAlpha at 2018-08-01 20:18:44:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten High Yield Healthcare "Safer" Dividend Stocks to Net 11.75% to 22.98% Gains To July 2019 Three of ten top 'safer' dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the top ten gainers for th… read more...

Meet The 'Safer' 35 Healthcare High Yield WallStars For July

via: SeekingAlpha at 2018-08-01 20:18:44:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten High Yield Healthcare "Safer" Dividend Stocks to Net 11.75% to 22.98% Gains To July 2019 Three of ten top 'safer' dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the top ten gainers for th… read more...

Meet The 'Safer' 35 Healthcare High Yield WallStars For July

via: SeekingAlpha at 2018-08-01 20:18:44:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten High Yield Healthcare "Safer" Dividend Stocks to Net 11.75% to 22.98% Gains To July 2019 Three of ten top 'safer' dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the top ten gainers for th… read more...

Wall Street Favorite Healthcare Equities For July Topped By CVS Health

via: SeekingAlpha at 2018-08-01 02:27:38:000

Actionable Conclusions (1-10): Analysts Projected 12.6% To 28.5% Net Gains For Top Ten Healthcare WallStars By July 2019 Four of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices. (The… read more...

Gilead: Is The Drama Over?

via: SeekingAlpha at 2018-08-01 00:06:59:000

Gilead ( GILD ) delivered a revenue and earnings beat for Q2. As importantly, the drama from declining HCV sales could be over. I had the following takeaways on the quarter. Is The HCV Drama Over? Gilead has almost become synonymous with HCV over the years. Sales of the product began to … read more...

Tiziana Life Sciences Files For Small IPO

via: SeekingAlpha at 2018-07-31 14:49:30:000

Quick Take Tiziana Life Sciences ( TLSA ) intends to raise gross proceeds of $11.5 million from a U.S. IPO, according to an F-1 registration statement . The firm is developing therapeutics and diagnosis for cancers and immune diseases. TLSA is preparing for Phase 3 trials for its le… read more...

Pfizer's Read thinks drug rebates going bye-bye in U.S.

via: SeekingAlpha at 2018-07-31 11:45:57:000

In this morning's earnings call, Pfizer ( PFE +3% ) chief Ian Read said he believes the Trump administration plans to eliminate rebates on prescription drug purchases, although he has no clear idea when such a policy would be implemented. More news on: Pfizer Inc., Health Care Select S… read more...

U.S. healthcare spending nearing 20% of GDP

via: SeekingAlpha at 2018-07-31 11:25:57:000

The WSJ reports that healthcare spending in the U.S. will soon reach 20% of GDP, a significantly higher proportion than any other major economy. The key cost driver has been price hikes, not increased demand. Since 1960, the CPI has risen ~700% while medical costs have risen 2,000%. Since … read more...

AbbVie: Undervalued And Strong Growth On The Horizon

via: SeekingAlpha at 2018-07-31 09:42:38:000

Pharmaceutical Overview AbbVie Inc. first gained notoriety in 2013, after it was formed during a split of Abbot Laboratories. This was because ( ABBV ) retained the rights to Humira and continued to develop and market the drug. As a treatment for rheumatoid arthritis, crohn's disease, pso… read more...

Sickle Cell Disease Breakthrough: Global Blood Therapeutics' Antisickling Agent Voxelotor

via: SeekingAlpha at 2018-07-31 08:35:18:000

Currently in talks with the FDA to accelerate their candidate's route to market (which could be as early as 2019), Global Blood Therapeutics (GBT) is banking on their Phase 3 part A results and a trophy cabinet of accolades (breakthrough drug designation, orphan drug designation) to disru… read more...

Celyad Looks To Take The Cake In Speculative Biotech

via: SeekingAlpha at 2018-07-30 14:53:05:000

Author's note: I am an affiliate of Avisol Capital Partners' Total Pharma Tracker . Although we have a business relationship, Avisol Capital Partners' coverage of Celyad on Seeking Alpha has not in any way informed my writing of this article, except for the mention of their article from … read more...

Gilead's Stock Price Is Ready To Soar

via: SeekingAlpha at 2018-07-30 02:44:46:000

Gilead ( GILD ) is a biotech company with leading franchises in Hepatitis C, HIV, and emerging platforms in Oncology, Hepatitis B, and NASH. To an extent, Gilead is a victim of its own success. The companys Hepatitis C (HCV) treatments cured the illness and for the la… read more...

Gilead Sciences: Insight Into The Kite And Gadeta Partnership For CAR-TCR Targeting Solid Tumors

via: SeekingAlpha at 2018-07-28 08:57:53:000

Before you invest, you must ensure that you have realistically assessed your probability of being right and how you will react to the consequences of being wrong. - Benjamin Graham Gilead Sciences (NASDAQ: GILD ) is a rare large capitalized bioscience that we featured at Integrated BioSc… read more...

Gilead Sciences: Insight Into The Kite And Gadeta Partnership For CAR-TCR Targeting Solid Tumors

via: SeekingAlpha at 2018-07-28 08:57:53:000

Before you invest, you must ensure that you have realistically assessed your probability of being right and how you will react to the consequences of being wrong. - Benjamin Graham Gilead Sciences (NASDAQ: GILD ) is a rare large capitalized bioscience that we featured at Integrated BioSc… read more...

Gilead Sciences: Stabilisation In Sight

via: SeekingAlpha at 2018-07-27 05:24:00:000

The narrative surrounding Gilead Sciences ( GILD ) remains the same. The company became a victim of its own success with its breakthrough therapies in HCV, creating a boom in sales and profits. That boom itself set the company up for a few years of very hard comparables, especially with "gap… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-07-26 08:07:16:000

Integra LifeSciences Holdings (NASDAQ: IART ) upgraded to Buy with a $69 (14% upside) price target at BTIG Research. More news on: Integra LifeSciences Holdings Corporation, Gilead Sciences, Inc., NovoCure, Healthcare stocks news, Stocks on the move, Read more … read more...

Stocks making the biggest moves premarket: CMCSA, LUV, FB, QCOM & more

via: CNBC at 2018-07-26 07:54:00:000

No summary available. read more...

Facebook Takes The FANGs Out (Wall Street Breakfast Podcast)

via: SeekingAlpha at 2018-07-26 07:36:41:000

Editor's note: Seeking Alpha is proud to welcome WSB Podcast as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Today's top … read more...

Wall Street Breakfast: Facebook Takes The FANGs Out

via: SeekingAlpha at 2018-07-26 07:02:33:000

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). The tech-heavy Nasdaq is set for a big down day after Facebook (FB) published quarterly results that underwhelmed inv… read more...

Gilead Sciences (GILD) Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-07-25 23:01:17:000

Gilead Sciences, Inc. (GILD) Q2 2018 Earnings Call July 25, 2018 5:00 pm ET Executives Sung Lee - Gilead Sciences, Inc. John F. Milligan - Gilead Sciences, Inc. Robin L. Washington - Gilead Sciences, Inc. Andrew Cheng - Gilead Sciences, Inc. John G. McHutchison - Gilead Scien… read more...

After-hours buzz: FB, F & more

via: CNBC at 2018-07-25 18:09:00:000

No summary available. read more...

'End of era' for Gilead as CEO and Chairman set exit

via: SeekingAlpha at 2018-07-25 17:22:47:000

So says Baird analyst Brian Skorney upon news that CEO John Milligan will step down before year-end, and Chairman John Martin will exit when a new CEO is hired. "Just shock," says Skorney of his reaction. More news on: Gilead Sciences, Inc., Healthcare stocks news, Stocks on the move, … read more...

Gilead Sciences declares $0.57 dividend

via: SeekingAlpha at 2018-07-25 17:10:19:000

Gilead Sciences (NASDAQ: GILD ) declares $0.57/share quarterly dividend , in line with previous. More news on: Gilead Sciences, Inc., Dividend News, Read more … read more...

Gilead Q2 revenues down 21%; earnings down 41%; shares down 2% after hours

via: SeekingAlpha at 2018-07-25 16:17:14:000

Gilead Sciences (NASDAQ: GILD ) Q2 results ($M): Revenues: 5,648 (-20.9%); Product sales: 5,540 (-21.4%). More news on: Gilead Sciences, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more … read more...

Gilead Sciences beats by $0.35, beats on revenue

via: SeekingAlpha at 2018-07-25 16:02:03:000

Gilead Sciences (NASDAQ: GILD ): Q2 EPS of $1.91 beats by $0.35 . Revenue of $5.65B (-20.9% Y/Y) beats by $440M . Press Release More news on: Gilead Sciences, Inc., Earnings news and commentary, Healthcare stocks news, read more...

Gilead Sciences Announces Third Quarter 2018 Dividend

via: Business Wire at 2018-07-25 16:02:00:000

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the companys Board of Directors has declared a cash dividend of $0.57 per share of common stock for the third quarter of 2018. The dividend is payable on September 27, 2018, to stockholders of record at the close of business o… read more...

Gilead Sciences Announces Second Quarter 2018 Financial Results

via: Business Wire at 2018-07-25 16:01:00:000

- Product Sales of $5.5 billion - - Diluted EPS of $1.39 per share - - Non-GAAP Diluted EPS of $1.91 per share - - Revised Full Year 2018 Guidance for Non-GAAP Effective Tax Rate - Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations fo… read more...

Gilead Sciences Announces CEO John F. Milligan to Step Down

via: Business Wire at 2018-07-25 16:00:00:000

-- Dr. Milligan to Remain With Company Through Year End -- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that John F. Milligan, PhD, will step down as President and Chief Executive Officer after a 28-year career with the company. Dr. Milligan will remain in his current posi… read more...

What We Can Expect From Gilead

via: SeekingAlpha at 2018-07-25 11:28:44:000

Article Thesis Gilead ( GILD ) will report its second-quarter results on Wednesday evening. The company will likely report a small revenue increase compared to Q1. Due to the fact that Gilead's HCV business is becoming ever less important, the company's revenues could bottom out this year…. read more...

GlaxoSmithKline Achieves Successful 2-Drug Regimen Studies For HIV, Gilead Might Have Met Its Match

via: SeekingAlpha at 2018-07-25 07:42:45:000

Recently, GlaxoSmithKline ( GSK ) announced that it had obtained positive results from two phase 3 studies for a two-drug combination regimen to treat patients with HIV. This opens the door for the company to have the potential to go up against other competitors in the same space. I believe … read more...

Notable earnings after Wednesday's close

via: SeekingAlpha at 2018-07-24 17:35:22:000

ABX , AEM , AGNC , ALGN , ALGT , AMD , ANIK , ARI , ASGN , AXS , AXTI , BEAT , BPI , CCJ , CCMP , CDE , CHE , CLB , CLGX , CTXS , CUBI , CUZ , CVRR , CW , DDR , DLB , DRE , ECHO , EFX , EHC , EIG , ESRT , ESV , ETH , F , FARO , FB , FCPT , FFIV , FOE … read more...

Gilead's Truvada used for pre-exposure prophylaxis lowered new HIV infection rates in U.S.

via: SeekingAlpha at 2018-07-24 11:00:26:000

Data from a retrospective U.S. analysis of the impact of Gilead Sciences' ( GILD +1.4% ) Truvada (emtricitabine/TDF) used for pre-exposure prophylaxis (PrEP) showed a significant drop in new HIV infections. The results were presented at the International AIDS Conference in Amsterdam. … read more...

Gilead Announces New Data on the Impact of Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Pre-Exposure Prophylaxis (PrEP) on the Number of HIV Diagnoses in the United States

via: Business Wire at 2018-07-24 08:00:00:000

Data Show That States with Highest Use of Truvada for PrEP Had Significant Declines in New HIV Infections Gilead Sciences, Inc. (NASDAQ: GILD) today announced results of a retrospective nationwide analysis of the impact of Truvada (emtricitabine 200… read more...

4 Members Of The $800+ Billion Market Cap Club

via: SeekingAlpha at 2018-07-24 05:37:20:000

Below is an updated look at the 35 largest S&P 500 companies. It's worth noting that recent gains have put four companies into the $800+ billion market cap club . Apple (AAPL) is still on top with a market cap of $933 billion, followed by Amazon (AMZN) at $873 billion, Alphabet (GOOGL) at… read more...

Sangamo's Acquisition Of TxCell Is A Double Edged Sword

via: SeekingAlpha at 2018-07-23 21:10:23:000

Recently, Sangamo Therapeutics ( SGMO ) announced that it had acquired a biotech by the name of TxCell . This acquisition adds value to Sangamo, because it will expand its pipeline. The opportunity to add a new technology into its arsenal will increase the amount of market opportunities t… read more...

J&J Wants A Piece Of Gilead's HIV Market

via: SeekingAlpha at 2018-07-23 21:07:34:000

Recently, Johnson & Johnson ( JNJ ) announced that it had obtained FDA approval for its antiretroviral drug known as darunavir to treat patients with HIV. This newly approved drug will allow the company to compete against a host of other big pharmaceutical companies that sell HIV dru… read more...

Biotech Stocks Are Tariff-Safe And Building Momentum

via: SeekingAlpha at 2018-07-23 10:26:06:000

Biotech Pulse The first half of 2018 saw the Nasdaq Biotechnology Index ( IBB ) make a 52-week high in January and thereafter enter a 5-month consolidation period. Even though the index managed to eke out only a +3% gain in the first half, the second-half has started on a brisk note… read more...

Stocks To Watch: FANGs Out In Tech

via: SeekingAlpha at 2018-07-21 08:59:33:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. There's no hiding this week if you're an investor in the tech sector, with heavywei… read more...

Stocks To Watch: FANGs Out In Tech

via: SeekingAlpha at 2018-07-21 08:59:33:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. There's no hiding this week if you're an investor in the tech sector, with heavywei… read more...

Quarterly Review Of DivGro: Q2 2018

via: SeekingAlpha at 2018-07-20 23:49:17:000

Welcome to the 22nd quarterly review of DivGro, my portfolio of dividend growth stocks. My quarterly reviews provide a summary of dividend income, dividend changes, and transactions executed in the past quarter. I also provide some charts showing various portfolio statistics. While these rev… read more...

Quarterly Review Of DivGro: Q2 2018

via: SeekingAlpha at 2018-07-20 23:49:17:000

Welcome to the 22nd quarterly review of DivGro, my portfolio of dividend growth stocks. My quarterly reviews provide a summary of dividend income, dividend changes, and transactions executed in the past quarter. I also provide some charts showing various portfolio statistics. While these rev… read more...

Mustang Bio: A Differentiated CAR-T Innovator With Multiple Unlocking Catalysts

via: SeekingAlpha at 2018-07-20 05:02:11:000

If you cant figure out what category your stocks are in, then ask your broker. If a broker recommended the stock in the first place, then you definitely ought to ask, because how else are you to know what you're looking for? Are you looking for slow growth, fast growth, recession prot… read more...

Liquidia Technologies Readies $50 Million IPO

via: SeekingAlpha at 2018-07-19 14:29:28:000

Quick Take Liquidia Technologies ( LQDA ) intends to raise $50 million from the sale of its common stock in a U.S. IPO, according to an amended S-1/A registration statement . The company is advancing a pipeline of already-approved treatments using its proprietary dry inhaled technology…. read more...

Big Pharma in the red on ramped up pressure on drug prices

via: SeekingAlpha at 2018-07-19 11:10:23:000

Drug makers are under pressure as the Trump administration dials up the heat with its plan to corral prices. More news on: Health Care Select Sect SPDR ETF, iShares Nasdaq Biotechnology ETF, SPDR Biotech ETF, Healthcare stocks news, Stocks on the move, , News on ETFs, Read more … read more...

Kite and Gadeta Announce Strategic Collaboration to Advance Gamma Delta T Cell Receptor Technology for Solid Tumors

via: Business Wire at 2018-07-19 08:30:00:000

Kite, a Gilead Company (Nasdaq: GILD), and Gadeta B.V., a privately-held company focused on the discovery and development of novel cancer immunotherapies based on gamma delta T cell receptors (TCRs), have entered into a strategic collaboration to develop novel gamma delta TCR therapies in va… read more...

Madrigal Is Unreasonably Priced For Perfection And Limited Competition

via: SeekingAlpha at 2018-07-18 18:34:19:000

"She was here on earth to grasp the meaning of its wild enchantment, and to call each thing by its right name. By its right name." - Into The Wild I've written in depth concerning the potential and history of thyroid receptor agonists in treating NASH. There's no doubt about it - Madriga… read more...

FDA committed to easing approval path for biosimilars

via: SeekingAlpha at 2018-07-18 15:08:45:000

In remarks prepared for a presentation to the Brookings Institution, FDA Commissioner Scott Gottlieb, M.D. says the agency is committed to doing its part to reduce healthcare costs, especially as its relates to biosimilars. So far, the market impact of the 11 biosimilars approved in the U… read more...

You Can't Go Wrong Buying Netflix On Dips - Cramer's Mad Money (7/17/18)

via: SeekingAlpha at 2018-07-18 07:40:17:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday , July 17. The Nasdaq reached a high an the market refused to go lower on Tuesday. Even Netflix (NFLX) rallied parsing lot of its afterhours fall on Monday. "The mystery here is not why Netflix got shov… read more...

Cramer's charts suggest big-name biotech stocks Gilead and Celgene have more room to run

via: CNBC at 2018-07-17 18:45:00:000

No summary available. read more...

Gilead's HIV Franchise Under Assault As It Stares Down Paradigm-Changing Drug

via: SeekingAlpha at 2018-07-17 14:16:24:000

Gilead ( GILD ) has annual revenues in the HIV class of drugs of over $14.2 billion, and only has one phase 3 drug in clinical trials to protect its dominance in this category. GILDs $14 billion annual income stream could be in jeopardy, because they are literally one drug approval awa… read more...

My Top 5 Undervalued DGI Stocks

via: SeekingAlpha at 2018-07-17 05:14:01:000

On Saturday afternoon I was watching Regis Rougarou Prograis fight on ESPN. If youre a boxing fan, youve got to take a look at this heavy fisted southpaw. Hes got the entire city of New Orleans behind him and he brings a ton of energy to the ring. The ki… read more...

46 Nasdaq 'Safer' Dividend Net Gains Led By Lam, Western, Broadcom, Vodafone, And KLA-Tencor, Per Broker July Targets

via: SeekingAlpha at 2018-07-17 00:04:26:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten NASDAQ "Safer" Dividend Stocks to Net 13.7% to 50.5% Gains By July 2019 Five of the ten top yield "safer" Dividend NASDAQ stocks (with name backgrounds tinted grey in the list above) were found among the top ten gainers for the comin… read more...

Your 52 Top Yield, Upside, & Net Gain NASDAQ Stocks For July

via: SeekingAlpha at 2018-07-16 19:11:00:000

NAS (1A) GAINERS JL18-19 Actionable Conclusions (1-10): Brokers Predict 16.5% To 50.5% Net Gains From July's NASDAQ Top Ten Three of ten top yield NASDAQ dividend stocks were identified as being among the top ten net gainers for the coming year based on analyst 1-year target prices. … read more...

Stocks To Watch: Prime Time In Retail

via: SeekingAlpha at 2018-07-14 08:51:24:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Here we go. Amazon Prime Day is back as a global 36-hour event this year, with the … read more...

Stocks To Watch: Prime Time In Retail

via: SeekingAlpha at 2018-07-14 08:51:24:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Here we go. Amazon Prime Day is back as a global 36-hour event this year, with the … read more...

Stocks To Watch: Prime Time In Retail

via: SeekingAlpha at 2018-07-14 08:51:24:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Here we go. Amazon Prime Day is back as a global 36-hour event this year, with the … read more...

Gilead Sciences to Release Second Quarter 2018 Financial Results on Wednesday, July 25, 2018

via: Business Wire at 2018-07-13 16:01:00:000

Conference Call and Webcast to Follow Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2018 financial results will be released on Wednesday, July 25, after the market closes. At 5:00 p.m. Eastern Time, Gileads management will host a conference cal… read more...

Gilead: Cheap Valuation For Great Pipeline

via: SeekingAlpha at 2018-07-12 12:58:27:000

After Q1 earnings release in early May, Gilead (NASDAQ: GILD ) stock fell over 9% to around $65 per share, which is at the lower end of the 52-week range. To put this into perspective, GILD was trading slightly under $90 earlier this year. . Gilead has recognized falling revenue and EPS due to… read more...

Drug prices still marching upward - Bloomberg

via: SeekingAlpha at 2018-07-12 12:20:07:000

Bloomberg reports that, despite the recent concession from Pfizer to delay its price hikes until year-end, some drug makers are ignoring the political climate and instituting price increases now. Recent examples: More news on: Celgene Corporation, Novo Nordisk A/S, Intercept Pharmaceutic… read more...

Big Pharma in the red after Pfizer backs away from price hikes

via: SeekingAlpha at 2018-07-11 09:54:56:000

Members of Big Pharma are down in early trade after Pfizer ( PFE -0.6% ) rolled back its planned price increases after direct intervention from President Trump. Investors apparently perceive diminished prospects for large price increases in the future for drug makers. More news on: Pfize… read more...

Monthly Review Of DivGro: June 2018

via: SeekingAlpha at 2018-07-11 07:51:36:000

Welcome to the monthly review of DivGro, my portfolio of dividend growth stocks. The goal of these reviews is to provide a summary of dividends received and to detail buy and sell transactions. I also consider the impact on DivGro's projected annual dividend income (PADI). In June, I opene… read more...

Gilead: Laddered Calls

via: SeekingAlpha at 2018-07-10 20:29:31:000

Gilead Pharmaceuticals (GILD) has been the subject of many posts in this blog because it is a very good Dividend Machine stock. The best Dividend Machine stocks deliver dividends, dividend increases, and provide covered call opportunities. The best Dividend Machines deliver increasing divi… read more...

Pricing transparency law in California having effect, drug makers nix planned increases

via: SeekingAlpha at 2018-07-10 16:12:53:000

Bloomberg reports that some drug firms have axed plans to increase pricing for certain products or have rolled back hikes in response to a new law in California aimed at pricing transparency. The law, requiring drug makers to give advance notice of significant price increases, is designed … read more...

Celgene: Fears Are Overplayed

via: SeekingAlpha at 2018-07-10 15:41:48:000

Any company buying back a lot of stock always catches my attention. A stock has to be cheap and the balance sheet strong in order for a company to repurchase a large amount of the outstanding stock. Celgene ( CELG ) fits the equation after announcing another $3 billion buyback plan while t… read more...

Dividend Portfolio Review: Top 2 Dividend Income For June

via: SeekingAlpha at 2018-07-10 08:55:00:000

As the stakes are increasing with the U.S - China - EU trade wars German automobile stocks get pummeled and are trading at valuations not having been seen since the British cast their infamous BreXit vote. With markets becoming increasingly subject to Trump's intensified everyday Twitter activ… read more...

Cramer's lightning round: Calling bottom in Southwest Airlines despite oil trends

via: CNBC at 2018-07-09 18:51:00:000

No summary available. read more...

Michael Amoroso to Join Kite as Senior Vice President and Head of Worldwide Commercial, Cell Therapy

via: Business Wire at 2018-07-09 16:30:00:000

-- Mr. Amoroso Brings Significant Expertise in Oncology to New Role -- Kite, a Gilead Company (NASDAQ: GILD), announced today that Michael Amoroso will join the company as Senior Vice President and Head of Worldwide Commercial, Cell Therapy. In this position, Mr. Amoroso will have r… read more...

Gilead Sciences Near-Term Data Release For Rheumatoid Arthritis Is An Important Event

via: SeekingAlpha at 2018-07-09 09:24:05:000

Gilead Sciences ( GILD ) has been having issues relating to its Hepatitis C franchise. This by no means is a surprise as its Hepatitis C sales have slipped over the years. There are two upcoming readouts that could make a huge turnaround for Gilead. This involves filgotinib results in Rheuma… read more...

Using Ratios To Identify Stocks Set To Outperform Their Peers: Pharmaceutical Rankings Update

via: SeekingAlpha at 2018-07-09 09:18:26:000

Introduction Moving on to the third article in this series, the focus will be on major pharmaceutical companies. The stocks included are Johnson & Johnson ( JNJ ), Abbvie ( ABBV ), Merck ( MRK ), Gilead Sciences ( GILD ), and Pfizer ( PFE ). For the readers who haven't seen my previous r… read more...

Gilead Q2 Results Could Initiate A Rally

via: SeekingAlpha at 2018-07-09 08:58:07:000

Last winter I wrote the glum, only somewhat tongue-in-cheek, Gilead Sciences: Going Down When It Should Go Up . The day before it was published, Gilead Sciences (GILD) closed at $72.70. On July 6, 2018, it closed at $75.21, but it has been as low as $64.27 in the interim. Gilead seems to have… read more...

Learn How To Invest Against Acute Myeloid Leukemia, One Of The Fastest-Growing Cancer Markets

via: SeekingAlpha at 2018-07-09 08:00:00:000

The most important weapon we as investors have in our arsenals is knowledge. Many of the people I've spoken with on Seeking Alpha and other forums have demonstrated keen awareness of the clinical pipeline for their company of interest. However, it is often difficult for them to place the resul… read more...

Dividend Income Update: June 2018

via: SeekingAlpha at 2018-07-09 06:45:01:000

The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. No doubt, these are the best posts to write and read online as it only provides further proof that dividend invest… read more...

Galectin Therapeutics IPF Patent Solidifies Platform Technology Status

via: SeekingAlpha at 2018-07-05 14:46:02:000

Galectin Therapeutics (NASDAQ: GALT ) announced on June 27th its patent for the method and treatment of Idiopathic Pulmonary Fibrosis (IPF). The significance of this patent was initially received as extremely positive by the market, but recent structural pressures like the option exercise … read more...

Galectin Therapeutics IPF Patent Solidifies Platform Technology Status

via: SeekingAlpha at 2018-07-05 14:46:02:000

Galectin Therapeutics (NASDAQ: GALT ) announced on June 27th its patent for the method and treatment of Idiopathic Pulmonary Fibrosis (IPF). The significance of this patent was initially received as extremely positive by the market, but recent structural pressures like the option exercise … read more...

Galectin Therapeutics IPF Patent Solidifies Platform Technology Status

via: SeekingAlpha at 2018-07-05 14:46:02:000

Galectin Therapeutics (NASDAQ: GALT ) announced on June 27th its patent for the method and treatment of Idiopathic Pulmonary Fibrosis (IPF). The significance of this patent was initially received as extremely positive by the market, but recent structural pressures like the option exercise … read more...

Insurers making headway on corralling drug costs with copay accumulators

via: SeekingAlpha at 2018-07-05 09:24:45:000

Reuters reports that drug makers are "scrambling" to limit the financial impact of copay accumulator programs by insurers and pharmacy benefit managers (PBMs). The scheme, which forces drug manufacturers to pony up more money to assist patients with copay costs or face declining demand for… read more...

Insurers making headway on corralling drug costs with copay accumulators

via: SeekingAlpha at 2018-07-05 09:24:45:000

Reuters reports that drug makers are "scrambling" to limit the financial impact of copay accumulator programs by insurers and pharmacy benefit managers (PBMs). The scheme, which forces drug manufacturers to pony up more money to assist patients with copay costs or face declining demand for… read more...

Insurers making headway on corralling drug costs with copay accumulators

via: SeekingAlpha at 2018-07-05 09:24:45:000

Reuters reports that drug makers are "scrambling" to limit the financial impact of copay accumulator programs by insurers and pharmacy benefit managers (PBMs). The scheme, which forces drug manufacturers to pony up more money to assist patients with copay costs or face declining demand for… read more...

Liquidia Technologies Starts IPO Process

via: SeekingAlpha at 2018-07-03 12:00:43:000

Quick Take Liquidia Technologies ( LQDA ) intends to sell shares of its common stock for gross proceeds of $57.5 from a U.S. IPO, according to an S-1 registration statement . The firm is a biopharmaceutical company that improves the development of new therapies by engineering drug parti… read more...

Liquidia Technologies Starts IPO Process

via: SeekingAlpha at 2018-07-03 12:00:43:000

Quick Take Liquidia Technologies ( LQDA ) intends to sell shares of its common stock for gross proceeds of $57.5 from a U.S. IPO, according to an S-1 registration statement . The firm is a biopharmaceutical company that improves the development of new therapies by engineering drug parti… read more...

Pfizer boosts prices of certain drugs by almost 10%

via: SeekingAlpha at 2018-07-03 11:17:01:000

The Wall Street Journal reports that Pfizer ( PFE +0.5% ) has increased the list prices for over 40 medications, its second hike this year. Some, including Xalkori, Norvasc, Celebrex and Zoloft, were bumped 9.4%. More news on: Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi, Healt… read more...

Pfizer boosts prices of certain drugs by almost 10%

via: SeekingAlpha at 2018-07-03 11:17:01:000

The Wall Street Journal reports that Pfizer ( PFE +0.5% ) has increased the list prices for over 40 medications, its second hike this year. Some, including Xalkori, Norvasc, Celebrex and Zoloft, were bumped 9.4%. More news on: Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi, Healt… read more...

Gemphire's Positive Phase 2b Results Reignites The NASH Market Yet Again

via: SeekingAlpha at 2018-07-02 12:58:53:000

On Thursday, Gemphire Therapeutics ( GEMP ) announced positive results for its phase 2b study in treating patients with severe hypertriglyceridemia ((SHTG)). These positive results caused the stock to trade higher in after-hours trade by as much as 110%. These positive phase 2b results in SH… read more...

Your Daily Pharma Scoop: Spectrum Trial Proceeds, AzurRx Moves To Phase 3, Aptose Jumps

via: SeekingAlpha at 2018-07-02 07:20:07:000

Stocks in News: SPPI, AZRX Spectrum reports second late-stage Rolontis trial meets primary endpoint Discussion : Second Phase 3 trial of Spectrum Pharmaceuticals ( SPPI ) Rolontis met primary efficacy endpoint. The endpoint was non-inferiority in duration of severe neutropenia… read more...

Venture Capital Deals Of The Week: SoftBank Leads $200M Into Indian Insurance

via: SeekingAlpha at 2018-06-30 10:13:00:000

Welcome to Seeking Alphas Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. Indian digital insurance: SoftBanks ([[SFTBF]], [[SFTBY]]) Vision Fund led a $200M round in Indian… read more...

Venture Capital Deals Of The Week: SoftBank Leads $200M Into Indian Insurance

via: SeekingAlpha at 2018-06-30 10:13:00:000

Welcome to Seeking Alphas Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. Indian digital insurance: SoftBanks ([[SFTBF]], [[SFTBY]]) Vision Fund led a $200M round in Indian… read more...

Rival Novartis, Gilead CAR-T therapies win CHMP recommendations

via: SeekingAlpha at 2018-06-29 09:27:29:000

Rival cancer cell therapies from Novartis (NYSE: NVS ) and Gilead Sciences (NASDAQ: GILD ) win key recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use, likely clearing their way for approval. More news on: Novartis AG, Gilead Sciences, Inc…. read more...

European CHMP Adopts Positive Opinion for Yescarta® (axicabtagene ciloleucel) for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy

via: Business Wire at 2018-06-29 07:54:00:000

Kite, a Gilead Company (Nasdaq: GILD), today announced that the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the companys Marketing Authorization Application (MAA) for Yescarta (axicabtagene ci… read more...

5 Undervalued Large-Cap Stocks For Value Investors - June 2018

via: SeekingAlpha at 2018-06-28 13:40:46:000

There are a number of great companies in the market today. By using the ModernGraham valuation model, I've screened the 900+ companies reviewed by ModernGraham to select five large-cap undervalued companies for value investors. Each company has been determined to be suitable for either the … read more...

The problem with high drug prices isn't 'foreign freeloading,' it's the patent system

via: CNBC at 2018-06-27 09:08:00:000

No summary available. read more...

Here Are 43 Of 84 'Safer' Healthcare High Yield Dividend Equities For June

via: SeekingAlpha at 2018-06-26 22:51:03:000

Actionable Conclusions (1-10): Brokers Estimated Top 10 High Yield Healthcare "Safer" Dividend Stocks to Net 9% to 22.98% Gains To June 2019 Five of ten top "safer" dividend Healthcare stocks by yield (shaded in the chart above) were verified as being among the top 10 gainers for the comin… read more...

59 Top-Yield Healthcare Equities For June

via: SeekingAlpha at 2018-06-26 05:02:46:000

Actionable Conclusions (1-10): Analysts Projected 6% To 23% Net Gains For Top Ten Healthcare Stocks By June 2019 Just two of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year, based on broker 1-year target prices. (They a… read more...

Genomic Medicine: Is The Platform The FDA Product?

via: SeekingAlpha at 2018-06-25 12:24:52:000

Credit: Irvine/NIST The FDA is expected to release new guidelines in July which are part of an effort to modernize regulations related to cell and gene therapy. The key to these revisions may be tied to their belief that the use of novel platforms for gene therapy flips the risk profil… read more...

European Commission Grants Marketing Authorization for Gilead's Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection

via: Business Wire at 2018-06-25 08:03:00:000

In Clinical Trials, Biktarvy Demonstrated High Efficacy and Zero Resistance Through 48 Weeks Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the European Commission has granted Marketing Authorization for Biktarvy (bictegravir 50mg/emtricitabine 2… read more...

Gilead Sciences Is Too Cheap To Ignore - Cramer's Lightning Round (6/22/18)

via: SeekingAlpha at 2018-06-25 06:11:58:000

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday, June 22. Bullish Calls Gilead Sciences (GILD): It's too low to sell and has a good challenge. TrustCo Bank (TRST): It's one of the good companies to own in this environment. Crispr Therapeutics… read more...

2018 Call Portfolio

via: SeekingAlpha at 2018-06-24 23:57:00:000

In 2018 I am tracking a portfolio that is designed to deliver income mostly through call options. It is a limited portfolio with a basis of just over $68,000. This $68,000 has already created over $4,000 of income. I like this kind of income. This is not a growth portfolio and the stock pric… read more...

What Does Breakthrough Therapy Designation Really Mean For My Company?

via: SeekingAlpha at 2018-06-23 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. The world of biotech investing revolves first and foremost around the regulatory agencies like th… read more...

What Does Breakthrough Therapy Designation Really Mean For My Company?

via: SeekingAlpha at 2018-06-23 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. The world of biotech investing revolves first and foremost around the regulatory agencies like th… read more...

Cramer's lightning round: I don't like Snap's ownership structure

via: CNBC at 2018-06-22 18:47:00:000

No summary available. read more...

Arbutus Biopharma: The Next Big Breakout Biotech?

via: SeekingAlpha at 2018-06-22 10:18:28:000

Introduction Arbutus Biopharma (ABUS) is a biotech company with a market capitalization of $387 million. Arbutus focuses on developing treatments for HBV. The company has three different products in development targeting different steps in the viruses' life-cycle. Arbutus' lead compound ARB-… read more...

3 Things In Biotech, June 19: Geron Just Can't Win, Verastem Breaks Out

via: SeekingAlpha at 2018-06-20 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! What else do you get from me with a subscription ? Welcome to another edition of "3 Things In Biotech You Should Learn Today," … read more...

Does Gilead's Have A HBV Blockbuster Drug In The Works?

via: SeekingAlpha at 2018-06-19 13:14:32:000

Introduction The focus of this article will be on Gileads (NASDAQ: GILD ) HBV treatments and their future prospects. I will delve into the biology of HBV and why it is so difficult to cure. I will discuss how Viread and Vemildy are not game changers in the HBV field but provide a … read more...

Gilead Oncology CAR T-Cell Therapies Outlook Compelling

via: SeekingAlpha at 2018-06-18 12:38:56:000

The potential to deliver "one shot cures" is one of the most attractive aspects of gene therapy, genetically engineered cell therapy, and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies… While this proposition ... read more...

Dividend Portfolio Review: New Dividend Record

via: SeekingAlpha at 2018-06-18 08:40:48:000

It's May and this is the best time of the year for a German dividend investor as this is the month where most of Germany's companies distribute their annual dividends. As such it was no surprise that May set a new record in dividend income but I am still baffled by the amount and the growth co… read more...

Avoiding The 'Black Hole' Of Disease Development

via: SeekingAlpha at 2018-06-15 12:24:55:000

"Whoever fights monsters should see to it that in the process he does not become a monster. And if you gaze long enough into an abyss, the abyss will gaze back into you." - Friedrich Nietzsche Today, we are going to talk about two major disease areas that are garnering billions of dollars … read more...

Avoiding The 'Black Hole' Of Disease Development

via: SeekingAlpha at 2018-06-15 12:24:55:000

"Whoever fights monsters should see to it that in the process he does not become a monster. And if you gaze long enough into an abyss, the abyss will gaze back into you." - Friedrich Nietzsche Today, we are going to talk about two major disease areas that are garnering billions of dollars … read more...

Avoiding The 'Black Hole' Of Disease Development

via: SeekingAlpha at 2018-06-15 12:24:55:000

"Whoever fights monsters should see to it that in the process he does not become a monster. And if you gaze long enough into an abyss, the abyss will gaze back into you." - Friedrich Nietzsche Today, we are going to talk about two major disease areas that are garnering billions of dollars … read more...

Brief Mid-Year Update On 2018 Global Asset Allocation

via: SeekingAlpha at 2018-06-15 11:04:16:000

Time does fly, and today yet another World Cup starts, this time in Russia. Yesterday brought the somewhat ironic, yet overall positive (from my standpoint) news that the 2026 tournament will be hosted by the NAFTA countries of Canada, the US and Mexico. 2018 is almost half over, so it seems l… read more...

Brief Mid-Year Update On 2018 Global Asset Allocation

via: SeekingAlpha at 2018-06-15 11:04:16:000

Time does fly, and today yet another World Cup starts, this time in Russia. Yesterday brought the somewhat ironic, yet overall positive (from my standpoint) news that the 2026 tournament will be hosted by the NAFTA countries of Canada, the US and Mexico. 2018 is almost half over, so it seems l… read more...

Brief Mid-Year Update On 2018 Global Asset Allocation

via: SeekingAlpha at 2018-06-15 11:04:16:000

Time does fly, and today yet another World Cup starts, this time in Russia. Yesterday brought the somewhat ironic, yet overall positive (from my standpoint) news that the 2026 tournament will be hosted by the NAFTA countries of Canada, the US and Mexico. 2018 is almost half over, so it seems l… read more...

Gilead: Growth Pick For Your Portfolio

via: SeekingAlpha at 2018-06-15 08:45:13:000

At current streams of revenue, Gilead Sciences will continue its earnings depression. This is reflected within ( GILD )'s current price per share. However, the main drivers for GILD's future revenue growth will be determined by its acquisitions and the strength of its pipeline. How will Gile… read more...

Gilead: Growth Pick For Your Portfolio

via: SeekingAlpha at 2018-06-15 08:45:13:000

At current streams of revenue, Gilead Sciences will continue its earnings depression. This is reflected within ( GILD )'s current price per share. However, the main drivers for GILD's future revenue growth will be determined by its acquisitions and the strength of its pipeline. How will Gile… read more...

Gilead: Growth Pick For Your Portfolio

via: SeekingAlpha at 2018-06-15 08:45:13:000

At current streams of revenue, Gilead Sciences will continue its earnings depression. This is reflected within ( GILD )'s current price per share. However, the main drivers for GILD's future revenue growth will be determined by its acquisitions and the strength of its pipeline. How will Gile… read more...

Autolus Therapeutics Readies $125 Million U.S. IPO

via: SeekingAlpha at 2018-06-14 11:26:47:000

Quick Take Autolus Therapeutics Ltd. ( AUTL ) intends to raise $125 million in IPO gross proceeds from the sale of ADSs (American Depositary Receipts), per a registration statement . The company is developing a pipeline of blood cancer and solid tumor T cell treatments with advanced pro… read more...

ContraVir on go to start clinical development of HBV candidate CRV431 in U.S.; shares up 14% premarket

via: SeekingAlpha at 2018-06-14 08:37:31:000

The FDA has signed off on ContraVir Pharmaceuticals' (NASDAQ: CTRV ) IND for HBV candidate CRV431. More news on: ContraVir Pharmaceuticals, Inc., Gilead Sciences, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...

Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 39th Annual Global Healthcare Conference (Transcript)

via: SeekingAlpha at 2018-06-13 18:17:05:000

Gilead Sciences, Inc. (GILD) Goldman Sachs 39th Annual Global Healthcare Conference June 13, 2018 11:40 ET Executives Robin Washington - EVP & CFO John McHutchison - CSO Analysts Terence Flynn - Goldman Sachs & Co. LLC Presentation Terence Flynn Thank you. I… read more...

Apple: Can Shares Double Again In 2 Years?

via: SeekingAlpha at 2018-06-13 10:40:49:000

Warren Buffett said the following: I call investing the greatest business in the world because you never have to swing. You stand at the plate, the pitcher throws you General Motors (GM) at 47! U.S. Steel (X) at 39! And nobody calls a strike on you. Theres no penalty exce… read more...

Viking Therapeutics: Hallmark Moment

via: SeekingAlpha at 2018-06-13 10:19:16:000

Hallmark Moments… Writing the perfect greeting card is never easy. Wording needs to be precise. The length so exact. Find all those details you definitely want to include... or leave out. While still managing to strike just the proper tone. Nothing too dark and serious, but also not too ... read more...

Sangamo Therapeutics: Investibility Outlook

via: SeekingAlpha at 2018-06-13 09:15:21:000

Like BioTime ( BTX ), which we discussed recently, Sangamo ( SGMO ) is another company that began the wrong way, with a platform, and then, and only recently, moved on to therapeutics. But, oh boy, what a move it has been! The company changed its name from Sangamo Biosciences to Sangamo Therap… read more...

A Conservative Investment Strategy To Achieve 10%-12%+ Annual Cash Flow Returns

via: SeekingAlpha at 2018-06-11 19:04:16:000

Editor's note: Seeking Alpha is proud to welcome George Wanty as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Like a lot o… read more...

A Conservative Investment Strategy To Achieve 10%-12%+ Annual Cash Flow Returns

via: SeekingAlpha at 2018-06-11 19:04:16:000

Editor's note: Seeking Alpha is proud to welcome George Wanty as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Like a lot o… read more...

Gilead Sciences' Chief Scientific Officer John McHutchison Appointed Officer of the Order of Australia

via: Business Wire at 2018-06-11 08:30:00:000

Recognized for Services to Medical Research Gilead Sciences, Inc. (NASDAQ: GILD) announced today that John McHutchison, MD, Chief Scientific Officer and Head of Research and Development, has been appointed an Officer of the Order of Australia in recognition of his … read more...

Gilead Sciences' Chief Scientific Officer John McHutchison Appointed Officer of the Order of Australia

via: Business Wire at 2018-06-11 08:30:00:000

Recognized for Services to Medical Research Gilead Sciences, Inc. (NASDAQ: GILD) announced today that John McHutchison, MD, Chief Scientific Officer and Head of Research and Development, has been appointed an Officer of the Order of Australia in recognition of his … read more...

45 'Safer' Dividend Nasdaq Equities For June

via: SeekingAlpha at 2018-06-11 02:12:25:000

Actionable Conclusions (1-10): Brokers Estimate Top Ten "Safer" Dividend NASDAQ Stocks to Net 12.5% to 45% Gains By June, 2019 Three of the ten top yield "safer" Dividend NASDAQ stocks (with name backgrounds tinted grey in the list above) were found among the top ten gainers for the coming… read more...

45 'Safer' Dividend Nasdaq Equities For June

via: SeekingAlpha at 2018-06-11 02:12:25:000

Actionable Conclusions (1-10): Brokers Estimate Top Ten "Safer" Dividend NASDAQ Stocks to Net 12.5% to 45% Gains By June, 2019 Three of the ten top yield "safer" Dividend NASDAQ stocks (with name backgrounds tinted grey in the list above) were found among the top ten gainers for the coming… read more...

Your 52 Top Yield, Upside And Gains Nasdaq Index Stocks For June

via: SeekingAlpha at 2018-06-09 23:35:17:000

Actionable Conclusions (1-10): Brokers Predict 19% To 45% Net Gains From June's NASDAQ Top Ten Three of ten top yield NASDAQ dividend stocks were identified as being among the top ten net gainers for the coming year based on analyst 1-year target prices. (They are tinted gray in the c… read more...

Retirement: The Future-Proof Portfolio For Young Investors, Bought At A Market High, Is Reducing Its Losses

via: SeekingAlpha at 2018-06-09 01:31:15:000

On the 25th of January 2018, I started the future-proof portfolio to serve as an example how young investors who are saving for their retirement can choose to distribute their funds. In this portfolio, I am not focusing on dividend yield, but on future-proof companies and growth. Of course, it… read more...

Using Ratios To Identify Stocks Set To Outperform Their Peers: Introducing My Research

via: SeekingAlpha at 2018-06-08 12:10:33:000

Intro I've been fascinated with ratios and their ability to capture certain aspects of a business in just one number for quite a while. Sure, ratios use historical data and thus don't predict future performance, but they can give key insights as to how well a company is running. On this note… read more...

Alpine Immune Sciences: What The Q1 2018 Earnings Foretell?

via: SeekingAlpha at 2018-06-07 17:22:23:000

Without a saving faith in the future, no one would ever invest at all. To be an investor, you must be a believer in a better tomorrow. - Benjamin Graham In a Seeking Alpha interview back on Sep. 23, 2017, the ingenious market strategist (Robyn Conti) inquired, "What's one idea you feel s… read more...

Core Biotech Buys #18: Thoughts On ASCO And The End Of Core Biotech

via: SeekingAlpha at 2018-06-07 16:03:56:000

Welcome to the eighteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size… read more...

Galectin Therapeutics's Market Value Should Soar In The Coming Months

via: SeekingAlpha at 2018-06-07 11:43:34:000

Galectin Therapeutics Inc. (GALT) announced a key director was elevated to the position of Chairman of the Board of Directors and that Kevin Freeman was elected as the Vice Chairman. What is so noteworthy about this press release is that it signals the businessmen are now in control of the c… read more...

This One Study Could Radically Change The Cancer Immunotherapy Market

via: SeekingAlpha at 2018-06-07 10:22:51:000

This year's American Society of Clinical Oncology ((ASCO)) conference in Chicago was chock full of the latest in cancer research and advances, but one retrospective study in particular could help radically change the way cancer immunotherapy trials are conducted going forward. The change cou… read more...

An Integrated BioSci Research On Madrigal: What The Stellar Data Reporting For MGL-3196 Foretells

via: SeekingAlpha at 2018-06-07 07:12:20:000

The generally accepted view is that markets are always right - that is, market prices tend to discount future developments accurately even when it is unclear what those developments are. I start with the opposite view. I believe the market prices are always wrong in the sense that they presen… read more...

Gilead's Evolution In Oncology, With Comments On Valuation

via: SeekingAlpha at 2018-06-07 02:54:55:000

Background - Gilead's quest to go beyond antivirals goes way back - and has had sub-par results Before discussing the Kite story, it's necessary to have some context relating to Gilead Sciences' (GILD) diversification efforts. If you are familiar with GILD's R&D issues, feel free to skip… read more...

PBMs one-up drug makers on drug copay assistance schemes

via: SeekingAlpha at 2018-06-06 11:41:10:000

Reuters reports that U.S. drug prices fell 5.6% in Q1, 3.6% more than a year ago. Sector & Sovereign analyst Richard Evans believes most of the decline is from "copay accumulator" programs instituted by pharmacy benefit managers (PBMs) last quarter that do not allow copay assistance pa… read more...

Mining ASCO 2018's Gold, Part 12: Let's Talk About Blood, Baby

via: SeekingAlpha at 2018-06-06 09:00:00:000

Welcome to "Mining ASCO 2018's Gold," a series dedicated to helping you identify upcoming investment gems in biotech based on under-reported studies being presented at this year's big cancer meeting. But first, did you happen to miss any of the previous editions? If so, please do give them a… read more...

Your Daily Pharma Scoop: Iovance Zooms Ahead, Palatin Surges And Deciphera Moves Up

via: SeekingAlpha at 2018-06-06 01:36:03:000

Analysis Focus:IOVA Iovance Biotherapeutics (IOVA) is a small biopharma with about $1.3bn in market cap. This is our well-known Lion Bio which shot to some prominence last year and also changed its name to Iovance. Their lead product candidate is LN-144, an adoptive cell therapy in Phase 2… read more...

Biotech Analysis Central Pharma News: Roche Abandons Drug, Gilead's Early Stage Bet, Vaxart's Phase 2 Failure

via: SeekingAlpha at 2018-06-06 01:14:42:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Roche Dumps Breast Cancer Drug News: Roche ( RHHBY ) recently announced that it had decided to stop development of its PI3K cancer drug taselisib … read more...

My 30 Stock Portfolio +3 Adds

via: SeekingAlpha at 2018-06-05 09:45:40:000

Welcome to my second portfolio update of 2018. The goal of my portfolio is financial freedom. My plan is a combination of dividend growth investing and buying stocks that will beat the market. I call the DGI portion of my portfolio my "dividend machine", I do not DRIP, rather build up cash and… read more...

Gilead Sciences Announces Leadership Changes in Corporate Development and Strategy

via: Business Wire at 2018-06-04 17:00:00:000

Andrew Dickinson Promoted to Executive Vice President, Corporate Development and Strategy; Martin Silverstein, Executive Vice President, Strategy, to Leave Gilead at End of August Gilead Sciences, Inc. (NASDAQ: GILD) today announced the promotion of Andrew Dick… read more...

Crispr On Hold While Sangamo Accelerates

via: SeekingAlpha at 2018-06-04 15:21:46:000

We're at a key point when it comes to cell and gene therapy. These therapies have the potential to address hundreds, if not thousands, of different rare and common diseases. For a long time, they were largely theoretical constructs. Now they're a therapeutic reality. And it's my expectation … read more...

By The Numbers: Investing Ideas Based On Profitability, Value, And Momentum

via: SeekingAlpha at 2018-06-04 12:19:03:000

There is no infallible formula to pick winning stocks, however, statistical data shows that companies offering some specific quantitative attributes tend to outperform the markets in the long term. Among other factors, research has proven that profitability, valuation, and momentum are some of… read more...

Gilead up 1% on reported settlement with Mylan over Tybost, encouraging news on new cancer treatment

via: SeekingAlpha at 2018-06-04 11:35:47:000

Gilead Sciences ( GILD +1.4% ) perks up on below-average volume in apparent response to chatter that it is nearing a settlement with Mylan NV ( MYL -1.1% ) in a patent infringement dispute regarding Tybost (cobicistat). Gilead sued Mylan a couple of years ago in response to its filin… read more...

Biotech Bio Series #3: Should You Buy The Dip On AbbVie?

via: SeekingAlpha at 2018-06-04 09:27:10:000

This is the third article of the Biotech Bio Series. Big pharma and biotechnology is one of the most exciting sectors in the world today, researching and developing drugs that allow all of us to live longer than ever before. For companies behind this innovation, the approval of one drug may … read more...

Kite Announces Initial Results From a Phase 1 Study of T Cell Receptor (TCR) Cell Therapy in HPV-16-Positive Solid Tumors

via: Business Wire at 2018-06-04 09:00:00:000

National Cancer Institute (NCI) Study Shows Investigational TCR Therapy Induces Response in Patients with Epithelial Cancers Data at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting Support Development of KITE-439 for HPV-Associated Sol… read more...

Kite Announces New Data Analyses for CAR T Therapy in Patients with Blood Cancers at the 2018 American Society of Clinical Oncology Meeting

via: Business Wire at 2018-06-04 09:00:00:000

-- ZUMA-1 Data Suggest Patient Response to Yescarta (axicabtagene ciloleucel) at Three Months May be Predictive of Longer-Term Response in Refractory B-cell Lymphoma -- -- ZUMA-3 Analysis Suggests High Complete Response Rates with KTE-C19 in Adult Patients with Relap… read more...

Gilead Sciences Leads Its First Step Toward Pipeline Recovery With Clinical Candidate Filgotinib

via: SeekingAlpha at 2018-06-04 00:44:23:000

Recently, Gilead ( GILD ) and its partner Galapagos NV ( GLPG ) announced successful data from a phase 2 study treating patients with psoriatic arthritis. This will allow both companies to move the drug filgotinib forward to a late-stage study. This is one of the important drugs in the pip… read more...

Conatus Pharmaceuticals: What Investors Can Expect From This Interesting NASH Innovator?

via: SeekingAlpha at 2018-06-03 06:18:03:000

Diversification is an established tenet of conservative investment. - Benjamin Graham Conatus Pharmaceuticals (CNAT) is an intriguing bioscience taking on various giants, as the company is trying to deliver a solution to the lucrative $25.3B nonalcoholic steatohepatitis ("NASH") market . … read more...

Conatus Pharmaceuticals: What Investors Can Expect From This Interesting NASH Innovator?

via: SeekingAlpha at 2018-06-03 06:18:03:000

Diversification is an established tenet of conservative investment. - Benjamin Graham Conatus Pharmaceuticals (CNAT) is an intriguing bioscience taking on various giants, as the company is trying to deliver a solution to the lucrative $25.3B nonalcoholic steatohepatitis ("NASH") market . … read more...

Conatus Pharmaceuticals: What Investors Can Expect From This Interesting NASH Innovator?

via: SeekingAlpha at 2018-06-03 06:18:03:000

Diversification is an established tenet of conservative investment. - Benjamin Graham Conatus Pharmaceuticals (CNAT) is an intriguing bioscience taking on various giants, as the company is trying to deliver a solution to the lucrative $25.3B nonalcoholic steatohepatitis ("NASH") market . … read more...

Conatus Pharmaceuticals: What Investors Can Expect From This Interesting NASH Innovator?

via: SeekingAlpha at 2018-06-03 06:18:03:000

Diversification is an established tenet of conservative investment. - Benjamin Graham Conatus Pharmaceuticals (CNAT) is an intriguing bioscience taking on various giants, as the company is trying to deliver a solution to the lucrative $25.3B nonalcoholic steatohepatitis ("NASH") market . … read more...

Conatus Pharmaceuticals: What Investors Can Expect From This Interesting NASH Innovator?

via: SeekingAlpha at 2018-06-03 06:18:03:000

Diversification is an established tenet of conservative investment. - Benjamin Graham Conatus Pharmaceuticals (CNAT) is an intriguing bioscience taking on various giants, as the company is trying to deliver a solution to the lucrative $25.3B nonalcoholic steatohepatitis ("NASH") market . … read more...

Conatus Pharmaceuticals: What Investors Can Expect From This Interesting NASH Innovator?

via: SeekingAlpha at 2018-06-03 06:18:03:000

Diversification is an established tenet of conservative investment. - Benjamin Graham Conatus Pharmaceuticals (CNAT) is an intriguing bioscience taking on various giants, as the company is trying to deliver a solution to the lucrative $25.3B nonalcoholic steatohepatitis ("NASH") market . … read more...

Conatus Pharmaceuticals: What Investors Can Expect From This Interesting NASH Innovator?

via: SeekingAlpha at 2018-06-03 06:18:03:000

Diversification is an established tenet of conservative investment. - Benjamin Graham Conatus Pharmaceuticals (CNAT) is an intriguing bioscience taking on various giants, as the company is trying to deliver a solution to the lucrative $25.3B nonalcoholic steatohepatitis ("NASH") market . … read more...

Conatus Pharmaceuticals: What Investors Can Expect From This Interesting NASH Innovator?

via: SeekingAlpha at 2018-06-03 06:18:03:000

Diversification is an established tenet of conservative investment. - Benjamin Graham Conatus Pharmaceuticals (CNAT) is an intriguing bioscience taking on various giants, as the company is trying to deliver a solution to the lucrative $25.3B nonalcoholic steatohepatitis ("NASH") market . … read more...

Conatus Pharmaceuticals: What Investors Can Expect From This Interesting NASH Innovator?

via: SeekingAlpha at 2018-06-03 06:18:03:000

Diversification is an established tenet of conservative investment. - Benjamin Graham Conatus Pharmaceuticals (CNAT) is an intriguing bioscience taking on various giants, as the company is trying to deliver a solution to the lucrative $25.3B nonalcoholic steatohepatitis ("NASH") market . … read more...

Conatus Pharmaceuticals: What Investors Can Expect From This Interesting NASH Innovator?

via: SeekingAlpha at 2018-06-03 06:18:03:000

Diversification is an established tenet of conservative investment. - Benjamin Graham Conatus Pharmaceuticals (CNAT) is an intriguing bioscience taking on various giants, as the company is trying to deliver a solution to the lucrative $25.3B nonalcoholic steatohepatitis ("NASH") market . … read more...

Venture Capital Deals Of The Week: Goldman Bets On Supply Chain, Mobile Games

via: SeekingAlpha at 2018-06-02 11:02:50:000

Welcome to Seeking Alphas Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. Supply chain blockchain: Goldman Sachs (GS) co-led a $250M Series E round for supply chain payment and marketp… read more...

Venture Capital Deals Of The Week: Goldman Bets On Supply Chain, Mobile Games

via: SeekingAlpha at 2018-06-02 11:02:50:000

Welcome to Seeking Alphas Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. Supply chain blockchain: Goldman Sachs (GS) co-led a $250M Series E round for supply chain payment and marketp… read more...

Venture Capital Deals Of The Week: Goldman Bets On Supply Chain, Mobile Games

via: SeekingAlpha at 2018-06-02 11:02:50:000

Welcome to Seeking Alphas Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. Supply chain blockchain: Goldman Sachs (GS) co-led a $250M Series E round for supply chain payment and marketp… read more...

Venture Capital Deals Of The Week: Goldman Bets On Supply Chain, Mobile Games

via: SeekingAlpha at 2018-06-02 11:02:50:000

Welcome to Seeking Alphas Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. Supply chain blockchain: Goldman Sachs (GS) co-led a $250M Series E round for supply chain payment and marketp… read more...

Venture Capital Deals Of The Week: Goldman Bets On Supply Chain, Mobile Games

via: SeekingAlpha at 2018-06-02 11:02:50:000

Welcome to Seeking Alphas Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. Supply chain blockchain: Goldman Sachs (GS) co-led a $250M Series E round for supply chain payment and marketp… read more...

Venture Capital Deals Of The Week: Goldman Bets On Supply Chain, Mobile Games

via: SeekingAlpha at 2018-06-02 11:02:50:000

Welcome to Seeking Alphas Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. Supply chain blockchain: Goldman Sachs (GS) co-led a $250M Series E round for supply chain payment and marketp… read more...

Venture Capital Deals Of The Week: Goldman Bets On Supply Chain, Mobile Games

via: SeekingAlpha at 2018-06-02 11:02:50:000

Welcome to Seeking Alphas Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. Supply chain blockchain: Goldman Sachs (GS) co-led a $250M Series E round for supply chain payment and marketp… read more...

Venture Capital Deals Of The Week: Goldman Bets On Supply Chain, Mobile Games

via: SeekingAlpha at 2018-06-02 11:02:50:000

Welcome to Seeking Alphas Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. Supply chain blockchain: Goldman Sachs (GS) co-led a $250M Series E round for supply chain payment and marketp… read more...

Venture Capital Deals Of The Week: Goldman Bets On Supply Chain, Mobile Games

via: SeekingAlpha at 2018-06-02 11:02:50:000

Welcome to Seeking Alphas Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. Supply chain blockchain: Goldman Sachs (GS) co-led a $250M Series E round for supply chain payment and marketp… read more...

Venture Capital Deals Of The Week: Goldman Bets On Supply Chain, Mobile Games

via: SeekingAlpha at 2018-06-02 11:02:50:000

Welcome to Seeking Alphas Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday mornings. Supply chain blockchain: Goldman Sachs (GS) co-led a $250M Series E round for supply chain payment and marketp… read more...

Reader Inquiry: Is MorphoSys A Core Buy In Biotech?

via: SeekingAlpha at 2018-06-01 18:56:17:000

MorphoSys AG ( MOR ) is a recent addition to the Nasdaq, having raked in close to $208 million in their April IPO when 2,075,000 new ordinary shares in the form of 8,300,000 American Depositary Shares were priced at $25.04 per ADS. The fact that they were able to raise more than the ori… read more...

Reader Inquiry: Is MorphoSys A Core Buy In Biotech?

via: SeekingAlpha at 2018-06-01 18:56:17:000

MorphoSys AG ( MOR ) is a recent addition to the Nasdaq, having raked in close to $208 million in their April IPO when 2,075,000 new ordinary shares in the form of 8,300,000 American Depositary Shares were priced at $25.04 per ADS. The fact that they were able to raise more than the ori… read more...

Reader Inquiry: Is MorphoSys A Core Buy In Biotech?

via: SeekingAlpha at 2018-06-01 18:56:17:000

MorphoSys AG ( MOR ) is a recent addition to the Nasdaq, having raked in close to $208 million in their April IPO when 2,075,000 new ordinary shares in the form of 8,300,000 American Depositary Shares were priced at $25.04 per ADS. The fact that they were able to raise more than the ori… read more...

ASCO wary of Trump plan to lower drug prices

via: SeekingAlpha at 2018-06-01 15:48:36:000

Reuters reports that the American Society of Clinical Oncology (ASCO) is not entirely on board with President Trump's plan to corral drug prices, especially if Medicare is given the authority to negotiate what it pays for cancer meds. The rising cost of cancer care will be a key topic at t… read more...

ASCO wary of Trump plan to lower drug prices

via: SeekingAlpha at 2018-06-01 15:48:36:000

Reuters reports that the American Society of Clinical Oncology (ASCO) is not entirely on board with President Trump's plan to corral drug prices, especially if Medicare is given the authority to negotiate what it pays for cancer meds. The rising cost of cancer care will be a key topic at t… read more...

ASCO wary of Trump plan to lower drug prices

via: SeekingAlpha at 2018-06-01 15:48:36:000

Reuters reports that the American Society of Clinical Oncology (ASCO) is not entirely on board with President Trump's plan to corral drug prices, especially if Medicare is given the authority to negotiate what it pays for cancer meds. The rising cost of cancer care will be a key topic at t… read more...

Top Holdings Of Dividend ETFs (June 2018 Edition)

via: SeekingAlpha at 2018-06-01 13:17:03:000

From time to time, I compile a virtual portfolio of dividend growth ((DG)) stocks by analyzing the holdings of Dividend ETFs, Real Estate ETFs, or even the public portfolio of DG Bloggers. I find these exercises quite insightful and certainly worth the effort. Comparing my portfolio to the v… read more...

Top Holdings Of Dividend ETFs (June 2018 Edition)

via: SeekingAlpha at 2018-06-01 13:17:03:000

From time to time, I compile a virtual portfolio of dividend growth ((DG)) stocks by analyzing the holdings of Dividend ETFs, Real Estate ETFs, or even the public portfolio of DG Bloggers. I find these exercises quite insightful and certainly worth the effort. Comparing my portfolio to the v… read more...

June 2018 Stock Considerations

via: SeekingAlpha at 2018-06-01 01:29:59:000

As we approach a new month, it is time, once again, to outline my potential stock buys for June. Not to sound clich, but where has the time gone? Are we really approaching the half-way point of 2018 in one month? I guess so and I can take solace in the fact that I have remained invested … read more...

June 2018 Stock Considerations

via: SeekingAlpha at 2018-06-01 01:29:59:000

As we approach a new month, it is time, once again, to outline my potential stock buys for June. Not to sound clich, but where has the time gone? Are we really approaching the half-way point of 2018 in one month? I guess so and I can take solace in the fact that I have remained invested … read more...

Your Daily Pharma Scoop: Crispr On Hold, AstraZeneca Stumbles Again, TherapeuticsMD Receives FDA Approval

via: SeekingAlpha at 2018-05-31 18:00:00:000

Analysis Focus: CRSP Crispr Therapeutics (CRSP) is one of the three companies that specialises in CRISPR-Cas9 genome editing technique. All three companies had spectacular IPOs but presently Crispr Therapeutics is the only one that has retained the initial euphoria and has become a $3.472B… read more...

Biotechs: 4 Reasons And A Catalyst To Move Stocks Higher

via: SeekingAlpha at 2018-05-31 16:08:11:000

Biotech Pulse Small caps, a speculative segment of the market as opposed to mid and large caps, has made new highs. Can biotechs be far behind? Last week, we further discussed the leading role that small caps have assumed in the article Small Caps Charge Augurs Well for the Stock Market … read more...

Core Biotech Buys #17: Positive Commentary For Gene Therapy And Our First Swap

via: SeekingAlpha at 2018-05-31 13:23:00:000

Welcome to the seventeenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the siz… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-05-31 09:09:43:000

Agios Pharmaceuticals (NASDAQ: AGIO ) initiated with Overweight rating and $125 (38% upside) price target at Piper Jaffray. More news on: Agios Pharmaceuticals, Inc., Celyad, Edwards Lifesciences Corp, Healthcare stocks news, Stocks on the move, Read more … read more...

Mining ASCO 2018's Gold, Part 7: Digest This News And Get Valuable Information

via: SeekingAlpha at 2018-05-31 09:00:00:000

Continuing on our ASCO journey, we now move into the gastrointestinal malignancies, which have several incredibly difficult-to-treat tumor types. In case you haven't seen the previous editions, I'll link them off below. But this series is designed to help you parse out some of the news that is… read more...

Road To Financial Independence: My April 91-Stock Portfolio Review

via: SeekingAlpha at 2018-05-31 06:15:50:000

With the earnings seasons gaining full swing, stock markets recovered and concentrated on earnings, casting aside doubts about a looming economic downturn. The only exception here were classic dividend stocks which all took a beating, ranging from Procter & Gamble ( PG ), Altria ( MO ), AT… read more...

Gilead and Galapagos' filgotinib successful in mid-stage psoriatic arthritis study

via: SeekingAlpha at 2018-05-30 16:22:18:000

Galapagos NV (NASDAQ: GLPG ) and collaboration partner Gilead Sciences (NASDAQ: GILD ) announce positive results from a Phase 2 clinical trial, EQUATOR , evaluating JAK1 inhibitor filgotinib in adult patients with moderate-to-severe psoriatic arthritis (PA). More news on: Galapagos, Gil… read more...

Gilead and Galapagos' filgotinib successful in mid-stage psoriatic arthritis study

via: SeekingAlpha at 2018-05-30 16:22:18:000

Galapagos NV (NASDAQ: GLPG ) and collaboration partner Gilead Sciences (NASDAQ: GILD ) announce positive results from a Phase 2 clinical trial, EQUATOR , evaluating JAK1 inhibitor filgotinib in adult patients with moderate-to-severe psoriatic arthritis (PA). More news on: Galapagos, Gil… read more...

Gilead and Galapagos Announce Results With Filgotinib in the Phase 2 Equator Study in Psoriatic Arthritis and Progression Into Phase 3 for the Selection Study in Ulcerative Colitis

via: Business Wire at 2018-05-30 16:01:00:000

-- EQUATOR Achieves Primary Endpoint of ACR20 Response at Week 16 -- -- Galapagos to Receive $15 Million Payment from Gilead for Progression into Phase 3 of the Phase 2b/3 SELECTION Study of Filgotinib in Ulcerative Colitis -- Gilead Sciences, Inc. (NASDAQ: GILD) and Galapago… read more...

Gilead and Galapagos Announce Results With Filgotinib in the Phase 2 Equator Study in Psoriatic Arthritis and Progression Into Phase 3 for the Selection Study in Ulcerative Colitis

via: Business Wire at 2018-05-30 16:01:00:000

-- EQUATOR Achieves Primary Endpoint of ACR20 Response at Week 16 -- -- Galapagos to Receive $15 Million Payment from Gilead for Progression into Phase 3 of the Phase 2b/3 SELECTION Study of Filgotinib in Ulcerative Colitis -- Gilead Sciences, Inc. (NASDAQ: GILD) and Galapago… read more...

Gilead Sciences to Present at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13

via: Business Wire at 2018-05-30 16:01:00:000

Webcast Available Through Gilead Corporate Website Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Robin L. Washington, Gileads Executive Vice President and Chief Financial Officer, and John McHutchison, Gileads Chief Scientific Officer and Head of Research… read more...

Gilead Sciences to Present at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13

via: Business Wire at 2018-05-30 16:01:00:000

Webcast Available Through Gilead Corporate Website Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Robin L. Washington, Gileads Executive Vice President and Chief Financial Officer, and John McHutchison, Gileads Chief Scientific Officer and Head of Research… read more...

The Kite Killer - TapImmune And Marker Merger Challenge Gilead

via: SeekingAlpha at 2018-05-30 09:15:28:000

History could be repeating itself and TapImmune (TPIV) could be Kite 2.0. The TPIV merger with Marker Therapeutics strongly positions the company to take on market leader Gilead Sciences (GILD) which acquired Kite Pharma for $11.9 billion in August 2017. Before the GILD merger Kite Pharma w… read more...

The Kite Killer - TapImmune And Marker Merger Challenge Gilead

via: SeekingAlpha at 2018-05-30 09:15:28:000

History could be repeating itself and TapImmune (TPIV) could be Kite 2.0. The TPIV merger with Marker Therapeutics strongly positions the company to take on market leader Gilead Sciences (GILD) which acquired Kite Pharma for $11.9 billion in August 2017. Before the GILD merger Kite Pharma w… read more...

Gilead's Epclusa OK'd in China; shares up 1% premarket

via: SeekingAlpha at 2018-05-30 07:11:08:000

Gilead Sciences (NASDAQ: GILD ) is up 1% premarket on light volume in response to its announcement that the China Food and Drug Administration (CFDA) has approved Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg) for the treatment of adults with chronic hepatitis C virus (HCV) inf… read more...

China Drug Administration Approves Epclusa® (Sofosbuvir/Velpatasvir), Gilead's Pan-Genotypic Treatment for Chronic Hepatitis C Virus Infection

via: Business Wire at 2018-05-30 01:00:00:000

Epclusa is the First Approved Pan-Genotypic Once Daily Single Table Regimen for Chronic Hepatitis C Virus Infection in China Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the China Drug Administration (CDA) has approved Epclusa (sofosbuvir 400 m… read more...

Why It's Time That Markets Assign More Value To Celgene's Drug Pipeline

via: SeekingAlpha at 2018-05-29 06:00:39:000

Despite the advances Celgene Corporation ( CELG ) is accomplishing in its R&D efforts, the three major failures since last October 2017, shook up investor confidence. How, then, should investors interpret the companys latest deep dive in its multiple myeloma presentation? The upd… read more...

Why It's Time That Markets Assign More Value To Celgene's Drug Pipeline

via: SeekingAlpha at 2018-05-29 06:00:39:000

Despite the advances Celgene Corporation ( CELG ) is accomplishing in its R&D efforts, the three major failures since last October 2017, shook up investor confidence. How, then, should investors interpret the companys latest deep dive in its multiple myeloma presentation? The upd… read more...

Rounds Report: CryoPort Rallied While The FDA Approved Palynziq

via: SeekingAlpha at 2018-05-25 12:21:17:000

Develop into a lifelong self-learner through voracious reading; cultivate curiosity and strive to become a little wiser every day. - Charlie Munger Trading Analytics Welcome to the edition of Integrated BioSci Rounds Report for May 25, 2018. As usual, we'll elucidate notable trading anal… read more...

Rounds Report: CryoPort Rallied While The FDA Approved Palynziq

via: SeekingAlpha at 2018-05-25 12:21:17:000

Develop into a lifelong self-learner through voracious reading; cultivate curiosity and strive to become a little wiser every day. - Charlie Munger Trading Analytics Welcome to the edition of Integrated BioSci Rounds Report for May 25, 2018. As usual, we'll elucidate notable trading anal… read more...

Rounds Report: CryoPort Rallied While The FDA Approved Palynziq

via: SeekingAlpha at 2018-05-25 12:21:17:000

Develop into a lifelong self-learner through voracious reading; cultivate curiosity and strive to become a little wiser every day. - Charlie Munger Trading Analytics Welcome to the edition of Integrated BioSci Rounds Report for May 25, 2018. As usual, we'll elucidate notable trading anal… read more...

Rounds Report: CryoPort Rallied While The FDA Approved Palynziq

via: SeekingAlpha at 2018-05-25 12:21:17:000

Develop into a lifelong self-learner through voracious reading; cultivate curiosity and strive to become a little wiser every day. - Charlie Munger Trading Analytics Welcome to the edition of Integrated BioSci Rounds Report for May 25, 2018. As usual, we'll elucidate notable trading anal… read more...

Rounds Report: CryoPort Rallied While The FDA Approved Palynziq

via: SeekingAlpha at 2018-05-25 12:21:17:000

Develop into a lifelong self-learner through voracious reading; cultivate curiosity and strive to become a little wiser every day. - Charlie Munger Trading Analytics Welcome to the edition of Integrated BioSci Rounds Report for May 25, 2018. As usual, we'll elucidate notable trading anal… read more...

Rounds Report: CryoPort Rallied While The FDA Approved Palynziq

via: SeekingAlpha at 2018-05-25 12:21:17:000

Develop into a lifelong self-learner through voracious reading; cultivate curiosity and strive to become a little wiser every day. - Charlie Munger Trading Analytics Welcome to the edition of Integrated BioSci Rounds Report for May 25, 2018. As usual, we'll elucidate notable trading anal… read more...

Mining For ASCO 2018's Gold, Part 3: Making Money In The Brain

via: SeekingAlpha at 2018-05-25 09:00:00:000

The 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO 2018) is upon us, and it's about as close to Christmas as I get in my line of work. There's so much data presented here, with thousands of abstracts delivered to an audience of some 30,000 healthcare professionals, that… read more...

Mining For ASCO 2018's Gold, Part 3: Making Money In The Brain

via: SeekingAlpha at 2018-05-25 09:00:00:000

The 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO 2018) is upon us, and it's about as close to Christmas as I get in my line of work. There's so much data presented here, with thousands of abstracts delivered to an audience of some 30,000 healthcare professionals, that… read more...

Mining For ASCO 2018's Gold, Part 3: Making Money In The Brain

via: SeekingAlpha at 2018-05-25 09:00:00:000

The 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO 2018) is upon us, and it's about as close to Christmas as I get in my line of work. There's so much data presented here, with thousands of abstracts delivered to an audience of some 30,000 healthcare professionals, that… read more...

Mining For ASCO 2018's Gold, Part 3: Making Money In The Brain

via: SeekingAlpha at 2018-05-25 09:00:00:000

The 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO 2018) is upon us, and it's about as close to Christmas as I get in my line of work. There's so much data presented here, with thousands of abstracts delivered to an audience of some 30,000 healthcare professionals, that… read more...

Mining For ASCO 2018's Gold, Part 3: Making Money In The Brain

via: SeekingAlpha at 2018-05-25 09:00:00:000

The 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO 2018) is upon us, and it's about as close to Christmas as I get in my line of work. There's so much data presented here, with thousands of abstracts delivered to an audience of some 30,000 healthcare professionals, that… read more...

Mining For ASCO 2018's Gold, Part 3: Making Money In The Brain

via: SeekingAlpha at 2018-05-25 09:00:00:000

The 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO 2018) is upon us, and it's about as close to Christmas as I get in my line of work. There's so much data presented here, with thousands of abstracts delivered to an audience of some 30,000 healthcare professionals, that… read more...

'Safer' Dividend Healthcare Top WallStar Gainers Are Gilead, Sanofi, Amerisource, Anthem, And Johnson, Per Broker May Targets

via: SeekingAlpha at 2018-05-24 21:34:03:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten Healthcare "Safer" Dividend WallStars to Net 11.3% to 27.4% Gains To May 2019 Six of ten top 'safer' dividend Healthcare WallStars by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

'Safer' Dividend Healthcare Top WallStar Gainers Are Gilead, Sanofi, Amerisource, Anthem, And Johnson, Per Broker May Targets

via: SeekingAlpha at 2018-05-24 21:34:03:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten Healthcare "Safer" Dividend WallStars to Net 11.3% to 27.4% Gains To May 2019 Six of ten top 'safer' dividend Healthcare WallStars by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

'Safer' Dividend Healthcare Top WallStar Gainers Are Gilead, Sanofi, Amerisource, Anthem, And Johnson, Per Broker May Targets

via: SeekingAlpha at 2018-05-24 21:34:03:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten Healthcare "Safer" Dividend WallStars to Net 11.3% to 27.4% Gains To May 2019 Six of ten top 'safer' dividend Healthcare WallStars by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

'Safer' Dividend Healthcare Top WallStar Gainers Are Gilead, Sanofi, Amerisource, Anthem, And Johnson, Per Broker May Targets

via: SeekingAlpha at 2018-05-24 21:34:03:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten Healthcare "Safer" Dividend WallStars to Net 11.3% to 27.4% Gains To May 2019 Six of ten top 'safer' dividend Healthcare WallStars by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

'Safer' Dividend Healthcare Top WallStar Gainers Are Gilead, Sanofi, Amerisource, Anthem, And Johnson, Per Broker May Targets

via: SeekingAlpha at 2018-05-24 21:34:03:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten Healthcare "Safer" Dividend WallStars to Net 11.3% to 27.4% Gains To May 2019 Six of ten top 'safer' dividend Healthcare WallStars by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

'Safer' Dividend Healthcare Top WallStar Gainers Are Gilead, Sanofi, Amerisource, Anthem, And Johnson, Per Broker May Targets

via: SeekingAlpha at 2018-05-24 21:34:03:000

Actionable Conclusions (1-10): Brokers Estimated Top Ten Healthcare "Safer" Dividend WallStars to Net 11.3% to 27.4% Gains To May 2019 Six of ten top 'safer' dividend Healthcare WallStars by yield (shaded in the chart above) were verified as being among the top ten gainers for the coming y… read more...

The No. 1 Stock In The World (Revisited) - Visa And Apple Up, Kinder Morgan And Gilead Down

via: SeekingAlpha at 2018-05-24 13:00:53:000

Back in May of 2015, I asked 15 Seeking Alpha colleagues two simple (but audacious) questions: 1. If you could only own one company in your portfolio, which would it be? 2. If you had $25,000 to invest TODAY on one company and you planned to hold it for 10 years or more, which comp… read more...

The No. 1 Stock In The World (Revisited) - Visa And Apple Up, Kinder Morgan And Gilead Down

via: SeekingAlpha at 2018-05-24 13:00:53:000

Back in May of 2015, I asked 15 Seeking Alpha colleagues two simple (but audacious) questions: 1. If you could only own one company in your portfolio, which would it be? 2. If you had $25,000 to invest TODAY on one company and you planned to hold it for 10 years or more, which comp… read more...

The No. 1 Stock In The World (Revisited) - Visa And Apple Up, Kinder Morgan And Gilead Down

via: SeekingAlpha at 2018-05-24 13:00:53:000

Back in May of 2015, I asked 15 Seeking Alpha colleagues two simple (but audacious) questions: 1. If you could only own one company in your portfolio, which would it be? 2. If you had $25,000 to invest TODAY on one company and you planned to hold it for 10 years or more, which comp… read more...

Top Wall Street Healthcare Gainers For May: Allergan, CVS Health, Patterson, Sanofi, And Gilead

via: SeekingAlpha at 2018-05-24 12:24:11:000

Actionable Conclusions (1-10): Analysts Projected 18% To 34.65% Net Gains For Top Ten Healthcare WallStars By May 2019 Four of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices. (They … read more...

Top Wall Street Healthcare Gainers For May: Allergan, CVS Health, Patterson, Sanofi, And Gilead

via: SeekingAlpha at 2018-05-24 12:24:11:000

Actionable Conclusions (1-10): Analysts Projected 18% To 34.65% Net Gains For Top Ten Healthcare WallStars By May 2019 Four of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices. (They … read more...

Top Wall Street Healthcare Gainers For May: Allergan, CVS Health, Patterson, Sanofi, And Gilead

via: SeekingAlpha at 2018-05-24 12:24:11:000

Actionable Conclusions (1-10): Analysts Projected 18% To 34.65% Net Gains For Top Ten Healthcare WallStars By May 2019 Four of ten top dividend-yielding Healthcare stocks were verified as being among the top ten gainers for the coming year based on broker 1-year target prices. (They … read more...

Gilead: Novartis's Kymriah Is Coming To America

via: SeekingAlpha at 2018-05-24 03:49:06:000

From the movie "Coming To America." Source: Amazon.com Gilead (GILD) acquired Kite Pharma for $12 billion, and the novel CAR-T therapy received FDA approval within months. For a while, it seemed like Gilead would have the U.S. CAR-T market all to itself. However, Novartis's (NVS) Kymriah w… read more...

Gilead: Novartis's Kymriah Is Coming To America

via: SeekingAlpha at 2018-05-24 03:49:06:000

From the movie "Coming To America." Source: Amazon.com Gilead (GILD) acquired Kite Pharma for $12 billion, and the novel CAR-T therapy received FDA approval within months. For a while, it seemed like Gilead would have the U.S. CAR-T market all to itself. However, Novartis's (NVS) Kymriah w… read more...

Gilead: Novartis's Kymriah Is Coming To America

via: SeekingAlpha at 2018-05-24 03:49:06:000

From the movie "Coming To America." Source: Amazon.com Gilead (GILD) acquired Kite Pharma for $12 billion, and the novel CAR-T therapy received FDA approval within months. For a while, it seemed like Gilead would have the U.S. CAR-T market all to itself. However, Novartis's (NVS) Kymriah w… read more...

Gilead: Novartis's Kymriah Is Coming To America

via: SeekingAlpha at 2018-05-24 03:49:06:000

From the movie "Coming To America." Source: Amazon.com Gilead (GILD) acquired Kite Pharma for $12 billion, and the novel CAR-T therapy received FDA approval within months. For a while, it seemed like Gilead would have the U.S. CAR-T market all to itself. However, Novartis's (NVS) Kymriah w… read more...

Gilead Sciences to Present at the Jefferies 2018 Healthcare Conference on Wednesday, June 6

via: Business Wire at 2018-05-23 16:01:00:000

Webcast Available Through Gilead Corporate Website Gilead Sciences, Inc. (Nasdaq: GILD) today announced that John F. Milligan, PhD, Gileads President and Chief Executive Officer; Robin L. Washington, Gileads Executive Vice President and Chief Financial Officer; John … read more...

Gilead Sciences to Present at the Jefferies 2018 Healthcare Conference on Wednesday, June 6

via: Business Wire at 2018-05-23 16:01:00:000

Webcast Available Through Gilead Corporate Website Gilead Sciences, Inc. (Nasdaq: GILD) today announced that John F. Milligan, PhD, Gileads President and Chief Executive Officer; Robin L. Washington, Gileads Executive Vice President and Chief Financial Officer; John … read more...

Gilead Sciences to Present at the Jefferies 2018 Healthcare Conference on Wednesday, June 6

via: Business Wire at 2018-05-23 16:01:00:000

Webcast Available Through Gilead Corporate Website Gilead Sciences, Inc. (Nasdaq: GILD) today announced that John F. Milligan, PhD, Gileads President and Chief Executive Officer; Robin L. Washington, Gileads Executive Vice President and Chief Financial Officer; John … read more...

High Rates And Inflation Could Pose A Systemic Risk To Biotech

via: SeekingAlpha at 2018-05-23 12:28:47:000

When public money flows into any sector, prices go up. It has happened with federal student loans, which drive tuition higher. It has happened with real estate during the boom, when the federal government, through its GSEs, was snapping up mortgage-backed securities. It has been happening for … read more...

High Rates And Inflation Could Pose A Systemic Risk To Biotech

via: SeekingAlpha at 2018-05-23 12:28:47:000

When public money flows into any sector, prices go up. It has happened with federal student loans, which drive tuition higher. It has happened with real estate during the boom, when the federal government, through its GSEs, was snapping up mortgage-backed securities. It has been happening for … read more...

High Rates And Inflation Could Pose A Systemic Risk To Biotech

via: SeekingAlpha at 2018-05-23 12:28:47:000

When public money flows into any sector, prices go up. It has happened with federal student loans, which drive tuition higher. It has happened with real estate during the boom, when the federal government, through its GSEs, was snapping up mortgage-backed securities. It has been happening for … read more...

Is Celgene's Stock A Buy The Dip Opportunity?

via: SeekingAlpha at 2018-05-23 03:09:40:000

Celgene ( CELG ) has three key drugs in its late-stage pipeline and yet the market refuses to buy the stock. Bearishness is building up so much that the stock fell sharply on May 21. This continues the downtrend that began last year in Sept. 2017, when the stock traded at over $140 a share. … read more...

Is Celgene's Stock A Buy The Dip Opportunity?

via: SeekingAlpha at 2018-05-23 03:09:40:000

Celgene ( CELG ) has three key drugs in its late-stage pipeline and yet the market refuses to buy the stock. Bearishness is building up so much that the stock fell sharply on May 21. This continues the downtrend that began last year in Sept. 2017, when the stock traded at over $140 a share. … read more...

Is Celgene's Stock A Buy The Dip Opportunity?

via: SeekingAlpha at 2018-05-23 03:09:40:000

Celgene ( CELG ) has three key drugs in its late-stage pipeline and yet the market refuses to buy the stock. Bearishness is building up so much that the stock fell sharply on May 21. This continues the downtrend that began last year in Sept. 2017, when the stock traded at over $140 a share. … read more...

Core Biotech Buys #16: Taking Advantage Of Weakness To Add To Conviction Ideas

via: SeekingAlpha at 2018-05-22 12:03:38:000

Welcome to the sixteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size … read more...

Should The FDA Be Shaming Drug Companies? Financial Advisors' Daily Digest

via: SeekingAlpha at 2018-05-21 12:21:23:000

Last Thursday the FDA published a name-and-shame list of brand-name drug makers that may be withholding access to samples that competing drug makers could use to have generic versions available for use when the original manufacturers patent expires. Celgene (CELG), Johnson & John… read more...

Cellectis: Will Focus On Universal CAR-T Payoff?

via: SeekingAlpha at 2018-05-21 10:21:43:000

I believe gene therapy will become a mainstay in treating, and maybe curing, many of our most devastating and intractable illnesses. Scott Gottlieb, FDA Commissioner Cellectis S.A. ( CLLS ) announced news in 2015 that made me sit up and take notice of gene therapy. Layla, an 11-month-old… read more...

Gilead: Where's The Next Catalyst?

via: SeekingAlpha at 2018-05-18 14:23:31:000

There's no doubt that Gilead ( GILD ) holds strong competitive advantages in its arsenal. Despite revenues literally falling on a cliff in recent years, one just has to look at Gilead's entrenched position in both the HCV and HIV complexes to see that strong cash flows should continue for year… read more...

Investors bullish on biotechs after Trump drug pricing speech

via: SeekingAlpha at 2018-05-18 08:21:17:000

As any student of the healthcare equity market knows by now, money flow into biotech and healthcare funds jumped after President Trump revealed his (rather benign) plan to curb U.S. drug prices. STAT News' Adam Feuerstein reports that $819M flowed into the funds this week, the largest infu… read more...

How To Retire Today With $1 Million

via: SeekingAlpha at 2018-05-18 08:00:00:000

This research report was produced by The REIT Forum with assistance from Big Dog Investments . Investors need a plan for retirement. Social Security is not a plan. Social Security is one part of a comprehensive plan. As the author of The REIT Forum, we focus on high yields w… read more...

Gilead Sciences (GILD) Presents at the Bank of America Merrill Lynch 2018 Healthcare Conference (Transcript)

via: SeekingAlpha at 2018-05-16 18:41:04:000

Gilead Sciences, Inc. (GILD) Bank of America Merrill Lynch 2018 Healthcare Conference May 17, 2018 12:20 PM ET Executives Robin Washington - CFO John McHutchison - Chief Scientific Officer Analysts Ying Huang - Bank of America Merrill Lynch Presentation Ying Huang … read more...

Biotechs perk up ahead of ASCO abstract drop

via: SeekingAlpha at 2018-05-16 12:56:58:000

The SPDR S&P Biotech ETF ( XBI +1.1% ) is up 1% as investors ramp up buying ahead of the abstract drop for the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 1 - 5. More news on: SPDR Biotech ETF, Celgene Corporation, bluebird bio, Inc., He… read more...

Biotechs perk up ahead of ASCO abstract drop

via: SeekingAlpha at 2018-05-16 12:56:58:000

The SPDR S&P Biotech ETF ( XBI +1.1% ) is up 1% as investors ramp up buying ahead of the abstract drop for the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 1 - 5. More news on: SPDR Biotech ETF, Celgene Corporation, bluebird bio, Inc., He… read more...

Biotechs perk up ahead of ASCO abstract drop

via: SeekingAlpha at 2018-05-16 12:56:58:000

The SPDR S&P Biotech ETF ( XBI +1.1% ) is up 1% as investors ramp up buying ahead of the abstract drop for the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 1 - 5. More news on: SPDR Biotech ETF, Celgene Corporation, bluebird bio, Inc., He… read more...

Bluebird Bio: Gene Therapy Best In Class

via: SeekingAlpha at 2018-05-16 11:31:47:000

I can confirm that we're at the early stages of a transformation in medical treatment as a consequence of this new technology. FDA commissioner Scott Gottlieb oral testimony This article is part of a series on genomic medicine which is poised to transform healthcare over the next two… read more...

Bluebird Bio: Gene Therapy Best In Class

via: SeekingAlpha at 2018-05-16 11:31:47:000

I can confirm that we're at the early stages of a transformation in medical treatment as a consequence of this new technology. FDA commissioner Scott Gottlieb oral testimony This article is part of a series on genomic medicine which is poised to transform healthcare over the next two… read more...

Bluebird Bio: Gene Therapy Best In Class

via: SeekingAlpha at 2018-05-16 11:31:47:000

I can confirm that we're at the early stages of a transformation in medical treatment as a consequence of this new technology. FDA commissioner Scott Gottlieb oral testimony This article is part of a series on genomic medicine which is poised to transform healthcare over the next two… read more...

Bellicum Pharmaceuticals: Will This CAR-TCR Innovator Deliver Robust Profits?

via: SeekingAlpha at 2018-05-16 06:55:14:000

Bellicum Pharmaceuticals (NASDAQ: BLCM ) is a stellar therapeutic innovator that has experienced a share price depreciation for the past year. Nevertheless, the company is powering the robust development of a highly advanced chimeric antigen receptor and T-cell receptor (CAR-TCR) that, in an… read more...

Bellicum Pharmaceuticals: Will This CAR-TCR Innovator Deliver Robust Profits?

via: SeekingAlpha at 2018-05-16 06:55:14:000

Bellicum Pharmaceuticals (NASDAQ: BLCM ) is a stellar therapeutic innovator that has experienced a share price depreciation for the past year. Nevertheless, the company is powering the robust development of a highly advanced chimeric antigen receptor and T-cell receptor (CAR-TCR) that, in an… read more...

Bellicum Pharmaceuticals: Will This CAR-TCR Innovator Deliver Robust Profits?

via: SeekingAlpha at 2018-05-16 06:55:14:000

Bellicum Pharmaceuticals (NASDAQ: BLCM ) is a stellar therapeutic innovator that has experienced a share price depreciation for the past year. Nevertheless, the company is powering the robust development of a highly advanced chimeric antigen receptor and T-cell receptor (CAR-TCR) that, in an… read more...

5 Low P/E Companies In The S&P 500 - May 2018

via: SeekingAlpha at 2018-05-15 15:52:43:000

There are a number of great companies in the market today. By using the ModernGraham Valuation Model , I've selected some of the most undervalued companies of S&P 500. The ModernGraham model is based on the full teachings of Benjamin Graham. All of these companies are suitable for the De… read more...

5 Low P/E Companies In The S&P 500 - May 2018

via: SeekingAlpha at 2018-05-15 15:52:43:000

There are a number of great companies in the market today. By using the ModernGraham Valuation Model , I've selected some of the most undervalued companies of S&P 500. The ModernGraham model is based on the full teachings of Benjamin Graham. All of these companies are suitable for the De… read more...

5 Low P/E Companies In The S&P 500 - May 2018

via: SeekingAlpha at 2018-05-15 15:52:43:000

There are a number of great companies in the market today. By using the ModernGraham Valuation Model , I've selected some of the most undervalued companies of S&P 500. The ModernGraham model is based on the full teachings of Benjamin Graham. All of these companies are suitable for the De… read more...

Gilead Sciences: Resist Sentiment, Stop Speculating And Invest

via: SeekingAlpha at 2018-05-15 14:07:31:000

After a few months of rather positive signs and slight increase in bullishness, bearish sentiment seems to be back. In 2016 and 2017 Wall Street almost begged for an acquisition and when Gilead Sciences (Nasdaq: GILD ) finally announced the take-over of Kite Pharma, sentiment became more posi… read more...

Gilead Sciences: Resist Sentiment, Stop Speculating And Invest

via: SeekingAlpha at 2018-05-15 14:07:31:000

After a few months of rather positive signs and slight increase in bullishness, bearish sentiment seems to be back. In 2016 and 2017 Wall Street almost begged for an acquisition and when Gilead Sciences (Nasdaq: GILD ) finally announced the take-over of Kite Pharma, sentiment became more posi… read more...

Gilead Sciences: Resist Sentiment, Stop Speculating And Invest

via: SeekingAlpha at 2018-05-15 14:07:31:000

After a few months of rather positive signs and slight increase in bullishness, bearish sentiment seems to be back. In 2016 and 2017 Wall Street almost begged for an acquisition and when Gilead Sciences (Nasdaq: GILD ) finally announced the take-over of Kite Pharma, sentiment became more posi… read more...

U.S. Food and Drug Administration Approves Expanded Indication for Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents

via: Business Wire at 2018-05-15 10:59:00:000

First Agent Indicated for Uninfected Adolescents at Risk of Acquiring HIV Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada (emtricitabine 200 mg/tenofovir disoproxil fu… read more...

U.S. Food and Drug Administration Approves Expanded Indication for Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents

via: Business Wire at 2018-05-15 10:59:00:000

First Agent Indicated for Uninfected Adolescents at Risk of Acquiring HIV Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada (emtricitabine 200 mg/tenofovir disoproxil fu… read more...

U.S. Food and Drug Administration Approves Expanded Indication for Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents

via: Business Wire at 2018-05-15 10:59:00:000

First Agent Indicated for Uninfected Adolescents at Risk of Acquiring HIV Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada (emtricitabine 200 mg/tenofovir disoproxil fu… read more...

Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline

via: Business Wire at 2018-05-15 08:30:00:000

-- Facilities in the Netherlands and the United States Will Help Advance Manufacturing of Cell Therapies for People with Cancer -- Kite, a Gilead Company (Nasdaq: GILD), today announced it has leased a new facility in the Netherlands to engineer cell therapies in Europe. The 117,000… read more...

Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline

via: Business Wire at 2018-05-15 08:30:00:000

-- Facilities in the Netherlands and the United States Will Help Advance Manufacturing of Cell Therapies for People with Cancer -- Kite, a Gilead Company (Nasdaq: GILD), today announced it has leased a new facility in the Netherlands to engineer cell therapies in Europe. The 117,000… read more...

Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline

via: Business Wire at 2018-05-15 08:30:00:000

-- Facilities in the Netherlands and the United States Will Help Advance Manufacturing of Cell Therapies for People with Cancer -- Kite, a Gilead Company (Nasdaq: GILD), today announced it has leased a new facility in the Netherlands to engineer cell therapies in Europe. The 117,000… read more...

Genomic Medicine: Catch The Gene Therapy Wave

via: SeekingAlpha at 2018-05-14 15:12:28:000

Genomic medicine is the future of healthcare. Spawned by the Human Genome Project HGP this precise and personal approach to medicine is an emerging discipline with enormous disruptive potential. Though nascent, Genomic medicine is showing signs of being the transformative for… read more...

JF's Core Biotech Buys #15: Removal Of A Key Overhang, Buying Weakness In I-O, Updates And Adding To 2 Positions

via: SeekingAlpha at 2018-05-14 11:37:23:000

Welcome to the fifteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size … read more...

Week In Review: $3.4 Billion Week For China Life Science Deals

via: SeekingAlpha at 2018-05-13 11:40:35:000

Deals and Financings Armo BioSciences (ARMO), a Bay Area immuno-oncology company, agreed to be acquired by Eli Lilly (LLY) in a $1.6 billion transaction. Last year, Armo raised $67 million in a 2017 Series C-1 funding from China investors. Four months ago, Armo completed a $128 million IPO… read more...

NASDAQ 'Safer' Dividend Gainers Led By Lam, Western, Broadcom & Vodafone, Per February Broker Targets

via: SeekingAlpha at 2018-02-13 12:50:38:000

Actionable Conclusions (1-10): Brokers Estimate Top Ten "Safer" Dividend NASDAQ Stocks to Net 19.39% to 47.09% Gains By February, 2019 Two of the ten top yield "safer" Dividend NASDAQ stocks (see names tinted grey in the list above) were found among the top ten gainers for the coming… read more...

ROTY Edition 1 Volume 78: Simplify Your Decision-Making And Stick To Guidelines

via: SeekingAlpha at 2018-02-13 12:46:16:000

Welcome to the 78th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

10 Ways To Retire And Travel Around The World Cheaply

via: SeekingAlpha at 2018-02-13 09:09:29:000

Tips for travel are at the end. Tips for portfolio planning come first. Few workers plan ahead for the retirement they really want. We can make a few generalizations about different generations. These broad metrics should help investors understand the impending retirement crisis. Let&#x201… read more...

Crispr Therapeutics: Is There Something Else Behind The Potential Gilead Acquisition?

via: SeekingAlpha at 2018-02-12 12:24:30:000

"It is not necessary to do extraordinary things to get extraordinary results." - The Oracle of Omaha (Warren Buffett) Back on Feb. 8, 2018, we featured Crispr Therapeutics (NASDAQ: CRSP ), a leading gene-editing innovator to service cancers and rare genetic diseases, in the Integrated BioS… read more...

Crispr Therapeutics: Is There Something Else Behind The Potential Gilead Acquisition?

via: SeekingAlpha at 2018-02-12 12:24:30:000

"It is not necessary to do extraordinary things to get extraordinary results." - The Oracle of Omaha (Warren Buffett) Back on Feb. 8, 2018, we featured Crispr Therapeutics (NASDAQ: CRSP ), a leading gene-editing innovator to service cancers and rare genetic diseases, in the Integrated BioS… read more...

GDS Investments' 2017 Year-End Letter

via: SeekingAlpha at 2018-02-11 21:10:58:000

He that can have patience can have what he will. Benjamin Franklin The Big Money is not in the buying or the selling. But in the waiting. Charlie Munger We greet you as one extraordinary year ends, and another which promises to be no less exciting begins! With our… read more...

GDS Investments' 2017 Year-End Letter

via: SeekingAlpha at 2018-02-11 21:10:58:000

He that can have patience can have what he will. Benjamin Franklin The Big Money is not in the buying or the selling. But in the waiting. Charlie Munger We greet you as one extraordinary year ends, and another which promises to be no less exciting begins! With our… read more...

Retirement: A Future-Proof Portfolio For Young Investors - Dividend Increases And Watchlist

via: SeekingAlpha at 2018-02-10 00:30:48:000

On January 25th, I introduced my future-proof model portfolio for young investors in this article. Now I would like to discuss three things: how the portfolio is holding up, dividend increases and my watchlist. Portfolio This is the portfolio including weight of shares and the gain or lo… read more...

Retirement: A Future-Proof Portfolio For Young Investors - Dividend Increases And Watchlist

via: SeekingAlpha at 2018-02-10 00:30:48:000

On January 25th, I introduced my future-proof model portfolio for young investors in this article. Now I would like to discuss three things: how the portfolio is holding up, dividend increases and my watchlist. Portfolio This is the portfolio including weight of shares and the gain or lo… read more...

Retirement: A Future-Proof Portfolio For Young Investors - Dividend Increases And Watchlist

via: SeekingAlpha at 2018-02-10 00:30:48:000

On January 25th, I introduced my future-proof model portfolio for young investors in this article. Now I would like to discuss three things: how the portfolio is holding up, dividend increases and my watchlist. Portfolio This is the portfolio including weight of shares and the gain or lo… read more...

Retirement: A Future-Proof Portfolio For Young Investors - Dividend Increases And Watchlist

via: SeekingAlpha at 2018-02-10 00:30:48:000

On January 25th, I introduced my future-proof model portfolio for young investors in this article. Now I would like to discuss three things: how the portfolio is holding up, dividend increases and my watchlist. Portfolio This is the portfolio including weight of shares and the gain or lo… read more...

Mergers And Acquisitions: Is There A Pending Catalyst For Crispr Therapeutics?

via: SeekingAlpha at 2018-02-09 09:27:00:000

Not so very long ago, it seemed that outstanding technical ability was vital only to a few highly scientifically oriented industries such as electronics, aerospace, pharmaceuticals, and chemical manufacturing. As these have grown, their ever-widening technologies have so penetrated virtuall… read more...

Mergers And Acquisitions: Is There A Pending Catalyst For Crispr Therapeutics?

via: SeekingAlpha at 2018-02-09 09:27:00:000

Not so very long ago, it seemed that outstanding technical ability was vital only to a few highly scientifically oriented industries such as electronics, aerospace, pharmaceuticals, and chemical manufacturing. As these have grown, their ever-widening technologies have so penetrated virtuall… read more...

Mergers And Acquisitions: Is There A Pending Catalyst For Crispr Therapeutics?

via: SeekingAlpha at 2018-02-09 09:27:00:000

Not so very long ago, it seemed that outstanding technical ability was vital only to a few highly scientifically oriented industries such as electronics, aerospace, pharmaceuticals, and chemical manufacturing. As these have grown, their ever-widening technologies have so penetrated virtuall… read more...

Mergers And Acquisitions: Is There A Pending Catalyst For Crispr Therapeutics?

via: SeekingAlpha at 2018-02-09 09:27:00:000

Not so very long ago, it seemed that outstanding technical ability was vital only to a few highly scientifically oriented industries such as electronics, aerospace, pharmaceuticals, and chemical manufacturing. As these have grown, their ever-widening technologies have so penetrated virtuall… read more...

Mergers And Acquisitions: Is There A Pending Catalyst For Crispr Therapeutics?

via: SeekingAlpha at 2018-02-09 09:27:00:000

Not so very long ago, it seemed that outstanding technical ability was vital only to a few highly scientifically oriented industries such as electronics, aerospace, pharmaceuticals, and chemical manufacturing. As these have grown, their ever-widening technologies have so penetrated virtuall… read more...

Your Daily Pharma Scoop: Adamas' Gocovri Key Value Driver, BioMarin Data, Regeneron Q4 Results

via: SeekingAlpha at 2018-02-09 08:00:00:000

Analysis of top Seeking Alpha coverage: Adamas Pharmaceuticals Today we will focus on Adamas Pharmaceuticals ( ADMS ). On Thursday, the company reported data from the EASE LID 2 study. Adamas got an approval for Gocovri last year, the first treatment for levodopa induced dyskinesia i… read more...

Your Daily Pharma Scoop: Adamas' Gocovri Key Value Driver, BioMarin Data, Regeneron Q4 Results

via: SeekingAlpha at 2018-02-09 08:00:00:000

Analysis of top Seeking Alpha coverage: Adamas Pharmaceuticals Today we will focus on Adamas Pharmaceuticals ( ADMS ). On Thursday, the company reported data from the EASE LID 2 study. Adamas got an approval for Gocovri last year, the first treatment for levodopa induced dyskinesia i… read more...

Your Daily Pharma Scoop: Adamas' Gocovri Key Value Driver, BioMarin Data, Regeneron Q4 Results

via: SeekingAlpha at 2018-02-09 08:00:00:000

Analysis of top Seeking Alpha coverage: Adamas Pharmaceuticals Today we will focus on Adamas Pharmaceuticals ( ADMS ). On Thursday, the company reported data from the EASE LID 2 study. Adamas got an approval for Gocovri last year, the first treatment for levodopa induced dyskinesia i… read more...

Your Daily Pharma Scoop: Adamas' Gocovri Key Value Driver, BioMarin Data, Regeneron Q4 Results

via: SeekingAlpha at 2018-02-09 08:00:00:000

Analysis of top Seeking Alpha coverage: Adamas Pharmaceuticals Today we will focus on Adamas Pharmaceuticals ( ADMS ). On Thursday, the company reported data from the EASE LID 2 study. Adamas got an approval for Gocovri last year, the first treatment for levodopa induced dyskinesia i… read more...

Your Daily Pharma Scoop: Adamas' Gocovri Key Value Driver, BioMarin Data, Regeneron Q4 Results

via: SeekingAlpha at 2018-02-09 08:00:00:000

Analysis of top Seeking Alpha coverage: Adamas Pharmaceuticals Today we will focus on Adamas Pharmaceuticals ( ADMS ). On Thursday, the company reported data from the EASE LID 2 study. Adamas got an approval for Gocovri last year, the first treatment for levodopa induced dyskinesia i… read more...

ROTY Edition 1 Volume 77: Market Turmoil Continues - How To React

via: SeekingAlpha at 2018-02-09 07:54:39:000

Welcome to the 77th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

ROTY Edition 1 Volume 77: Market Turmoil Continues - How To React

via: SeekingAlpha at 2018-02-09 07:54:39:000

Welcome to the 77th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

ROTY Edition 1 Volume 77: Market Turmoil Continues - How To React

via: SeekingAlpha at 2018-02-09 07:54:39:000

Welcome to the 77th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

ROTY Edition 1 Volume 77: Market Turmoil Continues - How To React

via: SeekingAlpha at 2018-02-09 07:54:39:000

Welcome to the 77th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

ROTY Edition 1 Volume 77: Market Turmoil Continues - How To React

via: SeekingAlpha at 2018-02-09 07:54:39:000

Welcome to the 77th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

Gilead Sciences to Present at the RBC Capital Markets 2018 Global Healthcare Conference on Wednesday, February 21

via: Business Wire at 2018-02-08 16:01:00:000

Webcast Available Through Gilead Corporate Website Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Norbert W. Bischofberger, PhD, Gileads Executive Vice President, R&D and Chief Scientific Officer, and Robin L. Washington, Gileads Executive Vice Preside… read more...

Gilead Sciences to Present at the RBC Capital Markets 2018 Global Healthcare Conference on Wednesday, February 21

via: Business Wire at 2018-02-08 16:01:00:000

Webcast Available Through Gilead Corporate Website Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Norbert W. Bischofberger, PhD, Gileads Executive Vice President, R&D and Chief Scientific Officer, and Robin L. Washington, Gileads Executive Vice Preside… read more...

Gilead Sciences to Present at the RBC Capital Markets 2018 Global Healthcare Conference on Wednesday, February 21

via: Business Wire at 2018-02-08 16:01:00:000

Webcast Available Through Gilead Corporate Website Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Norbert W. Bischofberger, PhD, Gileads Executive Vice President, R&D and Chief Scientific Officer, and Robin L. Washington, Gileads Executive Vice Preside… read more...

Biolife Solutions: A Diversified, Profitable Play On Gene Therapy And Regenerative Medicine

via: SeekingAlpha at 2018-02-08 15:26:56:000

Diversified Play on Burgeoning Gene/Cell Therapy and Regenerative Medicine Market When looking to invest in the rapidly expanding gene/cell therapy and regenerative medicine space, there are many individual companies that are filled with the inherent binary risk-reward relationship that de… read more...

Biolife Solutions: A Diversified, Profitable Play On Gene Therapy And Regenerative Medicine

via: SeekingAlpha at 2018-02-08 15:26:56:000

Diversified Play on Burgeoning Gene/Cell Therapy and Regenerative Medicine Market When looking to invest in the rapidly expanding gene/cell therapy and regenerative medicine space, there are many individual companies that are filled with the inherent binary risk-reward relationship that de… read more...

Biolife Solutions: A Diversified, Profitable Play On Gene Therapy And Regenerative Medicine

via: SeekingAlpha at 2018-02-08 15:26:56:000

Diversified Play on Burgeoning Gene/Cell Therapy and Regenerative Medicine Market When looking to invest in the rapidly expanding gene/cell therapy and regenerative medicine space, there are many individual companies that are filled with the inherent binary risk-reward relationship that de… read more...

Does Gilead Stand A Chance After Its Q4 Earnings?

via: SeekingAlpha at 2018-02-08 11:35:43:000

Gilead Sciences ( GILD ) is an excellent shape after it had reported its fourth-quarter earnings report this week. That's because despite a decline in Hepatitis C sales, it had other key items that performed well. For example, Gilead still has its HIV franchise which is totally intact. In ad… read more...

Does Gilead Stand A Chance After Its Q4 Earnings?

via: SeekingAlpha at 2018-02-08 11:35:43:000

Gilead Sciences ( GILD ) is an excellent shape after it had reported its fourth-quarter earnings report this week. That's because despite a decline in Hepatitis C sales, it had other key items that performed well. For example, Gilead still has its HIV franchise which is totally intact. In ad… read more...

Does Gilead Stand A Chance After Its Q4 Earnings?

via: SeekingAlpha at 2018-02-08 11:35:43:000

Gilead Sciences ( GILD ) is an excellent shape after it had reported its fourth-quarter earnings report this week. That's because despite a decline in Hepatitis C sales, it had other key items that performed well. For example, Gilead still has its HIV franchise which is totally intact. In ad… read more...

Does Gilead Stand A Chance After Its Q4 Earnings?

via: SeekingAlpha at 2018-02-08 11:35:43:000

Gilead Sciences ( GILD ) is an excellent shape after it had reported its fourth-quarter earnings report this week. That's because despite a decline in Hepatitis C sales, it had other key items that performed well. For example, Gilead still has its HIV franchise which is totally intact. In ad… read more...

Your first trade for Thursday, February 8

via: CNBC at 2018-02-08 09:12:00:000

No summary available. read more...

Your first trade for Thursday, February 8

via: CNBC at 2018-02-08 09:12:00:000

No summary available. read more...

Your first trade for Thursday, February 8

via: CNBC at 2018-02-08 09:12:00:000

No summary available. read more...

Your first trade for Thursday, February 8

via: CNBC at 2018-02-08 09:12:00:000

No summary available. read more...

Gilead Does It Again

via: SeekingAlpha at 2018-02-08 09:00:16:000

Article thesis Gilead ( GILD ) remains a solid, long-term holding, despite ongoing revenue declines in the HCV space. Gilead has several avenues for growth over the coming years, trades at a low valuation, and continues to return cash to its owners. Gilead performs better than analysts exp… read more...

Gilead Does It Again

via: SeekingAlpha at 2018-02-08 09:00:16:000

Article thesis Gilead ( GILD ) remains a solid, long-term holding, despite ongoing revenue declines in the HCV space. Gilead has several avenues for growth over the coming years, trades at a low valuation, and continues to return cash to its owners. Gilead performs better than analysts exp… read more...

Gilead Does It Again

via: SeekingAlpha at 2018-02-08 09:00:16:000

Article thesis Gilead ( GILD ) remains a solid, long-term holding, despite ongoing revenue declines in the HCV space. Gilead has several avenues for growth over the coming years, trades at a low valuation, and continues to return cash to its owners. Gilead performs better than analysts exp… read more...

Gilead Does It Again

via: SeekingAlpha at 2018-02-08 09:00:16:000

Article thesis Gilead ( GILD ) remains a solid, long-term holding, despite ongoing revenue declines in the HCV space. Gilead has several avenues for growth over the coming years, trades at a low valuation, and continues to return cash to its owners. Gilead performs better than analysts exp… read more...

Your Daily Pharma Scoop: Abeona Surges, Gilead Results, Biogen Setback

via: SeekingAlpha at 2018-02-08 08:00:00:000

Analysis of top Seeking Alpha coverage: Abeona Today we will focus on Abeona Therapeutics ( ABEO ), which reported promising data for its gene therapy candidate for Sanfilipo B, an ultra-rare disease. Abeona today announced preliminary 30-day safety and biopotency signals from … read more...

Your Daily Pharma Scoop: Abeona Surges, Gilead Results, Biogen Setback

via: SeekingAlpha at 2018-02-08 08:00:00:000

Analysis of top Seeking Alpha coverage: Abeona Today we will focus on Abeona Therapeutics ( ABEO ), which reported promising data for its gene therapy candidate for Sanfilipo B, an ultra-rare disease. Abeona today announced preliminary 30-day safety and biopotency signals from … read more...

Your Daily Pharma Scoop: Abeona Surges, Gilead Results, Biogen Setback

via: SeekingAlpha at 2018-02-08 08:00:00:000

Analysis of top Seeking Alpha coverage: Abeona Today we will focus on Abeona Therapeutics ( ABEO ), which reported promising data for its gene therapy candidate for Sanfilipo B, an ultra-rare disease. Abeona today announced preliminary 30-day safety and biopotency signals from … read more...

Your Daily Pharma Scoop: Abeona Surges, Gilead Results, Biogen Setback

via: SeekingAlpha at 2018-02-08 08:00:00:000

Analysis of top Seeking Alpha coverage: Abeona Today we will focus on Abeona Therapeutics ( ABEO ), which reported promising data for its gene therapy candidate for Sanfilipo B, an ultra-rare disease. Abeona today announced preliminary 30-day safety and biopotency signals from … read more...

ViiV Healthcare sues Gilead for patent infringement over bictegravir

via: SeekingAlpha at 2018-02-08 06:16:40:000

ViiV Healthcare has filed a patent infringement lawsuit against Gilead Sciences (NASDAQ: GILD ) claiming bictegravir, a component of Gilead's just-approved triple combo HIV pill, infringes on ViiV's dolutegravir and other compounds. More news on: Gilead Sciences, Inc., GlaxoSmithKline, P… read more...

ViiV Healthcare sues Gilead for patent infringement over bictegravir

via: SeekingAlpha at 2018-02-08 06:16:40:000

ViiV Healthcare has filed a patent infringement lawsuit against Gilead Sciences (NASDAQ: GILD ) claiming bictegravir, a component of Gilead's just-approved triple combo HIV pill, infringes on ViiV's dolutegravir and other compounds. More news on: Gilead Sciences, Inc., GlaxoSmithKline, P… read more...

ViiV Healthcare sues Gilead for patent infringement over bictegravir

via: SeekingAlpha at 2018-02-08 06:16:40:000

ViiV Healthcare has filed a patent infringement lawsuit against Gilead Sciences (NASDAQ: GILD ) claiming bictegravir, a component of Gilead's just-approved triple combo HIV pill, infringes on ViiV's dolutegravir and other compounds. More news on: Gilead Sciences, Inc., GlaxoSmithKline, P… read more...

Gilead Sciences: Further Approvals Are Much Needed Amidst HCV Implosion

via: SeekingAlpha at 2018-02-08 06:08:25:000

Gilead Sciences ( GILD ) ended 2017 on a soft note, as could be expected as investors are not enticed yet with the prospects for the current year. The HCV franchise is imploding quicker than many could have foreseen, as this cannot be offset by the growing HIV franchise, while "other" revenu… read more...

Gilead Sciences: Further Approvals Are Much Needed Amidst HCV Implosion

via: SeekingAlpha at 2018-02-08 06:08:25:000

Gilead Sciences ( GILD ) ended 2017 on a soft note, as could be expected as investors are not enticed yet with the prospects for the current year. The HCV franchise is imploding quicker than many could have foreseen, as this cannot be offset by the growing HIV franchise, while "other" revenu… read more...

Gilead Sciences, Inc. 2017 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-02-07 14:51:03:000

The following slide deck was published by Gilead Sciences, Inc. in conjunction with their 2017 Q4 earnings Read more … read more...

Gilead Sciences, Inc. 2017 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-02-07 14:51:03:000

The following slide deck was published by Gilead Sciences, Inc. in conjunction with their 2017 Q4 earnings Read more … read more...

Biotech Forum Daily Digest For February 7th

via: SeekingAlpha at 2018-02-07 14:39:18:000

Anyone who has a continuous smile on his face conceals a toughness that is almost frightening . Greta Garbo The biotech sector continues to be volatile like the rest of the market. After big losses Monday when the Dow dropped nearly 1,100, the main biotech indices spent m… read more...

Biotech Forum Daily Digest For February 7th

via: SeekingAlpha at 2018-02-07 14:39:18:000

Anyone who has a continuous smile on his face conceals a toughness that is almost frightening . Greta Garbo The biotech sector continues to be volatile like the rest of the market. After big losses Monday when the Dow dropped nearly 1,100, the main biotech indices spent m… read more...

U.S. Food and Drug Administration Approves Gilead's Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection

via: Business Wire at 2018-02-07 14:22:00:000

In Clinical Trials, Biktarvy Demonstrated High Efficacy, Few Interactions With Other Drugs and a High Barrier to Resistance Through 48 Weeks Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy &… read more...

AbbVie: Looking Very Attractive In 2018

via: SeekingAlpha at 2018-02-07 10:02:16:000

I have always been in love with AbbVie ( ABBV ), and this article is just mostly a reiteration of my belief in this pharmaceutical company. And in its latest earnings release, the company has given me many reasons to believe that there is still significant upside potential left in this stock f… read more...

Stocks To Watch: Welcome To The Party Rising Rates

via: SeekingAlpha at 2018-02-03 08:45:32:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors might have a little more work to do now that higher interest rates have c… read more...

Stocks To Watch: Welcome To The Party Rising Rates

via: SeekingAlpha at 2018-02-03 08:45:32:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors might have a little more work to do now that higher interest rates have c… read more...

Kicking Off Avisol's 'Theme Of The Month' Series With A Look At NASH And Intercept

via: SeekingAlpha at 2018-02-02 12:03:00:000

We are kicking off our "Theme of the Month" series today, covering a themed topic for every month. For February, it's NASH (non-alcoholic steatohepatitis). In other months, we will take up diseases, conferences, or anything else that needs deep focus. For more details about the NASH schedule, … read more...

Kicking Off Avisol's 'Theme Of The Month' Series With A Look At NASH And Intercept

via: SeekingAlpha at 2018-02-02 12:03:00:000

We are kicking off our "Theme of the Month" series today, covering a themed topic for every month. For February, it's NASH (non-alcoholic steatohepatitis). In other months, we will take up diseases, conferences, or anything else that needs deep focus. For more details about the NASH schedule, … read more...

Kicking Off Avisol's 'Theme Of The Month' Series With A Look At NASH And Intercept

via: SeekingAlpha at 2018-02-02 12:03:00:000

We are kicking off our "Theme of the Month" series today, covering a themed topic for every month. For February, it's NASH (non-alcoholic steatohepatitis). In other months, we will take up diseases, conferences, or anything else that needs deep focus. For more details about the NASH schedule, … read more...

ROTY Edition 1 Volume 75: The Future Of ROTY, Cascadian Acquired And Updates

via: SeekingAlpha at 2018-02-02 10:50:57:000

Welcome to the 75th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

ROTY Edition 1 Volume 75: The Future Of ROTY, Cascadian Acquired And Updates

via: SeekingAlpha at 2018-02-02 10:50:57:000

Welcome to the 75th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

ROTY Edition 1 Volume 75: The Future Of ROTY, Cascadian Acquired And Updates

via: SeekingAlpha at 2018-02-02 10:50:57:000

Welcome to the 75th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-02-02 09:37:58:000

Noteworthy events for the week of Feb. 4 - 10 for healthcare investors: More news on: Protalix BioTherapeutics, Inc, Bristol-Myers Squibb Company, WellCare Health Plans, Inc., Healthcare stocks news, Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-02-02 09:37:58:000

Noteworthy events for the week of Feb. 4 - 10 for healthcare investors: More news on: Protalix BioTherapeutics, Inc, Bristol-Myers Squibb Company, WellCare Health Plans, Inc., Healthcare stocks news, Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2018-02-02 09:37:58:000

Noteworthy events for the week of Feb. 4 - 10 for healthcare investors: More news on: Protalix BioTherapeutics, Inc, Bristol-Myers Squibb Company, WellCare Health Plans, Inc., Healthcare stocks news, Read more … read more...

Jacqueline K. Barton, Ph.D., Joins Gilead Sciences' Board of Directors

via: Business Wire at 2018-02-01 16:05:00:000

Gilead Sciences, Inc.(Nasdaq: GILD) announced today that Jacqueline K. Barton, Ph.D., has been appointed to the companys Board of Directors. She previously served on Gileads Scientific Advisory Board from 1989 to 2007. Dr. Barton is the John G. Kirkwood and Arthur A… read more...

Jacqueline K. Barton, Ph.D., Joins Gilead Sciences' Board of Directors

via: Business Wire at 2018-02-01 16:05:00:000

Gilead Sciences, Inc.(Nasdaq: GILD) announced today that Jacqueline K. Barton, Ph.D., has been appointed to the companys Board of Directors. She previously served on Gileads Scientific Advisory Board from 1989 to 2007. Dr. Barton is the John G. Kirkwood and Arthur A… read more...

NASH Partnership Could Bring Significant Short-Term Value To CohBar

via: SeekingAlpha at 2018-02-01 15:41:30:000

According to its website : CohBar, Inc. is a leader in the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs with the potential to treat a wide range of diseases associated with aging and metabolic dysfunction including non-alcoholic steatohepat… read more...

NASH Partnership Could Bring Significant Short-Term Value To CohBar

via: SeekingAlpha at 2018-02-01 15:41:30:000

According to its website : CohBar, Inc. is a leader in the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs with the potential to treat a wide range of diseases associated with aging and metabolic dysfunction including non-alcoholic steatohepat… read more...

Galapagos: Continued Upside In 2018

via: SeekingAlpha at 2018-02-01 04:24:12:000

Shares of Belgian biotech Galapagos ( GLPG ) have risen by nearly 40% since my "buy the dip" piece published in December. Since suggesting the stock was "a long-term buy in biotech" in 2016 , it is up 115%. Figure 1: GLPG daily advanced chart (Source: Finviz Elite ) (Disclosure: Conta… read more...

Galapagos: Continued Upside In 2018

via: SeekingAlpha at 2018-02-01 04:24:12:000

Shares of Belgian biotech Galapagos ( GLPG ) have risen by nearly 40% since my "buy the dip" piece published in December. Since suggesting the stock was "a long-term buy in biotech" in 2016 , it is up 115%. Figure 1: GLPG daily advanced chart (Source: Finviz Elite ) (Disclosure: Conta… read more...

GlaxoSmithKline: Why This Diversified Stock Is A Definite Buy In 2018

via: SeekingAlpha at 2018-01-31 21:11:51:000

GlaxoSmithKline ( GSK ) is one pharmaceutical company, very well diversified across businesses as well as geographic markets. The three-part inter-conditional transaction with Novartis, implemented way back in March 2015 , has helped GlaxoSmithKline to position itself as a leading player in t… read more...

GlaxoSmithKline: Why This Diversified Stock Is A Definite Buy In 2018

via: SeekingAlpha at 2018-01-31 21:11:51:000

GlaxoSmithKline ( GSK ) is one pharmaceutical company, very well diversified across businesses as well as geographic markets. The three-part inter-conditional transaction with Novartis, implemented way back in March 2015 , has helped GlaxoSmithKline to position itself as a leading player in t… read more...

AbbVie With A Blowout Quarter But Should You Still Buy It?

via: SeekingAlpha at 2018-01-31 18:03:56:000

Big biotech AbbVie ( ABBV ) just posted stellar Q4/2017 results beating estimates top- and bottom-line and exciting investors about its bullish guidance pointing to a further acceleration in growth. Source: AbbVie Investor Relations Fueled by its Humira cash cow and spectacular growth in… read more...

AbbVie With A Blowout Quarter But Should You Still Buy It?

via: SeekingAlpha at 2018-01-31 18:03:56:000

Big biotech AbbVie ( ABBV ) just posted stellar Q4/2017 results beating estimates top- and bottom-line and exciting investors about its bullish guidance pointing to a further acceleration in growth. Source: AbbVie Investor Relations Fueled by its Humira cash cow and spectacular growth in… read more...

Gilead Sciences: Market Psychology Shift Will Last

via: SeekingAlpha at 2018-01-31 09:40:18:000

The purchase of Kite Pharma back in August was the catalyst that has Gilead Sciences ( GILD ) soaring to recent highs. The change in market psychology can take the biotech stock even higher considering Gilead traded at $115 back in 2016. Change In Analyst Psychology The call by Jefferie… read more...

Gilead Sciences: Market Psychology Shift Will Last

via: SeekingAlpha at 2018-01-31 09:40:18:000

The purchase of Kite Pharma back in August was the catalyst that has Gilead Sciences ( GILD ) soaring to recent highs. The change in market psychology can take the biotech stock even higher considering Gilead traded at $115 back in 2016. Change In Analyst Psychology The call by Jefferie… read more...

Miller Value Partners Opportunity Equity Q4 2017 Letter: The Value Of Doing Nothing

via: SeekingAlpha at 2018-01-31 05:44:22:000

The year 2017 ended up being a strong one for Opportunity Equity , which advanced 26.0% (net of fees) 1 , beating the S&P 500 by well over 400 basis points. A strategys performance always depends on a mixture of skill and luck (or lack thereof). Our strong performance is part… read more...

Miller Value Partners Opportunity Equity Q4 2017 Letter: The Value Of Doing Nothing

via: SeekingAlpha at 2018-01-31 05:44:22:000

The year 2017 ended up being a strong one for Opportunity Equity , which advanced 26.0% (net of fees) 1 , beating the S&P 500 by well over 400 basis points. A strategys performance always depends on a mixture of skill and luck (or lack thereof). Our strong performance is part… read more...

ROTY Edition 1 Volume 74: A New Feature For Readers, Updates And Trades

via: SeekingAlpha at 2018-01-30 11:51:02:000

Welcome to the 74th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

ROTY Edition 1 Volume 74: A New Feature For Readers, Updates And Trades

via: SeekingAlpha at 2018-01-30 11:51:02:000

Welcome to the 74th entry in our Runner of the Year (ROTY) series. Our model account utilizes a full position size of $10,000 and can hold up to 10 positions. Trades typically occur in quarter increments ($2,500) with cost averages calculated at the day's close. The model account is primaril… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-30 08:25:23:000

Rocket Pharmaceuticals (NASDAQ: RCKT ) initiated with Outperform rating and $27 (47% upside) price target at Evercore ISI. More news on: Rocket Pharmaceuticals, Inc., Select Medical Holdings Corporation, Community Health Systems, Inc., Healthcare stocks news, Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-01-30 08:25:23:000

Rocket Pharmaceuticals (NASDAQ: RCKT ) initiated with Outperform rating and $27 (47% upside) price target at Evercore ISI. More news on: Rocket Pharmaceuticals, Inc., Select Medical Holdings Corporation, Community Health Systems, Inc., Healthcare stocks news, Read more … read more...

How To Build A Better Retirement

via: SeekingAlpha at 2018-01-30 06:00:00:000

Retirees today face a daunting task. Saving for retirement is as hard as it has ever been. The low unemployment rate makes it much easier to find work, but high stock valuations make it difficult to find good investments. Many retirees end up working in retirement. That is a bit of an oxymor… read more...

How To Build A Better Retirement

via: SeekingAlpha at 2018-01-30 06:00:00:000

Retirees today face a daunting task. Saving for retirement is as hard as it has ever been. The low unemployment rate makes it much easier to find work, but high stock valuations make it difficult to find good investments. Many retirees end up working in retirement. That is a bit of an oxymor… read more...

BioSci Rounds Report (Edition 1 Volume 3): Jan. 29, 2018

via: SeekingAlpha at 2018-01-30 05:39:10:000

What is the company doing to maintain or to improve profit margins? - The Father of Growth Investing (Philip Fisher) Trading Analytics On Jan. 29, 2018, the shares of Crispr Therapeutics (NASDAQ: CRSP ), the premier gene-editing innovator, traded $4.94 higher at $44.39 (for +12.5% profit… read more...

BioSci Rounds Report (Edition 1 Volume 3): Jan. 29, 2018

via: SeekingAlpha at 2018-01-30 05:39:10:000

What is the company doing to maintain or to improve profit margins? - The Father of Growth Investing (Philip Fisher) Trading Analytics On Jan. 29, 2018, the shares of Crispr Therapeutics (NASDAQ: CRSP ), the premier gene-editing innovator, traded $4.94 higher at $44.39 (for +12.5% profit… read more...

DivGro Pulse: January 2018

via: SeekingAlpha at 2018-01-29 16:09:57:000

This month I'm celebrating the fifth anniversary of DivGro! I founded DivGro in January 2013 to focus on dividend growth ( DG ) investing. Since then, my portfolio steadily has grown well beyond what I could have imagined ! Just this week, I hit my 10th home run with DivGro, when my pos… read more...

DivGro Pulse: January 2018

via: SeekingAlpha at 2018-01-29 16:09:57:000

This month I'm celebrating the fifth anniversary of DivGro! I founded DivGro in January 2013 to focus on dividend growth ( DG ) investing. Since then, my portfolio steadily has grown well beyond what I could have imagined ! Just this week, I hit my 10th home run with DivGro, when my pos… read more...

DivGro Pulse: January 2018

via: SeekingAlpha at 2018-01-29 16:09:57:000

This month I'm celebrating the fifth anniversary of DivGro! I founded DivGro in January 2013 to focus on dividend growth ( DG ) investing. Since then, my portfolio steadily has grown well beyond what I could have imagined ! Just this week, I hit my 10th home run with DivGro, when my pos… read more...

Boston's Latest Biotech Arrival Is A Compelling 'Bolt-On' Opportunity

via: SeekingAlpha at 2018-01-29 14:38:10:000

Will 2018 be Alexion Pharmaceuticals (ALXN) annus mirabilis? After a management shakeup, pipeline scare, and mildly disappointing Q3 top line numbers, negative sentiment has clung to like a cheap suit for nearly a year. But there are reasons that suggest that ALXN is a… read more...

Boston's Latest Biotech Arrival Is A Compelling 'Bolt-On' Opportunity

via: SeekingAlpha at 2018-01-29 14:38:10:000

Will 2018 be Alexion Pharmaceuticals (ALXN) annus mirabilis? After a management shakeup, pipeline scare, and mildly disappointing Q3 top line numbers, negative sentiment has clung to like a cheap suit for nearly a year. But there are reasons that suggest that ALXN is a… read more...

Boston's Latest Biotech Arrival Is A Compelling 'Bolt-On' Opportunity

via: SeekingAlpha at 2018-01-29 14:38:10:000

Will 2018 be Alexion Pharmaceuticals (ALXN) annus mirabilis? After a management shakeup, pipeline scare, and mildly disappointing Q3 top line numbers, negative sentiment has clung to like a cheap suit for nearly a year. But there are reasons that suggest that ALXN is a… read more...

IMF January Buys: The 15 Stocks Added To My Fund

via: SeekingAlpha at 2018-01-29 13:13:36:000

My Ian's Million Fund, IMF, is a quasi-index fund where I have two main goals. One, beat the S&P 500 over time with my own diversified basket of stocks, while avoiding any ongoing management fees. Two, build a model that my non-investment professional friends can copy. If I didn't have ot… read more...

IMF January Buys: The 15 Stocks Added To My Fund

via: SeekingAlpha at 2018-01-29 13:13:36:000

My Ian's Million Fund, IMF, is a quasi-index fund where I have two main goals. One, beat the S&P 500 over time with my own diversified basket of stocks, while avoiding any ongoing management fees. Two, build a model that my non-investment professional friends can copy. If I didn't have ot… read more...

IMF January Buys: The 15 Stocks Added To My Fund

via: SeekingAlpha at 2018-01-29 13:13:36:000

My Ian's Million Fund, IMF, is a quasi-index fund where I have two main goals. One, beat the S&P 500 over time with my own diversified basket of stocks, while avoiding any ongoing management fees. Two, build a model that my non-investment professional friends can copy. If I didn't have ot… read more...

AbbVie: Too Darn Hot?

via: SeekingAlpha at 2018-01-29 04:46:24:000

Introduction To my surprise, AbbVie ( ABBV ) has turned into a growth stock. As noted next, I began seeing this when the stock was much lower than it is now, and not much has changed. This article addresses matters from the standpoint of an investor wondering about buying ABBV now that i… read more...

AbbVie: Too Darn Hot?

via: SeekingAlpha at 2018-01-29 04:46:24:000

Introduction To my surprise, AbbVie ( ABBV ) has turned into a growth stock. As noted next, I began seeing this when the stock was much lower than it is now, and not much has changed. This article addresses matters from the standpoint of an investor wondering about buying ABBV now that i… read more...

BioSci Rounds Report: Jan. 26, 2018

via: SeekingAlpha at 2018-01-28 03:41:05:000

It's better to hang out with people better than you. Pick out associates whose behavior is better than yours and you'll drift in that direction. - The Oracle Of Omaha (Warren Buffett) Trading Analytics We wish to welcome you to todays edition of Integrated BioSci rounds report. A… read more...

BioSci Rounds Report: Jan. 26, 2018

via: SeekingAlpha at 2018-01-28 03:41:05:000

It's better to hang out with people better than you. Pick out associates whose behavior is better than yours and you'll drift in that direction. - The Oracle Of Omaha (Warren Buffett) Trading Analytics We wish to welcome you to todays edition of Integrated BioSci rounds report. A… read more...

BioSci Rounds Report: Jan. 26, 2018

via: SeekingAlpha at 2018-01-28 03:41:05:000

It's better to hang out with people better than you. Pick out associates whose behavior is better than yours and you'll drift in that direction. - The Oracle Of Omaha (Warren Buffett) Trading Analytics We wish to welcome you to todays edition of Integrated BioSci rounds report. A… read more...

BioSci Rounds Report: Jan. 26, 2018

via: SeekingAlpha at 2018-01-28 03:41:05:000

It's better to hang out with people better than you. Pick out associates whose behavior is better than yours and you'll drift in that direction. - The Oracle Of Omaha (Warren Buffett) Trading Analytics We wish to welcome you to todays edition of Integrated BioSci rounds report. A… read more...

Venture capital deals of the week

via: SeekingAlpha at 2018-01-27 10:05:01:000

ID tech: Facebook (NASDAQ: FB ) acquired ID verification startup Confirm.io for undisclosed terms. The team and tech will fold into Facebook. More news on: Facebook, Gilead Sciences, Inc., Eli Lilly and Company, Tech stocks news, Healthcare stocks news, Energy stocks news, Consumer st… read more...

Venture capital deals of the week

via: SeekingAlpha at 2018-01-27 10:05:01:000

ID tech: Facebook (NASDAQ: FB ) acquired ID verification startup Confirm.io for undisclosed terms. The team and tech will fold into Facebook. More news on: Facebook, Gilead Sciences, Inc., Eli Lilly and Company, Tech stocks news, Healthcare stocks news, Energy stocks news, Consumer st… read more...

Venture capital deals of the week

via: SeekingAlpha at 2018-01-27 10:05:01:000

ID tech: Facebook (NASDAQ: FB ) acquired ID verification startup Confirm.io for undisclosed terms. The team and tech will fold into Facebook. More news on: Facebook, Gilead Sciences, Inc., Eli Lilly and Company, Tech stocks news, Healthcare stocks news, Energy stocks news, Consumer st… read more...

Venture capital deals of the week

via: SeekingAlpha at 2018-01-27 10:05:01:000

ID tech: Facebook (NASDAQ: FB ) acquired ID verification startup Confirm.io for undisclosed terms. The team and tech will fold into Facebook. More news on: Facebook, Gilead Sciences, Inc., Eli Lilly and Company, Tech stocks news, Healthcare stocks news, Energy stocks news, Consumer st… read more...

Venture capital deals of the week

via: SeekingAlpha at 2018-01-27 10:05:01:000

ID tech: Facebook (NASDAQ: FB ) acquired ID verification startup Confirm.io for undisclosed terms. The team and tech will fold into Facebook. More news on: Facebook, Gilead Sciences, Inc., Eli Lilly and Company, Tech stocks news, Healthcare stocks news, Energy stocks news, Consumer st… read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

Jefferies bullish on Gilead, sees 17% upside

via: SeekingAlpha at 2018-01-26 07:58:45:000

Jefferies' Michael Yee upgrades Gilead Sciences (NASDAQ: GILD ) to Buy and raises his price target to $95 (17% upside) from $87 citing positive prospects for CAR-T therapy Yescarta (axicabtagene ciloleucel) and its HIV franchise. More news on: Gilead Sciences, Inc., Healthcare stocks news,… read more...

Jefferies bullish on Gilead, sees 17% upside

via: SeekingAlpha at 2018-01-26 07:58:45:000

Jefferies' Michael Yee upgrades Gilead Sciences (NASDAQ: GILD ) to Buy and raises his price target to $95 (17% upside) from $87 citing positive prospects for CAR-T therapy Yescarta (axicabtagene ciloleucel) and its HIV franchise. More news on: Gilead Sciences, Inc., Healthcare stocks news,… read more...

Jefferies bullish on Gilead, sees 17% upside

via: SeekingAlpha at 2018-01-26 07:58:45:000

Jefferies' Michael Yee upgrades Gilead Sciences (NASDAQ: GILD ) to Buy and raises his price target to $95 (17% upside) from $87 citing positive prospects for CAR-T therapy Yescarta (axicabtagene ciloleucel) and its HIV franchise. More news on: Gilead Sciences, Inc., Healthcare stocks news,… read more...

Jefferies bullish on Gilead, sees 17% upside

via: SeekingAlpha at 2018-01-26 07:58:45:000

Jefferies' Michael Yee upgrades Gilead Sciences (NASDAQ: GILD ) to Buy and raises his price target to $95 (17% upside) from $87 citing positive prospects for CAR-T therapy Yescarta (axicabtagene ciloleucel) and its HIV franchise. More news on: Gilead Sciences, Inc., Healthcare stocks news,… read more...

Jefferies bullish on Gilead, sees 17% upside

via: SeekingAlpha at 2018-01-26 07:58:45:000

Jefferies' Michael Yee upgrades Gilead Sciences (NASDAQ: GILD ) to Buy and raises his price target to $95 (17% upside) from $87 citing positive prospects for CAR-T therapy Yescarta (axicabtagene ciloleucel) and its HIV franchise. More news on: Gilead Sciences, Inc., Healthcare stocks news,… read more...

What Netflix, Trump And The Fed May Be Implying About Equities

via: SeekingAlpha at 2018-01-25 15:41:00:000

Introduction - rationale for altering focus In August, I presented The Case For North American Cyclical Stocks . This article briefly reviews the stocks discussed then and presents updated picks and pans for the year ahead. The title presents three keys to the market now. The Netflix ( … read more...

What Netflix, Trump And The Fed May Be Implying About Equities

via: SeekingAlpha at 2018-01-25 15:41:00:000

Introduction - rationale for altering focus In August, I presented The Case For North American Cyclical Stocks . This article briefly reviews the stocks discussed then and presents updated picks and pans for the year ahead. The title presents three keys to the market now. The Netflix ( … read more...

Retirement: A Future-Proof Portfolio For Young Investors

via: SeekingAlpha at 2018-01-25 14:04:06:000

On Seeking Alpha, there exists a wealth of information about retirement and possible portfolio strategies to achieve this. Most of these portfolios focus on people who are relatively close to their retirement age. For a young investor, especially someone in his 30s or early 40s, there are a co… read more...

Retirement: A Future-Proof Portfolio For Young Investors

via: SeekingAlpha at 2018-01-25 14:04:06:000

On Seeking Alpha, there exists a wealth of information about retirement and possible portfolio strategies to achieve this. Most of these portfolios focus on people who are relatively close to their retirement age. For a young investor, especially someone in his 30s or early 40s, there are a co… read more...

Ionis Pharmaceuticals Is Poised To Disrupt Biotech

via: SeekingAlpha at 2018-01-23 21:11:37:000

I have written this article with the layperson in mind, but I will try to stay true to the underlying science. Targeting the "undruggable" The general mantra of traditional biopharmaceuticals is to develop chemical-based drugs that affect a particular protein, altering a disease process… read more...

Gilead Sciences to Release Fourth Quarter and Full Year 2017 Financial Results on Tuesday, February 6, 2018

via: Business Wire at 2018-01-23 16:01:00:000

Conference Call and Webcast to Follow Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2017 financial results will be released on Tuesday, February 6, after the market closes. At 4:30 p.m. Eastern Time, Gileads management will host a… read more...

3 Things In Biotech You Should Learn Today: January 22, 2018

via: SeekingAlpha at 2018-01-23 08:00:00:000

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Celgene buys Juno Company: Juno Therapeutics ( JUNO ) Therapy: Quite a few Disease… read more...

Tao Value Q4 2017 Letter

via: SeekingAlpha at 2018-01-23 07:27:22:000

Read more … read more...

What Can We Expect From Gilead?

via: SeekingAlpha at 2018-01-22 20:30:46:000

Article thesis In about two weeks Gilead ( GILD ) will report its fourth-quarter results, and I believe that the company has a good chance of beating estimates once again. With tailwinds such as the Yescarta roll-out and the approval of Sovaldi in China Gilead does not have a bad outlook at … read more...

Novo Nordisk: Still A Safe Bet Under One Condition

via: SeekingAlpha at 2018-01-22 10:02:42:000

(Source: 2016 Annual Report) ( Approximately 1 in 11 people have diabetes in the USA. Nova Nordisk creates products that help these people control their diabetes.) Novo Nordisk A/S (NONOF) is a Danish healthcare company that develops, manufactures, and markets pharmaceuticals related … read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
2017-12-14 2017-12-28 2017-12-15 2017-10-26 0.52 Dividend income Q
2017-09-14 2017-09-28 2017-09-15 2017-07-26 0.52 Dividend income Q
2017-06-14 2017-06-29 2017-06-16 2017-05-02 0.52 Dividend income Q
2017-03-14 2017-03-30 2017-03-16 2017-02-07 0.52 Dividend income Q
2016-12-13 2016-12-29 2016-12-15 2016-11-01 0.47 Dividend income Q
2016-09-14 2016-09-29 2016-09-16 2016-07-25 0.47 Dividend income Q
2016-06-14 2016-06-29 2016-06-16 2016-04-28 0.47 Dividend income Q
2016-03-14 2016-03-30 2016-03-16 2016-02-02 0.43 Dividend income Q
2015-12-14 2015-12-30 2015-12-16 2015-10-27 0.43 Dividend income Q
2015-09-14 2015-09-29 2015-09-16 2015-07-28 0.43 Dividend income Q
2015-06-12 2015-06-29 2015-06-16 2015-04-30 0.43 Dividend income Q
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
2013-01-28 2012-12-10 2013-01-07 2013-01-25 00:00:00 -0500 0.5 2.0 1.0
Data provided for free by IEX